WorldWideScience

Sample records for receptor positron emission

  1. Positron emission tomography studies of brain receptors

    International Nuclear Information System (INIS)

    Maziere, B.; Maziere, M.

    1991-01-01

    Probing the regional distribution and affinity of receptors in the brain, in vivo, in human and non human primates has become possible with the use of selective ligands labelled with positron emitting radionuclides and positron emission tomography (PET). After describing the techniques used in positron emission tomography to characterize a ligand receptor binding and discussing the choice of the label and the limitations and complexities of the in vivo approach, the results obtained in the PET studies of various neurotransmission systems: dopaminergic, opiate, benzodiazepine, serotonin and cholinergic systems are reviewed

  2. Imaging opiate receptors with positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Frost, J.J.; Dannals, R.F.; Ravert, H.T.; Wilson, A.A.; Wong, D.F.; Links, J.M.; Burns, H.D.; Kuhar, M.J.; Snyder, S.H.; Wagner, H.N. Jr.

    1984-01-01

    Opiate receptors exist in the mammalian brain and are thought to meditate the diverse pharmacological actions of the opiates, such as analgesia, euphoria, and sedation. The 4-carbomethoxyl derivatives of fentanyl, such as lofentanil and R31833 (4-carbomethoxyfentanyl) bind to the opiate receptor with high affinity. C-11 R31833 was synthesized by reacting C-11 methyl iodide with the appropriate carboxylate. Male ICR mice were injected intravenously with C-11 R31833 (5..mu..g/kg), killed 30 minutes later, and the brains rapidly dissected. The thalami, striata, and cerebral cortex are rich in opiate receptors, but the cerebellum contains a very low concentration of opiate receptors. The thalamus/cerebellum and striatum/cerebellum activity ratios, calculated per mg of wet tissue, were 4.1 and 5.2 respectively. Coinjection of 5mg/kg naloxone reduced the ratios to 1.1, which indicates that the preferential localization of C-11 R31833 in the thalami and striata is due to binding to opiate is due to binding to opiate receptors. A 22 kg anesthetized male baboon was imaged using the NeuroECAT after injection of 18.9 mCi of C-11 R13833 (0.50 ..mu..g/kg, specific activity 616 Ci/mmole at time of injection). From 15-70 minutes after injection preferential accumulation of activity could be seen in the thalami, caudate nuclei, and cerebral cortex and, conversely, low activity was demonstrated in the cerebellum. At one hour postinjection the maximum measured caudate/cerebellum activity ratio per pixel was 2.9. For the NeuroECAT the recovery coefficient for the baboon caudate is ca. 0.2-0.3, and therefore the actual caudate/cerebellum ratio is ca. 10-15.

  3. Imaging opiate receptors with positron emission tomography

    International Nuclear Information System (INIS)

    Frost, J.J.; Dannals, R.F.; Ravert, H.T.

    1984-01-01

    Opiate receptors exist in the mammalian brain and are thought to meditate the diverse pharmacological actions of the opiates, such as analgesia, euphoria, and sedation. The 4-carbomethoxyl derivatives of fentanyl, such as lofentanil and R31833 (4-carbomethoxyfentanyl) bind to the opiate receptor with high affinity. C-11 R31833 was synthesized by reacting C-11 methyl iodide with the appropriate carboxylate. Male ICR mice were injected intravenously with C-11 R31833 (5μg/kg), killed 30 minutes later, and the brains rapidly dissected. The thalami, striata, and cerebral cortex are rich in opiate receptors, but the cerebellum contains a very low concentration of opiate receptors. The thalamus/cerebellum and striatum/cerebellum activity ratios, calculated per mg of wet tissue, were 4.1 and 5.2 respectively. Coinjection of 5mg/kg naloxone reduced the ratios to 1.1, which indicates that the preferential localization of C-11 R31833 in the thalami and striata is due to binding to opiate is due to binding to opiate receptors. A 22 kg anesthetized male baboon was imaged using the NeuroECAT after injection of 18.9 mCi of C-11 R13833 (0.50 μg/kg, specific activity 616 Ci/mmole at time of injection). From 15-70 minutes after injection preferential accumulation of activity could be seen in the thalami, caudate nuclei, and cerebral cortex and, conversely, low activity was demonstrated in the cerebellum. At one hour postinjection the maximum measured caudate/cerebellum activity ratio per pixel was 2.9. For the NeuroECAT the recovery coefficient for the baboon caudate is ca. 0.2-0.3, and therefore the actual caudate/cerebellum ratio is ca. 10-15

  4. Development of radiotracers for imaging NR2B subtype NMDA receptors with positron emission tomography

    International Nuclear Information System (INIS)

    Labas, R.

    2007-01-01

    The aim of this thesis was to develop new radioactive tracers for imaging NR2B subtype NMDA receptors with positron emission tomography. Several compounds including 4-(4-fluoro-benzyl)piperidine and presenting interesting in vivo biological properties were the object of a labelling with a positrons emitter atom ( 11 C or 18 F)

  5. Positron emission tomography studies of central receptors in humans

    International Nuclear Information System (INIS)

    Baron, J.C.; Maziere, B.

    1986-01-01

    Central neurotransmitter systems and receptors are intimately involved in the mechanism of several neurologic and psychiatric disorders. One well-known example is the nigro-striatal dopaminergic system in akinesia of Parkinson's disease. Although neurotransmitter concentration and receptor function can be measured regionally post-mortem, positron tomography (PET) studies can be performed during life and therefore may provide insight into changes at early stages of the disease as well as follow-up data on, and pharmacological modification of, such changes. PET allows to monitor non-invasively the time-course of regional tissue tracer concentration following administration of a radioactive drug. If the latter is known to interact selectively with specific binding sites, it can be used to probe in vivo the regional distribution and affinity of the receptors involved. This principle was first pioneered using 3 H or 14 C-labeled ligands injected intravenously to laboratory animal, but necessitated brain tissue sampling for determination of regional radioactive concentration. The feasibility of the PET paradigm to characterize specific binding in vivo showed that trace amounts of 11 C-labeled flunitrazepam could be displaced specifically from the baboon's brain by a therapeutic load of the unlabeled competitor Lorazepam, indicating that specific in vivo binding of the radioligand to the benzodiazepine (BZD) receptors has taken place

  6. Preclinical evaluation of a positron emitting progestin ([18F]fluoro-16 alpha-methyl-19-norprogesterone) for imaging progesterone receptor positive tumours with positron emission tomography

    NARCIS (Netherlands)

    Verhagen, Aalt; Luurtsema, Gert; PESSER, JW; DEGROOT, TJ; OOSTERHUIS, JW; Vaalburg, Willem; Wouda, S.

    Three 21-fluoro-progestins were investigated as potential imaging agents for the in vivo assessment of human progesterone receptor positive neoplasms with positron emission tomography. In competitive binding assays these compounds demonstrated high specificity, competing only for progesterone

  7. Chemical neuroanatomy and in vitro receptor autoradiography: A basis for cerebral positron emission tomography

    International Nuclear Information System (INIS)

    Albin, R.L.; Young, A.B.; Penney, J.B.; Makowiec, R.L.; Gilman, S.

    1991-01-01

    We review chemical neuroanatomy and in vitro receptor (IVG) autoradiography as tools for the development of methods suitable for positron emission tomography (PET) studies. The organizations of monoaminergic, cholinergic, γ-aminobutyric acidergic (GABA), and excitatory amino acidergic (EAA) pathways within the central nervous system are summarized, as is the presently accepted classification of GABA and EAA receptors. We describe the technique of IVG and discuss its unique advantages for the selection of possible PET methods. Finally, we discuss receptor changes in Huntington's disease and olivopontocerebellar atrophy, two human diseases for which IVG has suggested possible targets for PET imaging

  8. Kinetic modeling of receptor-ligand binding applied to positron emission tomographic studies with neuroleptic tracers

    Energy Technology Data Exchange (ETDEWEB)

    Logan, J; Wolf, A P; Shiue, C Y; Fowler, J S

    1987-01-01

    Positron emission tomography (PET) with labeled neuroleptics has made possible the study of neurotransmitter-receptor systems in vivo. In this study we investigate the kinetics of the 3,4-dihydroxyphenylethylamine (dopamine) receptor-ligand binding using PET data from a series of experiments in the baboon with the /sup 18/F-labeled drugs spiperone, haloperidol, and benperidol. Models used to describe these systems are based on first-order kinetics which applies at high specific activity (low receptor occupancy). The parameters governing the uptake and loss of drug from the brain were found by fitting PET data from regions with little or no receptor concentration (cerebellum) and from experiments in which specific binding was blocked by pretreatment with the drug (+)-butaclamol. Receptor constants were determined by fitting data from receptor-containing structures. Correcting the arterial plasma activities (the model driving function) for the presence of drug metabolites was found to be important in the modeling of these systems.

  9. Positron Emission Tomography (PET) Imaging of Opioid Receptors

    NARCIS (Netherlands)

    van Waarde, Aren; Absalom, Anthony; Visser, Anniek; Dierckx, Rudi; Dierckx, Rudi AJO; Otte, Andreas; De Vries, Erik FJ; Van Waarde, Aren; Luiten, Paul GM

    2014-01-01

    The opioid system consists of opioid receptors (which mediate the actions of opium), their endogenous ligands (the enkephalins, endorphins, endomorphins, dynorphin, and nociceptin), and the proteins involved in opioid production, transport, and degradation. PET tracers for the various opioid

  10. Positron emission tomography. Positronemisionstomografi

    Energy Technology Data Exchange (ETDEWEB)

    Bolwig, T G; Haunsoe, S; Dahlgaard Hove, J; Hesse, B; Hoejgard, L; Jensen, M; Paulson, O B; Hastrup Svendsen, J; Soelvsten Soerensen, S

    1994-10-01

    Positron emission tomography (PET) is a method for quantitative imaging of regional physiological and biochemical parameters. Positron emitting radioactive isotopes can be produced by a cyclotron, eg. the biologically important carbon ([sup 11]C), oxygen ([sup 15]O), and nitrogen ([sup 13]N) elements. With the tomographic principles of the PET scanner the quantitative distribution of the administered isotopes can be determined and images can be provided as well as dynamic information on blood flow, metabolism and receptor function. In neurology PET has been used for investigations on numerous physiological processes in the brain: circulation, metabolism and receptor studies. In Parkinson's disease PET studies have been able to localize the pathology specifically, and in early stroke PET technique can outline focal areas with living but non-functioning cells, and this could make it possible to intervene in this early state. With positron emission tomography a quantitative evaluation of myocardial blood flow, glucose and fatty acid metabolism can be made as well as combined assessments of blood flow and metabolism. Combined studies of blood flow and metabolism can determine whether myocardial segments with abnormal motility consist of necrotic or viable tissue, thereby delineating effects of revascularisation. In the future it will probably be possible to characterize the myocardial receptor status in different cardiac diseases. The PET technique is used in oncology for clinical as well as more basic research on tumor perfusion and metabolism. Further, tumor uptake of positron labelled cytotoxic drugs might predict the clinical benefit of treatment. (au) (19 refs.).

  11. Positron emission tomography

    International Nuclear Information System (INIS)

    Bolwig, T.G.; Haunsoe, S.; Dahlgaard Hove, J.; Hesse, B.; Hoejgard, L.; Jensen, M.; Paulson, O.B.; Hastrup Svendsen, J.; Soelvsten Soerensen, S.

    1994-01-01

    Positron emission tomography (PET) is a method for quantitative imaging of regional physiological and biochemical parameters. Positron emitting radioactive isotopes can be produced by a cyclotron, eg. the biologically important carbon ( 11 C), oxygen ( 15 O), and nitrogen ( 13 N) elements. With the tomographic principles of the PET scanner the quantitative distribution of the administered isotopes can be determined and images can be provided as well as dynamic information on blood flow, metabolism and receptor function. In neurology PET has been used for investigations on numerous physiological processes in the brain: circulation, metabolism and receptor studies. In Parkinson's disease PET studies have been able to localize the pathology specifically, and in early stroke PET technique can outline focal areas with living but non-functioning cells, and this could make it possible to intervene in this early state. With positron emission tomography a quantitative evaluation of myocardial blood flow, glucose and fatty acid metabolism can be made as well as combined assessments of blood flow and metabolism. Combined studies of blood flow and metabolism can determine whether myocardial segments with abnormal motility consist of necrotic or viable tissue, thereby delineating effects of revascularisation. In the future it will probably be possible to characterize the myocardial receptor status in different cardiac diseases. The PET technique is used in oncology for clinical as well as more basic research on tumor perfusion and metabolism. Further, tumor uptake of positron labelled cytotoxic drugs might predict the clinical benefit of treatment. (au) (19 refs.)

  12. Positron Emission Tomography (PET Quantification of GABAA Receptors in the Brain of Fragile X Patients.

    Directory of Open Access Journals (Sweden)

    Charlotte D'Hulst

    Full Text Available Over the last several years, evidence has accumulated that the GABAA receptor is compromised in animal models for fragile X syndrome (FXS, a common hereditary form of intellectual disability. In mouse and fly models, agonists of the GABAA receptor were able to rescue specific consequences of the fragile X mutation. Here, we imaged and quantified GABAA receptors in vivo in brain of fragile X patients using Positron Emission Topography (PET and [11C]flumazenil, a known high-affinity and specific ligand for the benzodiazepine site of GABAA receptors. We measured regional GABAA receptor availability in 10 fragile X patients and 10 control subjects. We found a significant reduction of on average 10% in GABAA receptor binding potential throughout the brain in fragile X patients. In the thalamus, the brain region showing the largest difference, the GABAA receptor availability was even reduced with 17%. This is one of the first reports of a PET study of human fragile X brain and directly demonstrates that the GABAA receptor availability is reduced in fragile X patients. The study reinforces previous hypotheses that the GABAA receptor is a potential target for rational pharmacological treatment of fragile X syndrome.

  13. Positron emission tomography

    International Nuclear Information System (INIS)

    Reivich, M.; Alavi, A.

    1985-01-01

    This book contains 24 selections. Some of the titles are: Positron Emission Tomography Instrumentation, Generator Systems for Positron Emitters, Reconstruction Algorithms, Cerebral Glucose Consumption: Methodology and Validation, Cerebral Blood Flow Tomography Using Xenon-133 Inhalation: Methods and Clinical Applications, PET Studies of Stroke, Cardiac Positron Emission Tomography, and Use of PET in Oncology

  14. Positron emission tomography

    International Nuclear Information System (INIS)

    Iio, Masahiro

    1982-01-01

    Utilization of positron emission tomography was reviewed in relation to construction and planned construction of small-size medical cyclotrons, planned construction of positron cameras and utilization of short-lived radionuclides. (Chiba, N.)

  15. Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy.

    Science.gov (United States)

    Frost, J J; Mayberg, H S; Fisher, R S; Douglass, K H; Dannals, R F; Links, J M; Wilson, A A; Ravert, H T; Rosenbaum, A E; Snyder, S H

    1988-03-01

    Neurochemical studies in animal models of epilepsy have demonstrated the importance of multiple neurotransmitters and their receptors in mediating seizures. The role of opiate receptors and endogenous opioid peptides in seizure mechanisms is well developed and is the basis for measuring opiate receptors in patients with epilepsy. Patients with complex partial seizures due to unilateral temporal seizure foci were studied by positron emission tomography using 11C-carfentanil to measure mu-opiate receptors and 18F-fluoro-deoxy-D-glucose to measure glucose utilization. Opiate receptor binding is greater in the temporal neocortex on the side of the electrical focus than on the opposite side. Modeling studies indicate that the increase in binding is due to an increase in affinity or the number of unoccupied receptors. No significant asymmetry of 11C-carfentanil binding was detected in the amygdala or hippocampus. Glucose utilization correlated inversely with 11C-carfentanil binding in the temporal neocortex. Increased opiate receptors in the temporal neocortex may represent a tonic anticonvulsant system that limits the spread of electrical activity from other temporal lobe structures.

  16. Physiology and physiopathology of central type Benzodiazepine receptors: Study in the monkey and in human brain using positron emission tomography

    International Nuclear Information System (INIS)

    Hantraye, P.

    1987-01-01

    A new non-invasive technique that allows to study in a living subject central type benzodiazepine receptors is developed. A combined approach is applied using a specific positron-emitting radiotracer for the in vivo labelling of the receptors and positron emission tomography allowing, by external detection, a quantitative determination of tissue radioactivity. The radioligand used for the in vivo labelling of benzodiazepine receptors is the antagonist RO 15-1788 labelled with carbon 11. The various stages of the study are described: in vivo characterization in the monkey of central type benzodiazepine receptors; characterization of central type benzodiazepine receptors in human brain using selective molecules for the BZ1 benzodiazepine subclass; demonstration of the heterogeneity of central type benzodiazepine receptors in the brain; study of pathological alteration of benzodiazepine receptors in experimental epilepsy [fr

  17. Cardiac positron emission tomography

    International Nuclear Information System (INIS)

    Eftekhari, M.; Ejmalian, G.

    2003-01-01

    Positron emission tomography is an intrinsically tool that provide a unique and unparalleled approach for clinicians and researchers to interrogate the heart noninvasively. The ability to label substances of physiological interest with positron-emitting radioisotopes has permitted insight into normal blood flow and metabolism and the alterations that occur with disease states. Positron emission tomography of the heart has evolved as a unique, noninvasive approach for the assessment of myocardial perfusion, metabolism, and function. Because of the intrinsic quantitative nature of positron emission tomography measurements as well as the diverse compounds that can be labeled with positron- emitting radioisotopes, studies with positron emission tomography have provided rich insight into the physiology of the heart under diverse conditions

  18. Preparation of radiopharmaceuticals labelled with bromine positron emitting isotopes for the study of dopaminergic receptors of the central nervous system using positron emission tomography

    International Nuclear Information System (INIS)

    Loc'h, C.

    1988-04-01

    The in vivo study of dopaminergic receptors of the central nervous system using positron emission tomography requires the preparation of radiopharmaceuticals labelled with β + emitting isotopes. The chemical and pharmacological properties of these ligands are evaluated. Cyclotron produced 75 and 76 bromine β + emitting isotopes are incorporated into dopaminergic ligands by electrophilic substitution using peracetic acid in a no-carrier added form. Purity, lipophilicity and specific activity are analyzed. Pharmacological criteria (specificity, saturability, displacement, localization) required for ligand-receptor binding studies are evaluated in vitro on striatal membranes and in vivo in the rat. Positron emission tomographic studies show that the study of dopaminergic D2 receptors is possible using 75 and 76 bromine labelled bromospiperone and bromolisuride. These ligands are used in physiological and pharmacological studies of the central nervous system [fr

  19. Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart

    International Nuclear Information System (INIS)

    Delforge, J.; Janier, M.; Syrota, A.; Crouzel, C.; Vallois, J.M.; Cayla, J.; Lancon, J.P.; Mazoyer, B.M.

    1990-01-01

    The in vivo quantification of myocardial muscarinic receptors has been obtained in six closed-chest dogs by using positron emission tomography. The dogs were injected with a trace amount of 11C-labeled methylquinuclidinyl benzilate (MQNB), a nonmetabolized antagonist of the muscarinic receptor. This was followed 30 minutes later by an injection of an excess of unlabeled MQNB (displacement experiment). Two additional injections of unlabeled MQNB with [11C]MQNB and without [11C]MQNB (second displacement experiment) were administered after 70 and 120 minutes, respectively. This protocol allowed a separate evaluation of the quantity of available receptors (B'max) as well as the association and dissociation rate constants (k+1 and k-1) in each dog. The parameters were calculated by using a nonlinear mathematical model in regions of interest over the left ventricle and the interventricular septum. The average value of B'max was 42 +/- 11 pmol/ml tissue, the rate constants k+1, k-1, and Kd were 0.6 +/- 0.1 ml.pmol-1.min-1, 0.27 +/- 0.03 ml.pmol-1.min-1, and 0.49 +/- 0.14 pmol.ml-1, respectively, taking into account the MQNB reaction volume estimated to 0.15 ml/ml tissue. Although [11C]MQNB binding would appear irreversible, our findings indicate that the association of the antagonist is very rapid and that the dissociation is far from negligible. The dissociated ligand, however, has a high probability of rebinding to a free receptor site instead of escaping into the microcirculation. We deduce that the positron emission tomographic images obtained after injecting a trace amount of [11C]MQNB are more representative of blood flow than of receptor density or affinity. We also suggest a simplified protocol consisting of a tracer injection of [11C]MQNB and a second injection of an excess of cold MQNB, which is sufficient to measure B'max and Kd in humans

  20. Positron emission tomography

    International Nuclear Information System (INIS)

    Paans, A.M.J.

    1981-01-01

    Positron emitting radiopharmaceuticals have special applications in in-vivo studies of biochemical processes. The combination of a cyclotron for the production of radionuclides and a positron emission tomograph for the registration of the distribution of radioactivity in the body enables the measurement of local radioactivity concentration in tissues, and opens up new possibilities in the diagnosis and examination of abnormalities in the metabolism. The principles and procedures of positron emission tomography are described and the necessary apparatus considered, with emphasis on the positron camera. The first clinical applications using 55 Co bloemycine for tumor detection are presented. (C.F.)

  1. Positron emission tomography

    NARCIS (Netherlands)

    Paans, AMJ

    Positron Emission Tomography (PET) is a method for determining biochemical and physiological processes in vivo in a quantitative way by using radiopharmaceuticals labelled with positron emitting radionuclides as C-11, N-13, O-15 and F-18 and by measuring the annihilation radiation using a

  2. Elevated Brain Cannabinoid CB1 Receptor Availability in Posttraumatic Stress Disorder: A Positron Emission Tomography Study

    Science.gov (United States)

    Neumeister, Alexander; Normandin, Marc D.; Pietrzak, Robert H.; Piomelli, Daniele; Zheng, Ming-Qiang; Gujarro-Anton, Ana; Potenza, Marc N.; Bailey, Christopher R.; Lin, Shu-fei; Najafzadeh, Soheila; Ropchan, Jim; Henry, Shannan; Corsi-Travali, Stefani; Carson, Richard E.; Huang, Yiyun

    2013-01-01

    Endocannabinoids and their attending cannabinoid type 1 receptor (CB1) have been implicated in animal models of posttraumatic stress disorder (PTSD). However, their specific role has not been studied in people with PTSD. Herein, we present an in vivo imaging study using positron emission tomography (PET) and the CB1-selective radioligand [11C]OMAR in individuals with PTSD, and healthy controls with lifetime histories of trauma (trauma controls [TC]) and those without such histories (healthy controls [HC]). Untreated individuals with PTSD (N=25) with non-combat trauma histories, and TC (N=12) and HC (N=23) participated in a magnetic resonance (MR) imaging scan and a resting PET scan with the CB1 receptor antagonist radiotracer [11C]OMAR, which measures volume of distribution (VT) linearly related to CB1 receptor availability. Peripheral levels of anandamide, 2-arachidonoylglycerol (2-AG), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and cortisol were also assessed. In the PTSD group, relative to the HC and TC groups, we found elevated brain-wide [11C]OMAR VT values (F(2,53)=7.96, p=.001; 19.5% and 14.5% higher, respectively) which were most pronounced in women (F(1,53)=5.52, p=.023). Anandamide concentrations were reduced in the PTSD relative to the TC (53.1% lower) and HC (58.2% lower) groups. Cortisol levels were lower in the PTSD and TC groups relative to the HC group. Three biomarkers examined collectively—OMAR VT, anandamide, and cortisol—correctly classified nearly 85% of PTSD cases. These results suggest that abnormal CB1 receptor-mediated anandamide signaling is implicated in the etiology of PTSD, and provide a promising neurobiological model to develop novel, evidence-based pharmacotherapies for this disorder. PMID:23670490

  3. Positron emission computed tomography

    International Nuclear Information System (INIS)

    Grover, M.; Schelbert, H.R.

    1985-01-01

    Regional mycardial blood flow and substrate metabolism can be non-invasively evaluated and quantified with positron emission computed tomography (Positron-CT). Tracers of exogenous glucose utilization and fatty acid metabolism are available and have been extensively tested. Specific tracer kinetic models have been developed or are being tested so that glucose and fatty acid metabolism can be measured quantitatively by Positron-CT. Tracers of amino acid and oxygen metabolism are utilized in Positron-CT studies of the brain and development of such tracers for cardiac studies are in progress. Methods to quantify regional myocardial blood flow are also being developed. Previous studies have demonstrated the ability of Positron-/CT to document myocardial infarction. Experimental and clinical studies have begun to identify metabolic markers of reversibly ischemic myocardium. The potential of Positron-CT to reliably detect potentially salvageable myocardium and, hence, to identify appropriate therapeutic interventions is one of the most exciting applications of the technique

  4. Positron emission tomography

    International Nuclear Information System (INIS)

    Chandrasekhar, Preethi; Himabindu, Pucha

    2000-01-01

    Positron Emission Tomography (PET) is a non-invasive nuclear imaging technique used to study different molecular pathways and anatomical structures. PET has found extensive applications in various fields of medicine viz. cardiology, oncology, psychiatry/psychology, neuro science and pulmonology. This study paper basically deals with the physics, chemistry and biology behind the PET technique. It discusses the methodology for generation of the radiotracers responsible for emission of positrons and the annihilation and detection techniques. (author)

  5. Positron emission tomography

    International Nuclear Information System (INIS)

    Dvorak, O.

    1989-01-01

    The principle is briefly described of positron emission tomography, and its benefits and constraints are listed. It is emphasized that positron emission tomography (PET) provides valuable information on metabolic changes in the organism that are otherwise only very difficult to obtain, such as brain diagnosis including relationships between mental disorders and the physiology and pathophysiology of the brain. A PET machine is to be installed in Czechoslovakia in the near future. (L.O.)

  6. Positron emission tomography

    International Nuclear Information System (INIS)

    Wienhard, K.; Heiss, W.D.

    1984-01-01

    The principles and selected clinical applications of positron emission tomography are described. In this technique a chemical compound is labeled with a positron emitting isotope and its biochemical pathway is traced by coincidence detection of the two annihilation photons. The application of the techniques of computed tomography allows to reconstruct the spatial distribution of the radioactivity within a subject. The 18 F-deoxyglucose method for quantitative measurement of local glucose metabolism is discussed in order to illustrate the possibilities of positron emission tomography to record physiological processes in vivo. (orig.) [de

  7. Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study.

    Directory of Open Access Journals (Sweden)

    Pontus Plavén-Sigray

    Full Text Available Associations between dopamine receptor levels and pro- and antisocial behavior have previously been demonstrated in human subjects using positron emission tomography (PET and self-rated measures of personality traits. So far, only one study has focused on the dopamine D1-receptor (D1-R, finding a positive correlation with the trait social desirability, which is characterized by low dominant and high affiliative behavior, while physical aggression showed a negative correlation. The aim of the present study was to replicate these previous findings using a new independent sample of subjects.Twenty-six healthy males were examined with the radioligand [11C]SCH-23390, and completed the Swedish universities Scales of Personality (SSP which includes measures of social desirability and physical trait aggression. The simplified reference tissue model with cerebellum as reference region was used to calculate BPND values in the whole striatum and limbic striatum. The two regions were selected since they showed strong association between D1-R availability and personality scores in the previous study. Pearson's correlation coefficients and replication Bayes factors were then employed to assess the replicability and robustness of previous results.There were no significant correlations (all p values > 0.3 between regional BPND values and personality scale scores. Replication Bayes factors showed strong to moderate evidence in favor no relationship between D1-receptor availability and social desirability (striatum BF01 = 12.4; limbic striatum BF01 = 7.2 or physical aggression scale scores (limbic striatum BF01 = 3.3, compared to the original correlations.We could not replicate the previous findings of associations between D1-R availability and either pro- or antisocial behavior as measured using the SSP. Rather, there was evidence in favor of failed replications of associations between BPND and scale scores. Potential reasons for these results are restrictive

  8. Positron emission tomography

    International Nuclear Information System (INIS)

    Yamamoto, Y.L.; Thompson, C.J.; Diksic, M.; Meyer, E.; Feindel, W.H.

    1984-01-01

    One of the most exciting new technologies introduced in the last 10 yr is positron emission tomography (PET). PET provides quantitative, three-dimensional images for the study of specific biochemical and physiological processes in the human body. This approach is analogous to quantitative in-vivo autoradiography but has the added advantage of permitting non-invasive in vivo studies. PET scanning requires a small cyclotron to produce short-lived positron emitting isotopes such as oxygen-15, carbon-11, nitrogen-13 and fluorine-18. Proper radiochemical facilities and advanced computer equipment are also needed. Most important, PET requires a multidisciplinary scientific team of physicists, radiochemists, mathematicians, biochemists and physicians. The most recent trends are reviewed in the imaging technology, radiochemistry, methodology and clinical applications of positron emission tomography. (author)

  9. Positron emission tomography

    International Nuclear Information System (INIS)

    Pavuk, M.

    2003-12-01

    The aim of this project is to provide a simple summary of new trends in positron emission tomography and its basic physical principles. It provides thereby compendious introduction of the trends of the present development in diagnostics using PET systems. A review of available literature was performed. (author)

  10. Positron emission tomography

    CERN Document Server

    Paans, A M J

    2006-01-01

    Positron Emission Tomography (PET) is a method for measuring biochemical and physiological processes in vivo in a quantitative way by using radiopharmaceuticals labelled with positron emitting radionuclides such as 11C, 13N, 15O and 18F and by measuring the annihilation radiation using a coincidence technique. This includes also the measurement of the pharmacokinetics of labelled drugs and the measurement of the effects of drugs on metabolism. Also deviations of normal metabolism can be measured and insight into biological processes responsible for diseases can be obtained. At present the combined PET/CT scanner is the most frequently used scanner for whole-body scanning in the field of oncology.

  11. Tomography by positrons emission

    International Nuclear Information System (INIS)

    Mosconi, Sergio L.

    1999-01-01

    The tomography by positrons emission is a technology that allows to measure the concentration of positrons emission in a tri dimensional body through external measurements. Among the isotope emissions have carbon isotopes are ( 11 C), of the oxygen ( 15 O), of the nitrogen ( 13 N) that are three the element that constitute the base of the organic chemistry. Theses have on of the PET's most important advantages, since many biological interesting organic molecules can be tracer with these isotopes for the metabolism studies 'in vivo' through PET, without using organic tracers that modify the metabolism. The mentioned isotopes, also possess the characteristic of having short lifetime, that constitute on of PET's advantages from the dosimetric point of view. Among 11 C, 15 O, and 13 N, other isotopes that can be obtained of a generator as the 68 Ga and 82 Rb

  12. In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Fuge, Felix; Doleschel, Dennis; Rix, Anne; Gremse, Felix; Lederle, Wiltrud; Kiessling, Fabian [RWTH Aachen University, Department for Experimental Molecular Imaging (ExMI), Medical Faculty, Aachen (Germany); Wessner, Axel [Roche Diagnostics GmbH, R and D RPD Protein Chemistry, Penzberg (Germany); Winz, Oliver; Mottaghy, Felix [University Clinic RWTH Aachen, Clinic for Nuclear Medicine, Aachen (Germany)

    2014-09-09

    Recombinant human erythropoietin (rhuEpo) is used clinically to treat anaemia. However, rhuEpo-treated cancer patients show decreased survival rates and erythropoietin receptor (EpoR) expression has been found in patient tumour tissue. Thus, rhuEpo application might promote EpoR{sup +} tumour progression. We therefore developed the positron emission tomography (PET)-probe {sup 68}Ga-DOTA-rhuEpo and evaluated its performance in EpoR{sup +} A549 non-small-cell lung cancer (NSCLC) xenografts. {sup 68}Ga-DOTA-rhuEpo was generated by coupling DOTA-hydrazide to carbohydrate side-chains of rhuEpo. Biodistribution was determined in tumour-bearing mice 0.5, 3, 6, and 9 h after probe injection. Competition experiments were performed by co-injecting {sup 68}Ga-DOTA-rhuEpo and rhuEpo in five-fold excess. Probe specificity was further evaluated histologically using Epo-Cy5.5 stainings. The blood half-life of {sup 68}Ga-DOTA-rhuEpo was 2.6 h and the unbound fraction was cleared by the liver and kidney. After 6 h, the highest tumour to muscle ratio was reached. The highest {sup 68}Ga-DOTA-rhuEpo accumulation was found in liver (10.06 ± 6.26%ID/ml), followed by bone marrow (1.87 ± 0.53%ID/ml), kidney (1.58 ± 0.39 %ID/ml), and tumour (0.99 ± 0.16%ID/ml). EpoR presence in these organs was histologically confirmed. Competition experiments showed significantly (p < 0.05) lower PET-signals in tumour and bone marrow at 3 and 6 h. {sup 68}Ga-DOTA-rhuEpo shows favourable pharmacokinetic properties and detects EpoR specifically. Therefore, it might become a valuable radiotracer to monitor EpoR status in tumours and support decision-making in anaemia therapy. (orig.)

  13. Positron emission tomography

    International Nuclear Information System (INIS)

    Marchenkov, N.S.

    2000-01-01

    The foundations of the positron emission tomography (PET), widely used for the medical diagnostics, are considered. The brief description of the cyclotron for production of radionuclides, applied in the PET, the target devices for manufacturing the position emitters, the moduli for the radiopharmaceuticals synthesis (RPS) for the PET is presented. The necessity and concept of complete automation of the RPS for the PET are discussed [ru

  14. Positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Lindback, Stig [GEMS PET Systems AB, Uppsala (Sweden)

    1995-07-15

    Positron Emission Tomography (PET) is an advanced nuclear medicine technique used for research at major centres. Unique diagnostic information is obtained from tomographic measurements of the biochemistry and physiology of tissues and organs. In theory, diseases are related to biochemical changes and these can be observed with PET long before any anatomical changes are detectable. In PET the radioactive component is a positron-emitting isotope or 'tracer'. The positrons annihilate with electrons in the body to produce two gamma rays 180° apart; coincidence detection of these gammas provides a very efficient method of determining the spatial distribution of the radioisotope tracer. Because physiological measurements are usually required in a single imaging session, very short-lived isotopes are used to label the tracer molecules; isotope production and labelling is usually carried out in situ. The most commonly used radionuclides are carbon- 11 (half-life 20 minutes), nitrogen-13 (10 minutes), oxygen-15 (2 minutes), and fluorine-18 (110 minutes). A PET system has three major components: - a particle accelerator with targets for production of the positron-emitting isotopes; - chemistry modules for synthesis and labelling of the desired tracers; - and a PET camera for in-vivo measurements of the distribution of the tracer in the body.

  15. Positron emission tomography

    International Nuclear Information System (INIS)

    Lindback, Stig

    1995-01-01

    Positron Emission Tomography (PET) is an advanced nuclear medicine technique used for research at major centres. Unique diagnostic information is obtained from tomographic measurements of the biochemistry and physiology of tissues and organs. In theory, diseases are related to biochemical changes and these can be observed with PET long before any anatomical changes are detectable. In PET the radioactive component is a positron-emitting isotope or 'tracer'. The positrons annihilate with electrons in the body to produce two gamma rays 180° apart; coincidence detection of these gammas provides a very efficient method of determining the spatial distribution of the radioisotope tracer. Because physiological measurements are usually required in a single imaging session, very short-lived isotopes are used to label the tracer molecules; isotope production and labelling is usually carried out in situ. The most commonly used radionuclides are carbon- 11 (half-life 20 minutes), nitrogen-13 (10 minutes), oxygen-15 (2 minutes), and fluorine-18 (110 minutes). A PET system has three major components: - a particle accelerator with targets for production of the positron-emitting isotopes; - chemistry modules for synthesis and labelling of the desired tracers; - and a PET camera for in-vivo measurements of the distribution of the tracer in the body

  16. Positron emission tomography camera

    International Nuclear Information System (INIS)

    Anon.

    1986-01-01

    A positron emission tomography camera having a plurality of detector rings positioned side-by-side or offset by one-half of the detector cross section around a patient area to detect radiation therefrom. Each ring contains a plurality of scintillation detectors which are positioned around an inner circumference with a septum ring extending inwardly from the inner circumference along each outer edge of each ring. An additional septum ring is positioned in the middle of each ring of detectors and parallel to the other septa rings, whereby the inward extent of all the septa rings may be reduced by one-half and the number of detectors required in each ring is reduced. The additional septa reduces the costs of the positron camera and improves its performance

  17. Positron emission tomography camera

    International Nuclear Information System (INIS)

    Anon.

    1987-01-01

    A positron emission tomography camera having a plurality of detector rings positioned side-by-side or offset by one-half of the detector cross section around a patient area to detect radiation therefrom. Each detector ring or offset ring includes a plurality of photomultiplier tubes and a plurality of scintillation crystals are positioned relative to the photomultiplier tubes whereby each tube is responsive to more than one crystal. Each alternate crystal in the ring is offset by one-half or less of the thickness of the crystal such that the staggered crystals are seen by more than one photomultiplier tube. This sharing of crystals and photomultiplier tubes allows identification of the staggered crystal and the use of smaller detectors shared by larger photomultiplier tubes thereby requiring less photomultiplier tubes, creating more scanning slices, providing better data sampling, and reducing the cost of the camera. The offset detector ring geometry reduces the costs of the positron camera and improves its performance

  18. Preclinical studies on [{sup 11}C]MPDX for mapping adenosine A{sub 1} receptors by positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Ishiwata, Kiichi; Kimura, Yuichi; Oda, Keiichi; Kawamura, Kazunori; Ishii, Kenji; Senda, Michio [Tokyo Metropolitan Inst. of Gerontology (Japan). Positron Medical Center; Nariai, Tadashi; Wakabayashi, Shinichi [Tokyo Medical and Dental Univ. (Japan). School of Medicine; Shimada, Junichi [Kyowa Hakko Kogyo Co. Ltd., Tokyo (Japan). Pharmaceutical Research Inst.

    2002-09-01

    In previous in vivo studies with mice, rats and cats, we have demonstrated that [{sup 11}C]MPDX ([1-methyl-{sup 11}C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine) is a potential radioligand for mapping adenosine A{sub 1} receptors of the brain by positron emission tomography (PET). In the present study, we performed a preclinical study. The radiation absorbed-dose by [{sup 11}C]MPDX in humans estimated from the tissue distribution in mice was low enough for clinical use, and the acute toxicity and mutagenicity of MPDX were not found. The monkey brain was clearly visualized by PET with [{sup 11}C]MPDX. We have concluded that [{sup 11}C]MPDX is suitable for mapping adenosine A{sub 1} receptors in the human brain by PET. (author)

  19. Experimental design optimisation: theory and application to estimation of receptor model parameters using dynamic positron emission tomography

    International Nuclear Information System (INIS)

    Delforge, J.; Syrota, A.; Mazoyer, B.M.

    1989-01-01

    General framework and various criteria for experimental design optimisation are presented. The methodology is applied to estimation of receptor-ligand reaction model parameters with dynamic positron emission tomography data. The possibility of improving parameter estimation using a new experimental design combining an injection of the β + -labelled ligand and an injection of the cold ligand is investigated. Numerical simulations predict remarkable improvement in the accuracy of parameter estimates with this new experimental design and particularly the possibility of separate estimations of the association constant (k +1 ) and of receptor density (B' max ) in a single experiment. Simulation predictions are validated using experimental PET data in which parameter uncertainties are reduced by factors ranging from 17 to 1000. (author)

  20. Positron Emission Tomography (PET)

    International Nuclear Information System (INIS)

    Welch, M.J.

    1990-01-01

    Positron emission tomography (PET) assesses biochemical processes in the living subject, producing images of function rather than form. Using PET, physicians are able to obtain not the anatomical information provided by other medical imaging techniques, but pictures of physiological activity. In metaphoric terms, traditional imaging methods supply a map of the body's roadways, its, anatomy; PET shows the traffic along those paths, its biochemistry. This document discusses the principles of PET, the radiopharmaceuticals in PET, PET research, clinical applications of PET, the cost of PET, training of individuals for PET, the role of the United States Department of Energy in PET, and the futures of PET. 22 figs

  1. Positron Emission Tomography (PET)

    Energy Technology Data Exchange (ETDEWEB)

    Welch, M.J.

    1990-01-01

    Positron emission tomography (PET) assesses biochemical processes in the living subject, producing images of function rather than form. Using PET, physicians are able to obtain not the anatomical information provided by other medical imaging techniques, but pictures of physiological activity. In metaphoric terms, traditional imaging methods supply a map of the body's roadways, its, anatomy; PET shows the traffic along those paths, its biochemistry. This document discusses the principles of PET, the radiopharmaceuticals in PET, PET research, clinical applications of PET, the cost of PET, training of individuals for PET, the role of the United States Department of Energy in PET, and the futures of PET. 22 figs.

  2. Positron Emission Tomography (PET)

    Science.gov (United States)

    Welch, M. J.

    1990-01-01

    Positron emission tomography (PET) assesses biochemical processes in the living subject, producing images of function rather than form. Using PET, physicians are able to obtain not the anatomical information provided by other medical imaging techniques, but pictures of physiological activity. In metaphoric terms, traditional imaging methods supply a map of the body's roadways, its, anatomy; PET shows the traffic along those paths, its biochemistry. This document discusses the principles of PET, the radiopharmaceuticals in PET, PET research, clinical applications of PET, the cost of PET, training of individuals for PET, the role of the United States Department of Energy in PET, and the futures of PET.

  3. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride

    International Nuclear Information System (INIS)

    Farde, L.; Wiesel, F.A.; Stone-Elander, S.; Halldin, C.; Nordstroem, A.L.H.; Hall, H.; Sedvall, G.

    1990-01-01

    Several groups have reported increased densities of D2 dopamine receptors in the basal ganglia of schizophrenic brains postmortem. The significance of this finding has been questioned, since an upregulation of receptor number may be a neuronal response to neuroleptic drug treatment. We have used positron emission tomography and [ 11 C]raclopride to examine central D2 dopamine receptor binding in 20 healthy subjects and 18 newly admitted, young, neuroleptic-naive patients with schizophrenia. An in vivo saturation procedure was applied for quantitative determination of D2 dopamine receptor density (Bmax) and affinity (Kd). When the two groups were compared, no significant difference in Bmax or Kd values was found in the putamen or the caudate nucleus. The hypothesis of generally elevated central D2 dopamine receptor densities in schizophrenia was thus not supported by the present findings. In the patients but not in the healthy controls, significantly higher densities were found in the left than in the right putamen but not in the caudate nucleus

  4. Cholinergic Receptor Binding in Alzheimer Disease and Healthy Aging: Assessment In Vivo with Positron Emission Tomography Imaging.

    Science.gov (United States)

    Sultzer, David L; Melrose, Rebecca J; Riskin-Jones, Hannah; Narvaez, Theresa A; Veliz, Joseph; Ando, Timothy K; Juarez, Kevin O; Harwood, Dylan G; Brody, Arthur L; Mandelkern, Mark A

    2017-04-01

    To compare regional nicotinic cholinergic receptor binding in older adults with Alzheimer disease (AD) and healthy older adults in vivo and to assess relationships between receptor binding and clinical symptoms. Using cross-sectional positron emission tomography (PET) neuroimaging and structured clinical assessment, outpatients with mild to moderate AD (N = 24) and healthy older adults without cognitive complaints (C group; N = 22) were studied. PET imaging of α4β2* nicotinic cholinergic receptor binding using 2-[ 18 F]fluoro-3-(2(S)azetidinylmethoxy)pyridine (2FA) and clinical measures of global cognition, attention/processing speed, verbal memory, visuospatial memory, and neuropsychiatric symptoms were used. 2FA binding was lower in the AD group compared with the C group in the medial thalamus, medial temporal cortex, anterior cingulate, insula/opercula, inferior caudate, and brainstem (p healthy older adults, lower receptor binding may be associated with slower processing speed. Cholinergic receptor binding in vivo may reveal links to other key brain changes associated with aging and AD and may provide a potential molecular treatment target. Published by Elsevier Inc.

  5. Development of radiotracers for imaging NR2B subtype NMDA receptors with positron emission tomography; Developpement de radiotraceurs pour la visualisation des recepteurs NMDA de sous-type NR2B par tomographie par emission de positons

    Energy Technology Data Exchange (ETDEWEB)

    Labas, R

    2007-07-01

    The aim of this thesis was to develop new radioactive tracers for imaging NR2B subtype NMDA receptors with positron emission tomography. Several compounds including 4-(4-fluoro-benzyl)piperidine and presenting interesting in vivo biological properties were the object of a labelling with a positrons emitter atom ({sup 11}C or {sup 18}F)

  6. Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography.

    Science.gov (United States)

    Mayberg, H S; Sadzot, B; Meltzer, C C; Fisher, R S; Lesser, R P; Dannals, R F; Lever, J R; Wilson, A A; Ravert, H T; Wagner, H N

    1991-07-01

    Alterations in a variety of neurotransmitter systems have been identified in experimental models of epilepsy and in brain tissue from patients with intractable temporal lobe seizures. The availability of new high-affinity radioligands permits the study of some neuroreceptors in vivo with positron emission tomography (PET). We previously characterized the in vivo binding of 11C-carfentanil, a potent and selective mu opiate receptor agonist, and described increases in 11C-carfentanil binding in the temporal neocortex of patients with unilateral temporal lobe epilepsy. These studies have been extended to 11C-diprenorphine, which labels mu, kappa, and delta opiate receptor subtypes. Paired measurements of opiate receptor binding were performed with PET using 11C-carfentanil and 11C-diprenorphine in patients with unilateral temporal lobe seizures. Carfentanil binding, reflecting changes in mu opiate receptors, was increased in the temporal neocortex and decreased in the amygdala on the side of the epileptic focus. Diprenorphine binding, reflecting mu as well as non-mu opiate subtypes, was not significantly different among regions in the focus and nonfocus temporal lobes. Regional glucose metabolism, measured using 18F-2-fluoro-2-deoxyglucose, was decreased in the mesial and lateral aspects of the temporal lobe ipsilateral to the epileptogenic focus. The variation in pattern of carfentanil and diprenorphine binding supports a differential regulation of opiate subtypes in unilateral temporal lobe epilepsy.

  7. Effects of trihexyphenidyl and L-dopa on brain muscarinic cholinergic receptor binding measured by positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Shinotoh, H; Asahina, M; Hirayama, K [Dept. of Neurology, School of Medicine, Chiba Univ., Chiba (Japan); Inoue, O; Suhara, T; Tateno, Y [Division of Clinical Research, National Inst. of Radiological Sciences, Chiba (Japan)

    1994-01-01

    The effects of pharmacological intervention on brain muscarinic cholinergic receptor (mAChR) binding were assessed in seven patients with Parkinson's disease by positron emission tomography and carbon-11 labelled N-methyl-4-piperidyl benzilate ([[sup 11]C]NMPB). [[sup 11]C]NMPB was injected twice, approximately 2 hours apart, in each patient, to assess the effect of single doses of 4 mg of trihexyphenidyl (n=5) or 400 mg of L-dopa with 57 mg of benserazide (n=2) on the binding parameter of mAChRs (K[sub 3]). There was a mean 28% inhibition of K[sub 3] values in the brain in the presence of trihexyphenidyl, which was assumed to reflect mAChR occupancy. No significant change in K[sub 3] was observed in the presence of L-dopa. This study demonstrates the feasibility of measuring mAChR occupancy by an anticholinergic medication with PET.

  8. Long-term changes of striatal dopamine D-2 receptors in patients with Parkinson's disease : A study with positron emission tomography and [C-11]Raclopride

    NARCIS (Netherlands)

    Antonini, A; Schwarz, J; Oertel, WH; Pogarell, O; Leenders, KL

    We used [C-11]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D-2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug-naive stage and 3-5 years later, when motor fluctuations had appeared in seven of them. Patients were

  9. Positron emission tomography camera

    International Nuclear Information System (INIS)

    Anon.

    1987-01-01

    A positron emission tomography camera having a plurality of detector planes positioned side-by-side around a patient area to detect radiation. Each plane includes a plurality of photomultiplier tubes and at least two rows of scintillation crystals on each photomultiplier tube extend across to adjacent photomultiplier tubes for detecting radiation from the patient area. Each row of crystals on each photomultiplier tube is offset from the other rows of crystals, and the area of each crystal on each tube in each row is different than the area of the crystals on the tube in other rows for detecting which crystal is actuated and allowing the detector to detect more inter-plane slides. The crystals are offset by an amount equal to the length of the crystal divided by the number of rows. The rows of crystals on opposite sides of the patient may be rotated 90 degrees relative to each other

  10. Positron emission tomography. Basic principles

    International Nuclear Information System (INIS)

    Rodriguez, Jose Luis; Massardo, Teresa; Gonzalez, Patricio

    2001-01-01

    The basic principles of positron emission tomography (PET) technique are reviewed. lt allows to obtain functional images from gamma rays produced by annihilation of a positron, a positive beta particle. This paper analyzes positron emitters production in a cyclotron, its general mechanisms, and the various detection systems. The most important clinical applications are also mentioned, related to oncological uses of fluor-l8-deoxyglucose

  11. Synthesis and evaluation of fluorine-18-labeled SA4503 as a selective sigma1 receptor ligand for positron emission tomography

    International Nuclear Information System (INIS)

    Kawamura, Kazunori; Tsukada, Hideo; Shiba, Kazuhiro; Tsuji, Chieko; Harada, Norihiro; Kimura, Yuichi; Ishiwata, Kiichi

    2007-01-01

    The [ 18 F]fluoromethyl analog of the sigma 1 selective ligand 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA4503) ([ 18 F]FM-SA4503) was prepared and its potential evaluated for the in vivo measurement of sigma 1 receptors with positron emission tomography (PET). FM-SA4503 had selective affinity for the sigma 1 receptor ( K i for sigma 1 receptor, 6.4 nM; K i for sigma 2 receptor, 250 nM) that was compatible with the affinity of SA4503 ( K i for sigma 1 receptor, 4.4 nM; K i for sigma 2 receptor, 242 nM). [ 18 F]FM-SA4503 was synthesized by 18 F-fluoromethylation of O-demethyl SA4503 in the radiochemical yield of 2.9-16.6% at the end of bombardment with a specific activity of 37.8-283 TBq/mmol at the end of synthesis. In mice, the uptake of [ 18 F]FM-SA4503 in the brain was gradually increased for 30 min after injection, and then decreased. In the blocking study, brain uptake was significantly decreased by co-injection of haloperidol to 32% of control, and FM-SA4503 to 52% of control. In PET study of the monkey brain, high uptake was found in the cerebral cortex, thalamus and striatum. The radioactivity level of [ 18 F]FM-SA4503 in the brain regions gradually increased over a period of 120 min after injection, followed by a stable plateau phase until 180 min after injection. In pretreatment with haloperidol measurement of the monkey brain, the radioactivity level was 22-32% and 11-25% of the baseline at 60 and 180 min, respectively, after injection, suggesting high receptor-specific binding. [ 18 F]FM-SA4503 showed specific binding to sigma 1 receptors in mice and monkeys; therefore, [ 18 F]FM-SA4503 has the potential for mapping sigma 1 receptors in the brain

  12. Positron emission tomography and migraine

    International Nuclear Information System (INIS)

    Chabriat, H.

    1992-01-01

    Positron emission tomography (PET) is a brain imaging technique that allows in vivo studies of numerous physiological parameters. There have been few PET studies in migraine patients. Cerebral blood flow changes with no variations in brain oxygen consumption have been reported in patients with prolonged neurologic manifestations during migraine attacks. Parenteral administration of reserpine during migraine headache has been followed by a fall in the overall cerebral uptake of glucose. The small sample sizes and a number of methodologic problems complicate the interpretation of these results. Recent technical advances and the development of new PET tracers can be expected to provide further insight into the pathophysiology of migraine. Today cerebral cortex 5 HT 2 serotonin receptors can be studied in migraine patients with PET

  13. Synthesis and evaluation of fluorinated derivatives of fentanyl as candidates for opiate receptor studies using positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Dahren Hwang; Feliu, A.L.; Wolf, A.P.; MacGregor, R.R.; Fowler, J.S.; Arnett, C.D.

    1986-03-01

    Three fluorinated derivatives of fentanyl, fluorofentanyl (3), keto-fluorofentanyl (5), and fluorofentanol (6), were synthesized and their abilities to compete with /sup 3/diprenorphine for binding sites in guinea pig brain membranes were determined. The relative potencies were fentanyl > 3 approx.= 6 >> 5. On the basis of its apparent affinity for opiate receptors and its relative ease of synthesis, 6 was selected for further study. Fentanyl was slightly better than 6 in its ability to compete with (/sup 3/H)naltrexone for binding sites in rat brain membranes. Both fentayl and 6 exhibited a similar high ''sodium ratio'' (quotient of the IC/sub 50/'s against (/sup 3/H)naltrexone in the presence and absence of sodium chloride) generally characteristic of opiate agonists. The analgesic potencies of fentanyl and 6 were determined in rats by measuring suppression of locomotion and vocalization responses to footshock. 6 appeared slightly less potent than fentanyl, but produced a similar analgesia and catalepsy which was entirely blocked by pretreatment of rats with naloxone, an opiate antagonist. A rapid synthesis of (/sup 18/F)-6 was developed and the tissue distribution of (/sup 18/F)-6 in mice was determined 5, 60, and 120 minutes after intravenous injection. The use of this general route to /sup 18/F-labeled derivatives of fentanyl for studies of the opiate receptor using positron emission tomography is planned.

  14. Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol

    International Nuclear Information System (INIS)

    Karbe, H.; Wienhard, K.; Huber, M.; Herholz, K.; Heiss, W.D.; Hamacher, K.; Coenen, H.H.; Stoecklin, G.; Loevenich, A.

    1991-01-01

    Four schizophrenic patients were investigated with dynamic positron emission tomography (PET) using ( 18 F)fluorodeoxyglucose (FDG) and ( 18 F)methylspiperone (MSP) as tracers. Two schizophrenics were on haloperidol therapy at the time of MSP PET. The other two schizophrenics were treated with clozapine, in one of them MSP PET was carried out twice with different daily doses (100 mg and 450mg respectively). Neuroleptic serum levels were measured in all patients. Results were compared with MSP PET of two drugfree male control subjects and with a previous fluoroethylspiperone (FESP) study of normals. Three hours after tracer injection specific binding of MSP was observed in the striatum in all cases. The striatum to cerebellum ratio was used to estimate the degree of neuroleptic-caused striatal D 2 dopamine receptor occupancy. In the haloperidol treated patients MSP binding was significantly decreased, whereas in the clozapine treated patients striatum to cerebellum ratio was normal. Even the increase of clozapine dose in the same patient had no influence on this ratio. Despite the smaller number of patients the study shows for the first time in humans that striatal MSP binding reflects the different D 2 dopamine receptor affinities of clozapine and haloperidol. (authors)

  15. Synthesis and evaluation of fluorinated derivatives of fentanyl as candidates for opiate receptor studies using positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Hwang, Dahren; Feliu, A L; Wolf, A P; MacGregor, R R; Fowler, J S; Arnett, C D

    1986-03-01

    Three fluorinated derivatives of fentanyl, fluorofentanyl (3), keto-fluorofentanyl (5), and fluorofentanol (6), were synthesized and their abilities to compete with /sup 3/diprenorphine for binding sites in guinea pig brain membranes were determined. The relative potencies were fentanyl > 3 approx.= 6 >> 5. On the basis of its apparent affinity for opiate receptors and its relative ease of synthesis, 6 was selected for further study. Fentanyl was slightly better than 6 in its ability to compete with (/sup 3/H)naltrexone for binding sites in rat brain membranes. Both fentayl and 6 exhibited a similar high ''sodium ratio'' (quotient of the IC/sub 50/'s against (/sup 3/H)naltrexone in the presence and absence of sodium chloride) generally characteristic of opiate agonists. The analgesic potencies of fentanyl and 6 were determined in rats by measuring suppression of locomotion and vocalization responses to footshock. 6 appeared slightly less potent than fentanyl, but produced a similar analgesia and catalepsy which was entirely blocked by pretreatment of rats with naloxone, an opiate antagonist. A rapid synthesis of (/sup 18/F)-6 was developed and the tissue distribution of (/sup 18/F)-6 in mice was determined 5, 60, and 120 minutes after intravenous injection. The use of this general route to /sup 18/F-labeled derivatives of fentanyl for studies of the opiate receptor using positron emission tomography is planned.

  16. Synthesis and evaluation of fluorinated derivatives of fentanyl as candidates for opiate receptor studies using positron emission tomography

    International Nuclear Information System (INIS)

    Dahren Hwang; Feliu, A.L.; Wolf, A.P.; MacGregor, R.R.; Fowler, J.S.; Arnett, C.D.

    1986-01-01

    Three fluorinated derivatives of fentanyl, fluorofentanyl (3), keto-fluorofentanyl (5), and fluorofentanol (6), were synthesized and their abilities to compete with 3 diprenorphine for binding sites in guinea pig brain membranes were determined. The relative potencies were fentanyl > 3 approx.= 6 >> 5. On the basis of its apparent affinity for opiate receptors and its relative ease of synthesis, 6 was selected for further study. Fentanyl was slightly better than 6 in its ability to compete with [ 3 H]naltrexone for binding sites in rat brain membranes. Both fentayl and 6 exhibited a similar high ''sodium ratio'' (quotient of the IC 50 's against [ 3 H]naltrexone in the presence and absence of sodium chloride) generally characteristic of opiate agonists. The analgesic potencies of fentanyl and 6 were determined in rats by measuring suppression of locomotion and vocalization responses to footshock. 6 appeared slightly less potent than fentanyl, but produced a similar analgesia and catalepsy which was entirely blocked by pretreatment of rats with naloxone, an opiate antagonist. A rapid synthesis of [ 18 F]-6 was developed and the tissue distribution of [ 18 F]-6 in mice was determined 5, 60, and 120 minutes after intravenous injection. The use of this general route to 18 F-labeled derivatives of fentanyl for studies of the opiate receptor using positron emission tomography is planned. (author)

  17. Beta adrenergic receptors in dog heart characterised in vivo by sup 11 C-CGP 12117 and positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Seto, Mikito [Kanazawa Univ. (Japan). School of Medicine

    1989-06-01

    Beta adrenergic receptors in the dog heart were demonstrated in vivo using a potent antagonist, {sup 11}C-CGP 12117 (Kd=0.2 nmol/kg, in vitro), and positron emission tomography (PET). {sup 11}C-CGP at a high specific radioactivity (approximately 500 Ci/mmol) was intravenously injectd in dogs. Axial transverse slices of the heart were obtained. The concentration of {sup 11}C-CGP 12177 in the myocardium rapidly increased and then remained nearly constant for about 30 minutes, before decreasing slowly. Designing a new method to distinguish specific receptor binding from the total ligand concentration in the heart measured by PET, beta adrenoceptor density in the dog myocardium (Bmax) was found to be 113 pmol/cm{sup 3}. Displacement and pre-saturation studies were performed to demonstrate the specifity of {sup 11}C-CGP 12177 binding for noradrenaline binding sites. The bolus injection of unlabeled CGP 12177 25 min following {sup 11}C-CGP 12177 injection led to a rapid decrease in the myocardial ligand concentration and a rapid fall in the heart rate. Both the pharmacological effect of CGP 12177 and the binding inhibition of radioligand were synchronous with the increasing amount of antagonist injected for displacement. In experiments of presaturation with an excessive dose of unlabeled antagonist injection 10 min before {sup 11}C-CGP 12177 injection, the heart/blood radioligand concentration ratio as a function of time was significantly lower than that in the control study. Thus, specific receptor binding of {sup 11}C-CGP 12177 for noradrenaline binding sites in the living heart was proved by PET, which might be the ideal method to study the physiologically active form of receptors in vivo. (author).

  18. Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography

    International Nuclear Information System (INIS)

    Naganawa, Mika; Kimura, Yuichi; Oda, Keiichi; Ishii, Kenji; Ishiwata, Kiichi; Mishina, Masahiro; Manabe, Yoshitsugu; Chihara, Kunihiro

    2007-01-01

    [7-methyl- 11 C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine ([ 11 C]TMSX) is a positron-emitting adenosine A 2A receptor (A2AR) antagonist for visualisation of A2AR distribution by positron emission tomography (PET). The aims of this paper were to use a kinetic model to analyse the behaviour of [ 11 C]TMSX in the brain and to examine the applicability of the Logan plot. We also studied the applicability of a simplified Logan plot by omitting metabolite correction and arterial blood sampling. The centrum semiovale was used as a reference region on the basis of a post-mortem study showing that it has a negligibly low density of A2ARs. Compartmental analysis was performed in five normal subjects. Parametric images of A2AR binding potential (BP) were also generated using a Logan plot with or without metabolite correction and with or without arterial blood sampling. To omit arterial blood sampling, we applied a method to extract the plasma-related information using independent component analysis (EPICA). The estimated K 1 /k 2 was confirmed to be common in the centrum semiovale and main cortices. The three-compartment model was well fitted to the other regions using the fixed value of K 1 /k 2 estimated from the centrum semiovale. The estimated BPs using the Logan plot matched those derived from compartment analysis. Without the metabolite correction, the estimate of BP underestimated the true value by 5%. The estimated BPs agreed regardless of arterial blood sampling. A three-compartment model with a reference region, the centrum semiovale, describes the kinetic behaviour of [ 11 C]TMSX PET images. A2ARs in the human brain can be visualised as a BP image using [ 11 C]TMSX PET without arterial blood sampling. (orig.)

  19. Positron emission tomography study of pindolol occupancy of 5-HT1A receptors in humans: preliminary analyses

    International Nuclear Information System (INIS)

    Martinez, Diana; Mawlawi, Osama; Hwang, Dah-Ren; Kent, Justine; Simpson, Norman; Parsey, Ramin V.; Hashimoto, Tomoki; Slifstein, Mark; Huang Yiyun; Heertum, Ronald van; Abi-Dargham, Anissa; Caltabiano, Stephen; Malizia, Andrea; Cowley, Hugh; Mann, J. John; Laruelle, Marc

    2000-01-01

    Preclinical studies in rodents suggest that augmentation of serotonin reuptake inhibitors (SSRIs) therapy by the 5-hydroxytryptamine 1A (5-HT 1A ) receptor agent pindolol might reduce the delay between initiation of treatment and antidepressant response. This hypothesis is based on the ability of pindolol to potentiate the increase in serotonin (5-HT) transmission induced by SSRIs, an effect achieved by blockade of the 5-HT 1A autoreceptors in the dorsal raphe nuclei (DRN). However, placebo-controlled clinical studies of pindolol augmentation of antidepressant therapy have reported inconsistent results. Here, we evaluated the occupancy of 5-HT 1A receptors following treatment with controlled release pindolol in nine healthy volunteers with positron-emission tomography (PET). Each subject was studied four times: at baseline (scan 1), following 1 week of oral administration of pindolol CR (7.5 mg/day) at peak level, 4 h after the dose (scan 2), and at 10 h following the dose (scan 3), and following one dose of pindolol CR (30 mg) (at peak level, 4 h) (scan 4). Pindolol occupancy of 5-HT 1A receptors was evaluated in the DRN and cortical regions as the decrease in binding potential (BP) of the radiolabelled selective 5-HT 1A antagonist [carbonyl- 11 C]WAY-100635 or [carbonyl- 11 C] N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl) cyclohexanecarboxamide abbreviated as [ 11 C]WAY-100635. Pindolol dose-dependently decreased [ 11 C]WAY-100635 BP. Combining all the regions, occupancy was 20 ± 8% at scan 2, 14 ± 8% at scan 3, and 44 ± 8% at scan 4. The results of this study suggest that at doses used in clinical studies of augmentation of the SSRI effect by pindolol (2.5 mg t.i.d.), the occupancy of 5-HT 1A receptors is moderate and highly variable between subjects. This factor might explain the variable results obtained in clinical studies. On the other hand, at each dose tested, pindolol occupancy of 5-HT 1A receptors was higher in the DRN compared to

  20. Positron emission tomography imaging studies of dopamine receptors in primate models of addiction

    OpenAIRE

    Nader, Michael A; Czoty, Paul W; Gould, Robert W; Riddick, Natallia V

    2008-01-01

    Animal models have provided valuable information related to trait and state variables associated with vulnerability to drug addiction. Our brain imaging studies in monkeys have implicated D2 receptors in cocaine addiction. For example, an inverse relationship between D2 receptor availability and rates of cocaine self-administration has been documented. Moreover, environmental variables, such as those associated with formation of the social hierarchy, can impact receptor availability and sensi...

  1. Fundamentals of positron emission tomography

    International Nuclear Information System (INIS)

    Ostertag, H.

    1989-01-01

    Positron emission tomography is a modern radionuclide method of measuring physiological quantities or metabolic parameters in vivo. The methods is based on: (1) Radioactive labelling with positron emitters; (2) the coincidence technique for the measurement of the annihilation radiation following positron decay; (3) analysis of the data measured using biological models. The basic aspects and problems of the method are discussed. The main fields of future research are the synthesis of new labelled compounds and the development of mathematical models of the biological processes to be investigated. (orig.) [de

  2. Sex-related differences in the muscarinic acetylcholinergic receptor in the healthy human brain. A positron emission tomography study

    Energy Technology Data Exchange (ETDEWEB)

    Yoshida, Tsuyoshi; Kuwabara, Yasuo; Sasaki, Masayuki; Ichimiya, Atsushi; Takita, Masashi; Ogomori, Koji; Masuda, Kouji [Kyushu Univ., Fukuoka (Japan). Graduate School of Medical Sciences; Fukumura, Toshimitsu; Ichiya, Yuichi

    2000-04-01

    We evaluated the sex-related differences in the decline of the cerebral muscarinic acetylcholinergic receptor (mACh-R) due to aging by using {sup 11}C-N-methyl-4-piperidyl benzilate ({sup 11}C-NMPB) and positron emission tomography (PET). The subjects consisted of 37 (20 males and 17 females) healthy volunteers. The {sup 11}C-NMPB uptake was evaluated by the ratio method (regional {sup 11}C-NMPB uptake/Cerebellar {sup 11}C-NMPB uptake; rNMPB ratio). The correlation between sex, aging, and the rNMPB ratio in normal aging was evaluated by a multiple regression analysis. The rNMPB ratio was higher in females than in males throughout the entire cerebral region (p<0.01-p<0.0001) and the rNMPB ratio might thus possibly decline with age more rapidly in females. Our study therefore revealed the existence of sex-related differences in the cerebral mACh-R. (author)

  3. Sex-related differences in the muscarinic acetylcholinergic receptor in the healthy human brain. A positron emission tomography study

    International Nuclear Information System (INIS)

    Yoshida, Tsuyoshi; Kuwabara, Yasuo; Sasaki, Masayuki; Ichimiya, Atsushi; Takita, Masashi; Ogomori, Koji; Masuda, Kouji; Fukumura, Toshimitsu; Ichiya, Yuichi

    2000-01-01

    We evaluated the sex-related differences in the decline of the cerebral muscarinic acetylcholinergic receptor (mACh-R) due to aging by using 11 C-N-methyl-4-piperidyl benzilate ( 11 C-NMPB) and positron emission tomography (PET). The subjects consisted of 37 (20 males and 17 females) healthy volunteers. The 11 C-NMPB uptake was evaluated by the ratio method (regional 11 C-NMPB uptake/Cerebellar 11 C-NMPB uptake; rNMPB ratio). The correlation between sex, aging, and the rNMPB ratio in normal aging was evaluated by a multiple regression analysis. The rNMPB ratio was higher in females than in males throughout the entire cerebral region (p<0.01-p<0.0001) and the rNMPB ratio might thus possibly decline with age more rapidly in females. Our study therefore revealed the existence of sex-related differences in the cerebral mACh-R. (author)

  4. Instrumentation for positron emission tomography

    International Nuclear Information System (INIS)

    Budinger, T.F.; Derenzo, S.E.; Huesman, R.H.

    1984-01-01

    Positron emission tomography with a spatial resolution of 2 mm full width at half maximum for quantitation in regions of interest 4 mm in diameter will become possible with the development of detectors that achieve ultrahigh resolution. Improved resolution will be possible using solid-state photodetectors for crystal identification or photomultiplier tubes with many small electron multipliers. Temporal resolution of 2 seconds and gating of cyclic events can be accomplished if statistical requirements are met. The major physical considerations in achieving high-resolution positron emission tomography are the degradation in resolution resulting from positron range, emission angle, parallax error, detector sampling density, the sensitivity of various detector materials and packing schemes, and the tradeoff between temporal resolution and statistical accuracy. The accuracy of data required for physiological models depends primarily on the fidelity of spatial sampling independent of statistical constraints

  5. Opiate receptors in idiopathic generalised epilepsy measured with [11C]diprenorphine and positron emission tomography.

    Science.gov (United States)

    Prevett, M C; Cunningham, V J; Brooks, D J; Fish, D R; Duncan, J S

    1994-09-01

    The neurochemical basis of absence seizures is uncertain. A previous PET study has provided evidence for release of endogenous opioids from cerebral cortex at the time of absence seizures, but it is has not yet been established whether there is an abnormality of opiate receptor numbers interictally. In the present study, the non-specific opiate receptor ligand, [11C]diprenorphine, was used to measure cerebral opiate receptors interictally in patients with childhood and juvenile absence epilepsy. Eight patients and eight normal controls had a single scan after a high specific activity injection of [11C]diprenorphine. The cerebral volume of distribution (Vd) of [11C]diprenorphine relative to plasma was calculated on a pixel-by-pixel basis. There were no significant differences in [11C]diprenorphine Vd between patients and control subjects in either cortex or thalamus, structures thought to be involved in the pathogenesis of absence seizures. The results suggest that there is no overall abnormality of opioid receptors in patients with childhood and juvenile absence epilepsy. Studies with specific ligands may provide information about the different receptor subtypes.

  6. Positron emission tomography in oncology

    International Nuclear Information System (INIS)

    Anon.

    1988-01-01

    This report describes the current and potential uses of positron emission tomography in clinical medicine and research related to oncology. Assessment will be possible of metabolism and physiology of tumors and their effects on adjacent tissues. Specific probes are likely to be developed for target sites on tumors, including monoclonal antibodies and specific growth factors that recognize tumors. To date, most oncological applications of positron emission tomography tracers have been qualitative; in the future, quantitative metabolic measurements should aid in the evaluation of tumor biology and response to treatment

  7. NMF on positron emission tomography

    DEFF Research Database (Denmark)

    Bödvarsson, Bjarni; Hansen, Lars Kai; Svarer, Claus

    2007-01-01

    In positron emission tomography, kinetic modelling of brain tracer uptake, metabolism or binding requires knowledge of the cerebral input function. Traditionally, this is achieved with arterial blood sampling in the arm or as shown in (Liptrot, M, et al., 2004) by non-invasive K-means clustering....... We propose another method to estimate time-activity curves (TAC) extracted directly from dynamic positron emission tomography (PET) scans by non-negative matrix factorization (NMF). Since the scaling of the basis curves is lost in the NMF the estimated TAC is scaled by a vector alpha which...

  8. Multicompartmental analysis of (/sup 11/C)-carfentanil binding to opiate receptors in humans measured by positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Frost, J.J.; Douglass, K.H.; Mayberg, H.S.; Dannals, R.F.; Links, J.M.; Wilson, A.A.; Ravert, H.T.; Crozier, W.C.; Wagner, H.N. Jr.

    1989-06-01

    (11C)-Carfentanil is a high affinity opiate agonist that can be used to localize mu opiate receptors in humans by positron emission tomography (PET). A four-compartment model was used to obtain quantitative estimates of rate constants for receptor association and dissociation. PET studies were performed in five normal subjects in the absence and presence of 1 mg/kg naloxone. Arterial plasma concentration of (11C)-carfentanil and its labeled metabolites were determined during each PET study. The value of k3/k4 = Bmax/kD was determined for each subject in the presence and absence of naloxone. There was a significant reduction in the value of k3/k4 from 3.4 +/- 0.92 to 0.26 +/- 0.13 in the thalamus (p less than 0.01) and from 1.8 +/- 0.33 to 0.16 +/- 0.065 in the frontal cortex (p less than 0.001). Mean values of frontal cortex/occipital cortex and thalamus/occipital cortex ratios were determined for the interval 35-70 min after injection when receptor binding is high relative to nonspecific binding. The relationship between the measured region/occipital cortex values and the corresponding values of k3/k4 in the presence and absence of naloxone was: regions/occipital cortex = 0.95 + 0.74 (k3/k4) with r = 0.98 (n = 20). Simulation studies also demonstrated a linear relationship between the thalamus/occipital cortex or frontal cortex/occipital cortex ratio and k3/k4 for less than twofold increases or decreases in k3/k4. Simulation studies in which thalamic blood flow was varied demonstrated no significant effect on the region/occipital cortex ratio at 35-70 min for a twofold increase or fourfold decrease in blood flow. Therefore, the region/occipital cortex ratio can be used to quantitate changes in k3/k4 when tracer kinetic modeling is not feasible.

  9. Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography

    International Nuclear Information System (INIS)

    Frost, J.J.; Douglass, K.H.; Mayberg, H.S.; Dannals, R.F.; Links, J.M.; Wilson, A.A.; Ravert, H.T.; Crozier, W.C.; Wagner, H.N. Jr.

    1989-01-01

    [11C]-Carfentanil is a high affinity opiate agonist that can be used to localize mu opiate receptors in humans by positron emission tomography (PET). A four-compartment model was used to obtain quantitative estimates of rate constants for receptor association and dissociation. PET studies were performed in five normal subjects in the absence and presence of 1 mg/kg naloxone. Arterial plasma concentration of [11C]-carfentanil and its labeled metabolites were determined during each PET study. The value of k3/k4 = Bmax/kD was determined for each subject in the presence and absence of naloxone. There was a significant reduction in the value of k3/k4 from 3.4 +/- 0.92 to 0.26 +/- 0.13 in the thalamus (p less than 0.01) and from 1.8 +/- 0.33 to 0.16 +/- 0.065 in the frontal cortex (p less than 0.001). Mean values of frontal cortex/occipital cortex and thalamus/occipital cortex ratios were determined for the interval 35-70 min after injection when receptor binding is high relative to nonspecific binding. The relationship between the measured region/occipital cortex values and the corresponding values of k3/k4 in the presence and absence of naloxone was: regions/occipital cortex = 0.95 + 0.74 (k3/k4) with r = 0.98 (n = 20). Simulation studies also demonstrated a linear relationship between the thalamus/occipital cortex or frontal cortex/occipital cortex ratio and k3/k4 for less than twofold increases or decreases in k3/k4. Simulation studies in which thalamic blood flow was varied demonstrated no significant effect on the region/occipital cortex ratio at 35-70 min for a twofold increase or fourfold decrease in blood flow. Therefore, the region/occipital cortex ratio can be used to quantitate changes in k3/k4 when tracer kinetic modeling is not feasible

  10. Positron emission tomography in neuropsychology.

    Science.gov (United States)

    Heiss, W D; Herholz, K; Pawlik, G; Wagner, R; Wienhard, K

    1986-01-01

    By positron emission tomography (PET) of 18F-2-fluoro-2-deoxy-D-glucose (FDG) local cerebral metabolic rate for glucose (LCMRGl) can be measured in man. Normal values in cerebral cortex and basal ganglia range from 35 to 50 mumol/100 g/min, the values in gray matter structures of the posterior fossa were 25-30 mumol/100 g/min, the lowest LCMRGl was found in the white matter (15-20 mumol/100 g/min). During sensory stimulation by various modalities functional activation increases LCMRGl in the respective special areas, while sleep decreases metabolic rate in all cortical and basal gray matter structures. In many neurological disorders CMRGl is altered in a disease-specific pattern. In dementia of the Alzheimer type CMRGl is impaired even in early stages with accentuation in the parieto-temporal cortex, while in multi-infarct dementia glucose uptake is mainly reduced in the multifocal small infarcts. In Huntington's chorea the most conspicuous changes are found in the caudate nucleus and putamen. In cases of focal lesions (e.g. ischemic infarcts) metabolic disturbances extend far beyond the site of the primary lesion and inactivation of metabolism is found in intact brain structures far away from the anatomical lesion. Additional applications of PET include determination of the metabolism of various substrates, of protein synthesis, of function and distribution of receptors, of tumor growth and of the distribution of drugs as well as the measurement of oxygen consumption, blood flow and blood volume.

  11. Imaging benzodiazepine receptors in man with C-11-suriclone and positron emission tomography

    International Nuclear Information System (INIS)

    Frost, J.J.; Dannals, R.F.; Ravert, H.T.; Wilson, A.A.; Links, J.M.; Trifiletti, R.; Snyder, S.H.; Wagner, H.N. Jr.

    1985-01-01

    Suriclone is a potent cyclopyrrolone, anti-anxiety drug which binds to the benzodiazepine receptor complex (BZR) with high affinity. Suriclone binds to a site on the BZR distinct from the site where benzodiazepines bind. The K/sub D/ of suriclone at 37oC is 0.03 nM. C-11-suriclone (SUR) was synthesized by reacting C-CH3I with the appropriate amine precursor. SUR (1 μg/kg) was injected IV into a baboon alone or with 1 mg/kg of Ro-151788, a benzodiazepine antagonist, and serial PET scans of the brain were obtained. High radioactivity concentrations were observed in the cerebral cortex and cerebellum which contain high densities of BZR, intermediate concentrations in thalamus and low concentrations in the striatum. When Ro-151788 was given a uniform distribution of radioactivity was observed; the radioactivity was reduced to ca. 25% of control values in the brain which was contained within the PET slice. SUR (0.2 μg/kg) was next administered to a human subject. From 30-60 minutes after injection high radioactivity concentrations were observed in the cerebral cortex and cerebellum, intermediate concentrations in the thalamus and a low concentration in the caudate. Radioactivity in the cerebral cortex and cerebellum decreased slowly with time, implying that binding of SUR to a high affinity site had occurred. These results demonstrate utility of SUR for measuring binding to the benzodiazepine receptor complex non-invasively in man

  12. Positron emission tomography study of pindolol occupancy of 5-HT{sub 1A} receptors in humans: preliminary analyses

    Energy Technology Data Exchange (ETDEWEB)

    Martinez, Diana; Mawlawi, Osama; Hwang, Dah-Ren; Kent, Justine; Simpson, Norman; Parsey, Ramin V.; Hashimoto, Tomoki; Slifstein, Mark; Huang Yiyun; Heertum, Ronald van; Abi-Dargham, Anissa; Caltabiano, Stephen; Malizia, Andrea; Cowley, Hugh; Mann, J. John; Laruelle, Marc

    2000-07-01

    Preclinical studies in rodents suggest that augmentation of serotonin reuptake inhibitors (SSRIs) therapy by the 5-hydroxytryptamine{sub 1A} (5-HT{sub 1A}) receptor agent pindolol might reduce the delay between initiation of treatment and antidepressant response. This hypothesis is based on the ability of pindolol to potentiate the increase in serotonin (5-HT) transmission induced by SSRIs, an effect achieved by blockade of the 5-HT{sub 1A} autoreceptors in the dorsal raphe nuclei (DRN). However, placebo-controlled clinical studies of pindolol augmentation of antidepressant therapy have reported inconsistent results. Here, we evaluated the occupancy of 5-HT{sub 1A} receptors following treatment with controlled release pindolol in nine healthy volunteers with positron-emission tomography (PET). Each subject was studied four times: at baseline (scan 1), following 1 week of oral administration of pindolol CR (7.5 mg/day) at peak level, 4 h after the dose (scan 2), and at 10 h following the dose (scan 3), and following one dose of pindolol CR (30 mg) (at peak level, 4 h) (scan 4). Pindolol occupancy of 5-HT{sub 1A} receptors was evaluated in the DRN and cortical regions as the decrease in binding potential (BP) of the radiolabelled selective 5-HT{sub 1A} antagonist [carbonyl-{sup 11}C]WAY-100635 or [carbonyl-{sup 11}C] N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl) cyclohexanecarboxamide abbreviated as [{sup 11}C]WAY-100635. Pindolol dose-dependently decreased [{sup 11}C]WAY-100635 BP. Combining all the regions, occupancy was 20 {+-} 8% at scan 2, 14 {+-} 8% at scan 3, and 44 {+-} 8% at scan 4. The results of this study suggest that at doses used in clinical studies of augmentation of the SSRI effect by pindolol (2.5 mg t.i.d.), the occupancy of 5-HT{sub 1A} receptors is moderate and highly variable between subjects. This factor might explain the variable results obtained in clinical studies. On the other hand, at each dose tested, pindolol occupancy of 5

  13. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.

    Science.gov (United States)

    Searle, Graham; Beaver, John D; Comley, Robert A; Bani, Massimo; Tziortzi, Andri; Slifstein, Mark; Mugnaini, Manolo; Griffante, Cristiana; Wilson, Alan A; Merlo-Pich, Emilio; Houle, Sylvain; Gunn, Roger; Rabiner, Eugenii A; Laruelle, Marc

    2010-08-15

    Dopamine D(3) receptors are involved in the pathophysiology of several neuropsychiatric conditions. [(11)C]-(+)-PHNO is a radiolabeled D(2) and D(3) agonist, suitable for imaging the agonist binding sites (denoted D(2HIGH) and D(3)) of these receptors with positron emission tomography (PET). PET studies in nonhuman primates documented that, in vivo, [(11)C]-(+)-PHNO displays a relative selectivity for D(3) compared with D(2HIGH) receptor sites and that the [(11)C]-(+)-PHNO signal is enriched in D(3) contribution compared with conventional ligands such as [(11)C] raclopride. To define the D(3) contribution (f(PHNO)(D3)) to [(11)C]-(+)-PHNO binding potential (BP(ND)) in healthy humans, 52 PET scans were obtained in 19 healthy volunteers at baseline and following oral administration of various doses of the selective D(3) receptor antagonist, GSK598809. The impact of GSK598809 on [(11)C]-(+)-PHNO was regionally selective. In dorsal regions of the striatum, GSK598809 did not significantly affect [(11)C]-(+)-PHNO BP(ND) (f(PHNO)(D3) approximately 0%). Conversely, in the substantia nigra, GSK598809 dose-dependently reduced [(11)C]-(+)-PHNO binding to nonspecific level (f(PHNO)(D3) approximately 100%). In ventral striatum (VST), globus pallidus and thalamus (THA), [(11)C]-(+)-PHNO BP(ND) was attributable to a combination of D(2HIGH) and D(3) receptor sites, with f(PHNO)(D3) of 26%, 67% and 46%, respectively. D(3) receptor binding potential (BP(ND)(D3)) was highest in globus pallidus (1.90) and substantial nigra (1.39), with lower levels in VST (.77) and THA (.18) and negligible levels in dorsal striatum. This study elucidated the pharmacologic nature of the [(11)C]-(+)-PHNO signal in healthy subjects and provided the first quantification of D(3) receptor availability with PET in the living human brain. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

  14. Positron emission tomography quantification of serotonin(1A) receptor binding in suicide attempters with major depressive disorder.

    Science.gov (United States)

    Sullivan, Gregory M; Oquendo, Maria A; Milak, Matthew; Miller, Jeffrey M; Burke, Ainsley; Ogden, R Todd; Parsey, Ramin V; Mann, J John

    2015-02-01

    Serotonergic system dysfunction has been associated with increased lethal suicide attempts and suicide. Dysfunction includes higher binding of serotonin(1A) autoreceptor in the brainstem raphe of individuals who die by suicide. To determine the relationships between brain serotonin(1A) binding and suicidal behavior in vivo in major depressive disorder (MDD) using positron emission tomography and the serotonin(1A) antagonist radiotracer carbon C 11 [11C]-labeled WAY-100635. Cross-sectional positron emission tomography study at an academic medical center from 1999 through 2009. We compared serotonin(1A) binding between individuals with MDD who did not attempt suicide (nonattempters) (n = 62) and those who attempted suicide (attempters) (n = 29). We subdivided the attempters into those with lower (n = 16) and higher (n = 13) levels of lethality. The binding potential (BPF) of [11C]WAY-100635 (calculated as the number of receptors available divided by affinity) in the prefrontal cortex (PFC) and brainstem, estimated by kinetic modeling with an arterial input function; the severity of suicidal behaviors, including lethality and intent of suicide attempts; and suicidal ideation. Using a linear mixed-effects model, we found no difference between attempters and nonattempters with MDD in serotonin(1A) BPF in the PFC regions (F1,88 = 0.03; P = .87) or in the raphe nuclei (F1,88 = 0.29; P = .59). Raphe nuclei serotonin(1A) BPF was 45.1% greater in higher-lethality attempters compared with lower-lethality attempters (F1,25 = 7.33; P = .01), whereas no difference was observed in the PFC regions (F1,25 = 0.12; P = .73). Serotonin(1A )BPF in the raphe nuclei of suicide attempters was positively correlated with the lethality rating (F1,25 = 10.56; P = .003) and the subjective lethal intent factor (F1,25 = 10.63; P = .003; R2 = 0.32) based on the most recent suicide attempt. Suicide ideation in participants with

  15. Positron Emission Tomography Quantification of Serotonin1A Receptor Binding in Suicide Attempters With Major Depressive Disorder

    Science.gov (United States)

    Sullivan, Gregory M.; Oquendo, Maria A.; Milak, Matthew; Miller, Jeffrey M.; Burke, Ainsley; Ogden, R. Todd; Parsey, Ramin V.; Mann, J. John

    2015-01-01

    IMPORTANCE Serotonergic system dysfunction has been associated with increased lethal suicide attempts and suicide. Dysfunction includes higher binding of serotonin1A autoreceptor in the brainstem raphe of individuals who die by suicide. OBJECTIVES To determine the relationships between brain serotonin1A binding and suicidal behavior in vivo in major depressive disorder (MDD) using positron emission tomography and the serotonin1A antagonist radiotracer carbon C 11 [11C]–labeled WAY-100635. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional positron emission tomography study at an academic medical center from 1999 through 2009. We compared serotonin1A binding between individuals with MDD who did not attempt suicide (nonattempters) (n = 62) and those who attempted suicide (attempters) (n = 29). We subdivided the attempters into those with lower (n = 16) and higher (n = 13) levels of lethality. MAIN OUTCOMES AND MEASURES The binding potential (BPF) of [11C]WAY-100635 (calculated as the number of receptors available divided by affinity) in the prefrontal cortex (PFC) and brainstem, estimated by kinetic modeling with an arterial input function; the severity of suicidal behaviors, including lethality and intent of suicide attempts; and suicidal ideation. RESULTS Using a linear mixed-effects model, we found no difference between attempters and nonattempters with MDD in serotonin1A BPF in the PFC regions (F1,88 = 0.03; P = .87) or in the raphe nuclei (F1,88 = 0.29; P = .59). Raphe nuclei serotonin1A BPF was 45.1% greater in higher-lethality attempters compared with lower-lethality attempters (F1,25 = 7.33; P = .01), whereas no difference was observed in the PFC regions (F1,25 = 0.12; P = .73). Serotonin1A BPF in the raphe nuclei of suicide attempters was positively correlated with the lethality rating (F1,25 = 10.56; P = .003) and the subjective lethal intent factor (F1,25 = 10.63; P = .003; R2 = 0.32) based on the most recent suicide attempt. Suicide ideation in

  16. 5-HT(1A) receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-(11)C]WAY-100635.

    Science.gov (United States)

    Sargent, Peter A; Rabiner, Eugenii A; Bhagwagar, Zubin; Clark, Luke; Cowen, Philip; Goodwin, Guy M; Grasby, Paul M

    2010-06-01

    This study was undertaken to examine whether brain 5-HT(1A) receptor binding is reduced in euthymic bipolar patients. Eight medicated euthymic bipolar patients and 8 healthy volunteers underwent positron emission tomography scanning using the selective 5-HT(1A) receptor radioligand [carbonyl-(11)C]WAY-100635. No significant difference in global postsynaptic parametric binding potential (BP(ND)) was found between euthymic bipolar patients (mean + or - SD, 4.24 + or - 0.76) and healthy volunteers (mean + or - SD, 4.34 + or - 0.86). Ninety five percent Confidence Intervals for the difference in group mean global postsynaptic BP(ND) were -0.77 to 0.97. Analysis of regional BP(ND) did not reveal regional differences between patients and healthy controls. The number of subjects studied was limited and all subjects were on medication. In contrast to previous findings of reduced 5-HT(1A) receptor binding in untreated unipolar and bipolar depressed patients [Sargent, P.A., Kjaer, K.H., Bench, C.J., Rabiner, E.A., Messa, C., Meyer, J., Gunn, R.N., Grasby, P.M., Cowen, P.J., 2000. Brain serotonin1A receptor binding measured by positron emission tomography with [(11)C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 57, 174-180]; [Drevets, W.C., Frank, E., Price, J.C., Kupfer, D.J., Holt, D., Greer, P.J., Huang, Y., Gautier, C., Mathis, C., 1999. PET imaging of serotonin1A receptor binding in depression. Biol. Psychiatry 46, 1375-1387] and in recovered unipolar depressed patients [Bhagwagar, Z., Rabiner, E.A., Sargent, P.A., Grasby, P.M., Cowen, P.J., 2004. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [(11)C]WAY-100635. Mol. Psychiatry 9, 386-92], this study found no difference in 5-HT(1A) receptor BP(ND) between medicated euthymic bipolar patients and healthy controls. Normal 5-HT(1A) receptor BP(ND) in these patients may be a result of drug treatment or

  17. Quantitative analysis of adenosine A1 receptors in human brain using positron emission tomography and [1 -methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine

    International Nuclear Information System (INIS)

    Kimura, Yuichi; Ishii, Kenji; Fukumitsu, Nobuyoshi; Oda, Keiichi; Sasaki, Toru; Kawamura, Kazunori; Ishiwata, Kiichi

    2004-01-01

    Fully quantitative analysis of the adenosine A 1 receptor (A1R) in the brain with 11 C-MPDX and positron emission tomography is reported. The kinetics is described using a two-tissue three-compartment model, and estimated binding potentials correspond well with the estimates made by Logan plot. The image of the binding potential of the MPDX is physiologically reasonable. We conclude that MPDX is applicable to the visualization of the A1Rs in the brain with Logan plot

  18. Adenosine A1 receptors in human sleep regulation studied by electroencephalography (EEG) and positron emission tomography (PET)

    International Nuclear Information System (INIS)

    Geissler, E.

    2007-01-01

    Sleep is an essential physiological process. However, the functions of sleep and the endogenous mechanisms involved in sleep regulation are only partially understood. Convergent lines of evidence support the hypothesis that the build-up of sleep propensity during wakefulness and its decline during sleep are associated with alterations in brain adenosine levels and adenosine receptor concentrations. The non-selective A 1 and A 2A adenosine receptor antagonist caffeine stimulates alertness and is known to attenuate changes in the waking and sleep electroencephalogram (EEG) typically observed after prolonged waking. Several findings point to an important function of the adenosine A 1 receptor (A 1 AR) in the modulation of vigilance states. The A 1 AR is densely expressed in brain regions involved in sleep regulation, and pharmacological manipulations affecting the A 1 AR were shown to influence sleep propensity and sleep depth. However, an involvement of the A 2A adenosine receptor (A 2A AR) is also assumed. The distinct functions of the A 1 and A 2A receptor subtypes in sleep-wake regulation and in mediating the effects of caffeine have not been identified so far. The selective adenosine A 1 receptor antagonist, 8-cyclopentyl-3-(3- 18 Ffluoropropyl)- 1-propylxanthine ( 18 F-CPFPX), offers the opportunity to get further insights into adenosinergic mechanisms by in vivo imaging of the A 1 AR subtype with positron emission tomography (PET). The aim of this thesis was to elucidate the role of adenosine A 1 receptors in human sleep regulation, combining 18 F-CPFPX PET brain imaging and EEG recordings, the gold standard in sleep research. It was hypothesized that sleep deprivation would induce adenosine accumulation and/or changes in A 1 AR density. Thus, the question was addressed whether these effects of prolonged wakefulness can be visualized by altered 18 F-CPFPX binding. Moreover, it was investigated whether radioligand uptake might be influenced by caffeine, since

  19. Positron emission tomography takes lead

    International Nuclear Information System (INIS)

    Simms, R.

    1989-01-01

    Positron emission tomography (PET)'s ability to detect functional abnormalities before they manifest anatomically is examined and some of its most common applications are outlined. It is emphasised that when PET facility and Australian Nuclear Science and Technology Organization's national cyclotron are established at the Royal Prince Alfred Hospital, the availability of short-lived tracers such as oxygen 15, nitrogen 13 and fluorine 18 would improve the specificity of tests(e.g. for brain tumors or cardiac viability) further. Construction of the cyclotron will start shortly and is due to be completed and operating by the end of 1991

  20. Specific in vivo binding in the rat brain of [18F]RP 62203: A selective 5-HT2A receptor radioligand for positron emission tomography

    International Nuclear Information System (INIS)

    Besret, Laurent; Dauphin, Francois; Huard, Cecile; Lasne, Marie-Claire; Vivet, Richard; Mickala, Patrick; Barbelivien, Alexandra; Baron, Jean-Claude

    1996-01-01

    In vivo pharmacokinetic and brain binding characteristics of [ 18 F]RP 62203, a selective high-affinity serotonergic 5-HT 2A receptor antagonist, were assessed in the rat following intravenous injection of trace amount of the radioligand. The radioactive distribution profile observed in the brain 60 min after injection was characterized by greater than fourfold higher uptake in neocortex as compared to cerebellum (0.38 ± 0.07% injected dose/g, % ID/g and 0.08 ± 0.01 ID/g, respectively), consistent with in vivo specific binding to the 5-HT 2A receptor. Furthermore, specific [ 18 F]RP 62203 binding significantly correlated with the reported in vitro distribution of 5-HT 2A receptors, but not with known concentration profiles of dopaminergic D 2 or adrenergic α 1 receptors. Finally, detectable specific binding was abolished by pretreatment with large doses of ritanserin, a selective 5-HT 2A antagonist, which resulted in uniform uptakes across cortical, striatal and cerebellar tissues. Thus, [ 18 F]RP 62203 appears to be a promising selective tool to visualize and quantify 5-HT 2A brain receptors in vivo with positron emission tomography

  1. An in vivo study of the dopaminergic receptors in the brain of man using 11C-pimozide and positron emission tomography

    International Nuclear Information System (INIS)

    Baron, J.C.; Comar, D.; Crouzel, C.; Mestelan, G.; Zarifian, E.; Loo, H.; Agid, Y.

    1982-09-01

    Positron emission tomography was used to establish the regional cerebral pharmacokinetics of a carbon 11-labelled neuroleptic, pimozide, in an attempt to observe its specific bonding to dopaminergic receptors in vivo. The 11 C-pimozide kinetics were compared in two brain structures at the two ends of the dopaminergic receptor density scale: the striatum and cerebellum, very rich in and devoid of these receptors respectively. In 8 patients a significant radioactivity uptake was observed in the striatum as compared with the cerebellum, in agreement with in vivo studies on animals using tritiated pimozide. In 5 patients pre-treated by a therapeutic dose of a cold neuroleptic (haloperidol) this difference in kinetics no longer existed. Moreover no kinetic difference is observed, either before or after haloperidol administration, between the frontal cortex (relatively low in dopaminergic receptors) and cerebellum. These results strongly suggest that pharmacokinetic phenomena directly related to the specific bonding of 11 C-pimozide on the striatal dopaminergic receptors are observable on man in vivo. This specific bonding however remains quantitatively weak as compared with the strong non-specific bonding

  2. Positron emission tomography of the heart

    International Nuclear Information System (INIS)

    Budinger, T.F.; Yano, Y.; Mathis, C.A.; Moyer, B.R.; Huesman, R.H.; Derenzo, S.E.

    1983-01-01

    Positron emission tomography (PET) offers the opportunity to noninvasively measure heart muscle blood perfusion, oxygen utilization, metabolism of fatty acids, sugars and amino acids. This paper reviews physiological principles which are basic to PET instrumentation for imaging the heart and gives examples of the application of positron emission tomography for measuring myocardial flow and metabolism. 33 references, 11 figures, 1 table

  3. Positron emission tomography tracers for imaging angiogenesis

    International Nuclear Information System (INIS)

    Haubner, Roland; Beer, Ambros J.; Wang, Hui; Chen, Xiaoyuan

    2010-01-01

    Position emission tomography imaging of angiogenesis may provide non-invasive insights into the corresponding molecular processes and may be applied for individualized treatment planning of antiangiogenic therapies. At the moment, most strategies are focusing on the development of radiolabelled proteins and antibody formats targeting VEGF and its receptor or the ED-B domain of a fibronectin isoform as well as radiolabelled matrix metalloproteinase inhibitors or α v β 3 integrin antagonists. Great efforts are being made to develop suitable tracers for different target structures. All of the major strategies focusing on the development of radiolabelled compounds for use with positron emission tomography are summarized in this review. However, because the most intensive work is concentrated on the development of radiolabelled RGD peptides for imaging α v β 3 expression, which has successfully made its way from bench to bedside, these developments are especially emphasized. (orig.)

  4. Improved positron emission tomography camera

    International Nuclear Information System (INIS)

    Mullani, N.A.

    1986-01-01

    A positron emission tomography camera having a plurality of rings of detectors positioned side-by-side or offset by one-half of the detector cross section around a patient area to detect radiation therefrom, and a plurality of scintillation crystals positioned relative to the photomultiplier tubes whereby each tube is responsive to more than one crystal. Each alternate crystal in the ring may be offset by one-half or less of the thickness of the crystal such that the staggered crystals are seen by more than one photomultiplier tube. This sharing of crystals and photomultiplier tubes allows identification of the staggered crystal and the use of smaller detectors shared by larger photomultiplier tubes thereby requiring less photomultiplier tubes, creating more scanning slices, providing better data sampling, and reducing the cost of the camera. (author)

  5. Positron emission tomography basic sciences

    CERN Document Server

    Townsend, D W; Valk, P E; Maisey, M N

    2003-01-01

    Essential for students, science and medical graduates who want to understand the basic science of Positron Emission Tomography (PET), this book describes the physics, chemistry, technology and overview of the clinical uses behind the science of PET and the imaging techniques it uses. In recent years, PET has moved from high-end research imaging tool used by the highly specialized to an essential component of clinical evaluation in the clinic, especially in cancer management. Previously being the realm of scientists, this book explains PET instrumentation, radiochemistry, PET data acquisition and image formation, integration of structural and functional images, radiation dosimetry and protection, and applications in dedicated areas such as drug development, oncology, and gene expression imaging. The technologist, the science, engineering or chemistry graduate seeking further detailed information about PET, or the medical advanced trainee wishing to gain insight into the basic science of PET will find this book...

  6. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil.

    Science.gov (United States)

    Heinz, Andreas; Reimold, Matthias; Wrase, Jana; Hermann, Derik; Croissant, Bernhard; Mundle, Götz; Dohmen, Bernhard M; Braus, Dieter F; Braus, Dieter H; Schumann, Gunter; Machulla, Hans-Jürgen; Bares, Roland; Mann, Karl

    2005-01-01

    The pleasant effects of food and alcohol intake are partially mediated by mu-opiate receptors in the ventral striatum, a central area of the brain reward system. Blockade of mu-opiate receptors with naltrexone reduces the relapse risk among some but not all alcoholic individuals. To test the hypothesis that alcohol craving is pronounced among alcoholic individuals with a high availability of mu-opiate receptors in the brain reward system. Patients and comparison sample. The availability of central mu-opiate receptors was measured in vivo with positron emission tomography (PET) and the radioligand carbon 11-labeled carfentanil in the ventral striatum and compared with the severity of alcohol craving as assessed by the Obsessive Compulsive Drinking Scale (OCDS). Hospitalized care. Volunteer sample of 25 male alcohol-dependent inpatients assessed after detoxification of whom 12 underwent PET again 5 weeks later. Control group of 10 healthy men. After 1 to 3 weeks of abstinence, the availability of mu-opiate receptors in the ventral striatum, including the nucleus accumbens, was significantly elevated in alcoholic patients compared with healthy controls and remained elevated when 12 alcoholic patients had these levels measured 5 weeks later (P<.05 corrected for multiple testing). Higher availability of mu-opiate receptors in this brain area correlated significantly with the intensity of alcohol craving as assessed by the OCDS. Abstinent alcoholic patients displayed an increase in mu-opiate receptors in the ventral striatum, including the nucleus accumbens, which correlated with the severity of alcohol craving. These findings point to a neuronal correlate of alcohol urges.

  7. N-(3-( sup 18 F)fluoropropyl)-N-nordiprenorphine: Synthesis and characterization of a new agent for imaging opioid receptors with positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Chesis, P.L.; Hwang, D.R.; Welch, M.J. (Washington Univ. School of Medicine, St. Louis, MO (USA))

    1990-05-01

    A series of N-fluoroalkyl (1-5) and N-alkyl (6-8) analogues of the high-affinity opioid receptor antagonist diprenorphine (9) has been synthesized and evaluated with in vitro binding assays. Three of the N-fluoroalkyl compounds were prepared with the positron-emitting radionuclide {sup 18}F (1a, 2a, 5a), and their biodistribution was determined in rats. Compounds 2a and 5a were made by using a two-step labeling procedure, ({sup 18}F)fluoride displacement of an iodoalkyl triflate followed by N-alkylation, that required 2 h and proceeded in 4-6% overall radiochemical yield at the end of synthesis. The effective specific activity of compounds 2a and 5a, determined by competitive receptor binding assay, was 840-1820 Ci/mmol. Compound 1a was made by the same two-step procedure, with the bromoalkyl triflate, in 0.3-0.6% radiochemical yield at an effective specific activity of 106-264 Ci/mmol. Specificity of binding in vivo was measured as the percent injected dose/gram of striatal tissue divided by the percent injected dose/gram of cerebellar tissue. The best striatum to cerebellum ratio (3.32 +/- 0.74 at 30 min) was achieved with N-(3-({sup 18}F)-fluoropropyl)-N-nordiprenorphine (2a, ({sup 18}F)FPND). The high specific binding demonstrated by this compound indicates that it may be useful for in vivo imaging of opioid receptors with positron emission tomography.

  8. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.

    Science.gov (United States)

    Sako, Takeo; Hasegawa, Koki; Nishimura, Mie; Kanayama, Yousuke; Wada, Yasuhiro; Hayashinaka, Emi; Cui, Yilong; Kataoka, Yosky; Senda, Michio; Watanabe, Yasuyoshi

    2013-12-06

    Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia, and the loss or dysfunction of pancreatic beta cells has been reported before the appearance of clinical symptoms and hyperglycemia. To evaluate beta cell mass (BCM) for improving the detection and treatment of DM at earlier stages, we focused on somatostatin receptors that are highly expressed in the pancreatic beta cells, and developed a positron emission tomography (PET) probe derived from octreotide, a metabolically stable somatostatin analog. Octreotide was conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), a chelating agent, and labeled with (68)Gallium ((68)Ga). After intravenous injection of (68)Ga-DOTA-octreotide, a 90-min emission scan of the abdomen was performed in normal and DM model rats. The PET studies showed that (68)Ga-DOTA-octreotide radioactivity was highly accumulated in the pancreas of normal rats and that the pancreatic accumulation was significantly reduced in the rats administered with an excess amount of unlabeled octreotide or after treatment with streptozotocin, which was used for the chemical induction of DM in rats. These results were in good agreement with the ex vivo biodistribution data. These results indicated that the pancreatic accumulation of (68)Ga-DOTA-octreotide represented specific binding to the somatostatin receptors and reflected BCM. Therefore, PET imaging with (68)Ga-DOTA-octreotide could be a potential tool for evaluating BCM. Copyright © 2013 Elsevier Inc. All rights reserved.

  9. Positron emission tomography imaging--technical considerations

    International Nuclear Information System (INIS)

    Muehllehner, G.; Karp, J.S.

    1986-01-01

    Positron imaging instrumentation has improved rapidly in the last few years. Scanners currently under development are beginning to approach fundamental limits set by positron range and noncolinearity effects. This report reviews the latest developments in positron emission tomography (PET) instrumentation, emphasizing the development of coding schemes that reduce the complexity and cost of high-resolution scanners. The relative benefits of using time-of-flight (TOF) information is discussed as well. 68 references

  10. Positron emission tomography in oncology

    International Nuclear Information System (INIS)

    Lecomte, R.; Bentourkia, M.; Benard, F.

    2002-01-01

    Positron Emission Tomography is a sophisticated molecular imaging technique, using a special scanner, that displays the functional status of tissues in the body at the cellular level (their metabolism). It is a diagnostic scan that provides the physician with information not available with traditional anatomic studies such as CT or MRI. PET can detect changes in cell function (disease) long before they are evident as physical (anatomic) changes seen on CT or MRI. In this way PET can add important information about many diseases allowing the physician to make a diagnosis often much earlier than with anatomic imaging techniques such as CT or MRI alone. In addition, in cases where an abnormality is noted on CT or MRI, PET can help differentiate benign changes from changes due to disease. PET scanning also typically images the entire body, unlike CT/MRI which is usually broken up into specific limited body section scans. All cells use glucose as an energy source but cancer cells use much more since they are growing much faster and out of control. This is the basis of imaging with F-18 FDG glucose, the radiotracer agent use in a PET oncology study. The abnormal, accelerated glucose used by cancer cells is detected by the PET scanner that processes the emissions from the F-18 FDG glucose by abnormally high levels of metabolism (tumor)

  11. Scintillators for positron emission tomography

    International Nuclear Information System (INIS)

    Moses, W.W.; Derenzo, S.E.

    1995-09-01

    Like most applications that utilize scintillators for gamma detection, Positron Emission Tomography (PET) desires materials with high light output, short decay time, and excellent stopping power that are also inexpensive, mechanically rugged, and chemically inert. Realizing that this ''ultimate'' scintillator may not exist, this paper evaluates the relative importance of these qualities and describes their impact on the imaging performance of PET. The most important PET scintillator quality is the ability to absorb 511 keV photons in a small volume, which affects the spatial resolution of the camera. The dominant factor is a short attenuation length (≤ 1.5 cm is required), although a high photoelectric fraction is also important (> 30% is desired). The next most important quality is a short decay time, which affects both the dead time and the coincidence timing resolution. Detection rates for single 511 keV photons can be extremely high, so decay times ≤ 500 ns are essential to avoid dead time losses. In addition, positron annihilations are identified by time coincidence so ≤5 ns fwhm coincidence pair timing resolution is required to identify events with narrow coincidence windows, reducing contamination due to accidental coincidences. Current trends in PET cameras are toward septaless, ''fully-3D'' cameras, which have significantly higher count rates than conventional 2-D cameras and so place higher demands on scintillator decay time. Light output affects energy resolution, and thus the ability of the camera to identify and reject events where the initial 511 keV photon has undergone Compton scatter in the patient. The scatter to true event fraction is much higher in fully-3D cameras than in 2-D cameras, so future PET cameras would benefit from scintillators with a 511 keV energy resolution < 10--12% fwhm

  12. The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study.

    Science.gov (United States)

    Mendez, Maria Andreina; Horder, Jamie; Myers, Jim; Coghlan, Suzanne; Stokes, Paul; Erritzoe, David; Howes, Oliver; Lingford-Hughes, Anne; Murphy, Declan; Nutt, David

    2013-05-01

    GABA (gamma-amino-butyric-acid) is the primary inhibitory neurotransmitter in the human brain. It has been proposed that the symptoms of autism spectrum disorders (ASDs) are the result of deficient GABA neurotransmission, possibly including reduced expression of GABAA receptors. However, this hypothesis has not been directly tested in living adults with ASD. In this preliminary investigation, we used Positron Emission Tomography (PET) with the benzodiazepine receptor PET ligand [(11)C]Ro15-4513 to measure α1 and α5 subtypes of the GABAA receptor levels in the brain of three adult males with well-characterized high-functioning ASD compared with three healthy matched volunteers. We found significantly lower [(11)C]Ro15-4513 binding throughout the brain of participants with ASD (p < 0.0001) compared with controls. Planned region of interest analyses also revealed significant reductions in two limbic brain regions, namely the amygdala and nucleus accumbens bilaterally. Further analysis suggested that these results were driven by lower levels of the GABAA α5 subtype. These results provide initial evidence of a GABAA α5 deficit in ASD and support further investigations of the GABA system in this disorder. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'. Copyright © 2012 Elsevier Ltd. All rights reserved.

  13. Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.

    Science.gov (United States)

    Kang, Jee In; Park, Hae-Jeong; Kim, Se Joo; Kim, Kyung Ran; Lee, Su Young; Lee, Eun; An, Suk Kyoon; Kwon, Jun Soo; Lee, Jong Doo

    2014-05-01

    Altered transmission of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter, may contribute to the development of schizophrenia. The purpose of the present study was to investigate the presence of GABA-A/benzodiazepine (BZ) receptor binding abnormalities in individuals at ultra-high risk (UHR) for psychosis in comparison with normal controls using [(18)F]-fluoroflumazenil (FFMZ) positron emission tomography (PET). In particular, we set regions of interest in the striatum (caudate, putamen, and nucleus accumbens) and medial temporal area (hippocampus and parahippocampal gyrus). Eleven BZ-naive people at UHR and 15 normal controls underwent PET scanning using [(18)F]-FFMZ to measure GABA-A/BZ receptor binding potential. The regional group differences between UHR individuals and normal controls were analyzed using Statistical Parametric Mapping 8 software. Participants were evaluated using the structured interview for prodromal syndromes and neurocognitive function tasks. People at UHR demonstrated significantly reduced binding potential of GABA-A/BZ receptors in the right caudate. Altered GABAergic transmission and/or the imbalance of inhibitory and excitatory systems in the striatum may be present at the putative prodromal stage and play a pivotal role in the pathophysiology of psychosis.

  14. Positron emission tomography in drug development

    International Nuclear Information System (INIS)

    Rubin, R. H.; Fischman, A. J.

    1997-01-01

    There are four kinds of measurements that can be carried out with positron emission tomography (PET) that can contribute significantly to the process of drug development: pharmacodynamic measurement of tissue metabolism influenced by a given drug; precise measurements of tissue blood flow; tissue pharmacokinetics of a given drug following administration of a particular dose; and the temporal course of ligand-receptor interaction. One or more of these measurements can greatly improve the decision making involved in determining the appropriate dose of a drug, the clinical situations in which a drug might be useful, and the linkage of pharmacokinetics with pharmacodynamics, which is at the heart of effective drug development. The greater the potential of a particular compound as a therapeutic agent, the greater the potential for PET to contribute to the drug development process

  15. Synthesis and evaluation of fluorine-18-labeled SA4503 as a selective sigma{sub 1} receptor ligand for positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Kawamura, Kazunori [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo 173-0022 (Japan) and Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata, Niigata, Niigata 951-8585 (Japan)]. E-mail: kawamurak@bri.niigata-u.ac.jp; Tsukada, Hideo [Central Research Laboratory, Hamamatsu Photonics, K.K., Hamamatsu, Shizuoka 434-8601 (Japan); Shiba, Kazuhiro [Advanced Science Research Center, Kanazawa University, Kanazawa, Ishikawa 920-8640 (Japan); Tsuji, Chieko [NARD Institute, Ltd., Amagasaki, Hyogo 660-0805 (Japan); Harada, Norihiro [Central Research Laboratory, Hamamatsu Photonics, K.K., Hamamatsu, Shizuoka 434-8601 (Japan); Kimura, Yuichi [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo 173-0022 (Japan); Ishiwata, Kiichi [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo 173-0022 (Japan)

    2007-07-15

    The [{sup 18}F]fluoromethyl analog of the sigma{sub 1} selective ligand 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA4503) ([{sup 18}F]FM-SA4503) was prepared and its potential evaluated for the in vivo measurement of sigma{sub 1} receptors with positron emission tomography (PET). FM-SA4503 had selective affinity for the sigma{sub 1} receptor ( K {sub i} for sigma{sub 1} receptor, 6.4 nM; K {sub i} for sigma{sub 2} receptor, 250 nM) that was compatible with the affinity of SA4503 ( K {sub i} for sigma{sub 1} receptor, 4.4 nM; K {sub i} for sigma{sub 2} receptor, 242 nM). [{sup 18}F]FM-SA4503 was synthesized by {sup 18}F-fluoromethylation of O-demethyl SA4503 in the radiochemical yield of 2.9-16.6% at the end of bombardment with a specific activity of 37.8-283 TBq/mmol at the end of synthesis. In mice, the uptake of [{sup 18}F]FM-SA4503 in the brain was gradually increased for 30 min after injection, and then decreased. In the blocking study, brain uptake was significantly decreased by co-injection of haloperidol to 32% of control, and FM-SA4503 to 52% of control. In PET study of the monkey brain, high uptake was found in the cerebral cortex, thalamus and striatum. The radioactivity level of [{sup 18}F]FM-SA4503 in the brain regions gradually increased over a period of 120 min after injection, followed by a stable plateau phase until 180 min after injection. In pretreatment with haloperidol measurement of the monkey brain, the radioactivity level was 22-32% and 11-25% of the baseline at 60 and 180 min, respectively, after injection, suggesting high receptor-specific binding. [{sup 18}F]FM-SA4503 showed specific binding to sigma{sub 1} receptors in mice and monkeys; therefore, [{sup 18}F]FM-SA4503 has the potential for mapping sigma{sub 1} receptors in the brain.

  16. Positron emission tomography in epilepsy

    International Nuclear Information System (INIS)

    Hosokawa, Shinichi; Kato, Motohiro; Otsuka, Makoto; Kuwabara, Yasuo; Ichiya, Yuichi; Goto, Ikuo

    1989-01-01

    Positron emission tomography (PET) was performed with the 18 F-fluoro-deoxy-glucose method on 29 patients with epilepsy (generalized epilepsy, 4; partial epilepsy, 24; undetermined type, 1). The subjects were restricted to patients with epilepsy without focal abnormality on X-CT. All the patients with generalized epilepsy showed a normal pattern on PET. Fourteen out of the 24 patients with partial epilepsy and the 1 with epilepsy of undermined type showed focal hypometabolism on PET. The hypometabolic zone was localized in areas including the temporal cortex in 11 patients, frontal in 2 and thalamus in 1. The location of hypometabolic zone and that of interictal paroxysmal activity on EEG were well correlated in most patients. The patients with poorly-controlled seizure showed a higher incidence of PET abnormality (12 out of 13) than those with well-controlled seizures (2 out of 11). The incidence of abnormality on PET and MRI and the location of both abnormality were not necessarily coincident. These results indicated that the PET examination in epilepsy provides valuable information about the location of epileptic focus, and that the findings on PET in patients with partial epilepsy may be one of the good indicators about the intractability of partial epilepsy, and that PET and MRI provide complementary information in the diagnosis of epilepsy. (author)

  17. Radiopharmaceutical chemistry for positron emission tomography

    NARCIS (Netherlands)

    Elsinga, PH

    Radiopharmaceutical chemistry includes the selection, preparation, and preclinical evaluation of radiolabeled compounds. This paper describes selection criteria for candidates for positron emission tomography (PET) investigations. Practical aspects of nucleophilic and electrophilic

  18. The metabolism of the human brain studied with positron emission tomography

    International Nuclear Information System (INIS)

    Greitz, T.; Ingvar, D.H.; Widen, L.

    1985-01-01

    This volume presents coverage of the use of positron emission tomography (PET) to study the human brain. The contributors assess new developments in high-resolution positron emission tomography, cyclotrons, radiochemistry, and tracer kinetic models, and explore the use of PET in brain energy metabolism, blood flow, and protein synthesis measurements, receptor analysis, and pH determinations, In addition, they discuss the relevance and applications of positron emission tomography from the perspectives of physiology, neurology, and psychiatry

  19. Preparation and biodistribution in mice of ( sup 11 C)carfentanil; A radiopharmaceutical for studying brain. mu. -opioid receptors by positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Saji, Hideo; Tsutsumi, Daisuke; Iida, Yasuhiko; Yokoyama, Akira (Kyoto Univ. (Japan). Faculty of Pharmaceutical Science); Magata, Yasuhiro; Konishi, Junji

    1992-02-01

    A potent {mu}-opioid agonist, ({sup 11}C)carfentanil, was prepared by the methylation of carfentanil carboxylic acid with ({sup 11}C)methyl iodide in order to study brain {mu}-opioid receptors by positron emission tomography. Synthesis (including purification) was completed within 25 min and the radiochemical yield was approximately 40%. The radiochemical purity of the product was more than 99% and its specific activity was 3.7-7.4 GBq/{mu}mol. Biodistribution studies performed in mice after intravenous injection showed a high brain uptake and rapid blood clearance, so a high brain/blood ratio of 1.5-1.8 was found from 5 to 30 min. Regional cerebral distribution studies in the mouse showed a significantly higher uptake of ({sup 11}C)carfentanil by the thalamus and striatum than by the cerebellum, with the radioactivity in the striatum disappearing more rapidly than that in the thalamus. Treatment with naloxone significantly reduced the uptake of ({sup 11}C)carfentanil by the thalamus and striatum. These results indicate that ({sup 11}C)carfentanil binds specifically to brain {mu}-opioid receptors. (author).

  20. Positron emission tomography with ( sup 18 F)methylspiperone demonstrates D sub 2 dopamine receptor binding differences of clozapine and haloperidol

    Energy Technology Data Exchange (ETDEWEB)

    Karbe, H; Wienhard, K; Huber, M; Herholz, K; Heiss, W D [Klinik fuer Neurologie, Univ. of Koeln, Koeln (Germany); Hamacher, K; Coenen, H H; Stoecklin, G [Inst. fuer Chemie 1, Forschungszentrum Juelich Gmbh (Germany); Loevenich, A [Klinik fuer Psychiatrie, Univ. of Koeln, Koeln (Germany)

    1991-01-01

    Four schizophrenic patients were investigated with dynamic positron emission tomography (PET) using ({sup 18}F)fluorodeoxyglucose (FDG) and ({sup 18}F)methylspiperone (MSP) as tracers. Two schizophrenics were on haloperidol therapy at the time of MSP PET. The other two schizophrenics were treated with clozapine, in one of them MSP PET was carried out twice with different daily doses (100 mg and 450mg respectively). Neuroleptic serum levels were measured in all patients. Results were compared with MSP PET of two drugfree male control subjects and with a previous fluoroethylspiperone (FESP) study of normals. Three hours after tracer injection specific binding of MSP was observed in the striatum in all cases. The striatum to cerebellum ratio was used to estimate the degree of neuroleptic-caused striatal D{sub 2} dopamine receptor occupancy. In the haloperidol treated patients MSP binding was significantly decreased, whereas in the clozapine treated patients striatum to cerebellum ratio was normal. Even the increase of clozapine dose in the same patient had no influence on this ratio. Despite the smaller number of patients the study shows for the first time in humans that striatal MSP binding reflects the different D{sub 2} dopamine receptor affinities of clozapine and haloperidol. (authors).

  1. Striatal adenosine A2A receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [18F]-MRS5425

    International Nuclear Information System (INIS)

    Bhattacharjee, Abesh Kumar; Lang Lixin; Jacobson, Orit; Shinkre, Bidhan; Ma Ying; Niu Gang; Trenkle, William C.; Jacobson, Kenneth A.; Chen Xiaoyuan; Kiesewetter, Dale O.

    2011-01-01

    Introduction: A 2A receptors are expressed in the basal ganglia, specifically in striatopallidal GABAergic neurons in the striatum (caudate-putamen). This brain region undergoes degeneration of presynaptic dopamine projections and depletion of dopamine in Parkinson's disease. We developed an 18 F-labeled A 2A analog radiotracer ([ 18 F]-MRS5425) for A 2A receptor imaging using positron emission tomography (PET). We hypothesized that this tracer could image A 2A receptor changes in the rat model for Parkinson's disease, which is created following unilateral injection of the monoaminergic toxin 6-hydroxydopamine (6-OHDA) into the substantia nigra. Methods: [ 18 F]-MRS5425 was injected intravenously in anesthetized rats, and PET imaging data were collected. Image-derived percentage injected doses per gram (%ID/g) in regions of interest was measured in the striatum of normal rats and in rats unilaterally lesioned with 6-OHDA after intravenous administration of saline (baseline), D 2 agonist quinpirole (1.0 mg/kg) or D 2 antagonist raclopride (6.0 mg/kg). Results: Baseline %ID/g reached a maximum at 90 s and maintained plateau for 3.5 min, and then declined slowly thereafter. In 6-OHDA-lesioned rats, %ID/g was significantly higher in the lesioned side compared to the intact side, and the baseline total %ID/g (data from both hemispheres were combined) was significantly higher compared to quinpirole stimulation starting from 4.5 min until the end of acquisition at 30 min. Raclopride did not produce any change in uptake compared to baseline or between the hemispheres. Conclusion: Thus, increase of A 2A receptor-mediated uptake of radioactive MRS5425 could be a superior molecular target for Parkinson's imaging.

  2. Striatal adenosine A{sub 2A} receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [{sup 18}F]-MRS5425

    Energy Technology Data Exchange (ETDEWEB)

    Bhattacharjee, Abesh Kumar; Lang Lixin; Jacobson, Orit [Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892 (United States); Shinkre, Bidhan [Chemical Biology Unit, Laboratory of Cell Biochemistry and Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 (United States); Ma Ying [Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892 (United States); Niu Gang [Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892 (United States); Department of Radiology and Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 (United States); Trenkle, William C. [Chemical Biology Unit, Laboratory of Cell Biochemistry and Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 (United States); Jacobson, Kenneth A. [Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 (United States); Chen Xiaoyuan [Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892 (United States); Kiesewetter, Dale O., E-mail: dk7k@nih.gov [Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892 (United States)

    2011-08-15

    Introduction: A{sub 2A} receptors are expressed in the basal ganglia, specifically in striatopallidal GABAergic neurons in the striatum (caudate-putamen). This brain region undergoes degeneration of presynaptic dopamine projections and depletion of dopamine in Parkinson's disease. We developed an {sup 18}F-labeled A{sub 2A} analog radiotracer ([{sup 18}F]-MRS5425) for A{sub 2A} receptor imaging using positron emission tomography (PET). We hypothesized that this tracer could image A{sub 2A} receptor changes in the rat model for Parkinson's disease, which is created following unilateral injection of the monoaminergic toxin 6-hydroxydopamine (6-OHDA) into the substantia nigra. Methods: [{sup 18}F]-MRS5425 was injected intravenously in anesthetized rats, and PET imaging data were collected. Image-derived percentage injected doses per gram (%ID/g) in regions of interest was measured in the striatum of normal rats and in rats unilaterally lesioned with 6-OHDA after intravenous administration of saline (baseline), D{sub 2} agonist quinpirole (1.0 mg/kg) or D{sub 2} antagonist raclopride (6.0 mg/kg). Results: Baseline %ID/g reached a maximum at 90 s and maintained plateau for 3.5 min, and then declined slowly thereafter. In 6-OHDA-lesioned rats, %ID/g was significantly higher in the lesioned side compared to the intact side, and the baseline total %ID/g (data from both hemispheres were combined) was significantly higher compared to quinpirole stimulation starting from 4.5 min until the end of acquisition at 30 min. Raclopride did not produce any change in uptake compared to baseline or between the hemispheres. Conclusion: Thus, increase of A{sub 2A} receptor-mediated uptake of radioactive MRS5425 could be a superior molecular target for Parkinson's imaging.

  3. New Possibilities of Positron-Emission Tomography

    Science.gov (United States)

    Volobuev, A. N.

    2018-01-01

    The reasons for the emergence of the angular distribution of photons generated as a result of annihilation of an electron and a positron in a positron-emission tomograph are investigated. It is shown that the angular distribution of the radiation intensity (i.e., the probability of photon emission at different angles) is a consequence of the Doppler effect in the center-of-mass reference system of the electron and the positron. In the reference frame attached to the electron, the angular distribution of the number of emitted photons does not exists but is replaced by the Doppler shift of the frequency of photons. The results obtained in this study make it possible to extend the potentialities of the positron-emission tomograph in the diagnostics of diseases and to obtain additional mechanical characteristics of human tissues, such as density and viscosity.

  4. Quantification of adenosine A{sub 2A} receptors in the human brain using [{sup 11}C]TMSX and positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Naganawa, Mika [Tokyo Metropolitan Institute of Gerontology, Positron Medical Center, Tokyo (Japan); Japan Society for the Promotion of Science, Tokyo (Japan); Kimura, Yuichi; Oda, Keiichi; Ishii, Kenji; Ishiwata, Kiichi [Tokyo Metropolitan Institute of Gerontology, Positron Medical Center, Tokyo (Japan); Mishina, Masahiro [Nippon Medical School Chiba-Hokusoh Hospital, Neurological Institute, Chiba (Japan); Manabe, Yoshitsugu; Chihara, Kunihiro [Nara Institute of Science and Technology, Graduate School of Information Science, Nara (Japan)

    2007-05-15

    [7-methyl-{sup 11}C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine ([{sup 11}C]TMSX) is a positron-emitting adenosine A{sub 2A} receptor (A2AR) antagonist for visualisation of A2AR distribution by positron emission tomography (PET). The aims of this paper were to use a kinetic model to analyse the behaviour of [{sup 11}C]TMSX in the brain and to examine the applicability of the Logan plot. We also studied the applicability of a simplified Logan plot by omitting metabolite correction and arterial blood sampling. The centrum semiovale was used as a reference region on the basis of a post-mortem study showing that it has a negligibly low density of A2ARs. Compartmental analysis was performed in five normal subjects. Parametric images of A2AR binding potential (BP) were also generated using a Logan plot with or without metabolite correction and with or without arterial blood sampling. To omit arterial blood sampling, we applied a method to extract the plasma-related information using independent component analysis (EPICA). The estimated K{sub 1}/k{sub 2} was confirmed to be common in the centrum semiovale and main cortices. The three-compartment model was well fitted to the other regions using the fixed value of K{sub 1}/k{sub 2} estimated from the centrum semiovale. The estimated BPs using the Logan plot matched those derived from compartment analysis. Without the metabolite correction, the estimate of BP underestimated the true value by 5%. The estimated BPs agreed regardless of arterial blood sampling. A three-compartment model with a reference region, the centrum semiovale, describes the kinetic behaviour of [{sup 11}C]TMSX PET images. A2ARs in the human brain can be visualised as a BP image using [{sup 11}C]TMSX PET without arterial blood sampling. (orig.)

  5. Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography.

    Science.gov (United States)

    Wegner, Florian; Wilke, Florian; Raab, Peter; Tayeb, Said Ben; Boeck, Anna-Lena; Haense, Cathleen; Trebst, Corinna; Voss, Elke; Schrader, Christoph; Logemann, Frank; Ahrens, Jörg; Leffler, Andreas; Rodriguez-Raecke, Rea; Dengler, Reinhard; Geworski, Lilli; Bengel, Frank M; Berding, Georg; Stangel, Martin; Nabavi, Elham

    2014-06-20

    Pathogenic autoantibodies targeting the recently identified leucine rich glioma inactivated 1 protein and the subunit 1 of the N-methyl-D-aspartate receptor induce autoimmune encephalitis. A comparison of brain metabolic patterns in 18F-fluoro-2-deoxy-d-glucose positron emission tomography of anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis patients has not been performed yet and shall be helpful in differentiating these two most common forms of autoimmune encephalitis. The brain 18F-fluoro-2-deoxy-d-glucose uptake from whole-body positron emission tomography of six anti-N-methyl-D-aspartate receptor encephalitis patients and four patients with anti-leucine rich glioma inactivated 1 protein encephalitis admitted to Hannover Medical School between 2008 and 2012 was retrospectively analyzed and compared to matched controls. Group analysis of anti-N-methyl-D-aspartate encephalitis patients demonstrated regionally limited hypermetabolism in frontotemporal areas contrasting an extensive hypometabolism in parietal lobes, whereas the anti-leucine rich glioma inactivated 1 protein syndrome was characterized by hypermetabolism in cerebellar, basal ganglia, occipital and precentral areas and minor frontomesial hypometabolism. This retrospective 18F-fluoro-2-deoxy-d-glucose positron emission tomography study provides novel evidence for distinct brain metabolic patterns in patients with anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis.

  6. Positron emission tomography with Positome, 2

    International Nuclear Information System (INIS)

    Nukui, Hideaki; Yamamoto, Y.L.; Thompson, C.J.; Feindel, W.

    1979-01-01

    Positron emission tomography with Positome II using 68 Ga-EDTA was performed in cases with brain tumor and cerebral arteriovenous malformation. A significant focal uptake in static study and hemodynamic changes in dynamic study were noted in all cases except one case with intracranial lipoma. Comparing this method with sup(99m) Tc-pertechnetate cerebral image study and computerized axial tomography, the diagnostic rate for detecting brain tumor was almost equal in all of these three methods. However, detecting and localizing was easier and clearer in static positron emission tomography with 68 Ga-EDTA than in sup(99m) Tc-pertechnetate cerebral image and computerized axial tomography without infusion of contrast medium. Furthermore, static positron emission tomography with 68 Ga-EDTA was superior to computerized axial tomography without infusion of contrast medium for detecting cerebral arteriovenous malformation. Concerning dynamic positron emission tomography with 68 Ga-EDTA, semiquantitative values obtained by this method correlated well with findings of computerized axial tomography and was thought to be more precise and in detail than the findings of sup(99m) Tc-pertechnetate cerebral image study. Summation of the previous studies about dynamic positron emission tomography with 77 Kr in occlusive cerebrovascular disease is also reported. In conclusion, static positron emission tomography with 68 Ga-EDTA is a very useful diagnostic method for detecting and localizing brain tumor and cerebral arteriovenous malformation without any attendant complications. Furthermore, a good combination of static and dynamic positron emission tomography and computerized axial tomography appear to be outstandingly effective for not only detecting the lesion but also understanding the pathophysiological aspect in cases with various intracranial lesions. (author)

  7. Quantification of human opiate receptor concentration and affinity using high and low specific activity ( sup 11 C)diprenorphine and positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Sadzot, B.; Price, J.C.; Mayberg, H.S.; Douglass, K.H.; Dannals, R.F.; Lever, J.R.; Ravert, H.T.; Wilson, A.A.; Wagner, H.N. Jr.; Feldman, M.A. (Johns Hopkins Medical Institutions, Baltimore, MD (USA))

    1991-03-01

    (11C)Diprenorphine, a weak partial opiate agonist, and positron emission tomography were used to obtain noninvasive regional estimates of opiate receptor concentration (Bmax) and affinity (Kd) in human brain. Different compartmental models and fitting strategies were compared statistically to establish the most reliable method of parameter estimation. Paired studies were performed in six normal subjects using high (769-5,920 Ci/mmol) and low (27-80 Ci/mmol) specific activity (SA) (11C)diprenorphine. Two subjects were studied a third time using high SA (11C)diprenorphine after a pretreatment with 1-1.5 mg/kg of the opiate antagonist naloxone. After the plasma radioactivity was corrected for metabolites, the brain data were analyzed using a three-compartment model and nonlinear least-squares curve fitting. Linear differential equations were used to describe the high SA (low receptor occupancy) kinetics. The k3/k4 ratio varied from 1.0 +/- 0.2 (occipital cortex) to 8.6 +/- 1.6 (thalamus). Nonlinear differential equations were used to describe the low SA (high receptor occupancy) kinetics and the curve fits provided the konf2 product. The measured free fraction of (11C)diprenorphine in plasma (f1) was 0.30 +/- 0.03, the average K1/k2 ratio from the two naloxone studies was 1.1 +/- 0.2, and the calculated free fraction of (11C)diprenorphine in the brain (f2) was 0.3. Using the paired SA studies, the estimated kinetic parameters, and f2, separate estimates of Bmax and Kd were obtained. Bmax varied from 2.3 +/- 0.5 (occipital cortex) to 20.6 +/- 7.3 (cingulate cortex) nM. The average Kd (eight brain regions) was 0.85 +/- 0.17 nM.

  8. Positron-molecule interactions and corresponding positron attachment to molecules. As a basis for positron emission tomography (PET)

    International Nuclear Information System (INIS)

    Tachikawa, Masanori; Kimura, Mineo; Pichl, Lukas

    2007-01-01

    Through positron and electron interactions, they annihilate emitting primarily two gamma rays with 180-degree opposite directions. Positron spectroscopy using the characteristics of these gamma rays has been employed for analyzing various properties of material as well as for positron emission tomography (PET). However, its fundamental physics of positron-electron interactions and resulting features of emitting gamma rays are not well understood. By obtaining better understanding of positron interactions, it should become possible to provide the firm bases for positron spectroscopy in finer accuracy and quality. Here, we propose a significant mechanism for positron annihilation through positron attachment process, which may help increase the quality of positron spectroscopy. (author)

  9. Biodistribution and radiation dosimetry of a positron emission tomographic ligand, 18F-SP203, to image metabotropic glutamate subtype 5 receptors in humans

    International Nuclear Information System (INIS)

    Kimura, Yasuyuki; Simeon, Fabrice G.; Pike, Victor W.; Innis, Robert B.; Fujita, Masahiro; Hatazawa, Jun; Mozley, P.D.

    2010-01-01

    A new PET ligand, 3-fluoro-5-(2-(2- 18 F-(fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ( 18 F-SP203), is a positron emission tomographic radioligand selective for metabotropic glutamate subtype 5 receptors. The purposes of this study were to estimate the radiation-absorbed doses of 18 F-SP203 in humans and to determine from the distribution of radioactivity in bone structures with various proportions of bone and red marrow whether 18 F-SP203 undergoes defluorination. Whole-body images were acquired for 5 h after injecting 18 F-SP203 in seven healthy humans. Urine was collected at various time points. Radiation-absorbed doses were estimated by the Medical Internal Radiation Dose scheme. After injecting 18 F-SP203, the two organs with highest radiation exposure were urinary bladder wall and gallbladder wall, consistent with both urinary and fecal excretion. In the skeleton, most of the radioactivity was in bone structures that contain red marrow and not in those without red marrow. Although the dose to red marrow (30.9 μSv/MBq) was unusually high, the effective dose (17.8 μSv/MBq) of 18 F-SP203 was typical of that of other 18 F radiotracers. 18 F-SP203 causes an effective dose in humans typical of several other 18 F radioligands and undergoes little defluorination. (orig.)

  10. [11C]-MeJDTic: a novel radioligand for κ-opioid receptor positron emission tomography imaging

    International Nuclear Information System (INIS)

    Poisnel, Geraldine; Oueslati, Farhana; Dhilly, Martine; Delamare, Jerome; Perrio, Cecile; Debruyne, Daniele; Barre, Louisa

    2008-01-01

    Introduction: Radiopharmaceuticals that can bind selectively the κ-opioid receptor may present opportunities for staging clinical brain disorders and evaluating the efficiency of new therapies related to stroke, neurodegenerative diseases or opiate addiction. The N-methylated derivative of JDTic (named MeJDTic), which has been recently described as a potent and selective antagonist of κ-opioid receptor in vitro, was labeled with carbon-11 and evaluated for in vivo imaging the κ-opioid receptor in mice. Methods: [ 11 C]-MeJDTic was prepared by methylation of JDTic with [ 11 C]-methyl triflate. The binding of [ 11 C]-MeJDTic to κ-opioid receptor was investigated ex vivo by biodistribution and competition studies using nonfasted male CD1 mice. Results: [ 11 C]-MeJDTic exhibited a high and rapid distribution in peripheral organs. The uptake was maximal in lung where the κ receptor is largely expressed. [ 11 C]-MeJDTic rapidly crossed the blood-brain barrier and accumulated in the brain regions of interest (hypothalamus). The parent ligand remained the major radioactive compound in brain during the experiment. Chase studies with U50,488 (a κ referring agonist), morphine (a μ agonist) and naltrindole (a δ antagonist) demonstrated that this uptake was the result of specific binding to the κ-opioid receptor. Conclusion: These findings suggested that [ 11 C]-MeJDTic appeared to be a promising selective 'lead' radioligand for κ-opioid receptor PET imaging

  11. Evaluation of 4-[(18)F]fluorobenzoyl-FALGEA-NH(2) as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer

    DEFF Research Database (Denmark)

    Denholt, Charlotte Lund; Binderup, Tina; Stockhausen, Marie-Thérése

    2011-01-01

    This study describes the radiosynthesis, in vitro and in vivo evaluation of the novel small peptide radioligand, 4-[(18)F]fluorobenzoyl-Phe-Ala-Leu-Gly-Glu-Ala-NH(2,) ([(18)F]FBA-FALGEA-NH(2)) as a positron emission tomography (PET) tracer for imaging of the cancer specific epidermal growth facto...

  12. Decreased cerebral {alpha}4{beta}2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Kendziorra, Kai; Meyer, Philipp Mael; Barthel, Henryk; Hesse, Swen; Becker, Georg Alexander; Luthardt, Julia; Schildan, Andreas; Patt, Marianne; Sorger, Dietlind; Seese, Anita; Sabri, Osama [University of Leipzig, Department of Nuclear Medicine, Leipzig (Germany); Wolf, Henrike [University of Leipzig, Department of Psychiatry, Leipzig (Germany); University of Zurich, Department of Old Age Psychiatry and Psychiatry Research, Psychiatric University Hospital (PUK) Zurich, Zurich (Switzerland); Gertz, Herman-Josef [University of Leipzig, Department of Psychiatry, Leipzig (Germany)

    2011-03-15

    Postmortem studies indicate a loss of nicotinic acetylcholine receptor (nAChRs) in Alzheimer's disease (AD). In order to establish whether these changes in the cholinergic system occur at an early stage of AD, we carried out positron emission tomography (PET) with a specific radioligand for the {alpha}4{beta}2* nicotinic acetylcholine receptor ({alpha}4{beta}2* nAChR) in patients with mild to moderate AD and in patients with amnestic mild cognitive impairment (MCI), who have a high risk to progress to AD. Nine patients with moderate AD, eight patients with MCI and seven age-matched healthy controls underwent 2-[{sup 18}F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[{sup 18}F]FA-85380) PET. After coregistration with individual magnetic resonance imaging the binding potential (BP{sub ND}) of 2-[{sup 18}F]FA-85380 was calculated using either the corpus callosum or the cerebellum as reference regions. PET data were analysed by region of interest analysis and by voxel-based analysis. Both patients with AD and MCI showed a significant reduction in 2-[{sup 18}F]FA-85380 BP{sub ND} in typical AD-affected brain regions. Thereby, the corpus callosum was identified as the most suitable reference region. The 2-[{sup 18}F]FA-85380 BP{sub ND} correlated with the severity of cognitive impairment. Only MCI patients that converted to AD in the later course (n = 5) had a reduction in 2-[{sup 18}F]FA-85380 BP{sub ND}. 2-[{sup 18}F]FA-85380 PET appears to be a sensitive and feasible tool for the detection of a reduction in {alpha}4{beta}2* nAChRs which seems to be an early event in AD. In addition, 2-[{sup 18}F]FA-85380 PET might give prognostic information about a conversion from MCI to AD. (orig.)

  13. The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction:Combining preclinical evidence with human Positron Emission Tomography (PET studies

    Directory of Open Access Journals (Sweden)

    Sylvia eTerbeck

    2015-03-01

    Full Text Available In the present review, we deliver an overview of the involvement of metabotropic glutamate receptor 5 (mGluR5 activity and density in pathological anxiety, mood disorders and addiction. Specifically, we will describe mGluR5 studies in humans that employed Positron Emission Tomography (PET and combined the findings with preclinical animal research. This combined view of different methodological approaches — from basic neurobiological approaches to human studies — might give a more comprehensive and clinically relevant view of mGluR5 function in mental health than the view on preclinical data alone. We will also review the current research data on mGluR5 along the Research Domain Criteria (RDoC. Firstly, we found evidence of abnormal glutamate activity related to the positive and negative valence systems, which would suggest that antagonistic mGluR5 intervention has prominent anti-addictive, anti-depressive and anxiolytic effects. Secondly, there is evidence that mGluR5 plays in important role in systems for social functioning and the response to social stress. Finally, mGluR5’s important role in sleep homeostasis suggests that this glutamate receptor may play an important role in RDoC’s arousal and modulatory systems domain. Glutamate was previously mostly investigate in non-human studies, however initial human clinical PET research now also supports the hypothesis that, by mediating brain excitability, neuroplasticity and social cognition, abnormal metabotropic glutamate activity might predispose individuals to a broad range of psychiatric problems.

  14. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study

    Science.gov (United States)

    Fervaha, Gagan; Caravaggio, Fernando; Mamo, David C.; Mulsant, Benoit H.; Pollock, Bruce G.; Nakajima, Shinichiro; Gerretsen, Philip; Rajji, Tarek K.; Mar, Wanna; Iwata, Yusuke; Plitman, Eric; Chung, Jun Ku; Remington, Gary; Graff-Guerrero, Ariel

    2016-01-01

    Rationale Several pre-clinical studies suggest that antipsychotic medications cause secondary negative symptoms. However, direct evidence for a relationship among antipsychotic medications, their direct effects on neurotransmitter systems, and negative symptoms in schizophrenia remains controversial. Objective The objective of this study was to examine the relationship between antipsychotic-related dopamine D2/3 receptor occupancy and negative symptoms in patients with schizophrenia. Methods Forty-one clinically stable outpatients with schizophrenia participated in this prospective dose reduction positron emission tomography (PET) study. Clinical assessments and [11C]-raclopride PET scans were performed before and after participants underwent gradual dose reduction of their antipsychotic medication by up to 40% from the baseline dose. Results No significant relationship was found between antipsychotic-related dopamine D2/3 receptor occupancy and negative symptom severity at baseline or follow-up. Similar null findings were found for subdomains of negative symptoms (amotivation and diminished expression). Occupancy was significantly lower following dose reduction; however, negative symptom severity did not change significantly, though a trend toward reduction was noted. Examination of change scores between these two variables revealed no systematic relationship. Conclusions Our cross-sectional and longitudinal results failed to find a significant dose-dependent relationship between severity of negative symptoms and antipsychotic-related dopaminergic antagonism in schizophrenia. These findings argue against the notion that antipsychotics necessarily cause secondary negative symptoms. Our results are also in contrast with the behavioural effects of dopaminergic antagonism routinely reported in pre-clinical investigations, suggesting that the role of this variable in the context of chronic treatment and schizophrenia needs to be re-examined. PMID:27557949

  15. [{sup 11}C]-MeJDTic: a novel radioligand for {kappa}-opioid receptor positron emission tomography imaging

    Energy Technology Data Exchange (ETDEWEB)

    Poisnel, Geraldine; Oueslati, Farhana; Dhilly, Martine; Delamare, Jerome [Groupe de Developpements Methodologiques en Tomographie par Emission de Positons, DSV/DRM UMR CEA 2E, Universite de Caen-Basse Normandie, Centre Cyceron, 14074 Caen Cedex (France); Perrio, Cecile [Groupe de Developpements Methodologiques en Tomographie par Emission de Positons, DSV/DRM UMR CEA 2E, Universite de Caen-Basse Normandie, Centre Cyceron, 14074 Caen Cedex (France)], E-mail: perrio@cyceron.fr; Debruyne, Daniele [Groupe de Developpements Methodologiques en Tomographie par Emission de Positons, DSV/DRM UMR CEA 2E, Universite de Caen-Basse Normandie, Centre Cyceron, 14074 Caen Cedex (France)], E-mail: debruyne@cyceron.fr; Barre, Louisa [Groupe de Developpements Methodologiques en Tomographie par Emission de Positons, DSV/DRM UMR CEA 2E, Universite de Caen-Basse Normandie, Centre Cyceron, 14074 Caen Cedex (France)

    2008-07-15

    Introduction: Radiopharmaceuticals that can bind selectively the {kappa}-opioid receptor may present opportunities for staging clinical brain disorders and evaluating the efficiency of new therapies related to stroke, neurodegenerative diseases or opiate addiction. The N-methylated derivative of JDTic (named MeJDTic), which has been recently described as a potent and selective antagonist of {kappa}-opioid receptor in vitro, was labeled with carbon-11 and evaluated for in vivo imaging the {kappa}-opioid receptor in mice. Methods: [{sup 11}C]-MeJDTic was prepared by methylation of JDTic with [{sup 11}C]-methyl triflate. The binding of [{sup 11}C]-MeJDTic to {kappa}-opioid receptor was investigated ex vivo by biodistribution and competition studies using nonfasted male CD1 mice. Results: [{sup 11}C]-MeJDTic exhibited a high and rapid distribution in peripheral organs. The uptake was maximal in lung where the {kappa} receptor is largely expressed. [{sup 11}C]-MeJDTic rapidly crossed the blood-brain barrier and accumulated in the brain regions of interest (hypothalamus). The parent ligand remained the major radioactive compound in brain during the experiment. Chase studies with U50,488 (a {kappa} referring agonist), morphine (a {mu} agonist) and naltrindole (a {delta} antagonist) demonstrated that this uptake was the result of specific binding to the {kappa}-opioid receptor. Conclusion: These findings suggested that [{sup 11}C]-MeJDTic appeared to be a promising selective 'lead' radioligand for {kappa}-opioid receptor PET imaging.

  16. Positron emission tomography imaging of gene expression

    International Nuclear Information System (INIS)

    Tang Ganghua

    2001-01-01

    The merging of molecular biology and nuclear medicine is developed into molecular nuclear medicine. Positron emission tomography (PET) of gene expression in molecular nuclear medicine has become an attractive area. Positron emission tomography imaging gene expression includes the antisense PET imaging and the reporter gene PET imaging. It is likely that the antisense PET imaging will lag behind the reporter gene PET imaging because of the numerous issues that have not yet to be resolved with this approach. The reporter gene PET imaging has wide application into animal experimental research and human applications of this approach will likely be reported soon

  17. Ionization and positron emission in giant quasiatoms

    International Nuclear Information System (INIS)

    Soff, G.; Reinhardt, J.; Reus, T. de; Wietschorke, K.H.; Schaefer, A.; Mueller, B.; Greiner, W.; Mueller, U.; Schlueter, P.

    1985-07-01

    Electron excitation processes in superheavy quasiatoms are treated within a relativistic framework. Theoretical results on K-hole production rates as well as delta-electron and positron spectra are compared with experimental data. It is demonstrated that the study of heavy ion collisions with nuclear time delay promises a signature for the spontaneous positron formation in overcritical systems. Corresponding experimental results are confronted with our theoretical hypothesis. Recent speculations on the origin of the observed peak structures in positron spectra are critically reviewed. Atomic excitations are also employed to obtain information on the course of a nuclear reaction. Using a semiclassical picture we calculate the emission of delta-electrons and positrons in deep-inelastic nuclear reactions. Furthermore some consequences of conversion processes in giant systems are investigated. (orig.)

  18. Mapping adenosine A1 receptors in the cat brain by positron emission tomography with [11C]MPDX

    International Nuclear Information System (INIS)

    Shimada, Yuhei; Ishiwata, Kiichi; Kiyosawa, Motohiro; Nariai, Tadashi; Oda, Keiichi; Toyama, Hinako; Suzuki, Fumio; Ono, Kenichirou; Senda, Michio

    2002-01-01

    We evaluated the potential of [ 11 C]MPDX as a radioligand for mapping adenosine A 1 receptors in comparison with previously proposed [ 11 C]KF15372 in cat brain by PET. Two tracers showed the same brain distribution. Brain uptake of [ 11 C]MPDX (Ki=4.2 nM) was much higher and washed out faster than that of [ 11 C]KF15372 (Ki=3.0 nM), and was blocked by carrier-loading or displaced with an A 1 antagonist. The regional A 1 receptor distribution evaluated with kinetic analysis is consistent with that previously measured in vitro. [ 11 C]MPDX PET has a potential for mapping adenosine A 1 receptors in brain

  19. In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and (XWBr)bromospiperone

    Energy Technology Data Exchange (ETDEWEB)

    Maziere, B; Loc' h, C; Barton, J -C; Sgouropoulos, P; Duquesnoy, N; Antona, R d' ; Cambon, H

    1985-08-27

    The brain regional distribution and kinetics of (XWBr)bromospiperone, a derivative of a neuroleptic (spiperone) labeled with the positron emitter bromine-76, were studied by time-of-flight tomography after i.v. injection in man. In a control subject the kinetic distribution study showed an accumulation of radioactivity which reached a maximum 3 h postinjection in the frontal cortex and cerebellum regions and 4-5 h postinjection in the basal ganglia. Thereafter the striatal activity remained essentially constant over a period of 25 h. In a group of 13 control subjects, the mean value for the striatum-to-cerebellum ratio, at 4.5 h postinjection, was 1.84 (S.D. 0.21). In two schizophrenics treated with high doses of haloperidol, this ratio was found to be only 1.22. These data indicate that radiolabeled bromospiperone is very suitable for human pharmacological or pathological investigations of the central dopaminergic system. (Auth.). 20 refs.; 3 figs.; 1 table.

  20. Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography

    International Nuclear Information System (INIS)

    Terry, Garth E.; Hirvonen, Jussi; Liow, Jeih-San; Seneca, Nicholas; Morse, Cheryl L.; Pike, Victor W.; Innis, Robert B.; Tauscher, Johannes T.; Schaus, John M.; Phebus, Lee; Felder, Christian C.; Halldin, Christer

    2010-01-01

    Cannabinoid subtype 1 (CB 1 ) receptors are found in nearly every organ in the body, may be involved in several neuropsychiatric and metabolic disorders, and are therefore an active target for pharmacotherapy and biomarker development. We recently reported brain imaging of CB 1 receptors with two PET radioligands: 11 C-MePPEP and 18 F-FMPEP-d 2 . Here we describe the biodistribution and dosimetry estimates for these two radioligands. Seven healthy subjects (four men and three women) underwent whole-body PET scans for 120 min after injection with 11 C-MePPEP. Another seven healthy subjects (two men and five women) underwent whole-body PET scans for 300 min after injection with 18 F-FMPEP-d 2 . Residence times were acquired from regions of interest drawn on tomographic images of visually identifiable organs for both radioligands and from radioactivity excreted in urine for 18 F-FMPEP-d 2 . The effective doses of 11 C-MePPEP and 18 F-FMPEP-d 2 are 4.6 and 19.7 μSv/MBq, respectively. Both radioligands demonstrated high uptake of radioactivity in liver, lung, and brain shortly after injection and accumulated radioactivity in bone marrow towards the end of the scan. After injection of 11 C-MePPEP, radioactivity apparently underwent hepatobiliary excretion only, while radioactivity from 18 F-FMPEP-d 2 showed both hepatobiliary and urinary excretion. 11 C-MePPEP and 18 F-FMPEP-d 2 yield an effective dose similar to other PET radioligands labeled with either 11 C or 18 F. The high uptake in brain confirms the utility of these two radioligands to image CB 1 receptors in brain, and both may also be useful to image CB 1 receptors in the periphery. (orig.)

  1. Brain penetrant small molecule 18F-GnRH receptor (GnRH-R) antagonists: Synthesis and preliminary positron emission tomography imaging in rats

    International Nuclear Information System (INIS)

    Olberg, Dag E.; Bauer, Nadine; Andressen, Kjetil W.; Hjørnevik, Trine; Cumming, Paul; Levy, Finn O.; Klaveness, Jo; Haraldsen, Ira; Sutcliffe, Julie L.

    2016-01-01

    Introduction: The gonadotropin releasing hormone receptor (GnRH-R) has a well-described neuroendocrine function in the anterior pituitary. However, little is known about its function in the central nervous system (CNS), where it is most abundantly expressed in hippocampus and amygdala. Since peptide ligands based upon the endogenous decapetide GnRH do not pass the blood–brain-barrier, we are seeking a high-affinity small molecule GnRH-R ligand suitable for brain imaging by positron emission tomography. We have previously reported the radiosynthesis and in vitro evaluation of two novel [ 18 F]fluorinated GnRH-R ligands belonging to the furamide class of antagonists, with molecular weight less than 500 Da. We now extend this work using palladium coupling for the synthesis of four novel radioligands, with putatively reduced polar surface area and hydrophilicity relative to the two previously described compounds, and report the uptake of these 18 F-labeled compounds in brain of living rats. Methods: We synthesized reference standards of the small molecule GnRH-R antagonists as well as mesylate precursors for 18 F-labeling. The antagonists were tested for binding affinity for both human and rat GnRH-R. Serum and blood stability in vitro and in vivo were studied. Biodistribution and PET imaging studies were performed in male rats in order to assess brain penetration in vivo. Results: A palladium coupling methodology served for the synthesis of four novel fluorinated furamide GnRH receptor antagonists with reduced heteroatomic count. Radioligand binding assays in vitro revealed subnanomolar affinity of the new fluorinated compounds for both human and rat GnRH-R. The 18 F-GnRH antagonists were synthesized from the corresponding mesylate precursors in 5–15% overall radiochemical yield. The radiolabeled compounds demonstrated good in vivo stability. PET imaging with the 18 F-radiotracers in naive rats showed good permeability into brain and rapid washout, but absence of

  2. Carbon-11 pb-12: an attempt to visualize the dopamine d{sub 4} receptor in the primate brain with positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Langer, Oliver E-mail: oliver.langer@psyk.ks.se; Halldin, Christer; Chou Yuanhwa; Sandell, Johan; Swahn, Carl-Gunnar; Naagren, Kjell; Perrone, Roberto; Berardi, Francesco; Leopoldo, Marcello; Farde, Lars

    2000-11-01

    The dopamine D{sub 4} receptor (D{sub 4}R) is expressed in low density in various extrastriatal brain regions. This receptor subtype is discussed in relation to the pathophysiology and treatment of schizophrenia but no selective positron emission tomography (PET) ligand is available to date to study the distribution in vivo. The arylpiperazine derivative N-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide (PB-12) is a novel, high-affinity ( K{sub i}=0.040 nM) and selective D{sub 4}R ligand. We radiolabeled PB-12 with carbon-11 (t{sub 1/2} 20.4 min) by O-methylation of the corresponding desmethyl analogue N-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-3-hydroxybenzamide (LM-190) with [{sup 11}C]methyl triflate. Derivative LM-190 was prepared by condensing 3-hydroxybenzoic acid with the appropriate amine. For the radiolabeling, the incorporation yield was >90% and the total synthesis time including high performance liquid chromatography (HPLC) purification was about 35 min. The specific radioactivity of [{sup 11}C]PB-12 at time of injection was 67-118 GBq{center_dot}{mu}mol{sup -1}. PET studies in a cynomolgus monkey showed a high uptake and widespread distribution of radioactivity in the brain, including the neocortex and thalamus. About 40% of total radioactivity in plasma represented unchanged radioligand at 60 min after injection as determined by HPLC. Pretreatment with the D{sub 4}R ligand 3-{l_brace}[4-(4-chlorophenyl)piperazin-1-yl]methyl{r_brace}-1H-pyrollo[2,3-b]pyridine (L-745,870) prior to radioligand injection failed to demonstrate receptor-specific binding in the monkey brain. Furthermore, the brain radioactivity distribution was left unaffected by pretreating with unlabeled PB-12. This failure to detect a D{sub 4}R-specific signal may be related to a very low density of the D{sub 4}R in primate brain, insufficient binding affinity of the radioligand, and a high background of nonspecific binding. It can be concluded from these findings that

  3. Positron emission tomography in brain function study

    International Nuclear Information System (INIS)

    Wu Hua

    2006-01-01

    Little has been recognized about the advanced brain function. Recent years several new techniques such as event-related potentials, megnetoencephalography, functional magnetic resonance imaging and positron emission tomography (PET) have been used in the study of brain function. The methodology, application study in normal people and clinical patients of PET in brain function are reviewed. (authors)

  4. Positron emission tomography of the heart

    International Nuclear Information System (INIS)

    Budinger, T.F.; Yano, Y.; Moyer, B.R.; Mathis, C.A.; Ganz, E.; Huesman, R.H.; Derenzo, S.E.

    1982-01-01

    Positron emission tomography (PET) of the heart can measure blood perfusion, metabolism of fatty acids, metabolism of sugars, uptake of amino acids and can quantitate infarction volume. The principles which are basic to PET instrumentation and procedures for quantitative studies of the heart muscle with examples of measurements of myocardial flow and metabolism, are reviewed

  5. Positron emission tomography of the heart

    International Nuclear Information System (INIS)

    Budinger, T.F.; Yano, Y.; Huesman, R.H.; Derenzo, S.E.; Moyer, B.R.; Mathis, C.A.; Ganz, E.; Knittel, B.

    1983-01-01

    Positron emission tomography (PET) of the heart can measure blood perfusion, metabolism of fatty acids, metabolism of sugars, uptake of amino acids and can quantitate infarction volume. The principles are reviewed which are basic to PET instrumentation and procedures for quantitative studies of human physiology with examples of measurements of myocardial flow and metabolism

  6. Is positron emission tomography useful in stroke?

    NARCIS (Netherlands)

    DeReuck, J; Leys, D; DeKeyser, J

    Positron emission tomography (PET) has been widely used in the study of stroke and related cerebrovascular diseases. It has shown the various stages leading to cerebral infarction and defined the significance of the ischaemic penumbra. PET scan can predict the clinical outcome of patients with acute

  7. Positron emission tomography in malignant haematological disease

    NARCIS (Netherlands)

    Schot, Bartholomeus Wilhelmus

    2007-01-01

    Positron emission tomography (PET) is a diagnostic technique with a promising role especially in the haemato-oncology. Although its use in the management ; of malignant lymphoma seems to be established already, much about the true potential and drawbacks of FDG-PET in this disease are still unknown.

  8. Positron emission tomography applied to fluidization engineering

    NARCIS (Netherlands)

    Dechsiri, C; Ghione, A; van de Wiel, F; Dehling, HG; Paans, AMJ; Hoffmann, AC

    The movement of particles in a laboratory fluidized bed has been studied using Positron Emission Tomography (PET). With this non-invasive technique both pulses of various shapes and single tracer particles were followed in 3-D. The equipment and materials used made it possible to label actual bed

  9. Advanced Instrumentation for Positron Emission Tomography [PET

    Science.gov (United States)

    Derenzo, S. E.; Budinger, T. F.

    1985-04-01

    This paper summarizes the physical processes and medical science goals that underlay modern instrumentation design for Positron Emission Tomography. The paper discusses design factors such as detector material, crystalphototube coupling, shielding geometry, sampling motion, electronics design, time-of-flight, and the interrelationships with quantitative accuracy, spatial resolution, temporal resolution, maximum data rates, and cost.

  10. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography

    International Nuclear Information System (INIS)

    Biver, F.; Goldman, S.; Luxen, A.; Monclus, M.; Forestini, M.; Mendlewicz, J.; Lotstra, F.

    1994-01-01

    Serotoninergic type 2 (5HT 2 ) receptors have been implicated in the regulation of many brain functions in humans and may play a role in several neurological and psychiatric diseases. Fluorine-18 altanserin has been proposed as a new radiotracer for the study of 5HT 2 receptors by PET because of its high affinity for 5HT 2 receptors (Ki: 0.13 nM) and its good specificity in in vitro studies. Dynamic PET studies were carried out in 12 healthy volunteers after intravenous injection of 0.1 mCi/kg [ 18 F] altanserin. Ninety minutes after injection, we observed mainly cortical binding. Basal ganglia and cerebellum showed very low uptake and the frontal cortex to cerebellum ratio was about 3. To evaluate the quantitative distribution of this ligand in the brain, we used two different methods of data analysis: a four-compartment model was used to achieve quantitative evaluation of rate constants (K 1 and k 2 through k 6 ) by non-linear regression, and a multiple-time graphical analysis technique for reversible binding was employed for the measurement of k 1 /k 2 and k 3 /k 4 ratios. Using both methods, we found significant differences in binding capacity (estimated by k 3 /k 4 = B max /K d ) between regions, the values increasing as follows: occipital, limbic, parietal, frontal and temporal cortex. After correction of values obtained by the graphical method for the existence of non-specific binding, results generated by the two methods were consistent. (orig.)

  11. Somatostatin receptor positron emission tomography/computed tomography (PET/CT) in the evaluation of opsoclonus-myoclonus ataxia syndrome

    International Nuclear Information System (INIS)

    Joshi, Prathamesh; Lele, Vikram

    2013-01-01

    Opsoclonus-myoclonus ataxia (OMA) syndrome is the most common paraneoplastic neurological syndrome of childhood, associated with occult neuroblastoma in 20%-50% of all cases. OMA is the initial presentation of neuroblastoma in 1%-3% of children. Conventional radiological imaging approaches include chest radiography and abdominal computed tomography (CT). Nuclear medicine techniques, in form of 123 I/ 131 I-metaiodobenzylguanidine (MIBG) scintigraphy have been incorporated in various diagnostic algorithms for evaluation of OMA. We describe use of somatostatin receptor PET/CT with 68 Gallium- DOTA-DPhe 1 , Tyr 3 -octreotate (DOTATATE) in diagnosis of neuroblastoma in two cases of OMA

  12. Somatostatin receptor positron emission tomography/computed tomography (PET/CT) in the evaluation of opsoclonus-myoclonus ataxia syndrome.

    Science.gov (United States)

    Joshi, Prathamesh; Lele, Vikram

    2013-04-01

    Opsoclonus-myoclonus ataxia (OMA) syndrome is the most common paraneoplastic neurological syndrome of childhood, associated with occult neuroblastoma in 20%-50% of all cases. OMA is the initial presentation of neuroblastoma in 1%-3% of children. Conventional radiological imaging approaches include chest radiography and abdominal computed tomography (CT). Nuclear medicine techniques, in form of (123)I/(131)I-metaiodobenzylguanidine (MIBG) scintigraphy have been incorporated in various diagnostic algorithms for evaluation of OMA. We describe use of somatostatin receptor PET/CT with (68)Gallium- DOTA-DPhe(1), Tyr(3)-octreotate (DOTATATE) in diagnosis of neuroblastoma in two cases of OMA.

  13. No evidence for a role of the serotonin 4 receptor in five-factor personality traits: A positron emission tomography brain study.

    Directory of Open Access Journals (Sweden)

    Dea Siggaard Stenbæk

    Full Text Available Serotonin (5-HT brain architecture appears to be implicated in normal personality traits as supported by genetic associations and studies using molecular brain imaging. However, so far, no studies have addressed potential contributions to variation in normal personality traits from in vivo serotonin 4 receptor (5-HT4R brain availability, which has recently become possible to image with Positron Emission Tomography (PET. This is particularly relevant since availability of 5-HT4R has been shown to adapt to synaptic levels of 5-HT and thus offers information about serotonergic tone in the healthy brain. In 69 healthy participants (18 females, the associations between personality traits assessed with the five-factor NEO Personality Inventory-Revised (NEO PI-R and regional cerebral 5-HT4R binding in neocortex, amygdala, hippocampus, and anterior cingulate cortex (ACC were investigated using linear regression models. The associations between each of the five personality traits and a latent variable construct of global 5-HT4R levels were also evaluated using latent variable structural equation models. We found no significant associations between the five NEO personality traits and regional 5-HT4R binding (all p-values > .17 or the latent construct of global 5-HT4R levels (all p-values > .37. Our findings indicate that NEO personality traits and 5-HT4R are not related in healthy participants. Under the assumption that global 5-HT4R levels index 5-HT tone, our data also suggest that 5-HT tone per se is not directly implicated in normal personality traits.

  14. Synthesis and organ distribution of [18F]Fluoro-Org 6141 in the rat: A potential glucocorticoid receptor ligand for positron emission tomography

    International Nuclear Information System (INIS)

    Visser, G.M.; Krugers, H.J.; Luurtsema, G.; Waarde, A. van; Elsinga, P.H.; DeKloet, E.R.; Groen, M.B.; Bohus, B.; Go, K.G.; Paans, A.M.J.; Korf, J.; Vaalburg, W.

    1995-01-01

    For the synthesis of [ 18 F]Fluoro-Org 6141 via a nucleophilic substitution reaction with 18 F - , the tosyl group was chosen as the leaving group because of its stability and excellent leaving group ability. The biodistribution of the high affinity and moderate lipophilicity (log P 2.66, calculated value) ligand [ 18 F]Fluoro-Org 6141 (specific activity 8.2 to 37 TBq/mmol, yield 10% at EOB) was examined in sham adrenalectomized (sADX) and adrenalectomized (ADX) male Wistar rats. Two days after ADX or sADX, the animals were anesthetized and 0.37 to 1.85 MBq of [ 18 F]Fluoro-Org 6141 was administered intravenously. Kinetics of 18 F activity uptake were monitored for 3 h using a stationary double-headed positron emission tomography (PET) camera, and the biodistribution was assessed by ex vivo determination of radioactivity in several tissues and different brain areas. One hour after injection of the radioligand, the bladder, kidney, liver, trachea, and bone of sADX animals contained more concentration on a wet weight basis than blood. Three hours post injection, radioactivity was retained in bladder, trachea, and bone. The accumulation of radioactivity in brain corresponded to the concentration of activity in the blood within the first hours after injection. ADX animals showed a higher uptake of 18 F activity in spleen, testes, and brain areas (hippocampus and brainstem) but a lower uptake in bone than sADX rats. PET scans suggested that 18 F activity uptake in the brain had not yet reached a maximum at this interval. Although [ 18 F]Fluoro-Org 6141 is not useful for PET studies of glucocorticoid receptors (GRs), the results obtained with this compound indicate a synthetic strategy suitable for the synthesis of high-affinity radioligands for GRs

  15. Cerebral (18)FluoroDeoxy-Glucose Positron Emission Tomography in paediatric anti N-methyl-D-aspartate receptor encephalitis: A case series.

    Science.gov (United States)

    Lagarde, Stanislas; Lepine, Anne; Caietta, Emilie; Pelletier, Florence; Boucraut, José; Chabrol, Brigitte; Milh, Mathieu; Guedj, Eric

    2016-05-01

    Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a frequent and severe cause of encephalitis in children with potential efficient treatment (immunotherapy). Suggestive clinical features are behavioural troubles, seizures and movement disorders. Prompt diagnosis and treatment initiation are needed to guarantee favourable outcome. Nevertheless, diagnosis may be challenging because of the classical ancillary test (magnetic resonance imaging (MRI), electroencephalogram, standard cerebro-spinal fluid analysis) have limited sensitivity. Currently, immunological analyses are needed for the diagnostic confirmation. In adult patients, some studies suggested a potential role of cerebral (18)FluoroDeoxy-Glucose Positron Emission Tomography (FDG-PET) in the evaluation of anti-NMDAR encephalitis. Nevertheless, almost no data exist in paediatric population. We report retrospectively clinical, ancillary tests and cerebral FDG-PET data in 6 young patients (median age=10.5 years, 4 girls) with immunologically confirmed anti-NMDAR encephalitis. Our patients presented classical clinical features of anti-NMDAR encephalitis with severe course (notably four patients had normal MRI). Our series shows the feasibility and the good sensitivity of cerebral FDG-PET (6/6 patients with brain metabolism alteration) in paediatric population. We report some particular features in this population: extensive, symmetric cortical hypometabolism especially in posterior areas; asymmetric anterior focus of hypermetabolism; and basal ganglia hypermetabolism. We found also a good correlation between the clinical severity and the cerebral metabolism changes. Moreover, serial cerebral FDG-PET showed parallel brain metabolism and clinical improvement. Our study reveals the existence of specific patterns of brain metabolism alteration in anti-NMDAR encephalitis in paediatric population. Copyright © 2015 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

  16. No evidence for a role of the serotonin 4 receptor in five-factor personality traits: A positron emission tomography brain study.

    Science.gov (United States)

    Stenbæk, Dea Siggaard; Dam, Vibeke Høyrup; Fisher, Patrick MacDonald; Hansen, Nanna; Hjordt, Liv Vadskjær; Frokjaer, Vibe Gedsoe

    2017-01-01

    Serotonin (5-HT) brain architecture appears to be implicated in normal personality traits as supported by genetic associations and studies using molecular brain imaging. However, so far, no studies have addressed potential contributions to variation in normal personality traits from in vivo serotonin 4 receptor (5-HT4R) brain availability, which has recently become possible to image with Positron Emission Tomography (PET). This is particularly relevant since availability of 5-HT4R has been shown to adapt to synaptic levels of 5-HT and thus offers information about serotonergic tone in the healthy brain. In 69 healthy participants (18 females), the associations between personality traits assessed with the five-factor NEO Personality Inventory-Revised (NEO PI-R) and regional cerebral 5-HT4R binding in neocortex, amygdala, hippocampus, and anterior cingulate cortex (ACC) were investigated using linear regression models. The associations between each of the five personality traits and a latent variable construct of global 5-HT4R levels were also evaluated using latent variable structural equation models. We found no significant associations between the five NEO personality traits and regional 5-HT4R binding (all p-values > .17) or the latent construct of global 5-HT4R levels (all p-values > .37). Our findings indicate that NEO personality traits and 5-HT4R are not related in healthy participants. Under the assumption that global 5-HT4R levels index 5-HT tone, our data also suggest that 5-HT tone per se is not directly implicated in normal personality traits.

  17. In vivo positron emission tomography imaging with [{sup 11}C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons

    Energy Technology Data Exchange (ETDEWEB)

    DeLorenzo, Christine; Brennan, Kathleen G. [Columbia University College of Physicians and Surgeons, Division of Molecular Imaging and Neuropathology, Department of Psychiatry, NYSPI Mail Unit 42, New York, NY (United States); Milak, Matthew S.; Parsey, Ramin V. [Columbia University College of Physicians and Surgeons, Division of Molecular Imaging and Neuropathology, Department of Psychiatry, NYSPI Mail Unit 42, New York, NY (United States); New York State Psychiatric Institute, New York, NY (United States); Kumar, J.S.D.; Mann, J.J. [Columbia University College of Physicians and Surgeons, Division of Molecular Imaging and Neuropathology, Department of Psychiatry, NYSPI Mail Unit 42, New York, NY (United States); New York State Psychiatric Institute, New York, NY (United States); Columbia University College of Physicians and Surgeons, Department of Radiology, New York, NY (United States)

    2011-06-15

    Metabotropic glutamate receptor subtype 5 (mGluR5) dysfunction has been implicated in several disorders. [{sup 11}C]ABP688, a positron emission tomography (PET) ligand targeting mGluR5, could be a valuable tool in the development of novel therapeutics for these disorders by establishing in vivo drug occupancy. Due to safety concerns in humans, these studies may be performed in nonhuman primates. Therefore, in vivo characterization of [{sup 11}C]ABP688 in nonhuman primates is essential. Test-retest studies were performed in baboons (Papio anubis) to compare modeling approaches and determine the optimal reference region. The mGluR5-specific antagonist 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP) was then used in test-block studies, in which ligand binding was measured before and after MTEP administration. Test/block data were analyzed both by calculating changes in binding and using a graphical approach, which allowed estimation of both MTEP occupancy and nonspecific binding. Test-retest results, which have not been previously reported for [{sup 11}C]ABP688, indicated that [{sup 11}C]ABP688 variability is low using an unconstrained two-tissue compartment model. The most appropriate, though not ideal, reference region was found to be the gray matter of the cerebellum. Using these optimal modeling techniques on the test/block data, about 90% occupancy was estimated by the graphical approach. These studies are the first to demonstrate the specificity of [{sup 11}C]ABP688 for mGluR5 with in vivo PET in nonhuman primates. The results indicate that, in baboons, occupancy of mGluR5 is detectable by in vivo PET, a useful finding for proceeding to human studies, or performing further baboon studies, quantifying the in vivo occupancy of novel therapeutics targeting mGluR5. (orig.)

  18. Positron emission tomography - a new approach to brain chemistry

    International Nuclear Information System (INIS)

    Jacobson, H.G.

    1988-01-01

    Positron emission tomography permits examination of the chemistry of the brain in living beings. Until recently, positron emission tomography had been considered a research tool, but it is rapidly moving into clinical practice. This report describes the uses and applications of positron emission tomography in examinations of patients with strokes, epilepsy, malignancies, dementias, and schizophrenia and in basic studies of synaptic neurotransmission

  19. Features and applications of positron emission tomography

    International Nuclear Information System (INIS)

    Fan Mingwu

    1997-01-01

    Positron emission tomography, the so-called world's smartest camera, is based on a NaI or BGO detector and imaging of positron-emitting radioisotopes which are introduced as a tracer into the regional tissue or organ of interest. With the aid of a computer visual images of a series of these distributions can be built into a picture of the functional status of the tissue or organ being imaged. This highly accurate imaging technique is already widely used for clinical diagnostics heart disease, brain disorder, tumors and so on

  20. Electrocardiographic gating in positron emission computed tomography

    International Nuclear Information System (INIS)

    Hoffman, E.J.; Phelps, M.E.; Wisenberg, G.; Schelbert, H.R.; Kuhl, D.E.

    1979-01-01

    Electrocardiographic (ECG) synchronized multiple gated data acquisition was employed with positron emission computed tomography (ECT) to obtain images of myocardial blood pool and myocardium. The feasibility and requirements of multiple gated data acquisition in positron ECT were investigated for 13NH3, ( 18 F)-2-fluoro-2-D-deoxyglucose, and ( 11 C)-carboxyhemoglobin. Examples are shown in which image detail is enhanced and image interpretation is facilitated when ECG gating is employed in the data collection. Analysis of count rate data from a series of volunteers indicates that multiple, statistically adequate images can be obtained under a multiple gated data collection format without an increase in administered dose

  1. Preclinical and the first clinical studies on [11C]ITMM for mapping metabotropic glutamate receptor subtype 1 by positron emission tomography

    International Nuclear Information System (INIS)

    Toyohara, Jun; Sakata, Muneyuki; Fujinaga, Masayuki; Yamasaki, Tomoteru; Oda, Keiichi; Ishii, Kenji; Zhang, Ming Rong; Moriguchi Jeckel, Cristina Maria; Ishiwata, Kiichi

    2013-01-01

    Introduction: Preclinical studies and first positron emission tomography (PET) imaging studies were performed using N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-4-[ 11 C] methoxy-N-methylbenzamide ([ 11 C]ITMM) to map metabotropic glutamate receptor type 1 (mGluR1) in the human brain. Methods: [ 11 C]ITMM was synthesized by O-methylation of the desmethyl precursor with [ 11 C]methyl triflate in the presence of NaOH at room temperature. In vitro selectivity and brain distributions of [ 11 C]ITMM in mice were characterized. Radiation absorbed-dose by [ 11 C]ITMM in humans was calculated from mouse distribution data. Acute toxicity of ITMM at 4.72 mg/kg body weight (> 74,000-fold clinical equivalent dose of [ 11 C]ITMM) was evaluated. Mutagenicity of ITMM was studied by the Ames test. Clinical PET imaging of mGluR1 with [ 11 C] ITMM was performed in a healthy volunteer. Results: ITMM had low activity for a 28-standard receptor binding profile. Regional brain uptake of [ 11 C]ITMM in mice was heterogeneous and consistent with known mGluR1 distributions. The radiation absorbed-dose by [ 11 C]ITMM in humans was sufficiently low for clinical use, and no acute toxicity or mutagenicity of ITMM occurred. A 90-min dynamic PET scan with [ 11 C]ITMM in a healthy volunteer showed a gradual increase of radioactivity in the cerebellum. Total distribution volume of [ 11 C]ITMM was highest in the cerebellum, followed by thalamus, cerebral cortex, and striatum; regional differences in brain radioactivity corresponded to the mGluR1 distribution in the brain. Peripherally, [ 11 C]ITMM was stable in humans: 60% of the plasma radioactivity remained in the unchanged form for 60 min. Conclusions: [ 11 C] ITMM is a suitable radioligand for imaging mGluR1 in the human brain providing acceptable dosimetry and pharmacological safety at the dose required for PET

  2. Positron emission tomography of the lung

    International Nuclear Information System (INIS)

    Wollmer, P.

    1984-01-01

    Positron emission tomography enables the distribution of positron emitting isotopes to be imaged in a transverse plane through the body and the regional concentration of the isotope to be measured quantitatively. This thesis reports some applications of positron emission tomography to studies of pulmonary pathophysiology. Measurements in lung phantoms showed that regional lung density could be measured from a transmission tomogram obtained with an external source of positron emitting isotope. The regional, fractional blood volume was measured after labelling the blood with carbon-11-monoxide. Regional extravascular lung density (lung tissue and interstitial water per unit thoracic volume) was obtained by subtracting fractional blood volume from lung density. Measurements in normal subjects revealed large regional variations in lung density and fractional blood volume in the supine posture. Extravascular lung density showed a more uniform distribution. The technique has been used to study patients with chronic interstitial pulmonary oedema, pulmonary sarcoidosis and fibrosis, pulmonary arterial hypertension and patients with intracardiac, left-to-right shunt. Tomographic measurements of pulmonary tissue concentration of radionuclides are difficult, since corrections for the blood content and the inflation of the lung must be applied. A simultaneous measurement of lung density and fractional blood volume allows such corrections to be made and the extravascular tracer concentration to be calculated. This has been applied to measurements of the tissue penetration of carbon-11-labelled erythromycin in patients with lobar pneumonia. (author)

  3. Positron emission tomography in movement disorders

    International Nuclear Information System (INIS)

    Martin, W.R.W.

    1985-01-01

    Positron emission tomography provides a method for the quantitation of regional function within the living human brain. Studies of cerebral metabolism and blood flow in patients with Huntington's disease, Parkinson's disease and focal dystonia have revealed functional abnormalities within substructures of the basal ganglia. Recent developments permit assessment of both pre-synaptic and post-synaptic function ion dopaminergic pathways. These techniques are now being applied to studies of movement disorders in human subjects

  4. Positron emission tomography in movement disorders

    Energy Technology Data Exchange (ETDEWEB)

    Martin, W R.W.

    1985-02-01

    Positron emission tomography provides a method for the quantitation of regional function within the living human brain. Studies of cerebral metabolism and blood flow in patients with Huntington's disease, Parkinson's disease and focal dystonia have revealed functional abnormalities within substructures of the basal ganglia. Recent developments permit assessment of both pre-synaptic and post-synaptic function in dopaminergic pathways. These techniques are now being applied to studies of movement disorders in human subjects.

  5. Synthesis and characterization of [{sup 76}Br]-labeled high-affinity A{sub 3} adenosine receptor ligands for positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Kiesewetter, Dale O. [Positron Emission Tomography Radiochemistry Group, NIBIB, Clinical Center, National Institutes of Health, Bethesda, MD 20892 (United States)], E-mail: dk7k@nih.gov; Lang Lixin; Ma Ying; Bhattacharjee, Abesh Kumar [Positron Emission Tomography Radiochemistry Group, NIBIB, Clinical Center, National Institutes of Health, Bethesda, MD 20892 (United States); Gao, Zhan-Guo; Joshi, Bhalchandra V.; Melman, Artem; Castro, Sonia de; Jacobson, Kenneth A. [Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 (United States)

    2009-01-15

    Introduction: Bromine-76-radiolabeled analogues of previously reported high-affinity A{sub 3} adenosine receptor (A{sub 3}AR) nucleoside ligands have been prepared as potential radiotracers for positron emission tomography. Methods: The radiosyntheses were accomplished by oxidative radiobromination on the N{sup 6}-benzyl moiety of trimethyltin precursors. Biodistribution studies of the kinetics of uptake were conducted in awake rats. Results: We prepared an agonist ligand {l_brace}[{sup 76}Br](1'S,2'R,3'S,4'R,5'S)-4'-{l_brace}2-chloro-6-[(3-bromophenylmethyl)amino] purin-9-yl{r_brace}-1'-(methylaminocarbonyl)bicyclo[3.1.0]hexane-2',3'-diol (MRS3581){r_brace} in 59% radiochemical yield with a specific activity of 19.5 GBq/{mu}mol and an antagonist ligand {l_brace}[{sup 76}Br](1'R,2'R,3'S,4'R,5'S)-4'-(6-(3-bromobenzylamino) -2-chloro-9H-purin-9-yl)bicyclo[3.1.0]hexane-2',3'-diol (MRS5147){r_brace} in 65% radiochemical yield with a specific activity of 22 GBq/{mu}mol. The resultant products exhibited the expected high affinity (K{sub i}{approx}0.6 nM) and specific binding at the human A{sub 3}AR in vitro. Biodistribution studies in the rat showed uptake in the organs of excretion and metabolism. The antagonist MRS5147 exhibited increasing uptake in testes, an organ that contains significant quantities of A{sub 3}AR, over a 2-h time course, which suggests the presence of a specific A{sub 3}AR retention mechanism. Conclusion: We were able to compare uptake of the [{sup 76}Br]-labeled antagonist MRS5147 to [{sup 76}Br]agonist MRS3581. The antagonist MRS5147 shows increasing uptake in the testes, an A{sub 3}AR-rich tissue, suggesting that this ligand may have promise as a molecular imaging agent.

  6. Quantitative analysis of adenosine A{sub 1} receptors in human brain using positron emission tomography and [1 -methyl-{sup 11}C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine

    Energy Technology Data Exchange (ETDEWEB)

    Kimura, Yuichi [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Naka, Itabashi, Tokyo, 173-0022 (Japan)]. E-mail: ukimura@ieee.org; Ishii, Kenji [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Naka, Itabashi, Tokyo, 173-0022 (Japan); Fukumitsu, Nobuyoshi [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Naka, Itabashi, Tokyo, 173-0022 (Japan); Department of Radiation Oncology, University of Tsukuba Hospital, Amakubo, 2-1-1, Tsukuba, 305-8576 (Japan); Oda, Keiichi [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Naka, Itabashi, Tokyo, 173-0022 (Japan); Sasaki, Toru [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Naka, Itabashi, Tokyo, 173-0022 (Japan); Kawamura, Kazunori [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Naka, Itabashi, Tokyo, 173-0022 (Japan); SHI Accelerator Service Ltd., 1-17-6, Ohsaki, Shinagawa, Tokyo, 141-0032 (Japan); Ishiwata, Kiichi [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Naka, Itabashi, Tokyo, 173-0022 (Japan)

    2004-11-01

    Fully quantitative analysis of the adenosine A{sub 1} receptor (A1R) in the brain with {sup 11}C-MPDX and positron emission tomography is reported. The kinetics is described using a two-tissue three-compartment model, and estimated binding potentials correspond well with the estimates made by Logan plot. The image of the binding potential of the MPDX is physiologically reasonable. We conclude that MPDX is applicable to the visualization of the A1Rs in the brain with Logan plot.

  7. Positron emission tomography now and in the future

    International Nuclear Information System (INIS)

    Vaalburg, W.

    1987-01-01

    A survey is given of positron emission tomography used in nuclear medicine. The production of positron emitting radionuclides is discussed. The development of positron detectors is described. The application of positron emission tomography in cardiology, oncology and neurology is treated. The authors conclude that PET is a unique method to examine metabolic processes, although the method is still in its infancy. 7 refs.; 1 table

  8. Studies of the brain cannabinoid system using positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Gatley, S.J.; Volkow, N.D.

    1995-10-01

    Studies using radiolabeled psychoactive drugs in conjunction with positron emission tomography (PET) have permitted the imaging of binding sites in the human brain. Similar studies of marijuana have been hampered by the unsuitability of radiolabeled THC for PET studies, and the current unavailability of other in vivo imaging agents for cannabinoid receptors. Recent developments in medicinal chemistry suggest that a PET radiotracer for cannabinoid receptors will soon become available. This chapter briefly reviews these developments, together with the results of PET studies of the effects of marijuana and other abused drugs on brain metabolism. It also reviews PET studies of cocaine binding sites, to demonstrate the kind of investigations that will be possible when a cannabinoid receptor PET radioligand becomes available.

  9. Studies of the brain cannabinoid system using positron emission tomography

    International Nuclear Information System (INIS)

    Gatley, S.J.; Volkow, N.D.

    1995-01-01

    Studies using radiolabeled psychoactive drugs in conjunction with positron emission tomography (PET) have permitted the imaging of binding sites in the human brain. Similar studies of marijuana have been hampered by the unsuitability of radiolabeled THC for PET studies, and the current unavailability of other in vivo imaging agents for cannabinoid receptors. Recent developments in medicinal chemistry suggest that a PET radiotracer for cannabinoid receptors will soon become available. This chapter briefly reviews these developments, together with the results of PET studies of the effects of marijuana and other abused drugs on brain metabolism. It also reviews PET studies of cocaine binding sites, to demonstrate the kind of investigations that will be possible when a cannabinoid receptor PET radioligand becomes available

  10. Adenosine A{sub 1} receptors in human sleep regulation studied by electroencephalography (EEG) and positron emission tomography (PET)[Dissertation 17227

    Energy Technology Data Exchange (ETDEWEB)

    Geissler, E

    2007-07-01

    Sleep is an essential physiological process. However, the functions of sleep and the endogenous mechanisms involved in sleep regulation are only partially understood. Convergent lines of evidence support the hypothesis that the build-up of sleep propensity during wakefulness and its decline during sleep are associated with alterations in brain adenosine levels and adenosine receptor concentrations. The non-selective A{sub 1} and A{sub 2A} adenosine receptor antagonist caffeine stimulates alertness and is known to attenuate changes in the waking and sleep electroencephalogram (EEG) typically observed after prolonged waking. Several findings point to an important function of the adenosine A{sub 1} receptor (A{sub 1}AR) in the modulation of vigilance states. The A{sub 1}AR is densely expressed in brain regions involved in sleep regulation, and pharmacological manipulations affecting the A{sub 1}AR were shown to influence sleep propensity and sleep depth. However, an involvement of the A{sub 2A} adenosine receptor (A{sub 2A}AR) is also assumed. The distinct functions of the A{sub 1} and A{sub 2A} receptor subtypes in sleep-wake regulation and in mediating the effects of caffeine have not been identified so far. The selective adenosine A{sub 1} receptor antagonist, 8-cyclopentyl-3-(3-{sup 18}Ffluoropropyl)- 1-propylxanthine ({sup 18}F-CPFPX), offers the opportunity to get further insights into adenosinergic mechanisms by in vivo imaging of the A{sub 1}AR subtype with positron emission tomography (PET). The aim of this thesis was to elucidate the role of adenosine A{sub 1} receptors in human sleep regulation, combining {sup 18}F-CPFPX PET brain imaging and EEG recordings, the gold standard in sleep research. It was hypothesized that sleep deprivation would induce adenosine accumulation and/or changes in A{sub 1}AR density. Thus, the question was addressed whether these effects of prolonged wakefulness can be visualized by altered {sup 18}F-CPFPX binding. Moreover, it was

  11. In-situ positron emission of CO oxidation

    NARCIS (Netherlands)

    Vonkeman, K.A.; Jonkers, G.; Wal, van der S.W.A.; Santen, van R.A.

    1993-01-01

    Using a Neuro ECAT positron tomog., the Positron Emission computed Tomog. (PET) was utilized to image the catalytic oxidn. of CO by using CO and CO2, labeled with short lived positron emitting nuclides. Studies were performed over highly dispersed CeO2/g-Al2O3 supported Pt and Rh catalysts. With a

  12. Positron emission tomography of FDG in schizophrenia

    International Nuclear Information System (INIS)

    Sargent, T. III; Kusubov, N.

    1986-01-01

    The use of the Donner dynamic positron emission tomograph to study fluorodeoxyglucose labelled 18 F uptake in the brain of six patients with schizophrenia is reported. The glucose metabolic rate and the local cerebral metabolic rate were calculated. The dynamic brain uptake data and the blood input function were used to calculate rate constants by an iterative least squares fitting program for all regions of interest chosen in the brain. Although the number of patients was small, differences in k3 were statistically significant in several brain regions compared with normal controls

  13. Positron Emission Tomography: Its 65 years

    International Nuclear Information System (INIS)

    Del Guerra, A.; Belcari, N.; Bisogni, M.

    2016-01-01

    Positron Emission Tomography (PET) is a well-established imaging technique for in vivo molecular imaging. In this review after a brief history of PET there are presented its physical principles and the technology that has been developed for bringing PET from a bench experiment to a clinical indispensable instrument. The limitations and performance of the PET tomographs are discussed, both as for the hardware and software aspects. The status of art of clinical, preclinical and hybrid scanners (i.e., PET/CT and PET/MR) is reported. Finally the actual trend and the recent and future technological developments are fully illustrated.

  14. Methods and instrumentation for positron emission tomography

    International Nuclear Information System (INIS)

    Mandelkern, M.A.; Phelps, M.E.

    1988-01-01

    This paper reports on positron emission tomography (PET), a technique for the noninvasive measurement of local tissue concentrations of injected radioactive tracers. Tracer kinetics techniques can be applied to this information to quantify physiologic function in human tissue. In the tracer method, a pharmaceutical is labeled by a radioactive atom. When introduced into the subject that molecule follows a physiologic pathway. The space- and time-dependent distribution of the radionuclide is obtained via an imaging technique. If the radiopharmaceutical is sufficiently analogous to a natural substrate or other substance of interest, a quantitative image can be translated into a physiologic measurement

  15. Contribution of positron emission tomography in neurology

    International Nuclear Information System (INIS)

    Salmon, E.; Franck, G.

    1992-01-01

    Positron Emission Tomography (PET) is a scanner technique using tracers labelled with shortlived radioisotopes which allows to study and quantify human metabolic processes or drug pharmacology in vivo. The technique is first applied in physiological studies. Sleep, normal brain metabolism or cerebral activations have been studied. The pharmacological approach concerns both drug distribution in the human brain and blood flow or metabolic variations under treatment. Main neurological applications in pathology are cerebrovascular disorders, diseases leading to dementia, epilepsy, movement disorders, and brain tumors. In each field of application, PET gives unique and frequently early informations. It nicely combines both dynamic informations and measurement precision. (author)

  16. Positron Emission Tomographic Imaging of the Cannabinoid Type 1 Receptor System with [11C]OMAR ([11C]JHU75528: Improvements in Image Quantification Using Wild-Type and Knockout Mice

    Directory of Open Access Journals (Sweden)

    Raúl Herance

    2011-11-01

    Full Text Available In this study, we assessed the feasibility of using positron emission tomography (PET and the tracer [11C]OMAR ([11C]JHU75528, an analogue of rimonabant, to study the brain cannabinoid type 1 (CB1 receptor system. Wild-type (WT andCB1 knockout (KO animals were imaged at baseline and after pretreatment with blocking doses of rimonabant. Brain uptake in WT animals was higher (50% than in KO animals in baseline conditions. After pretreatment with rimonabant, WT uptake lowered to the level of KO animals. The results of this study support the feasibility of using PET with the radiotracer [11C]JHU75528 to image the brain CB1 receptor system in mice. In addition, this methodology can be used to assess the effect of new drugs in preclinical studies using genetically manipulated animals.

  17. Radiosynthesis of an opiate receptor-binding radiotracer for positron emission tomography: (C-11 methyl)-methyl-4-(N-(1-oxopropyl)-N-phenylamino)-4-piperidine carboxylate (C-11 4-carbomethoxyfentanyl)

    Energy Technology Data Exchange (ETDEWEB)

    Dannals, R.F.; Ravert, H.T.; Frost, J.J.; Wilson, A.A.; Burns, H.D.; Wagner, H.N. Jr.

    1984-01-01

    The development of high affinity, high specific activity tritium-labeled neurotransmitter receptor ligands has made it possible to determine the spatial distribution and relative regional concentration of several neuroreceptors by means of in vivo receptor labeling techniques in animals. This development made possible the biochemical identification of opiate receptors by autoradiographic visualization in experimental animals. The quantitation and localization of opiate receptors in man using non-invasive methods, such as positron emission tomography, could provide a means of obtaining information about a variety of receptor-linked neuropsychiatric diseases as well as normal brain mechanisms regulating pain and emotions. As part of a continuing program to identify and radiolabel high affinity, highly specific ligands for the opiate receptor, the authors have selected two derivatives of fentanyl, a well-known analgesic, as candidates for radiolabeling: R-31,833 (4-carbomethoxy-fentanyl) and R-34,995 (lofentanil). Carbon-11 labeled R-31,833 was synthesized by the methylation of the appropriate carboxylate with C-11 methyl iodide in dimethylformamide at room temperature and purified by high performance liquid chromatography. The average synthesis time from end-of-bombardment (E.O.B.) was 30 minutes. The average specific activity was determined by ultraviolet spectroscopy to be 890 mCi/..mu..mole end-of-synthesis (approx. 2500 mCi/..mu..mole E.O.B.).

  18. Radiosynthesis of an opiate receptor-binding radiotracer for positron emission tomography: [C-11 methyl]-methyl-4-[N-(1-oxopropyl)-N-phenylamino]-4-piperidine carboxylate (C-11 4-carbomethoxyfentanyl)

    International Nuclear Information System (INIS)

    Dannals, R.F.; Ravert, H.T.; Frost, J.J.; Wilson, A.A.; Burns, H.D.; Wagner, H.N. Jr.

    1984-01-01

    The development of high affinity, high specific activity tritium-labeled neurotransmitter receptor ligands has made it possible to determine the spatial distribution and relative regional concentration of several neuroreceptors by means of in vivo receptor labeling techniques in animals. This development made possible the biochemical identification of opiate receptors by autoradiographic visualization in experimental animals. The quantitation and localization of opiate receptors in man using non-invasive methods, such as positron emission tomography, could provide a means of obtaining information about a variety of receptor-linked neuropsychiatric diseases as well as normal brain mechanisms regulating pain and emotions. As part of a continuing program to identify and radiolabel high affinity, highly specific ligands for the opiate receptor, the authors have selected two derivatives of fentanyl, a well-known analgesic, as candidates for radiolabeling: R-31,833 (4-carbomethoxy-fentanyl) and R-34,995 (lofentanil). Carbon-11 labeled R-31,833 was synthesized by the methylation of the appropriate carboxylate with C-11 methyl iodide in dimethylformamide at room temperature and purified by high performance liquid chromatography. The average synthesis time from end-of-bombardment (E.O.B.) was 30 minutes. The average specific activity was determined by ultraviolet spectroscopy to be 890 mCi/μmole end-of-synthesis (approx. 2500 mCi/μmole E.O.B.)

  19. Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR)

    DEFF Research Database (Denmark)

    Loft, Mathias Dyrberg; Sun, Yao; Liu, Changhao

    2017-01-01

    for non-invasive positron emission tomography (PET) imaging of uPAR. Despite the optimal physical properties of68Ga for peptide-based PET imaging, low tumor uptakes have previously been reported using68Ga-labeled AE105-NH2-based tracers. In an attempt to optimize the tumor uptake, we developed three novel...... to the non-spacer version, NODAGA-AE105-NH2. Following radiolabeling with68Ga, we evaluated the in vitro and in vivo performance in mice bearing subcutaneous tumors derived from the uPAR-expressing human GBM cell line U87MG. In vivo PET/CT imaging showed that introduction of PEG spacers more than doubled...... confirmed the improved tumor uptakes of the PEG-modified tracers.68Ga-NODAGA-PEG8-AE105-NH2is thus a promising candidate for human translation for PET imaging of GBM....

  20. New octreotide derivatives for in vivo targeting of somatostatin receptor-positive tumors for Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)

    International Nuclear Information System (INIS)

    Maecke, H.R.; Smith-Jones, P.; Maina, T.; Stolz, B.; Albert, R.; Bruns, C.; Reist, H.

    1993-01-01

    Two new modifications of the somatostatin analog octreotide, designed to hold the gallium isotopes 67 Ga and 68 Ga (DFO-SMS) and 99m Tc (PnAO-SMS) have been synthesized and evaluated in vitro and in vivo in tumor bearing rats. DFO-SMS can be labeled with 67 Ga 3+ and 68 Ga 3+ with high specific activity within less than 30 minutes in a ''cold kit'' type formulation. The labeled conjugate is stable under physiologgical conditions. Moreover the binding affinity to somatostatin receptors on rat brain cortex membranes was shown to be retained. In vivo fast tumor localization was demonstrated and the pharmacokinetics proved to be favourable as the main excretion route was via the kidneys. First PET studies with [ 68 Ga]-DFO-SMS showed a rapid accumulation in the tumor and a residence half-life at the tumor site of about 6 hours. PnAO-SMS can be labeled with 99m Tc with high radiochemical purity. In vivo the radiotracer accumulates well in the tumor but due to its high lipohilicity, its main excretion route is via the hepatobiliary system. (orig.)

  1. Specific in vivo binding in the rat brain of [{sup 18}F]RP 62203: A selective 5-HT{sub 2A} receptor radioligand for positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Besret, Laurent; Dauphin, Francois; Huard, Cecile; Lasne, Marie-Claire; Vivet, Richard; Mickala, Patrick; Barbelivien, Alexandra; Baron, Jean-Claude

    1996-02-01

    In vivo pharmacokinetic and brain binding characteristics of [{sup 18}F]RP 62203, a selective high-affinity serotonergic 5-HT{sub 2A} receptor antagonist, were assessed in the rat following intravenous injection of trace amount of the radioligand. The radioactive distribution profile observed in the brain 60 min after injection was characterized by greater than fourfold higher uptake in neocortex as compared to cerebellum (0.38 {+-} 0.07% injected dose/g, % ID/g and 0.08 {+-} 0.01 ID/g, respectively), consistent with in vivo specific binding to the 5-HT{sub 2A} receptor. Furthermore, specific [{sup 18}F]RP 62203 binding significantly correlated with the reported in vitro distribution of 5-HT{sub 2A} receptors, but not with known concentration profiles of dopaminergic D{sub 2} or adrenergic {alpha}{sub 1} receptors. Finally, detectable specific binding was abolished by pretreatment with large doses of ritanserin, a selective 5-HT{sub 2A} antagonist, which resulted in uniform uptakes across cortical, striatal and cerebellar tissues. Thus, [{sup 18}F]RP 62203 appears to be a promising selective tool to visualize and quantify 5-HT{sub 2A} brain receptors in vivo with positron emission tomography.

  2. F-18-fluorodeoxyglucose-positron emission tomography in colorectal cancer

    International Nuclear Information System (INIS)

    Joerg, L.; Langsteger, W.

    2002-01-01

    Whole-body positron emission tomography (PET) with the radiolabeled glucose analog F-18-fluorodeoxyglucose (F-18-FDG) is a sensitive diagnostic tool that images tumors based on increased uptake of glucose. Several recent publications have shown that F-18-fluorodeoxyglucose-positron emission tomography is more sensitive than computed-tomography (CT) in detecting colorectal cancer. In patients with increasing CEA (carcinoembryonic antigen) and no evidence of recurrent disease on CT F-18-fluorodeoxyglucose-positron emission tomography often detects recurrent cancer. In all, patient management seems to be changed in about 25 % of patients who undergo F-18-fluorodeoxyglucose-positron emission tomography in addition to standard staging procedure. Limited reports to date on both chemotherapy and radiotherapy support the role of F-18-fluorodeoxyglucose-positron emission tomography in assessing treatment response. Also regarding preoperative staging of primary colorectal cancer the literature is very limited. (author)

  3. The Positron Emission Tomography. A diagnostic technique

    International Nuclear Information System (INIS)

    Salvadori, P.

    2001-01-01

    Positron Emission Tomography (PET) is a new imaging modality, which is able to assess non-invasively the biochemical mechanisms, underlying physiological and pathophysiological processes in vivo in humans. The technique relies on the administration of radioactive tracers labeled with short-lived positron emitters, which need to be produced on site via a particle accelerator (cyclotron). Radionuclides are produced upon request and formulated into biologically active organic molecules having precise pharmacokinetics and specificity. The radiotracer can be detected by the PET scanner and represented as tomographic sections (images of body sections) showing its regional distribution and concentration. This makes it possible to address clinical questions concerning occurrence and evolution of many diseases as well as their response to therapy. The ability to image (measure) biological processes and not only anatomy enables PET to explore diseases in the very early stage, including those diseases which are not related to modifications of organ structure (e.g. psychiatric diseases, metabolic disorders, biochemical disfunction). PET plays a major role, in conjunction with the other imaging modalities, to improve diagnosis capabilities and disease mechanism understanding [it

  4. Positron emission tomography (PET) in psychiatry

    International Nuclear Information System (INIS)

    Buchsbaum, M.S.

    1984-01-01

    In the past the approach to the brain has been necessarily indirect, employing peripheral fluids to assess central and regional neurochemical processes. Blood, urine, skin and muscle biopsy, and cerebrospinal fluid are valuable reflectors of the neurochemical and neuropharmacological activity of the brain, but are removed in time and place from disordered thought processes and diluted by the products of both functional and dysfunctional brain systems. Biopsy studies have helped in studying the functional disorders of organs like the liver, but they are destructive to the brain and less useful because unlike these organs, the brain has a regional variation in its chemistry. The experimental insights from animal studies focusing on the pharmacology of individual cell groups - in striatum or locus coeruleus, for example - cannot easily or unambigiously be applied to clinical populations. Positron emission tomography (PET) is a versatile approach utilizing the mathematics of x-ray transmission scanning (CT scanning) to produce slice images of radioisotope distribution. PET makes possible a wide range of metabolic studies. Positron emitters such as carbon-11 or fluorine-18 can be used to label glucose, amino acids, drugs, neurotransmitter precursors, and many other molecules and examine their distribution and fate in discrete cell groups

  5. Positron emission tomography of the heart

    Energy Technology Data Exchange (ETDEWEB)

    Schelbert, H.R.; Phelps, M.E.; Kuhl, D.E.

    1979-01-01

    Positron emission computed tomography (PCT) represents an important new tool for the noninvasive evaluation and, more importantly, quantification of myocardial performance. Most currently available techniques permit assessment of only one aspect of cardiac function, i.e., myocardial perfusion by gamma scintillation camera imaging with Thallium-201 or left ventricular function by echocardiography or radionuclide angiocardiography. With PCT it may become possible to study all three major segments of myocardial performance, i.e., regional blood flow, mechanical function and, most importantly, myocardial metabolism. Each of these segments can either be evaluated separately or in combination. This report briefly describes the principles and technological advantages of the imaging device, reviews currently available radioactive tracers and how they can be employed for the assessment of flow, function and metabolism; and, lastly, discusses possible applications of PCT for the study of cardiac physiology or its potential role in the diagnosis of cardiac disease.

  6. Positron emission tomography of the heart

    International Nuclear Information System (INIS)

    Schelbert, H.R.; Phelps, M.E.; Kuhl, D.E.

    1979-01-01

    Positron emission computed tomography (PCT) represents an important new tool for the noninvasive evaluation and, more importantly, quantification of myocardial performance. Most currently available techniques permit assessment of only one aspect of cardiac function, i.e., myocardial perfusion by gamma scintillation camera imaging with Thallium-201 or left ventricular function by echocardiography or radionuclide angiocardiography. With PCT it may become possible to study all three major segments of myocardial performance, i.e., regional blood flow, mechanical function and, most importantly, myocardial metabolism. Each of these segments can either be evaluated separately or in combination. This report briefly describes the principles and technological advantages of the imaging device, reviews currently available radioactive tracers and how they can be employed for the assessment of flow, function and metabolism; and, lastly, discusses possible applications of PCT for the study of cardiac physiology or its potential role in the diagnosis of cardiac disease

  7. Applications of positron emission tomography to psychiatry

    International Nuclear Information System (INIS)

    Volkow, N.D.; Brodie, J.D.; Gomez-mont, F.

    1985-01-01

    The brain's inaccessibility has hampered investigation of the metabolic changes underlying the behavioral and psychological symptoms of psychiatric patients. Using positron emission transaxial tomography (PET) to study the functioning human brain opens the possibility of directly investigating the patterns of activity associated with mental illness. A major focus of present-day research in psychiatry has been to identify etiological agents that fit a medical model of psychiatric illness. Experiments seeking pathophysiological indices that would permit objective classification of psychiatric illnesses have failed to reveal consistent abnormalities. The lack of consistency is explained in part by research designs that deal with the brain as if it were a homogeneous organ. PET offers a unique technique for monitoring the regional biochemical activity that is associated with the different ''brain states'' and ''brain traits'' of normal subjects and psychiatric patients

  8. Motion correction in thoracic positron emission tomography

    CERN Document Server

    Gigengack, Fabian; Dawood, Mohammad; Schäfers, Klaus P

    2015-01-01

    Respiratory and cardiac motion leads to image degradation in Positron Emission Tomography (PET), which impairs quantification. In this book, the authors present approaches to motion estimation and motion correction in thoracic PET. The approaches for motion estimation are based on dual gating and mass-preserving image registration (VAMPIRE) and mass-preserving optical flow (MPOF). With mass-preservation, image intensity modulations caused by highly non-rigid cardiac motion are accounted for. Within the image registration framework different data terms, different variants of regularization and parametric and non-parametric motion models are examined. Within the optical flow framework, different data terms and further non-quadratic penalization are also discussed. The approaches for motion correction particularly focus on pipelines in dual gated PET. A quantitative evaluation of the proposed approaches is performed on software phantom data with accompanied ground-truth motion information. Further, clinical appl...

  9. Positron emission tomography and basal ganglia functions

    Energy Technology Data Exchange (ETDEWEB)

    Kato, Motohiro; Otsuka, Makoto; Taniwaki, Koukyo; Hosokawa, Shinichi; Kuwabara, Yasuo; Ichiya, Yuichi [Kyushu Univ., Fukuoka (Japan). Faculty of Medicine

    1990-05-01

    With the advent of positron emission tomography (PET), studies on the human brain function and pathophysiology of brain damage have been extremely progressed. It is well-known that the basal ganglia plays an important role as one of the central nervous system involved in exercise regulation. More recently, the potential involvement of the basal ganglia in psychological processes, such as cognitive function, has been pointed out, receiving much attention. In spite of such a lot of studies, however, basal ganglia function remains unclear. This paper describes the relationships between PET findings and basal ganglia function. PET findings are discussed in relation to brain energy metabolism and striatal dopamine function. Pathophysiology of the basal ganglia are described in terms of the following diseases: Parkinson's disease, Parkinson's syndrome, progressive supranuclear palsy, Huntington's disease, and dystonia. Physiological backgrounds of the basal ganglia for PET images are also referred to. (N.K.) 75 refs.

  10. Instrumentation optimization for positron emission mammography

    International Nuclear Information System (INIS)

    Moses, William W.; Qi, Jinyi

    2003-01-01

    The past several years have seen designs for PET cameras optimized to image the breast, commonly known as Positron Emission Mammography or PEM cameras. The guiding principal behind PEM instrumentation is that a camera whose field of view is restricted to a single breast has higher performance and lower cost than a conventional PET camera. The most common geometry is a pair of parallel planes of detector modules, although geometries that encircle the breast have also been proposed. The ability of the detector modules to measure the depth of interaction (DOI) is also a relevant feature. This paper finds that while both the additional solid angle coverage afforded by encircling the breast and the decreased blurring afforded by the DOI measurement improve performance, the ability to measure DOI is more important than the ability to encircle the breast

  11. Positron emission tomography and basal ganglia functions

    International Nuclear Information System (INIS)

    Kato, Motohiro; Otsuka, Makoto; Taniwaki, Koukyo; Hosokawa, Shinichi; Kuwabara, Yasuo; Ichiya, Yuichi

    1990-01-01

    With the advent of positron emission tomography (PET), studies on the human brain function and pathophysiology of brain damage have been extremely progressed. It is well-known that the basal ganglia plays an important role as one of the central nervous system involved in exercise regulation. More recently, the potential involvement of the basal ganglia in psychological processes, such as cognitive function, has been pointed out, receiving much attention. In spite of such a lot of studies, however, basal ganglia function remains unclear. This paper describes the relationships between PET findings and basal ganglia function. PET findings are discussed in relation to brain energy metabolism and striatal dopamine function. Pathophysiology of the basal ganglia are described in terms of the following diseases: Parkinson's disease, Parkinson's syndrome, progressive supranuclear palsy, Huntington's disease, and dystonia. Physiological backgrounds of the basal ganglia for PET images are also referred to. (N.K.) 75 refs

  12. Fundamental limits of positron emission mammography

    International Nuclear Information System (INIS)

    Moses, William W.; Qi, Jinyi

    2001-01-01

    We explore the causes of performance limitation in positron emission mammography cameras. We compare two basic camera geometries containing the same volume of 511 keV photon detectors, one with a parallel plane geometry and another with a rectangular geometry. We find that both geometries have similar performance for the phantom imaged (in Monte Carlo simulation), even though the solid angle coverage of the rectangular camera is about 50 percent higher than the parallel plane camera. The reconstruction algorithm used significantly affects the resulting image; iterative methods significantly outperform the commonly used focal plane tomography. Finally, the characteristics of the tumor itself, specifically the absolute amount of radiotracer taken up by the tumor, will significantly affect the imaging performance

  13. In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C]MPA compared with [11C]ABT-418 and (S)(-)[11C]nicotine in Rhesus monkeys

    International Nuclear Information System (INIS)

    Sihver, Wiebke; Fasth, Karl-Johan; Oegren, Matthias; Lundqvist, Hans; Bergstroem, Mats; Watanabe, Yasuyoshi; Laangstroem, Bengt; Nordberg, Agneta

    1999-01-01

    The novel 11 C-labeled nicotinic agonist (R,S)-1-[ 11 C]methyl-2(3-pyridyl)azetidine ([ 11 C]MPA) was evaluated as a positron emission tomography (PET) ligand for in vivo characterization of nicotinic acetylcholine receptors in the brain of Rhesus monkeys in comparison with the nicotinic ligands (S)-3-methyl-5-(1-[ 11 C]methyl-2-pyrrolidinyl)isoxazol ([ 11 C]ABT-418) and (S)(-)[ 11 C]nicotine. The nicotinic receptor agonist [ 11 C]MPA demonstrated rapid uptake into the brain to a similar extent as (S)(-) [ 11 C]nicotine and [ 11 C]ABT-418. When unlabeled (S)(-)nicotine (0.02 mg/kg) was administered 5 min before the radioactive tracers, the uptake of [ 11 C]MPA was decreased by 25% in the thalamus, 19% in the temporal cortex, and 11% in the cerebellum, whereas an increase was found for the uptake of (S)(-)[ 11 C]nicotine and [ 11 C]ABT-418. This finding indicates specific binding of [ 11 C]MPA to nicotinic receptors in the brain in a simple classical displacement study. [ 11 C]MPA seems to be a more promising radiotracer than (S)(-)[ 11 C]nicotine or [ 11 C]ABT-418 for PET studies to characterize nicotinic receptors in the brain

  14. Application of mathematical removal of positron range blurring in positron emission tomography

    International Nuclear Information System (INIS)

    Haber, S.F.; Derenzo, S.E.; Uber, D.

    1990-01-01

    The range of positrons in tissue is an important limitation to the ultimate spatial resolution achievable in positron emission tomography. In this work the authors have applied a Fourier deconvolution technique to remove range blurring in images taken by the Donner 600-crystal positron tomograph. Using phantom data, the authors have found significant improvement in the image quality and the FWHM for both 68 Ga and 82 Rb. These were successfully corrected so that the images and FWHM almost matched those of 18 F which has negligible positron range. However, statistical noise was increased by the deconvolution process and it was not practical to recover the full spatial resolution of the tomograph

  15. Cardiological applications of positron emission tomography

    International Nuclear Information System (INIS)

    Schelbert, H.; Czernin, J.

    1994-01-01

    Positron emission tomography (PET) expands the diagnostic possibilities of nuclear medicine techniques for the diagnosis of coronary artery disease and, especially, for the identification of myocardial viability. The presence of coronary artery disease can be detected by evaluation of myocardial blood flow at rest and during pharmacologically induced hyperemia with a sensitivity of 84 to 98% and a specificity of 78 to 100% according to recent studies. Comparative investigations in the same patients have demonstrated a significant gain in the diagnostic accuracy of PET as compared with single photon emission computed tomography (SPECT). PET has influenced even more profoundly the identification of myocardial viability. Measured against the functional outcome of regional contractile function after successful revascularization, an increase of glucose utilization relative to regional myocardial blood flow is 77 to 85% accurate in identifying reversibly injured myocardium. Conversely, PET is 78 to 92% accurate in identifying myocardium as irreversibly injured when pre-operative glucose uptake was reduced or absent. Recent studies have indicated that it is possible to predict to some extent post-revascularization improvement in left ventricular function as well as in congestive heart failure related symptoms in patients with ischemic cardiomyopathy. Furthermore, PET can identify patients with an increased risk of mortality and morbidity as a result of ischemic heart disease and, thus, stratify patients to the most appropriate and cost-effective therapeutic approach. (authors)

  16. Simultaneous emission and transmission scanning in positron emission tomography

    International Nuclear Information System (INIS)

    Satoh, Tomohiko; Tanaka, Kazumi; Kitamura, Keishi; Amano, Masaharu; Miura, Shuichi

    2001-01-01

    Examination by PET (positron emission tomography) scanning, following the dosage of 2-deoxy- 18 F fluoro-D-glucose (FDG), is positively utilized for the diagnosis of cancers, rather than for the purpose of studies. This is because the examination by FDG-PET (PET scanning following the dosage of FDG) ensures higher efficiency in discrimination of cancers, than conventional CT and PET. The method of whole body scanning by PET scanning following the dosage of FDG is effectively utilized not only for discrimination cancers, but also for determining the degree of malignancy of tumors and evaluating the methods of treatment of cancers. In conventional methods for examining the degree of malignancy of tumors and evaluating the methods of cancer treatment, it is necessary to correct for the gamma-ray attenuation, which requires a longer time for examination, increasing the physical and psychological pains of the patients. We have installed the simultaneous emission and transmission scanning capability into the HEADTOME-V of the Shimadzu SET-2000W Series positron emission tomographic scanning instruments, to establish an instrument that permits FDG-PET whole body scanning in actual clinical fields, with minimized physical and psychological pains of patients concerned, yet ensuring an outstandingly high examination efficiency. This report also presents some data obtained by this newly developed instrument and those obtained in practical applications. (author)

  17. Positron emission tomography in drug development and drug evaluation

    NARCIS (Netherlands)

    Paans, AMJ; Vaalburg, W

    2000-01-01

    Positron Emission Tomography (PET) is an imaging modality which can determine biochemical and physiological processes in vivo in a quantitative way by using radiopharmaceuticals labeled with positron emitting radionuclides as C-11, N-13, O-15 and F-18 and by measuring the annihilation radiation

  18. Recent developments in positron emission tomography (PET) instrumentation

    Energy Technology Data Exchange (ETDEWEB)

    Derenzo, S.E.; Budinger, T.F.

    1986-04-01

    This paper presents recent detector developments and perspectives for positron emission tomography (PET) instrumentation used for medical research, as well as the physical processes in positron annihilation, photon scattering and detection, tomograph design considerations, and the potentials for new advances in detectors. 117 refs., 4 figs., 4 tabs.

  19. Recent developments in positron emission tomography (PET) instrumentation

    International Nuclear Information System (INIS)

    Derenzo, S.E.; Budinger, T.F.

    1986-04-01

    This paper presents recent detector developments and perspectives for positron emission tomography (PET) instrumentation used for medical research, as well as the physical processes in positron annihilation, photon scattering and detection, tomograph design considerations, and the potentials for new advances in detectors. 117 refs., 4 figs., 4 tabs

  20. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots

    International Nuclear Information System (INIS)

    Chen, Kai; Li, Zi-Bo; Wang, Hui; Cai, Weibo; Chen, Xiaoyuan

    2008-01-01

    To date, the in vivo imaging of quantum dots (QDs) has been mostly qualitative or semiquantitative. The development of a dual-function positron emission tomography (PET)/near-infrared fluorescence (NIRF) probe might allow the accurate assessment of the tumor-targeting efficacy of QDs. An amine-functionalized QD was conjugated with VEGF protein and DOTA chelator for VEGFR-targeted PET/NIRF imaging after 64 Cu-labeling. The targeting efficacy of this dual functional probe was evaluated in vitro and in vivo through cell-binding assay, cell staining, in vivo optical/PET imaging, ex vivo optical/PET imaging, and histology. The DOTA-QD-VEGF exhibited VEGFR-specific binding in both cell-binding assay and cell staining experiment. Both NIR fluorescence imaging and microPET showed VEGFR-specific delivery of conjugated DOTA-QD-VEGF nanoparticle and prominent reticuloendothelial system uptake. The U87MG tumor uptake of 64 Cu-labeled DOTA-QD was less than one percentage injected dose per gram (%ID/g), significantly lower than that of 64 Cu-labeled DOTA-QD-VEGF (1.52±0.6%ID/g, 2.81±0.3%ID/g, 3.84± 0.4%ID/g, and 4.16±0.5%ID/g at 1,4,16, and 24 h post injection, respectively; n=3). Good correlation was also observed between the results measured by ex vivo PET and NIRF organ imaging. Histologic examination revealed that DOTA-QD-VEGF primarily targets the tumor vasculature through a VEGF-VEGFR interaction. We have successfully developed a QD-based nanoprobe for dual PET and NIRF imaging of tumor VEGFR expression. The success of this bifunctional imaging approach may render higher degree of accuracy for the quantitative targeted NIRF imaging in deep tissue. (orig.)

  1. Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors in older, healthy adults

    International Nuclear Information System (INIS)

    Chow, Tiffany W; Mamo, David C; Uchida, Hiroyuki; Graff-Guerrero, Ariel; Houle, Sylvain; Smith, Gwenn S; Pollock, Bruce G; Mulsant, Benoit H

    2009-01-01

    Position emission tomography (PET) imaging using [ 18 F]-setoperone to quantify cortical 5-HT 2A receptors has the potential to inform pharmacological treatments for geriatric depression and dementia. Prior reports indicate a significant normal aging effect on serotonin 5HT 2A receptor (5HT 2A R) binding potential. The purpose of this study was to assess the test-retest variability of [ 18 F]-setoperone PET with a high resolution scanner (HRRT) for measuring 5HT 2A R availability in subjects greater than 60 years old. Methods: Six healthy subjects (age range = 65–78 years) completed two [ 18 F]-setoperone PET scans on two separate occasions 5–16 weeks apart. The average difference in the binding potential (BP ND ) as measured on the two occasions in the frontal and temporal cortical regions ranged between 2 and 12%, with the lowest intraclass correlation coefficient in anterior cingulate regions. We conclude that the test-retest variability of [ 18 F]-setoperone PET in elderly subjects is comparable to that of [ 18 F]-setoperone and other 5HT 2A R radiotracers in younger subject samples

  2. Amorphous silicon detectors in positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Conti, M. (Istituto Nazionale di Fisica Nucleare, Pisa (Italy) Lawrence Berkeley Lab., CA (USA)); Perez-Mendez, V. (Lawrence Berkeley Lab., CA (USA))

    1989-12-01

    The physics of the detection process is studied and the performances of different Positron Emission Tomography (PET) system are evaluated by theoretical calculation and/or Monte Carlo Simulation (using the EGS code) in this paper, whose table of contents can be summarized as follows: a brief introduction to amorphous silicon detectors and some useful equation is presented; a Tantalum/Amorphous Silicon PET project is studied and the efficiency of the systems is studied by Monte Carlo Simulation; two similar CsI/Amorphous Silicon PET projects are presented and their efficiency and spatial resolution are studied by Monte Carlo Simulation, light yield and time characteristics of the scintillation light are discussed for different scintillators; some experimental result on light yield measurements are presented; a Xenon/Amorphous Silicon PET is presented, the physical mechanism of scintillation in Xenon is explained, a theoretical estimation of total light yield in Xenon and the resulting efficiency is discussed altogether with some consideration of the time resolution of the system; the amorphous silicon integrated electronics is presented, total noise and time resolution are evaluated in each of our applications; the merit parameters {epsilon}{sup 2}{tau}'s are evaluated and compared with other PET systems and conclusions are drawn; and a complete reference list for Xenon scintillation light physics and its applications is presented altogether with the listing of the developed simulation programs.

  3. Positron emission particle tracking in pulsatile flow

    Energy Technology Data Exchange (ETDEWEB)

    Patel, Nitant; Ruggles, Arthur [University of Tennessee-Knoxville, Department of Nuclear Engineering, Knoxville, TN (United States); Wiggins, Cody [University of Tennessee-Knoxville, Department of Physics and Astronomy, Knoxville, TN (United States)

    2017-05-15

    Positron emission particle tracking (PEPT) is increasingly used to understand the flow characteristics in complex systems. This research utilizes PEPT to measure pulsatile flow of frequency 2.1 Hz in an elastic Masterkleer PVC tube of 19 mm inner diameter and 3.2 mm wall thickness. Anion exchange resin beads are labeled with {sup 18}F and delivered to a pump driven flow loop with motorized ball valve used to develop the pulsatile flow. Data are collected in the tube with circular cross section, and measurements are also collected with a section of the tube pinched. Nominal flow velocities are near 1 m/s and Reynolds numbers near 20,000. Many thousand PEPT particle traces are collected and synchronized with the flow pulsation. These Lagrangian data are presented as a series of 20 still frames depicting the 3-D velocity field present during each phase of the flow pulsation. Pressure data are also collected to resolve the pressure wave front moving through the open elastic tube at velocity 15.2 m/s. (orig.)

  4. Functional cardiac imaging: positron emission tomography

    International Nuclear Information System (INIS)

    Mullani, N.A.; Gould, K.L.

    1984-01-01

    Dynamic cardiovascular imaging plays a vital role in the diagnosis and treatment of cardiac disease by providing information about the function of the heart. During the past 30 years, cardiovascular imaging has evolved from the simple chest x-ray and fluoroscopy to such sophisticated techniques as invasive cardiac angiography and cinearteriography and, more recently, to noninvasive cardiac CT scanning, nuclear magnetic resonance, and positron emission tomography, which reflect more complex physiologic functions. As research tools, CT, NMR, and PET provide quantitative information on global as well as regional ventricular function, coronary artery stenosis, myocardial perfusion, glucose and fatty acid metabolism, or oxygen utilization, with little discomfort or risk to the patient. As imaging modalities become more sophisticated and more oriented toward clinical application, the prospect of routinely obtaining such functional information about the heart is becoming realistic. However, these advances are double-edged in that the interpretation of functional data is more complex than that of the anatomic imaging familiar to most physicians. They will require an enhanced understanding of the physiologic and biochemical processes, as well as of the instrumentation and techniques for analyzing the data. Of the new imaging modalities that provide functional information about the heart, PET is the most useful because it quantitates the regional distribution of radionuclides in vivo. Clinical applications, interpretation of data, and the impact of PET on our understanding of cardiac pathophysiology are discussed. 5 figures

  5. Amorphous silicon detectors in positron emission tomography

    International Nuclear Information System (INIS)

    Conti, M.; Perez-Mendez, V.

    1989-12-01

    The physics of the detection process is studied and the performances of different Positron Emission Tomography (PET) system are evaluated by theoretical calculation and/or Monte Carlo Simulation (using the EGS code) in this paper, whose table of contents can be summarized as follows: a brief introduction to amorphous silicon detectors and some useful equation is presented; a Tantalum/Amorphous Silicon PET project is studied and the efficiency of the systems is studied by Monte Carlo Simulation; two similar CsI/Amorphous Silicon PET projects are presented and their efficiency and spatial resolution are studied by Monte Carlo Simulation, light yield and time characteristics of the scintillation light are discussed for different scintillators; some experimental result on light yield measurements are presented; a Xenon/Amorphous Silicon PET is presented, the physical mechanism of scintillation in Xenon is explained, a theoretical estimation of total light yield in Xenon and the resulting efficiency is discussed altogether with some consideration of the time resolution of the system; the amorphous silicon integrated electronics is presented, total noise and time resolution are evaluated in each of our applications; the merit parameters ε 2 τ's are evaluated and compared with other PET systems and conclusions are drawn; and a complete reference list for Xenon scintillation light physics and its applications is presented altogether with the listing of the developed simulation programs

  6. Positron emission tomography for the assessment of myocardial viability

    International Nuclear Information System (INIS)

    Schelbert, H.R.

    1991-01-01

    The detection of viable myocardium or ischemically injured myocardium with a reversible impairment of contractile function remains clinically important but challenging. Detection of reversible dysfunction and distinction from irreversible tissue injury by positron emission tomography is based on identification of preserved or even enhanced glucose metabolism with F-18 2-fluoro 2-deoxyglucose. Regional patterns of myocardial glucose utilization and blood flow, defined as perfusion-metabolism mismatches or matches, on positron emission tomography in patients with chronic or even acute ischemic heart disease are highly accurate in predicting the functional outcome after interventional revascularization. Compared with thallium-201 redistribution scintigraphy, positron emission tomography appears to be diagnostically more accurate, especially in patients with severely impaired left ventricular function. While larger clinical trials are needed for further confirmation, positron emission tomography has already proved clinically useful for stratifying patients with poor left ventricular function to the most appropriate therapeutic approach

  7. Simulation of the annihilation emission of galactic positrons

    International Nuclear Information System (INIS)

    Gillard, W.

    2008-01-01

    Positrons annihilate in the central region of our Galaxy. This has been known since the detection of a strong emission line centered on an energy of 511 keV in the direction of the Galactic center. This gamma-ray line is emitted during the annihilation of positrons with electrons from the interstellar medium. The spectrometer SPI, onboard the INTEGRAL observatory, performed spatial and spectral analyses of the positron annihilation emission. This thesis presents a study of the Galactic positron annihilation emission based on models of the different interactions undergone by positrons in the interstellar medium. The models are relied on our present knowledge of the properties of the interstellar medium in the Galactic bulge, where most of the positrons annihilate, and of the physics of positrons (production, propagation and annihilation processes). In order to obtain constraints on the positrons sources and physical characteristics of the annihilation medium, we compared the results of the models to measurements provided by the SPI spectrometer. (author)

  8. The practicality of high magnification imaging by positron emission

    International Nuclear Information System (INIS)

    Hulett, L.D. Jr.; Pendyala, S.

    1988-01-01

    The positron emission microscope has the capability of contrasting areas having high concentrations of monatomic vacancies and other defects. Since the positrons traveling through the specimen will have energies of the same magnitude as that of valence electrons, image contrast will be sensitive to the chemistry of the specimen. In the near future resolutions of 10 nm or lower will be achieved. Whether or not optical aberrations will permit one atom resolution is not clear. For one atom resolution to be obtained positron emission fluxes must be brightness enhanced to 10 11 sec/sup/minus/1/cm/sup/minus/2/ or greater. 5 refs., 1 fig

  9. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with {sup 68}Ga-DOTA-octreotide: A potential PET tracer for beta cell mass measurement

    Energy Technology Data Exchange (ETDEWEB)

    Sako, Takeo [Division of Bio-function Dynamics Imaging, RIKEN Center for Life Science Technologies, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047 (Japan); Division of Molecular Imaging, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047 (Japan); Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017 (Japan); Hasegawa, Koki; Nishimura, Mie; Kanayama, Yousuke; Wada, Yasuhiro; Hayashinaka, Emi; Cui, Yilong; Kataoka, Yosky [Division of Bio-function Dynamics Imaging, RIKEN Center for Life Science Technologies, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047 (Japan); Senda, Michio [Division of Bio-function Dynamics Imaging, RIKEN Center for Life Science Technologies, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047 (Japan); Division of Molecular Imaging, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047 (Japan); Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017 (Japan); Watanabe, Yasuyoshi, E-mail: yywata@riken.jp [Division of Bio-function Dynamics Imaging, RIKEN Center for Life Science Technologies, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047 (Japan)

    2013-12-06

    Highlights: •PET images showed high uptake of {sup 68}Ga-DOTA-octreotide in the normal pancreas. •{sup 68}Ga-DOTA-octreotide specifically binds to somatostatin receptors in the pancreas. •The pancreatic uptake of {sup 68}Ga-DOTA-octreotide was decreased in the diabetic rats. •{sup 68}Ga-DOTA-octreotide could be a candidate PET probe to measure the beta cell mass. -- Abstract: Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia, and the loss or dysfunction of pancreatic beta cells has been reported before the appearance of clinical symptoms and hyperglycemia. To evaluate beta cell mass (BCM) for improving the detection and treatment of DM at earlier stages, we focused on somatostatin receptors that are highly expressed in the pancreatic beta cells, and developed a positron emission tomography (PET) probe derived from octreotide, a metabolically stable somatostatin analog. Octreotide was conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), a chelating agent, and labeled with {sup 68}Gallium ({sup 68}Ga). After intravenous injection of {sup 68}Ga-DOTA-octreotide, a 90-min emission scan of the abdomen was performed in normal and DM model rats. The PET studies showed that {sup 68}Ga-DOTA-octreotide radioactivity was highly accumulated in the pancreas of normal rats and that the pancreatic accumulation was significantly reduced in the rats administered with an excess amount of unlabeled octreotide or after treatment with streptozotocin, which was used for the chemical induction of DM in rats. These results were in good agreement with the ex vivo biodistribution data. These results indicated that the pancreatic accumulation of {sup 68}Ga-DOTA-octreotide represented specific binding to the somatostatin receptors and reflected BCM. Therefore, PET imaging with {sup 68}Ga-DOTA-octreotide could be a potential tool for evaluating BCM.

  10. Simulation of the annihilation emission of galactic positrons; Modelisation de l'emission d'annihilation des positrons Galactiques

    Energy Technology Data Exchange (ETDEWEB)

    Gillard, W

    2008-01-15

    Positrons annihilate in the central region of our Galaxy. This has been known since the detection of a strong emission line centered on an energy of 511 keV in the direction of the Galactic center. This gamma-ray line is emitted during the annihilation of positrons with electrons from the interstellar medium. The spectrometer SPI, onboard the INTEGRAL observatory, performed spatial and spectral analyses of the positron annihilation emission. This thesis presents a study of the Galactic positron annihilation emission based on models of the different interactions undergone by positrons in the interstellar medium. The models are relied on our present knowledge of the properties of the interstellar medium in the Galactic bulge, where most of the positrons annihilate, and of the physics of positrons (production, propagation and annihilation processes). In order to obtain constraints on the positrons sources and physical characteristics of the annihilation medium, we compared the results of the models to measurements provided by the SPI spectrometer. (author)

  11. Shielding design for positron emission tomography facility

    International Nuclear Information System (INIS)

    Abdallah, I.I.

    2007-01-01

    With the recent advent of readily available tracer isotopes, there has been marked increase in the number of hospital-based and free-standing positron emission tomography (PET) clinics. PET facilities employ relatively large activities of high-energy photon emitting isotopes, which can be dangerous to the health of humans and animals. This coupled with the current dose limits for radiation worker and members of the public can result in shielding requirements. This research contributes to the calculation of the appropriate shielding to keep the level of radiation within an acceptable recommended limit. Two different methods were used including measurements made at selected points of an operating PET facility and computer simulations by using Monte Carlo Transport Code. The measurements mainly concerned the radiation exposure at different points around facility using the survey meter detectors and Thermoluminescent Dosimeters (TLD). Then the set of manual calculation procedures were used to estimate the shielding requirements for a newly built PEF facility. The results from the measurement and the computer simulation were compared to the results obtained from the set manual calculation procedure. In general, the estimated weekly dose at the points of interest is lower than the regulatory limits for the little company of Mary Hospital. Furthermore, the density and the HVL for normal strength concrete and clay bricks are almost similar. In conclusion, PET facilities present somewhat different design requirements and are more likely to require additional radiation shielding. Therefore, existing shields at the little Company of Mary Hospital are in general found to be adequate and satisfactory and additional shielding was found necessary at the new PET facility in the department of Nuclear Medicine of the Dr. George Mukhari Hospital. By use of appropriate design, by implying specific shielding requirements and by maintaining good operating practices, radiation doses to

  12. Fluorinated tracers for imaging cancer with positron emission tomography

    International Nuclear Information System (INIS)

    Couturier, Olivier; Chatal, Jean-Francois; Luxen, Andre; Vuillez, Jean-Philippe; Rigo, Pierre; Hustinx, Roland

    2004-01-01

    2-[ 18 F]fluoro-2-deoxy-d-glucose (FDG) is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET imaging owing to the low positron energy (0.64 MeV), which not only limits the dose rate to the patient but also results in a relatively short range of emission in tissue, thereby providing high-resolution images. Further, the 110-min physical half-life allows for high-yield radiosynthesis, transport from the production site to the imaging site and imaging protocols that may span hours, which permits dynamic studies and assessment of potentially fairly slow metabolic processes. The synthesis of fluorinated tracers as an alternative to FDG was initially tested using nucleophilic fluorination of the molecule, as performed when radiolabelling with iodine-124 or bromide-76. However, in addition to being long, with multiple steps, this procedure is not recommended for bioactive molecules containing reactive groups such as amine or thiol groups. Radiochemical yields are also often low. More recently, radiosynthesis from prosthetic group precursors, which allows easier radiolabelling of biomolecules, has led to the development of numerous fluorinated tracers. Given the wide availability of 18 F, such tracers may well develop into important routine tracers. This article is a review of the literature concerning fluorinated radiotracers recently developed and under investigation for possible PET imaging in cancer patients. Two groups can be distinguished. The first includes ''generalist'' tracers, i.e. tracers amenable to use in a wide variety of tumours and indications, very similar in this respect to FDG. These are tracers for non-specific cell metabolism, such as protein synthesis, amino acid transport, nucleic acid synthesis or membrane component synthesis. The second group consists of ''specific'' tracers for receptor expression (i.e. oestrogens or somatostatin), cell

  13. In-situ positron emission of CO oxidation

    OpenAIRE

    Vonkeman, K.A.; Jonkers, G.; Wal, van der, S.W.A.; Santen, van, R.A.

    1993-01-01

    Using a Neuro ECAT positron tomog., the Positron Emission computed Tomog. (PET) was utilized to image the catalytic oxidn. of CO by using CO and CO2, labeled with short lived positron emitting nuclides. Studies were performed over highly dispersed CeO2/g-Al2O3 supported Pt and Rh catalysts. With a math. model of the reaction kinetics, based on the elementary steps of the catalytic reaction and partially on literature surface science data, the effect of CeO2 promotion and the presence of NO we...

  14. A new liquid xenon scintillation detector for positron emission tomography

    International Nuclear Information System (INIS)

    Chepel, V.Yu.

    1993-01-01

    A new positron-sensitive detector of annihilation photons filled with liquid xenon is proposed for positron emission tomography. Simultaneous detection of both liquid xenon scintillation and ionization current produces a time resolution of < 1 ns and a position resolution in the tangential direction of the tomograph ring is ∼ 1 mm and in the radial direction is ∼ 5 mm. The advantages of a tomograph with new detectors are discussed. New algorithms of Compton scattering can be used. (author)

  15. Positron emission tomographic imaging of tumors using monoclonal antibodies

    Energy Technology Data Exchange (ETDEWEB)

    Zalutsky, M.R.

    1992-08-01

    This research project is developing methods for utilizing positron emission tomography (PET) to increase the clinical potential of radiolabeled monoclonal antibodies (MAbs). This report describes the development of methods for labeling MAbs and their fragments with positron-emitting halogen nuclides, fluorine-18 and iodine-124. These nulides were selected because of the widespread availability of F-18 and because of our extensive experience in the development of new protein radiohalogenation methods.

  16. Positron emission tomography and cerebral metabolism

    International Nuclear Information System (INIS)

    Comar, D.; Maziere, M.; Zarifian, E.; Naquet, R.

    1979-01-01

    The association of new methods of labelling with short lived radioisotopes and of visualisation 'in vivo' of these labelled molecules by emission tomography, provide the possibility of studying brain metabolism at different levels. Two examples will illustrate the possibilities of this methodology. Cerebral metabolism of methionine- 11 C in phenylketonutic patients: The cerebral uptake of methionine was measured in 24 PKU children aged 1 to 40 months on a low protein diet. Ten of them were examined twice at intervals of several months. Stopping the diet for one week leads to an increase in blood phenylalanine and to a significant important decrease in brain uptake of labelled methionine. Futhermore, for children under treatment having a low phenylalanine blood concentration, brain uptake of methionine decreases with age between 1 and 40 months. These results suggest that the treatment of this disease should be started as soon as possible after birth. Cerebral metabolism of psychoactive drugs: The study of the brain distribution and kinetics of psychoactive drugs may help in understanding their mode of action. Chlorpromazine- 11 C was administered i.v. to schyzophrenic patients not previously treated with neuroleptics. In all patients the brain uptake of the drug was high and rapid, and was localized mainly in the grey matter, probably in proportion to the blood flow. Non-specific binding of this drug to brain proteins prevented visualization of specific binding to dopaminergic or αnor-adrenergic receptors. Specific receptor binding of benzodiazepines was however visualized in the brain of baboons after injection of 11 C-flunitrazepam (specific activity = 600 Ci/μmole) and subsequent displacement of this radioactive ligand by a pharmacological dose of Lorazepam

  17. Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging

    International Nuclear Information System (INIS)

    Evens, Nele; Muccioli, Giulio G.; Houbrechts, Nele; Lambert, Didier M.; Verbruggen, Alfons M.; Van Laere, Koen; Bormans, Guy M.

    2009-01-01

    Introduction: The type 2 cannabinoid (CB 2 ) receptor is part of the endocannabinoid system and has been suggested as a mediator of several central and peripheral inflammatory processes. Imaging of the CB 2 receptor has been unsuccessful so far. We synthesized and evaluated a carbon-11- and a fluorine-18-labeled 2-oxoquinoline derivative as new PET tracers with high specificity and affinity for the CB 2 receptor. Methods: Two 2-oxoquinoline derivatives were synthesized and radiolabeled with either carbon-11 or fluorine-18. Their affinity and selectivity for the human CB 2 receptor were determined. Biological evaluation was done by biodistribution, radiometabolite and autoradiography studies in mice. Results: In vitro studies showed that both compounds are high affinity CB 2 -specific inverse agonists. Biodistribution study of the tracers in mice showed a high in vivo initial brain uptake and fast brain washout, in accordance with the low CB 2 receptor expression levels in normal brain. A persistently high in vivo binding to the spleen was observed, which was inhibited by pretreatment with two structurally unrelated CB 2 selective inverse agonists. In vitro autoradiography studies with the radioligands confirmed CB 2 -specific binding to the mouse spleen. Conclusion: We synthesized two novel CB 2 receptor PET tracers that show high affinity/selectivity for CB 2 receptors. Both tracers show favourable characteristics as radioligands for central and peripheral in vivo visualization of the CB 2 receptor and are promising candidates for primate and human CB 2 PET imaging.

  18. In vitro and in vivo binding of neuroactive steroids to the sigma-1 receptor as measured with the positron emission tomography radioligand [18F]FPS.

    Science.gov (United States)

    Waterhouse, Rikki N; Chang, Raymond C; Atuehene, Nana; Collier, Thomas Lee

    2007-07-01

    Sigma-1 receptors are widely expressed in the mammalian brain and also in organs of the immune, endocrine and reproductive systems. Based on behavioral and pharmacological assessments, sigma-1 receptors are important in memory and cognitive processes, and are thought to be involved in specific psychiatric illnesses, including schizophrenia, depression, and drug addiction. It is thought that specific neuroactive steroids are endogenous ligands for these sites. In addition, several sigma-1 receptor binding steroids including progesterone, dihydroepiandrosterone (DHEA), and testosterone are being examined clinically for specific therapeutic purposes; however, their mechanisms of action have not been clearly defined. We previously described the high affinity sigma-1 receptor selective PET tracer [(18)F]FPS. This study examines the effect of neuroactive steroids on [(18)F]FPS binding in vitro and in vivo. Inhibition constants were determined in vitro for progesterone, testosterone, DHEA, estradiol, and estriol binding to the [(18)F]FPS labeled receptor. The affinity order (K(i) values) for these steroids ranged from 36 nM for progesterone to >10,000 nM for estrodiol and estriol. Biodistribution studies revealed that i.v. coadministration of progesterone (10 mg/kg), testosterone (20 mg/kg), or DHEA (20 mg/kg) significantly decreased [(18)F]FPS uptake (%ID/g) by up to 50% in nearly all of eight brain regions examined. [(18)F]FPS uptake in several peripheral organs that express sigma-1 receptors (heart, spleen, muscle, lung) was also reduced (54-85%). These studies clearly demonstrate that exogenously administered steroids can occupy sigma-1 receptors in vivo, and that [(18)F]FPS may provide an effective tool for monitoring sigma-1 receptor occupancy of specific therapeutic steroids during clinical trials.

  19. New detector developments for high resolution positron emission tomography

    International Nuclear Information System (INIS)

    Ziegler, S.I.; Pichler, B.; Lorenz, E.

    1998-01-01

    The strength of quantitative, functional imaging using positron emission tomography, specially in small animals, is limited due to the spatial resolution. Therefore, various tomograph designs employing new scintillators, light sensors, or coincidence electronic are investigated to improve resolution without losses in sensitivity. Luminous scintillators with short light decay time in combination with novel readout schemes using photomultipliers or semiconductor detectors are currently tested by several groups and are implemented in tomographs for small animals. This review summarises the state of development in high resolution positron emission tomography with a detailed description of a system incorporating avalanche photodiode arrays and small scintillation crystals. (orig.) [de

  20. Positron emission tomography in oncology. Council on Scientific Affairs

    International Nuclear Information System (INIS)

    Anon.

    1988-01-01

    This report describes the current and potential uses of positron emission tomography in clinical medicine and research related to oncology. Assessment will be possible of metabolism and physiology of tumors and their effects on adjacent tissues. Specific probes are likely to be developed for target sites on tumors, including monoclonal antibodies and specific growth factors that recognize tumors. To date, most oncological applications of positron emission tomography tracers have been qualitative; in the future, quantitative metabolic measurements should aid in the evaluation of tumor biology and response to treatment. 41 references

  1. Physical and technical basis of positron emission tomography (PET)

    International Nuclear Information System (INIS)

    Bauer, R.

    1994-01-01

    Positron emission tomography utilizes the annihilation of positrons, generating pairs of gamma quanta which are emitted in opposing directions. 'Electronic collimation' is performed by coincident detection of both quanta. Thus, there is no need for mechanical collimators and no limiting connection between sensitivity and spatial resolution. Transversal tomograms are reconstructed from the projection data by means of highly sophisticated data processing. The half life of the most positron emitters used in medical applications is short and of the order of some minutes. Therefore, many positron emitters have to be produced on-side by means of a cyclotron. PET is superior to SPECT with respect to physical and technical aspects, but the high costs of PET limit its wide-spread use up to now. (orig.) [de

  2. Positron emission tomographic imaging of cardiac sympathetic innervation and function

    International Nuclear Information System (INIS)

    Goldstein, D.S.; Chang, P.C.; Eisenhofer, G.; Miletich, R.; Finn, R.; Bacher, J.; Kirk, K.L.; Bacharach, S.; Kopin, I.J.

    1990-01-01

    Sites of uptake, storage, and metabolism of [ 18 F]fluorodopamine and excretion of [ 18 F]fluorodopamine and its metabolites were visualized using positron emission tomographic (PET) scanning after intravenous injection of the tracer into anesthetized dogs. Radioactivity was concentrated in the renal pelvis, heart, liver, spleen, salivary glands, and gall bladder. Uptake of 18F by the heart resulted in striking delineation of the left ventricular myocardium. Pretreatment with desipramine markedly decreased cardiac positron emission, consistent with dependence of the heart on neuronal uptake (uptake-1) for removal of circulating catecholamines. In reserpinized animals, cardiac positron emission was absent within 30 minutes after injection of [ 18 F]-6-fluorodopamine, demonstrating that the emission in untreated animals was from radioactive labeling of the sympathetic storage vesicles. Decreased positron emission from denervated salivary glands confirmed that the tracer was concentrated in sympathetic neurons. Radioactivity in the gall bladder and urinary system depicted the hepatic and renal excretion of the tracer and its metabolites. Administration of tyramine or nitroprusside increased and ganglionic blockade with trimethaphan decreased the rate of loss of myocardial radioactivity. The results show that PET scanning after administration of [ 18 F]fluorodopamine can be used to visualize sites of sympathetic innervation, follow the metabolism and renal and hepatic excretion of catecholamines, and examine cardiac sympathetic function

  3. Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB{sub 1} receptors using positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Terry, Garth E. [National Institute of Mental Health, Molecular Imaging Branch, Bethesda, MD (United States); Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Stockholm (Sweden); Hirvonen, Jussi; Liow, Jeih-San; Seneca, Nicholas; Morse, Cheryl L.; Pike, Victor W.; Innis, Robert B. [National Institute of Mental Health, Molecular Imaging Branch, Bethesda, MD (United States); Tauscher, Johannes T.; Schaus, John M.; Phebus, Lee; Felder, Christian C. [Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN (United States); Halldin, Christer [Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Stockholm (Sweden)

    2010-08-15

    Cannabinoid subtype 1 (CB{sub 1}) receptors are found in nearly every organ in the body, may be involved in several neuropsychiatric and metabolic disorders, and are therefore an active target for pharmacotherapy and biomarker development. We recently reported brain imaging of CB{sub 1} receptors with two PET radioligands: {sup 11}C-MePPEP and {sup 18}F-FMPEP-d{sub 2}. Here we describe the biodistribution and dosimetry estimates for these two radioligands. Seven healthy subjects (four men and three women) underwent whole-body PET scans for 120 min after injection with {sup 11}C-MePPEP. Another seven healthy subjects (two men and five women) underwent whole-body PET scans for 300 min after injection with {sup 18}F-FMPEP-d{sub 2}. Residence times were acquired from regions of interest drawn on tomographic images of visually identifiable organs for both radioligands and from radioactivity excreted in urine for {sup 18}F-FMPEP-d{sub 2}. The effective doses of {sup 11}C-MePPEP and {sup 18}F-FMPEP-d{sub 2} are 4.6 and 19.7 {mu}Sv/MBq, respectively. Both radioligands demonstrated high uptake of radioactivity in liver, lung, and brain shortly after injection and accumulated radioactivity in bone marrow towards the end of the scan. After injection of {sup 11}C-MePPEP, radioactivity apparently underwent hepatobiliary excretion only, while radioactivity from {sup 18}F-FMPEP-d{sub 2} showed both hepatobiliary and urinary excretion. {sup 11}C-MePPEP and {sup 18}F-FMPEP-d{sub 2} yield an effective dose similar to other PET radioligands labeled with either {sup 11}C or {sup 18}F. The high uptake in brain confirms the utility of these two radioligands to image CB{sub 1} receptors in brain, and both may also be useful to image CB{sub 1} receptors in the periphery. (orig.)

  4. 3D fast reconstruction in positron emission tomography

    International Nuclear Information System (INIS)

    Egger, M.L.; Scheurer, A. Hermann; Joseph, C.; Morel, C.

    1996-01-01

    The issue of long reconstruction times in positron emission tomography (PET) has been addressed from several points of view, resulting in an affordable dedicated system capable of handling routine 3D reconstructions in a few minutes per frame : on the hardware side using fast processors and a parallel architecture, and on the software side, using efficient implementation of computationally less intensive algorithms

  5. Time-of-flight positron emission tomography and associated detectors

    International Nuclear Information System (INIS)

    Vacher, J.; Allemand, R.; Campagnolo, R.

    1983-04-01

    An analysis of the timing capabilities of the detectors (scintillators and photomultipliers) in time-of-flight positron emission tomography is presented. The advantages of BaF 2 compared with CsF for the futur tomographs are evaluated [fr

  6. Cobalt-55 positron emission tomography in recurrent ischaemic stroke

    NARCIS (Netherlands)

    De Reuck, J; Santens, P; Keppens, J; De Bleecker, J; Strijckmans, K; Goethals, P; Lemahieu, [No Value; Korf, J

    The present study investigates if Cobalt-55 (Co-55) positron emission tomography (PET) allows us to distinguish and detect recent, recurrent strokes in patients who had already suffered a previous infarct in the same vascular territory. Fourteen patients with recurrent strokes underwent a Co-55 PET

  7. Detectors, sampling, shielding, and electronics for positron emission tomography

    International Nuclear Information System (INIS)

    Derenzo, S.E.

    1981-08-01

    A brief discussion of the important design elements for positron emission tomographs is presented. The conclusions are that the instrumentation can be improved by the use of larger numbers of small, efficient detectors closely packed in many rings, the development of new detector materials, and novel electronic designs to reduce the deadtime and increase maximum event rates

  8. Measurement of absolute bone blood flow by positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Nahmias, C.; Cockshott, W.P.; Garnett, E.S.; Belbeck, L.W.

    1986-03-01

    A method of measuring bone blood flow has been developed using /sup 18/F sodium fluoride and positron emission tomography. The blood flow levels are in line with those obtained experimentally from microsphere embolisation. This investigative method could be applied to elucidate a number of clinical questions involving bone perfusion.

  9. Positron emission tomography/computed tomography scanning for ...

    African Journals Online (AJOL)

    Background: Although the site of nosocomial sepsis in the critically ill ventilated patient is usually identifiable, it may remain occult, despite numerous investigations. The rapid results and precise anatomical location of the septic source using positron emission tomography (PET) scanning, in combination with computed ...

  10. MR imaging and positron emission tomography of cortical heterotopia

    Energy Technology Data Exchange (ETDEWEB)

    Bairamian, D.; Di Chiro, G.; Theodore, W.H.; Holmes, M.D.; Dorwart, R.H.; Larson, S.M.

    1985-11-01

    Heterotopia of the gray matter is a developmental malformation in which ectopic cortex is found in the white matter of the brain. A case of a 33-year-old man with cortical heterotopia who had a lifelong history of seizures and psychomotor retardation is reported, including the results of cerebral CT, magnetic resonance imaging, and positron emission tomography using YF-2-deoxyglucose.

  11. MR imaging and positron emission tomography of cortical heterotopia

    International Nuclear Information System (INIS)

    Bairamian, D.; Di Chiro, G.; Theodore, W.H.; Holmes, M.D.; Dorwart, R.H.; Larson, S.M.

    1985-01-01

    Heterotopia of the gray matter is a developmental malformation in which ectopic cortex is found in the white matter of the brain. A case of a 33-year-old man with cortical heterotopia who had a lifelong history of seizures and psychomotor retardation is reported, including the results of cerebral CT, magnetic resonance imaging, and positron emission tomography using 18 F-2-deoxyglucose

  12. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy

    NARCIS (Netherlands)

    Kole, AC; Plukker, JT; Nieweg, OE; Vaalburg, W

    Positron emission tomography (PET) with [F-18]-fluoro-2-deoxy-D-glucose (FDG) was prospectively investigated as a means of detecting metastatic disease in patients with oesophageal tumours and compared with computerized tomography (CT), with the surgical findings as a gold standard. Twenty-six

  13. Amyloid-β positron emission tomography imaging probes

    DEFF Research Database (Denmark)

    Kepe, Vladimir; Moghbel, Mateen C; Långström, Bengt

    2013-01-01

    , a number of factors appear to preclude these probes from clinical utilization. As the available "amyloid specific" positron emission tomography imaging probes have failed to demonstrate diagnostic value and have shown limited utility for monitoring therapeutic interventions in humans, a debate...

  14. Positron emission tomography of incidentally detected small pulmonary nodules

    DEFF Research Database (Denmark)

    Fischer, B M; Mortensen, J; Dirksen, A

    2004-01-01

    The aim of this study was to assess the value of fluorodeoxyglucose positron emission tomography (FDG PET) imaging of small pulmonary nodules incidentally detected by spiral computed tomography (CT) in a high-risk population. Ten patients (five females, five males, aged 54-72 years) were recruited...

  15. Positron Emission Tomography : background, possibilities and perspectives in neuroscience

    NARCIS (Netherlands)

    Paans, AMJ

    Positron Emission Tomography (PET) is a method for determining biochemical and physiological processes in vivo in a quantitative way. This includes the measurement of the pharmacokinetics of labeled drugs and the measurement of the effects of drugs and/or therapy on metabolism. Also deviations of

  16. Physiopathology of ischemic strokes: the input of positron emission tomography

    International Nuclear Information System (INIS)

    Steinling, M.; Samson, Y.

    1999-01-01

    The tomography by positrons emissions has brought essential physiological and pathological knowledge relative to cerebral vascular accidents in the acute phase, because it is possible to measure the cerebral blood flow, the oxygen extraction rate and the local oxygen consumption. (N.C.)

  17. High resolution and high speed positron emission tomography data acquisition

    International Nuclear Information System (INIS)

    Burgiss, S.G.; Byars, L.G.; Jones, W.F.; Casey, M.E.

    1986-01-01

    High resolution positron emission tomography (PET) requires many detectors. Thus, data collection systems for PET must have high data rates, wide data paths, and large memories to histogram the events. This design uses the VMEbus to cost effectively provide these features. It provides for several modes of operation including real time sorting, list mode data storage, and replay of stored list mode data

  18. Positron emission tomography in presurgical diagnosis of partial epilepsies

    International Nuclear Information System (INIS)

    Hajek, M.; Leenders, K.L.; Wieser, H.G.

    1992-01-01

    We present results of studies in which positron emission tomography was applied to the presurgical evaluation of epileptics. Emphasis is placed on results of PET studies with various tracers in partial epilepsies and on the use of PET in age-related epileptic syndromes in children. (orig.) [de

  19. Serotonin synthesis studied with positron emission tomography, (PET)

    DEFF Research Database (Denmark)

    Honoré, Per Gustaf Hartvig; Lundquist, Pinelopi

    Positron emission tomography (PET) has the potential to study the biosynthesis and release of serotonin (5HT) at brain serotonergic neurons. PET requires probe compounds with specific attributes to enable imaging and quantification of biological processes. This section focuses on probes to measure...

  20. Quantification in dynamic and small-animal positron emission tomography

    NARCIS (Netherlands)

    Disselhorst, Johannes Antonius

    2011-01-01

    This thesis covers two aspects of positron emission tomography (PET) quantification. The first section addresses the characterization and optimization of a small-animal PET/CT scanner. The sensitivity and resolution as well as various parameters affecting image quality (reconstruction settings, type

  1. 77 FR 21783 - Guidance on Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography...

    Science.gov (United States)

    2012-04-11

    ...] Guidance on Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography Drugs... Aseptic Preparations for Positron Emission Tomography (PET) Drugs.'' This guidance is intended to help... Preparations for Positron Emission Tomography (PET) Drugs.'' Most PET drugs are designed for parenteral...

  2. Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours

    OpenAIRE

    Virgolini, Irene; Gabriel, Michael; Kroiss, Alexander; von Guggenberg, Elisabeth; Prommegger, Rupert; Warwitz, Boris; Nilica, Bernhard; Roig, llanos Geraldo; Rodrigues, Margarida; Uprimny, Christian

    2016-01-01

    Physiologically increased pancreatic uptake at the head/uncinate process is observed in more than one-third of patients after injection of one of the three 68Ga-labelled octreotide-based peptides used for somatostatin (sst) receptor (r) imaging. There are minor differences between these 68Ga-sstr-binding peptides in the imaging setting. On 68Ga-sstr-imaging the physiological uptake can be diffuse or focal and usually remains stable over time. Differences in the maximal standardised uptake val...

  3. Positron Emission Tomography Particle tracking using cluster analysis

    International Nuclear Information System (INIS)

    Gundogdu, O.

    2004-01-01

    Positron Emission Particle Tracking was successfully used in a wide range of industrial applications. This technique primarily uses a single positron emitting tracer particle. However, using multiple particles would provide more comparative information about the physical processes taking place in a system such as mixing or fluidised beds. In this paper, a unique method that enables us to track more than one particle is presented. This method is based on the midpoint of the closest distance between two trajectories or coincidence vectors. The technique presented in this paper employs a clustering method

  4. Positron Emission Tomography Particle tracking using cluster analysis

    Energy Technology Data Exchange (ETDEWEB)

    Gundogdu, O. [University of Birmingham, School of Physics and Astronomy, Birmingham, B15 2TT (United Kingdom)]. E-mail: o.gundogdu@surrey.ac.uk

    2004-12-01

    Positron Emission Particle Tracking was successfully used in a wide range of industrial applications. This technique primarily uses a single positron emitting tracer particle. However, using multiple particles would provide more comparative information about the physical processes taking place in a system such as mixing or fluidised beds. In this paper, a unique method that enables us to track more than one particle is presented. This method is based on the midpoint of the closest distance between two trajectories or coincidence vectors. The technique presented in this paper employs a clustering method.

  5. Images to visualize the brain. PET: Positron Emission Tomography

    International Nuclear Information System (INIS)

    1992-01-01

    Diagnosis instrument and research tool, Positron Emission Tomography permits advanced technological developments on positron camera, on molecule labelling and principally on very complex 3D image processing. Cyceron Centre in Caen-France works on brain diseases and try to understand the mechanism of observed troubles and to assess the treatment efficiency with PET. Service Hospitalier Frederic Joliot of CEA-France establishes a mapping of cognitive functions in PET as vision areas, anxiety regions, brain organization of language, different attention forms, voluntary actions and motor functions

  6. Positron emission tomography and migraine. Tomographie par emission de positons et migraine

    Energy Technology Data Exchange (ETDEWEB)

    Chabriat, H. (CEA, 91 - Orsay (France). Service Hospitalier Frederic Joliot)

    1992-04-01

    Positron emission tomography (PET) is a brain imaging technique that allows in vivo studies of numerous physiological parameters. There have been few PET studies in migraine patients. Cerebral blood flow changes with no variations in brain oxygen consumption have been reported in patients with prolonged neurologic manifestations during migraine attacks. Parenteral administration of reserpine during migraine headache has been followed by a fall in the overall cerebral uptake of glucose. The small sample sizes and a number of methodologic problems complicate the interpretation of these results. Recent technical advances and the development of new PET tracers can be expected to provide further insight into the pathophysiology of migraine. Today cerebral cortex 5 HT{sub 2} serotonin receptors can be studied in migraine patients with PET.

  7. Synthesis of N1'-([11C]methyl)naltrindole ([11C]MeMNTI): a radioligand for positron emission tomographic studies of delta opioid receptors

    International Nuclear Information System (INIS)

    Lever, J.R.; Dannals, R.F.; Kinter, C.M.; Mathews, W.B.

    1995-01-01

    A delta opioid receptor antagonist, Nl'-methylnaltrindole (MeNTI), has been labeled with carbon-11. The precursor for radiolabeling was prepared in 71% yield by benzylation of the phenolic moiety of naltrindole. Alkylation of the indole nitrogen using [ 11 C]iodomethane and aqueous tetra(n-butyl)ammonium hydroxide at 80 o C in dimethylformamide followed by hydrogenolysis (H 2 , 10% Pd-C) of the benzyl protecting group gave [ 11 C]MeNTI. The average (n = 10) time for radiosynthesis, HPLC purification and formulation was 24 min from end-of-bombardment. [ 11 C]MeNTI of high radiochemical purity was obtained at end-of-synthesis with an average specific activity of 2050 mCi/μmol and radiochemical yield, based on [ 11 C]iodomethane, of 6%. (Author)

  8. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors

    International Nuclear Information System (INIS)

    Ugur, Oemer; Kothari, Paresh J.; Finn, Ronald D.; Zanzonico, Pat; Ruan, Shutian; Guenther, Ilonka; Maecke, Helmut R.; Larson, Steven M.

    2002-01-01

    Radionuclide labeled somatostatin analogues selectively target somatostatin receptor (SSTR)-expressing tumors as a basis for diagnosis and treatment of these tumors. Recently, a DOTA-functionalized somatostatin analogue, DOTATOC (DOTA-DPhe 1 -Tyr 3 -octreotide) has been developed. This compound has been shown to be superior to the other somatostatin analogues as indicated by its uniquely high tumor-to-non-target tissue ratio. DOTATOC can be labeled with a variety of radiometals including gallium radioisotopes. Gallium-66 is a positron emitting radionuclide (T 1/2 =9.5 hr; β + =56%), that can be produced in carrier free form by a low-beam energy cyclotron. In this study we investigated SSTR targeting characteristics of 66 Ga-DOTATOC in AR42J rat pancreas tumor implanted nude mice as a potential agent for diagnosis and receptor-mediated internal radiotherapy of SSTR-expressing tumors. We compared our results with 67 Ga- and 68 Ga- labeled DOTATOC. The radiolabeling procedure gave labeling yield ranged from 85-95% and radiochemical and chemical purity was >95%. In-vitro competitive binding curves and in-vivo competitive displacement studies with an excess of unlabeled peptide indicates that there is specific binding of the radioligand to SSTR. Animal biodistribution data and serial microPET TM images demonstrated rapid tumor uptake and rapid clearance from the blood and all tissues except kidney. Maximum % ID/g values for tumor were 10.0±0.7, 13.2±2.1 and 9.8±1.5 for 66 Ga-, 67 Ga-, and 68 Ga-DOTATOC, respectively. Calculated tumor, kidney and bone marrow doses for 66 Ga-DOTATOC based on biodistribution data were 178, 109 and 1.2 cGy/MBq, respectively. We conclude that 66 Ga labeled DOTATOC can be used for PET diagnosis and quantitative imaging-based dosimetry of SSTR positive tumors. 66 Ga-DOTATOC may also be used in higher doses for ablation of these tumors. However, kidney is the critical organ for toxicity (tumor/kidney ratio 1.64), and high kidney uptake must

  9. Ga-66 labeled somatostatin analogue DOTA-DPhe{sup 1}-Tyr{sup 3}-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors

    Energy Technology Data Exchange (ETDEWEB)

    Ugur, Oemer E-mail: ougur@hacettepe.edu.tr; Kothari, Paresh J.; Finn, Ronald D.; Zanzonico, Pat; Ruan, Shutian; Guenther, Ilonka; Maecke, Helmut R.; Larson, Steven M

    2002-02-01

    Radionuclide labeled somatostatin analogues selectively target somatostatin receptor (SSTR)-expressing tumors as a basis for diagnosis and treatment of these tumors. Recently, a DOTA-functionalized somatostatin analogue, DOTATOC (DOTA-DPhe{sup 1}-Tyr{sup 3}-octreotide) has been developed. This compound has been shown to be superior to the other somatostatin analogues as indicated by its uniquely high tumor-to-non-target tissue ratio. DOTATOC can be labeled with a variety of radiometals including gallium radioisotopes. Gallium-66 is a positron emitting radionuclide (T{sub 1/2} =9.5 hr; {beta}{sup +}=56%), that can be produced in carrier free form by a low-beam energy cyclotron. In this study we investigated SSTR targeting characteristics of {sup 66}Ga-DOTATOC in AR42J rat pancreas tumor implanted nude mice as a potential agent for diagnosis and receptor-mediated internal radiotherapy of SSTR-expressing tumors. We compared our results with {sup 67}Ga- and {sup 68}Ga- labeled DOTATOC. The radiolabeling procedure gave labeling yield ranged from 85-95% and radiochemical and chemical purity was >95%. In-vitro competitive binding curves and in-vivo competitive displacement studies with an excess of unlabeled peptide indicates that there is specific binding of the radioligand to SSTR. Animal biodistribution data and serial microPET{sup TM} images demonstrated rapid tumor uptake and rapid clearance from the blood and all tissues except kidney. Maximum % ID/g values for tumor were 10.0{+-}0.7, 13.2{+-}2.1 and 9.8{+-}1.5 for {sup 66}Ga-, {sup 67}Ga-, and {sup 68}Ga-DOTATOC, respectively. Calculated tumor, kidney and bone marrow doses for {sup 66}Ga-DOTATOC based on biodistribution data were 178, 109 and 1.2 cGy/MBq, respectively. We conclude that {sup 66}Ga labeled DOTATOC can be used for PET diagnosis and quantitative imaging-based dosimetry of SSTR positive tumors. {sup 66}Ga-DOTATOC may also be used in higher doses for ablation of these tumors. However, kidney is the

  10. Positron emission tomography in a national research centre

    International Nuclear Information System (INIS)

    Weinreich, R.

    1989-01-01

    The example of the Paul Scherrer Institute shows that positron emission tomography can be implanted successfully as spin-off into an appropriate environment. The adaption to the existing irradiation facilities of the technique of production of the short-lived positron emitters is complex. However, the basic necessities of a tomography programme can be covered. Moreover, the relatively high energy of the institute's injector cyclotron allows additional production of rare-used longer-lived positron emitters. The scanner exceeded the guaranteed specifications. With respect to the somewhat lower availability of beam time compared to a usual baby cyclotron, the research programme must not be very patient-intense. A strong participation of the pharmaceutical industry has directed research priorities into the pharmacological area. (orig.) [de

  11. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography

    International Nuclear Information System (INIS)

    Leenders, K.L.; Frackowiak, R.S.; Quinn, N.; Marsden, C.D.

    1986-01-01

    A 48-year-old man with typical Huntington's disease was investigated with computed tomography (CT) and positron emission tomography. Regional cerebral blood flow, oxygen extraction, oxygen and glucose utilization, L-Dopa uptake, and dopamine (D2) receptor binding were measured using several positron-labelled tracers. CT showed slight atrophy of the head of caudate but no cortical atrophy, although distinct frontal lobe dysfunction was present on psychometric testing. Oxygen and glucose metabolism and cerebral blood flow were decreased in the striata and to a lesser extent in frontal cortex. Cerebral blood flow was in the low normal range throughout the remainder of the brain. A normal metabolic ratio was found in all regions, since the changes in glucose utilization paralleled those in oxygen consumption. The capacity of the striatum to store dopamine as assessed by L-[ 18 F]-fluorodopa uptake was normal, but dopamine (D2) receptor binding was decreased when compared to normal subjects

  12. Positron emission tomography: a new paradigm in cancer management

    International Nuclear Information System (INIS)

    Paez Gutierrez, Diana Isabel; De los Reyes, Amelia; Llamas Olier, Augusto

    2007-01-01

    The National Cancer Institute (NCI) is currently building a positron emission tomography facility that will house a cyclotron and a PET fusion scanner. lt should be operational as of december 2007, being a cancer dedicated national referral center, the NCI should provide both positron-emitting radiopharmaceuticals and medical services to institutions and patients nationwide. PET technology provides metabolic information that has been documented to be useful in patient care. The properties of positron decay allow accurate imaging of the in vivo distribution of positron-emitting radiopharmaceuticals. a wide array of positron-emitting radiopharmaceuticals has been used to characterize multiple physiologic and pathologic states. The major clinical PET applications are in cancer patients using fluorine-18 fluorodeoxyglucose (FDG). FDG, an analogue of glucose, accumulates in most tumors in a greater amount than it does in normal tissue. PET is being used in diagnosis and follow-up of several malignancies, and the list of articles supporting its use continues to grow. in this article, the instrumentation aspects of PET are described and most of the clinical applications in oncology are described

  13. [Human positron emission tomography with oral 11C-vinpocetine].

    Science.gov (United States)

    Vas, Adám; Christer, Halldin; Sóvágó, Judit; Johan, Sandell; Cselényi, Zsolt; Kiss, Béla; Kárpáti, Egon; Lars, Farde; Gulyás, Balázs

    2003-11-16

    Positron emission tomography (PET) is a useful tool for the investigation of certain physiological changes and for the evaluation of the distribution, and receptor binding of drugs labelled with positron emitting isotopes. Vinpocetine (ethyl-apovincaminate) is a neuroprotective drug widely used in the prevention and treatment of cerebrovascular diseases. In the clinical practice vinpocetine is usually administered to the patients in intravenous infusion followed by long-term oral treatment. Until presently human data describing vinpocetine's kinetics and brain distribution came from ex vivo (blood, plasma, liquor) and post mortem (brain autoradiography) measurements. The authors wished to investigate the kinetics and distribution of vinpocetine in the brain and body after oral administration with PET in order to prove, that PET is useful in the non-invasive in vivo determination of these parameters. Vinpocetine was labelled with carbon-11 and the radioactivity was measured by PET in the stomach, liver, brain, colon and kidneys in healthy male volunteers. The radioactivity in the blood and urine was also determined. After oral administration, [11C]vinpocetine appeared immediately in the stomach and within minutes in the liver and the blood. In the blood the level of radioactivity continuously increased until the end of the measurement period, whereas the fraction of the unchanged mother compound decreased. Radioactivity uptake and distribution in the brain were demonstrable from the tenth minute after the oral administration of the labelled drug (average maximum uptake: 0.7% of the administered total dose). Brain distribution was heterogeneous (with preferences in the thalamus, basal ganglia and occipital cortex), similar to the distribution previously reported by the authors after intravenous administration. Vinpocetine, administered orally to human volunteers, readily entered the bloodstream from the stomach and the gastrointestinal tract and thereafter passed the

  14. Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours

    International Nuclear Information System (INIS)

    Virgolini, Irene; Gabriel, Michael; Kroiss, Alexander; Guggenberg, Elisabeth von; Prommegger, Rupert; Warwitz, Boris; Nilica, Bernhard; Roig, Ilanos Geraldo; Rodrigues, Margarida; Uprimny, Christian

    2016-01-01

    Physiologically increased pancreatic uptake at the head/uncinate process is observed in more than one-third of patients after injection of one of the three 68 Ga-labelled octreotide-based peptides used for somatostatin (sst) receptor (r) imaging. There are minor differences between these 68 Ga-sstr-binding peptides in the imaging setting. On 68 Ga-sstr-imaging the physiological uptake can be diffuse or focal and usually remains stable over time. Differences in the maximal standardised uptake values (SUV max ) reported for the normal pancreas as well as for pancreatic neuroendocrine tumour (PNET) lesions may be related to several factors, including (a) differences in the peptide binding affinities as well as differences in sstr subtype expression of pancreatic α- and β-cells, and heterogeneity / density of tumour cells, (b) differences in scanner resolution, image reconstruction techniques and acquisition protocols, (c) mostly retrospective study designs, (d) mixed patient populations, or (e) interference with medications such as treatment with long-acting sst analogues. The major limitation in most of the studies lies in the lack of histopathological confirmation of abnormal findings. There is a significant overlap between the calculated SUV max -values for physiological pancreas and PNET-lesions of the head/uncinate process that do not favour the use of quantitative parameters in the clinical setting. Anecdotal long-term follow-up studies have even indicated that increased uptake in the head/uncinate process still can turn out to be malignant over years of follow up. SUV max -data for the pancreatic body and tail are limited. Therefore, any visible focal tracer uptake in the pancreas must be considered as suspicious for malignancy irrespective of quantitative parameters. In general, sstr-PET/CT has significant implications for the management of NET patients leading to a change in treatment decision in about one-third of patients. Therefore, follow-up with 68 Ga

  15. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.

    Science.gov (United States)

    Virgolini, Irene; Gabriel, Michael; Kroiss, Alexander; von Guggenberg, Elisabeth; Prommegger, Rupert; Warwitz, Boris; Nilica, Bernhard; Roig, Llanos Geraldo; Rodrigues, Margarida; Uprimny, Christian

    2016-10-01

    Physiologically increased pancreatic uptake at the head/uncinate process is observed in more than one-third of patients after injection of one of the three (68)Ga-labelled octreotide-based peptides used for somatostatin (sst) receptor (r) imaging. There are minor differences between these (68)Ga-sstr-binding peptides in the imaging setting. On (68)Ga-sstr-imaging the physiological uptake can be diffuse or focal and usually remains stable over time. Differences in the maximal standardised uptake values (SUVmax) reported for the normal pancreas as well as for pancreatic neuroendocrine tumour (PNET) lesions may be related to several factors, including (a) differences in the peptide binding affinities as well as differences in sstr subtype expression of pancreatic α- and β-cells, and heterogeneity / density of tumour cells, (b) differences in scanner resolution, image reconstruction techniques and acquisition protocols, (c) mostly retrospective study designs, (d) mixed patient populations, or (e) interference with medications such as treatment with long-acting sst analogues. The major limitation in most of the studies lies in the lack of histopathological confirmation of abnormal findings. There is a significant overlap between the calculated SUVmax-values for physiological pancreas and PNET-lesions of the head/uncinate process that do not favour the use of quantitative parameters in the clinical setting. Anecdotal long-term follow-up studies have even indicated that increased uptake in the head/uncinate process still can turn out to be malignant over years of follow up. SUVmax-data for the pancreatic body and tail are limited. Therefore, any visible focal tracer uptake in the pancreas must be considered as suspicious for malignancy irrespective of quantitative parameters. In general, sstr-PET/CT has significant implications for the management of NET patients leading to a change in treatment decision in about one-third of patients. Therefore, follow-up with (68)Ga

  16. Measurement of neurotransmitters with positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Laruelle, M.; Erritzoe, D.; Abi-Dargham, A.; Huang, Y. [Columbia Univ., Coll. of Physicians and Surgeons, Dept. of Psychiatry and Radiology, New York, NY (United States)

    2003-09-01

    Over the last decade several groups have provided evidence that PET and SPECT neuro-receptor imaging techniques might be applied to measure fluctuations of dopamine (DA) synaptic concentrations in the living human brain. It is generally believed that changes in the in vivo binding of radioligands following acute changes in transmitter levels are driven by binding competition. These techniques have been very successful in giving dynamic information regarding DA transmission. However, the development of similar techniques to study other neurotransmitter systems has proven difficult. This review paper first summarizes endogenous competition studies performed in animals and humans. The validity of the model underlying the interpretation of these data is critically assessed. Emerging data suggest that simple binding competition might not be the only phenomenon involved in these interactions; receptor trafficking might play an important role. A better understanding of the radioligand properties that determine sensitivity to endogenous molecules might facilitate the selective development of this type of radiotracer. (authors)

  17. Nuclear medicine and positron emission tomography: An overview

    International Nuclear Information System (INIS)

    McCarthy, T.J.; Schwarz, S.W.; Welch, M.J.

    1994-01-01

    Nuclear medicine is the field of medical practice that involves the oral or intravenous administration of radioactive materials for use in diagnosis and therapy. The majority of radiopharmaceutical available are used for diagnostic purposes. These involve the determination of organ function, shape, or position from an image of the radioactivity distribution within an organ or at a location within the body. After administration, the radiopharmaceutical localizes within an organ or target tissue due to its biological or physiologic characteristics. This diagnostic capability is usually the result of the emission of gamma radiation from the radiopharmaceutical localized within an organ. This allows for external detection and imaging using a special type of camera known as a gamma camera. When a positron-emitting radionuclide decays, a positron (positive electron) is emitted from the nucleus. The positron then annihilates with an electron, resulting in the release of energy in the form of two 511-KeV γ-rays at 180 degree to one another. The energy of these photons is sufficient to pass through tissue. Thus, placing a series of detectors around the patient allows technicians to monitor the emission of both of the photons that result from a single positron annihilation. this ultimately allows an accurate quantification of the distribution of radioactivity in the body not possible when only a single γ-ray is emitted

  18. Nonhuman primate positron emission tomography neuroimaging in drug abuse research.

    Science.gov (United States)

    Howell, Leonard Lee; Murnane, Kevin Sean

    2011-05-01

    Positron emission tomography (PET) neuroimaging in nonhuman primates has led to significant advances in our current understanding of the neurobiology and treatment of stimulant addiction in humans. PET neuroimaging has defined the in vivo biodistribution and pharmacokinetics of abused drugs and related these findings to the time course of behavioral effects associated with their addictive properties. With novel radiotracers and enhanced resolution, PET neuroimaging techniques have also characterized in vivo drug interactions with specific protein targets in the brain, including neurotransmitter receptors and transporters. In vivo determinations of cerebral blood flow and metabolism have localized brain circuits implicated in the effects of abused drugs and drug-associated stimuli. Moreover, determinations of the predisposing factors to chronic drug use and long-term neurobiological consequences of chronic drug use, such as potential neurotoxicity, have led to novel insights regarding the pathology and treatment of drug addiction. However, similar approaches clearly need to be extended to drug classes other than stimulants. Although dopaminergic systems have been extensively studied, other neurotransmitter systems known to play a critical role in the pharmacological effects of abused drugs have been largely ignored in nonhuman primate PET neuroimaging. Finally, the study of brain activation with PET neuroimaging has been replaced in humans mostly by functional magnetic resonance imaging (fMRI). There has been some success in implementing pharmacological fMRI in awake nonhuman primates. Nevertheless, the unique versatility of PET imaging will continue to complement the systems-level strengths of fMRI, especially in the context of nonhuman primate drug abuse research.

  19. Positron Emission Tomography: Principles, Technology, and Recent Developments

    Science.gov (United States)

    Ziegler, Sibylle I.

    2005-04-01

    Positron emission tomography (PET) is a nuclear medical imaging technique for quantitative measurement of physiologic parameters in vivo (an overview of principles and applications can be found in [P.E. Valk, et al., eds. Positron Emission Tomography. Basic Science and Clinical Practice. 2003, Springer: Heidelberg]), based on the detection of small amounts of posi-tron-emitter-labelled biologic molecules. Various radiotracers are available for neuro-logical, cardiological, and oncological applications in the clinic and in research proto-cols. This overview describes the basic principles, technology, and recent develop-ments in PET, followed by a section on the development of a tomograph with ava-lanche photodiodes dedicated for small animal imaging as an example of efforts in the domain of high resolution tomographs.

  20. Clinical applications of positron emission tomography at Montreal Neurological Institute

    International Nuclear Information System (INIS)

    Morgan, P.P.

    1983-01-01

    The Montreal Neurological Institute occupies a leading position in positron emission tomography (PET) of the brain with the help of the following three techological gains: they have acquired a 'Therascan' positron emission tomograph manufactured by Atomic Energy of Canada Ltd.; also, a 'Baby Cyclotron' manufactured by Japan Steel Works Ltd.; and they have written a computer program to display the results in colour. Four short-lived isotopes are used; 11 C, 15 O, 18 F, 13 N. Studies of the oxygen uptake of tumours, their glucose metabolism (as monitored by 18 F labelled 2-fluoro-2-deoxyglucose), and their uptake of therapeutic agents, provide valuable research and diagnostic information. PET is also being used to study epilepsy and cerebrovascular disease

  1. Positron emission zone plate holography for particle tracking

    Energy Technology Data Exchange (ETDEWEB)

    Gundogdu, O. [University of Birmingham, School of Physics and Astronomy, Birmingham B15 2TT (United Kingdom)]. E-mail: o.gundogdu@surrey.ac.uk

    2006-01-15

    Positron Emission Particle Tracking (PEPT) is a powerful non-invasive technique that has been used extensively for tracking a single particle. In this paper, we present a study of zone plate holography method in order to track multiple particles, mainly two particles. The main aim is to use as small number of events as possible in the order to make it possible to track particles in fast moving industrial systems. A zone plate with 100% focal efficiency is simulated and applied to the Positron Emission Tomography (PET) data for multiple particle tracking. A simple trajectory code was employed to explore the effects of the nature of the experimental trajectories. A computer holographic reconstruction code that simulates optical reconstruction was developed. The different aspects of the particle location, particle activity ratios for enabling tagging of particles and zone plate and hologram locations are investigated. The effect of the shot noise is investigated and the limitations of the zone plate holography are reported.

  2. Positron emission zone plate holography for particle tracking

    International Nuclear Information System (INIS)

    Gundogdu, O.

    2006-01-01

    Positron Emission Particle Tracking (PEPT) is a powerful non-invasive technique that has been used extensively for tracking a single particle. In this paper, we present a study of zone plate holography method in order to track multiple particles, mainly two particles. The main aim is to use as small number of events as possible in the order to make it possible to track particles in fast moving industrial systems. A zone plate with 100% focal efficiency is simulated and applied to the Positron Emission Tomography (PET) data for multiple particle tracking. A simple trajectory code was employed to explore the effects of the nature of the experimental trajectories. A computer holographic reconstruction code that simulates optical reconstruction was developed. The different aspects of the particle location, particle activity ratios for enabling tagging of particles and zone plate and hologram locations are investigated. The effect of the shot noise is investigated and the limitations of the zone plate holography are reported

  3. Application of positron emission tomography in the heart

    International Nuclear Information System (INIS)

    Anon.

    1988-01-01

    This report discusses experimental and clinical applications of positron emission tomography to the heart, including measurements of blood flow to the myocardium and studies of metabolism and experimental injury. Most initial clinical studies have concentrated on ischemic heart disease, but the technique also has potential for investigation of cardiomyopathies, studying the neural control of the heart, and evaluating the effects of drugs on cardiac tissues

  4. Photon emission by electrons and positrons traversing thin single crystal

    International Nuclear Information System (INIS)

    Ol'chak, A.S.

    1984-01-01

    Radiation emission by planar channeled particles (electrons, positrons) in a thin single crystal of thickness L is considered. It is shown that for L approximately πb/THETAsub(L) (b is the lattice constant, THETA sub(L) the Lindhard angle) besides the main spontaneous channeling maxima there exist auxiliary interference maxima, the positions of all the maxima depending on L. The dependence of the radiation spectral intensity on crystal thickness is discussed

  5. Contribution of positron emission tomography in pleural disease.

    OpenAIRE

    Duysinx, Bernard; Corhay, Jean-Louis; Larock, Marie-Paule; Withofs, Nadia; Bury, Thierry; Hustinx, Roland; Louis, Renaud

    2010-01-01

    INTRODUCTION: Positron emission tomography (PET) now plays a clear role in oncology, especially in chest tumours. We discuss the value of metabolic imaging in characterising pleural pathology in the light of our own experience and review the literature. BACKGROUND: PET is particularly useful in characterising malignant pleural pathologies and is a factor of prognosis in mesothelioma. Metabolic imaging also provides clinical information for staging lung cancer, in researching the primary tumou...

  6. Simulated annealing image reconstruction for positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Sundermann, E; Lemahieu, I; Desmedt, P [Department of Electronics and Information Systems, University of Ghent, St. Pietersnieuwstraat 41, B-9000 Ghent, Belgium (Belgium)

    1994-12-31

    In Positron Emission Tomography (PET) images have to be reconstructed from moisy projection data. The noise on the PET data can be modeled by a Poison distribution. In this paper, we present the results of using the simulated annealing technique to reconstruct PET images. Various parameter settings of the simulated annealing algorithm are discussed and optimized. The reconstructed images are of good quality and high contrast, in comparison to other reconstruction techniques. (authors). 11 refs., 2 figs.

  7. Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Disseminated Cryptococcosis

    Science.gov (United States)

    Tripathy, Sarthak; Parida, Girish Kumar; Roy, Shambo Guha; Singhal, Abhinav; Mallick, Saumya Ranjan; Tripathi, Madhavi; Shamim, Shamim Ahmed

    2017-01-01

    Disseminated cryptococcosis without pulmonary involvement is a very rare phenomenon. Patterns of organ involvement in cryptococcosis resemble various other infective conditions as well as malignant conditions on fluorodeoxyglucose positron emission tomography–computed tomography. We present a case of a 43-year-old male patient who had disseminated cryptococcosis. The rarity of the case being noninvolvement of lungs and meninges and resembling more like lymphoma due to the diffuse involvement of the lymph nodes on both sides of the diaphragm. PMID:29142368

  8. Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Disseminated Cryptococcosis.

    Science.gov (United States)

    Tripathy, Sarthak; Parida, Girish Kumar; Roy, Shambo Guha; Singhal, Abhinav; Mallick, Saumya Ranjan; Tripathi, Madhavi; Shamim, Shamim Ahmed

    2017-01-01

    Disseminated cryptococcosis without pulmonary involvement is a very rare phenomenon. Patterns of organ involvement in cryptococcosis resemble various other infective conditions as well as malignant conditions on fluorodeoxyglucose positron emission tomography-computed tomography. We present a case of a 43-year-old male patient who had disseminated cryptococcosis. The rarity of the case being noninvolvement of lungs and meninges and resembling more like lymphoma due to the diffuse involvement of the lymph nodes on both sides of the diaphragm.

  9. Detectors for high resolution dynamic positron emission tomography

    International Nuclear Information System (INIS)

    Derenzo, S.E.; Budinger, T.F.; Huesman, R.H.

    1985-01-01

    Tomography is the technique of producing a photographic image of an opaque specimen by transmitting a beam of x-rays or gamma rays through the specimen onto an adjacent photographic film. The image results from variations in thickness, density, and chemical composition, of the specimen. This technique is used to study the metabolism of the human brain. This article examines the design of equipment used for high resolution dynamic positron emission tomography. 27 references, 5 figures, 3 tables

  10. Measurement of brain pH with positron emission tomography

    International Nuclear Information System (INIS)

    Buxton, R.B.; Alpert, N.M.; Ackerman, R.H.; Wechsler, L.R.; Elmaleh, D.R.; Correia, J.A.

    1985-01-01

    With positron emission tomography (PET) it is now possible to measure local brain pH noninvasively in humans. The application of PET to the determination of pH is relatively new, so only a handful of papers on the subject have appeared in print. This chapter reviews the current strategies for measuring brain pH with PET, discuss methodological problems, and present initial results

  11. Simulated annealing image reconstruction for positron emission tomography

    International Nuclear Information System (INIS)

    Sundermann, E.; Lemahieu, I.; Desmedt, P.

    1994-01-01

    In Positron Emission Tomography (PET) images have to be reconstructed from moisy projection data. The noise on the PET data can be modeled by a Poison distribution. In this paper, we present the results of using the simulated annealing technique to reconstruct PET images. Various parameter settings of the simulated annealing algorithm are discussed and optimized. The reconstructed images are of good quality and high contrast, in comparison to other reconstruction techniques. (authors)

  12. Positron tomographic assessment of androgen receptors in prostatic carcinoma

    International Nuclear Information System (INIS)

    Dehdashti, Farrokh; Siegel, Barry A.; Welch, Michael J.; Picus, Joel; Michalski, Jeff M.; Dence, Carmen S.; Katzenellenbogen, John A.

    2005-01-01

    The purpose of this study was to evaluate the feasibility of androgen receptor (AR) imaging with 16β-[ 18 F]fluoro-5α-dihydrotestosterone (FDHT) by positron emission tomography (PET) and to assess the binding selectivity of FDHT to AR in patients with prostate cancer. Twenty men (age range 56-87 years) with advanced prostate cancer were studied. All except one had metastatic disease confirmed by biopsy and/or radiological studies. One patient who had radiological findings suggesting a single hepatic metastasis was found to have focal fatty infiltration on biopsy obtained after FDHT-PET and was excluded from further data analysis. FDHT uptake was assessed semiquantitatively by determination of the standardized uptake value (SUV) and tumor-to-muscle ratio (T/M). Additionally, to assess the AR binding selectivity of FDHT, patients with one or more foci of abnormally increased FDHT accumulation were studied after administration of an AR antagonist (flutamide). Conventional imaging demonstrated innumerable lesions in two patients and 43 lesions in the remaining 17 patients with advanced prostate cancer. FDHT-PET was positive in 12 of 19 patients (sensitivity of 63%), including the two patients with innumerable lesions. FDHT-PET detected 24 of 28 known lesions (86%) in the remaining ten patients. In addition, FDHT-PET detected 17 unsuspected lesions in five of these ten patients. All 12 patients with positive FDHT-PET underwent a repeat PET study after receiving flutamide for 1 day (250 mg t.i.d.). In all of these patients, there was a decrease in tumor FDHT uptake after flutamide; the mean (± standard deviation) SUV and T/M decreased from 7.0±4.7 and 6.9±3.9, respectively, to 3.0±1.5 and 3.0±1.6, respectively (p=0.002). The mean PSA in patients with positive FDHT-PET was significantly higher than that in patients with negative FDHT-PET (p=0.006). Our results document the feasibility of PET imaging of prostate cancer with FDHT and suggest that tumor uptake of FDHT

  13. Positron emission tomography in the evaluation of subdural hematomas

    International Nuclear Information System (INIS)

    Ericson, K.; Bergstroem, M.; Eriksson, L.

    1980-01-01

    Fifteen patients with 21 subdural effusions were investigated both with transmission computer assisted tomography (CAT) and positron emission tomography (PET). The tracer in the emission studies was 68 Ga-EDTA. Twelve lesions were visualized both with CAT and PET. Five lesions that were negative or doubtful on CAT were visualized with PET, whereas four lesions negative or doubtful on PET were demonstrated by CAT. The two methods complement each other due to the fact that they are based on different mechanisms: CAT mainly on attenuation of the fluid collection. PET on isotope accumulation, particularly in the hematoma membranes

  14. Attenuation Correction Strategies for Positron Emission Tomography/Computed Tomography and 4-Dimensional Positron Emission Tomography/Computed Tomography

    OpenAIRE

    Pan, Tinsu; Zaidi, Habib

    2013-01-01

    This article discusses attenuation correction strategies in positron emission tomography/computed tomography (PET/CT) and 4 dimensional PET/CT imaging. Average CT scan derived from averaging the high temporal resolution CT images is effective in improving the registration of the CT and the PET images and quantification of the PET data. It underscores list mode data acquisition in 4 dimensional PET and introduces 4 dimensional CT popular in thoracic treatment planning to 4 dimensional PET/CT. ...

  15. Comparison of Diagnostic Performance of Three-Dimensional Positron Emission Mammography versus Whole Body Positron Emission Tomography in Breast Cancer

    Directory of Open Access Journals (Sweden)

    Dong Dai

    2017-01-01

    Full Text Available Objective. To compare the diagnostic performance of three-dimensional (3D positron emission mammography (PEM versus whole body positron emission tomography (WBPET for breast cancer. Methods. A total of 410 women with normal breast or benign or highly suspicious malignant tumors were randomized at 1 : 1 ratio to undergo 3D-PEM followed by WBPET or WBPET followed by 3D-PEM. Lumpectomy or mastectomy was performed on eligible participants after the scanning. Results. The sensitivity and specificity of 3D-PEM were 92.8% and 54.5%, respectively. WBPET showed a sensitivity of 95.7% and specificity of 56.8%. After exclusion of the patients with lesions beyond the detecting range of the 3D-PEM instrument, 3D-PEM showed higher sensitivity than WBPET (97.0% versus 95.5%, P = 0.913, particularly for small lesions (<1 cm (72.0% versus 60.0%, P = 0.685. Conclusions. The 3D-PEM appears more sensitive to small lesions than WBPET but may fail to detect lesions that are beyond the detecting range. This study was approved by the Ethics Committee (E2012052 at the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China. The instrument positron emission mammography (PEMi was approved by China State Food and Drug Administration under the registration number 20153331166.

  16. Positron transaxial emission tomograph with computerized image reconstruction

    International Nuclear Information System (INIS)

    Jatteau, Michel.

    1981-01-01

    This invention concerns a positron transaxial emission tomography apparatus with computerized image reconstruction, like those used in nuclear medicine for studying the metabolism of organs, in physiological examinations and as a diagnosis aid. The operation is based on the principle of the detection of photons emitted when the positrons are annihilated by impact with an electron. The appliance is mainly composed of: (a) - a set of gamma ray detectors distributed on a polygonal arrangement around the body area to be examined, (b) - circuits for amplifying the signals delivered by the gamma ray detectors, (c) - computers essentially comprising energy integration and discrimination circuits and provided at the output of the detectors for calculating and delivering, as from the amplified signals, information on the position and energy relative to each occurrence constituted by the detections of photons, (d) - time coincidence circuits for selecting by emission of detector validation signals, only those occurrences, among the ensemble of those detected, which effectively result from the annihilation of positrons inside the area examined, (e) - a data processing system [fr

  17. Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis.

    Science.gov (United States)

    Jadvar, Hossein

    2015-09-01

    Prostate cancer is a prevalent public health problem worldwide. Over the past decade, there has been tremendous research activity in the potential use of positron emission tomography with a number of radiotracers targeted to various biological aspects of this complex tumor. Systematic reviews and meta-analysis are important contributions to the relevant literature that summarize the evidence while reducing the effect of various sources of bias in the published data. The accumulation of relevant data in this clinical setting has recently provided the opportunity for systematic reviews. In this brief article, I summarize the published systematic reviews and meta-analysis of positron emission tomography in prostate cancer. Most robust evidence suggests a probable role for first-line use of positron emission tomography with radiolabeled choline in restating patients with biochemical relapse of prostate cancer with the diagnostic performance that appears to be positively associated with the serum prostate specific antigen level and velocity. Future systematic reviews will be needed for other emerging radiotracers such as those based on prostate specific membrane antigen and gastrin-releasing peptide receptor.

  18. First image from a combined positron emission tomography and field-cycled MRI system.

    Science.gov (United States)

    Bindseil, Geron A; Gilbert, Kyle M; Scholl, Timothy J; Handler, William B; Chronik, Blaine A

    2011-07-01

    Combining positron emission tomography and MRI modalities typically requires using either conventional MRI with a MR-compatible positron emission tomography system or a modified MR system with conventional positron emission tomography. A feature of field-cycled MRI is that all magnetic fields can be turned off rapidly, enabling the use of conventional positron emission tomography detectors based on photomultiplier tubes. In this demonstration, two photomultiplier tube-based positron emission tomography detectors were integrated with a field-cycled MRI system (0.3 T/4 MHz) by placing them into a 9-cm axial gap. A positron emission tomography-MRI phantom consisting of a triangular arrangement of positron-emitting point sources embedded in an onion was imaged in a repeating interleaved sequence of ∼1 sec MRI then 1 sec positron emission tomography. The first multimodality images from the combined positron emission tomography and field-cycled MRI system show no additional artifacts due to interaction between the systems and demonstrate the potential of this approach to combining positron emission tomography and MRI. Copyright © 2010 Wiley-Liss, Inc.

  19. Investigation of granular impact using positron emission particle tracking

    KAUST Repository

    Marston, Jeremy O.

    2015-04-01

    We present results from an experimental study of granular impact using a combination of high-speed video and positron emission particle tracking (PEPT). The PEPT technique exploits the annihilation of photons from positron decay to determine the position of tracer particles either inside a small granular bed or attached to the object which impacts the bed. We use dense spheres as impactors and the granular beds are comprised of glass beads which are fluidised to achieve a range of different initial packing states. For the first time, we have simultaneously investigated both the trajectory of the sphere, the motion of particles in a 3-D granular bed and particles which jump into the resultant jet, which arises from the collapse of the cavity formed by the impacting sphere.

  20. An automated blood sampling system used in positron emission tomography

    International Nuclear Information System (INIS)

    Eriksson, L.; Bohm, C.; Kesselberg, M.

    1988-01-01

    Fast dynamic function studies with positron emission tomography (PET), has the potential to give accurate information of physiological functions of the brain. This capability can be realised if the positron camera system accurately quantitates the tracer uptake in the brain with sufficiently high efficiency and in sufficiently short time intervals. However, in addition, the tracer concentration in blood, as a function of time, must be accurately determined. This paper describes and evaluates an automated blood sampling system. Two different detector units are compared. The use of the automated blood sampling system is demonstrated in studies of cerebral blood flow, in studies of the blood-brain barrier transfer of amino acids and of the cerebral oxygen consumption. 5 refs.; 7 figs

  1. Clinical cardiac positron emission tomography: State of the art

    International Nuclear Information System (INIS)

    Gould, K.L.

    1991-01-01

    Cardiac positron emission tomography (PET) has evolved rapidly from a relatively esoteric research tool into clinical applications providing unique, quantitative information on myocardial perfusion, metabolism, and cell membrane function and having a potentially significant impact on cardiovascular medicine. Although there are many different positron radionuclides for imaging diverse myocardial behavior, three radionuclides have reached accepted clinical utility. Cardiac PET using nitrogen-13-ammonia, rubidium-82, and fluoro-18-deoxyglucose has proved accurate and definitive in multiple university and private-practice sites for diagnosing and assessing severity and location of coronary artery disease in symptomatic or asymptomatic patients, for identifying injured but viable myocardium potentially salvageable by revascularization, and for ruling out clinically significant coronary artery stenosis with a high specificity in patients who might otherwise undergo coronary arteriography to document the absence of significant disease. 89 references

  2. Evaluation of 4-[{sup 18}F]fluorobenzoyl-FALGEA-NH{sub 2} as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer

    Energy Technology Data Exchange (ETDEWEB)

    Lund Denholt, Charlotte, E-mail: charlotte.lund.denholt@rh.regionh.d [Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen O (Denmark); Binderup, Tina [Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen O (Denmark); Cluster for Molecular Imaging, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen N (Denmark); Stockhausen, Marie-Therese; Skovgaard Poulsen, Hans [Department of Radiation Biology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen O (Denmark); Spang-Thomsen, Mogens [Institute of Molecular Pathology, University of Copenhagen, 2200 Copenhagen N (Denmark); Hansen, Paul Robert [IGM-Bioorganic Chemistry, Faculty of Life Science, University of Copenhagen, 1871 Frederiksberg C (Denmark); Gillings, Nic [Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen O (Denmark); Kjaer, Andreas [Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen O (Denmark); Cluster for Molecular Imaging, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen N (Denmark)

    2011-05-15

    Introduction: This study describes the radiosynthesis, in vitro and in vivo evaluation of the novel small peptide radioligand, 4-[{sup 18}F]fluorobenzoyl-Phe-Ala-Leu-Gly-Glu-Ala-NH{sub 2,} ([{sup 18}F]FBA-FALGEA-NH{sub 2}) as a positron emission tomography (PET) tracer for imaging of the cancer specific epidermal growth factor receptor (EGFR) variant III mutation, EGFRvIII. Methods: For affinity, stability and PET measurements, H-FALGEA-NH{sub 2} was radiolabelled using 4-[{sup 18}F]fluorobenzoic acid ([{sup 18}F]FBA). The binding affinity of ([{sup 18}F]FBA)-FALGEA-NH{sub 2} was measured on EGFRvIII expressing cells, NR6M. Stability studies in vitro and in vivo were carried out in blood plasma from nude mice. PET investigations of [{sup 18}F]FBA-FALGEA-NH{sub 2} were performed on a MicroPET scanner, using seven nude mice xenografted subcutaneously with human glioblastoma multiforme (GBM) tumours, expressing the EGFRvIII in its native form, and five nude mice xenografted subcutaneously with GBM tumours lacking EGFRvIII expression. Images of [{sup 18}F]FDG were also obtained for comparison. The mice were injected with 5-10 MBq of the radiolabelled peptide or [{sup 18}F]FDG. Furthermore, the gene expression of EGFRvIII in the tumours was determined using quantitative real-time PCR. Results: Radiolabelling and purification was achieved within 180 min, with overall radiochemical yields of 2.6-9.8% (decay-corrected) and an average specific radioactivity of 6.4 GBq/{mu}mol. The binding affinity (K{sub d}) of [{sup 18}F]FBA-FALGEA-NH{sub 2} to EGFRvIII expressing cells was determined to be 23 nM. The radiolabelled peptide was moderately stable in the plasma from nude mice where 53% of the peptide was intact after 60 min of incubation in plasma but rapidly degraded in vivo, where no intact peptide was observed in plasma 5 min post-injection. The PET imaging showed that [{sup 18}F]FBA-FALGEA-NH{sub 2} accumulated preferentially in the human GBM xenografts which expressed

  3. Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

    International Nuclear Information System (INIS)

    Aboagye, Eric O.; Kenny, Laura M.; Myers, Melvyn; Gilbert, Fiona J.; Fleming, Ian N.; Beer, Ambros J.; Cunningham, Vincent J.; Marsden, Paul K.; Visvikis, Dimitris; Gee, Antony D.; Groves, Ashley M.; Cook, Gary J.; Kinahan, Paul E.; Clarke, Larry

    2012-01-01

    The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and radiotracers range from direct physiological functional tracers like [ 15 O]-water to macromolecular probes targeting integrin receptors expressed on neovasculature. Finally we make recommendations on ways to incorporate such measurements of tumour vascularity into early clinical trials of novel therapeutics. (orig.)

  4. Positron emission tomography - a new technique for studies of the central nervous system

    International Nuclear Information System (INIS)

    Eriksson, Lars; Dahlbom, Magnus; Widen, Lennart

    1990-01-01

    Positron emission tomography (PET) has become an important tool to study the central nervous system. Examples of such studies are cerebral blood flow and metabolism and determination of receptor characteristics of the brain. In the following the basic principles and the physics behind PET are given. Different aspects are discussed such as detector design, image reconstruction and data analyses. Since quantification is essential in PET, data have to be corrected for absorption, scatter and random coincidences. These corrections and their influence on image data are discussed. A review of state-of-the-art PET research of the brain is given. (author)

  5. Molecular Imaging of Transporters with Positron Emission Tomography

    Science.gov (United States)

    Antoni, Gunnar; Sörensen, Jens; Hall, Håkan

    Positron emission tomography (PET) visualization of brain components in vivo is a rapidly growing field. Molecular imaging with PET is also increasingly used in drug development, especially for the determination of drug receptor interaction for CNS-active drugs. This gives the opportunity to relate clinical efficacy to per cent receptor occupancy of a drug on a certain targeted receptor and to relate drug pharmacokinetics in plasma to interaction with target protein. In the present review we will focus on the study of transporters, such as the monoamine transporters, the P-glycoprotein (Pgp) transporter, the vesicular monoamine transporter type 2, and the glucose transporter using PET radioligands. Neurotransmitter transporters are presynaptically located and in vivo imaging using PET can therefore be used for the determination of the density of afferent neurons. Several promising PET ligands for the noradrenaline transporter (NET) have been labeled and evaluated in vivo including in man, but a really useful PET ligand for NET still remains to be identified. The most promising tracer to date is (S,S)-[18F]FMeNER-D2. The in vivo visualization of the dopamine transporter (DAT) may give clues in the evaluation of conditions related to dopamine, such as Parkinson's disease and drug abuse. The first PET radioligands based on cocaine were not selective, but more recently several selective tracers such as [11C]PE2I have been characterized and shown to be suitable as PET radioligands. Although there are a large number of serotonin transporter inhibitors used today as SSRIs, it was not until very recently, when [11C]McN5652 was synthesized, that this transporter was studied using PET. New candidates as PET radioligands for the SERT have subsequently been developed and [11C]DASB and [11C]MADAM and their analogues are today the most promising ligands. The existing radioligands for Pgp transporters seem to be suitable tools for the study of both peripheral and central drug

  6. Use of positron emission tomography in colorectal cancer

    International Nuclear Information System (INIS)

    Gonzalez E, Patricio; Jofre E, Josefina; Massardo V, Teresa; Humeres, Pamela; Canessa G, Jose; Sierralta C, Paulina

    2002-01-01

    The value of PET (Positron Emission Tomography) in colorectal cancer is presented. PET is a novel technique that uses F-18-FDG (fluorodeoxiglucose) to assess glucose metabolism by whole body imaging. It has been demonstrated that malignant cells have both increase of glucose uptake and utilization. In colorectal cancer, PET is indicated for staging, assess recurrence, liver metastasis and treatment follow-up. PET is more sensitive and specific than CT (Computed Tomography) and is cost effective. In 30% of cases PET may change patient management, avoiding unnecessary procedures (au)

  7. Contribution of positron emission tomography in pleural disease.

    Science.gov (United States)

    Duysinx, B; Corhay, J-L; Larock, M-P; Withofs, N; Bury, T; Hustinx, R; Louis, R

    2010-10-01

    Positron emission tomography (PET) now plays a clear role in oncology, especially in chest tumours. We discuss the value of metabolic imaging in characterising pleural pathology in the light of our own experience and review the literature. PET is particularly useful in characterising malignant pleural pathologies and is a factor of prognosis in mesothelioma. Metabolic imaging also provides clinical information for staging lung cancer, in researching the primary tumour in metastatic pleurisy and in monitoring chronic or recurrent pleural pathologies. PET should therefore be considered as a useful tool in the diagnosis of liquid or solid pleural pathologies. Copyright © 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.

  8. Positron emission tomography. Present status and Romanian perspectives

    International Nuclear Information System (INIS)

    Constantinescu, B.; Lungu, V.

    1995-01-01

    Basic principles of the positron emission tomography (PET) are summarised. The main PET methods using short-lived radioisotopes (i.e. 11 C, 13 N, 15 O, 18 F) are briefly reviewed. Three types of particle accelerators for radioisotopes production and medical uses (including radiotherapy), corresponding to the proton energy (E p p p < 200 MeV) are presented. PET imaging equipment and procedures are discussed. Main radiopharmaceuticals based on beta decay for PET studies and their role in medicine is also described. Finally, perspectives for a PET program in Romania (Cyclotron + Radiochemistry + Tomograph ) are discussed. (author)

  9. Design of a volume-imaging positron emission tomograph

    International Nuclear Information System (INIS)

    Harrop, R.; Rogers, J.G.; Coombes, G.H.; Wilkinson, N.A.; Pate, B.D.; Morrison, K.S.; Stazyk, M.; Dykstra, C.J.; Barney, J.S.; Atkins, M.S.; Doherty, P.W.; Saylor, D.P.

    1988-11-01

    Progress is reported in several areas of design of a positron volume imaging tomograph. As a means of increasing the volume imaged and the detector packing fraction, a lens system of detector light coupling is considered. A prototype layered scintillator detector demonstrates improved spatial resolution due to a unique Compton rejection capability. The conceptual design of a new mechanism for measuring scattered radiation during emission scans has been tested by Monte Carlo simulation. The problem of how to use effectively the resulting sampled scattered radiation projections is presented and discussed

  10. Kinetic modeling in pre-clinical positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Kuntner, Claudia [AIT Austrian Institute of Technology GmbH, Seibersdorf (Austria). Biomedical Systems, Health and Environment Dept.

    2014-07-01

    Pre-clinical positron emission tomography (PET) has evolved in the last few years from pure visualization of radiotracer uptake and distribution towards quantification of the physiological parameters. For reliable and reproducible quantification the kinetic modeling methods used to obtain relevant parameters of radiotracer tissue interaction are important. Here we present different kinetic modeling techniques with a focus on compartmental models including plasma input models and reference tissue input models. The experimental challenges of deriving the plasma input function in rodents and the effect of anesthesia are discussed. Finally, in vivo application of kinetic modeling in various areas of pre-clinical research is presented and compared to human data.

  11. Time-of-Flight Positron Emission Tomography with Radiofrequency Phototube

    International Nuclear Information System (INIS)

    Margaryan, A.; Kakoyan, V.; Knyazyan, S.

    2011-01-01

    In this paper γ-detector, based on the radiofrequency (RF) phototube and recently developed fast and ultrafast scintillators, is considered for Time-of-Flight positron emission tomography applications. Timing characteristics of such a device has been investigated by means of a dedicated Monte Carlo code based on the single photon counting concept. Biexponential timing model for scintillators have been used. The calculations have shown that such a timing model is in a good agreement with recently measured data. The timing resolution of -detectors can be significantly improved by using the RF phototube. (authors)

  12. Low-resource synchronous coincidence processor for positron emission tomography

    International Nuclear Information System (INIS)

    Sportelli, Giancarlo; Belcari, Nicola; Guerra, Pedro; Santos, Andres

    2011-01-01

    We developed a new FPGA-based method for coincidence detection in positron emission tomography. The method requires low device resources and no specific peripherals in order to resolve coincident digital pulses within a time window of a few nanoseconds. This method has been validated with a low-end Xilinx Spartan-3E and provided coincidence resolutions lower than 6 ns. This resolution depends directly on the signal propagation properties of the target device and the maximum available clock frequency, therefore it is expected to improve considerably on higher-end FPGAs.

  13. Functional imaging of the brain with positron emission tomography

    International Nuclear Information System (INIS)

    Alavi, A.; Reivich, M.; Jones, S.C.; Greenberg, J.H.; Wolf, A.P.

    1982-01-01

    An extensive review, with 191 references, of the development and diagnostic use of positron emission tomography (PET) of the brain is presented. An historical overview of functional studies of the brain reviews the use of nitrons oxide, 85 Kr and 133 Xe, [ 14 C]2-deoxyglucose, and [ 18 F]FDG. The [ 18 F]FDG technique allows the investigation of the effects of physiologic stimulation on the brain. Several studies using this technique are reported. The effects of stroke, seizure disorders, aging and dementia, and schizophrenia on cerebral metabolism as demosntrated by PET are explored

  14. Application of positron emission tomography in industrial research

    International Nuclear Information System (INIS)

    Jonkers, G.; van den Bergen, E.A.; Vonkeman, K.A.

    1990-01-01

    Positron Emission computed Tomography (PET) is a relatively new imaging technique, exploiting the 511 keV annihilation radiation characteristic of positron emitters. Although exclusively used till now in the field of nuclear medicine, the application of PET for the non-invasive, in-situ visualisation of processes of industrial interest is challenging, because PET can in principle be used to obtain quantitative, 2D/3D images of the flow and distribution of fluids inside process units, whose steel walls may be up to several centimeters thick. With the aid of a NeuroECAT positron tomographer the PET technique has been utilised to image important (model) processes in the petrochemical industry, using physical labelling of the phase to be imaged. First, the displacement of a brine/surfactant phase, labelled with 66 Ga-EDTA, in a piece of reservoir rock was imaged. Secondly, the dehydration of water-in-oil emulsions was monitored dynamically by labelling the water phase with 68 Ga-EDTA. The second study in particular demonstrates that in the presence of noisy data the image reconstruction method utilised strongly influences the results obtained. With the advent of PET in nuclear medicine the availability of short-lived positron emitting nuclides like 11 C (t1/2 = 20 min), 13 N (t1/2 = 10 min) and 15 0 (t1/2 = 2 min) has increased considerably, allowing the investigation of industrially important reactions by chemical labelling. Utilising the NeuroECAT in a special mode, the catalytic oxidation of carbon monoxide could be imaged in a model tubular reactor by using 11 C-labelled CO, providing information about the kinetics of the individual reaction steps and interactions and about the degree of occupation of catalytically active sites. (author)

  15. Basal ganglia disorders studied by positron emission tomography

    International Nuclear Information System (INIS)

    Shinotoh, Hitoshi

    1994-01-01

    Recent development of positron emitting radioligands has made it possible to investigate the alterations of neurotransmitter systems associated with basal ganglia disorders in vivo. The functional integrity of nigro-striatal dopaminergic terminals may be studied with [ 18 F]6-fluoro-L-dopa ([ 18 F]dopa), and striatal dopamine receptor density with suitable PET ligands. [ 18 F]dopa uptake in the striatum (putamen) is markedly reduced in patients with Parkinson's disease (PD). [ 18 F]dopa-PET is capable of detecting sub-clinical nigral dysfunction in asymptomatic patients with familial PD and those who become Parkinsonian on conventional doses of dopamine receptor antagonists. While putamen [ 18 F]dopa uptake is reduced to a similar level in patients with multiple system atrophy (MSA) and PD, caudate [ 18 F] dopa uptake is lower in MSA than PD. However, [ 18 F]dopa PET cannot consistently distinguish MSA from PD because individual ranges of caudate [ 18 F]dopa uptake overlap. D 1 and D 2 receptor binding is markedly reduced in the striatum (posterior putamen) of MSA patients. Therefore, dopamine receptor imaging is useful for the differential diagnosis of MSA and PD. Similar marked reductions in putamen and caudate [ 18 F]dopa uptake have been observed in patients with progressive supranuclear palsy (PSP). Moderate reductions in D 2 receptor binding have been reported in the striatum of PSP patients. The reduction in D 2 receptor binding is more prominent in the caudate than putamen. Striatal [ 18 F]dopa uptake is normal or only mildly reduced in patients with dopa responsive dystonia (DRD). D 2 receptor binding is markedly reduced in patients with Huntington's disease, while striatal [ 18 F]dopa uptake is normal or mildly reduced. In summary, PET can demonstrate characteristic patterns of disruption of dopaminergic systems associated with basal ganglia disorders. These PET findings are useful in the differential diagnosis of basal ganglia disorders. (J.P.N.) 55 refs

  16. Positron emission CT on post-traumatic epilepsy

    International Nuclear Information System (INIS)

    Tsukiyama, Takashi; Tsubokawa, Takashi; Doi, Nobuyasu; Sato, Kohten; Iio, Masaaki.

    1983-01-01

    Six patients suffering from post-traumatic epilepsy were checked by encephalography (EEG), X-ray CT and cerebral positron emission computed tomography (PECT) using 11 C-carbon dioxide ( 11 CO 2 ) and 11 C-glucoses as indicators of the local cerebral circulation and local cerebral glucose utilization, in order to assess the diagnostic value of PECT in post-traumatic epilepsy. In those patients (4 cases) who had focal electrical abnormalities or X-ray CT lesions, PECT clearly revealed localized regions of decreased cerebral circulation and glucose utilization. A focal hypometabolic zone also appeared in the post-traumatic epilepsy (1 case) which had a normal X-ray CT. One case, who had been treated for several years by medication but showed no EEG change and no abnormality on X-ray CT, revealed a normal circulation and metabolism by RECT. This case did not require any further medication for epilepsy. It is concluded that positron emission CT represents a useful diagnostic method for post-traumatic epilepsy which does not demonstrate any abnormality on X-ray CT. (author)

  17. Clinical applications of positron emission tomography in breast cancer patients

    International Nuclear Information System (INIS)

    Roemer, W.; Avril, N.; Schwaiger, M.

    1997-01-01

    Increased glucose metabolism by malignant tissue can be visualized with positron emission tomography (PET), using the radiolabeled glucose analogue F-18 fluorodeoxyglucose (FDG). Depending on the criteria of image interpretation FDG-PET allows detection of breast cancer with a sensitivity of 68% to 94 % and a specificity of 84 % to 97 %. However, sensitivity to visualize small tumors (< 1 cm) is limited. Positron emission tomography demonstrates tumor involvement of regional lymph nodes with high accuracy, predominantly in patients with advanced breast cancer. The sensitivity for the detection of axillary lymph node metastases was 79% with a corresponding specificity of 96 %. Lymph node metastases could not be identified in four of six patients with small primary breast cancer (stage pT1), resulting in a sensitivity of only 33% in these patients. By visualizing primary tumors and metastases in one imaging procedure, PET imaging may allow the effective staging of breast cancer patients. Further studies are needed to define the role of scintigraphic techniques for the diagnostic work-up in patients. (author)

  18. Positron Emission Tomography imaging with the SmartPET system

    Energy Technology Data Exchange (ETDEWEB)

    Cooper, R.J. [Department of Physics, University of Liverpool, Liverpool, Merseyside L69 7ZE (United Kingdom)], E-mail: cooperrj@ornl.gov; Boston, A.J.; Boston, H.C.; Cresswell, J.R.; Grint, A.N.; Harkness, L.J.; Nolan, P.J.; Oxley, D.C.; Scraggs, D.P.; Mather, A.R. [Department of Physics, University of Liverpool, Liverpool, Merseyside L69 7ZE (United Kingdom); Lazarus, I.; Simpson, J. [STFC Daresbury Laboratory, Daresbury, Warrington, Cheshire WA4 4AD (United Kingdom)

    2009-07-21

    The Small Animal Reconstruction Tomograph for Positron Emission Tomography (SmartPET) project is the development of a small animal Positron Emission Tomography (PET) demonstrator based on the use of High-Purity Germanium (HPGe) detectors and state of the art digital electronics. The experimental results presented demonstrate the current performance of this unique system. By performing high precision measurements of one of the SmartPET HPGe detectors with a range of finely collimated gamma-ray beams the response of the detector as a function of gamma-ray interaction position has been quantified, facilitating the development of parametric Pulse Shape Analysis (PSA) techniques and algorithms for the correction of imperfections in detector performance. These algorithms have then been applied to data from PET imaging measurements using two such detectors in conjunction with a specially designed rotating gantry. In this paper we show how the use of parametric PSA approaches allows over 60% of coincident events to be processed and how the nature and complexity of an event has direct implications for the quality of the resulting image.

  19. Positron emission tomography in the management of cervix cancer patients

    International Nuclear Information System (INIS)

    Bonardel, G.; Gontier, E.; Soret, M.; Dechaud, C.; Fayolle, M.; Foehrenbach, H.; Chargari, C.; Bauduceau, O.

    2009-01-01

    Since its introduction in clinical practice in the 1990 s, positron emission tomography (PET), usually with 18 F-fluoro-2-deoxy-D-glucose ( 18 F-F.D.G.), has become an important imaging modality in patients with cancer. For cervix carcinoma, F.D.G.-PET is significantly more accurate than computed tomography (CT) and is recommended for loco-regional lymph node and extra pelvic staging. The metabolic dimension of the technique provides additional prognostic information. Ongoing studies now concentrate on more advanced clinical applications, such as the planning of radiotherapy, the response evaluation after the induction of therapy, the early detection of recurrence. Technical innovations, such as PET cameras with better spatial resolution and hybrid positron emission tomography/computed tomography (PET-CT), available now on the whole territory, provide both anatomic and metabolic information in the same procedure. From the point of view of biological metabolism, new radiopharmaceutical probes are being developed. Those hold promise for future refinements in this field. This article reviews the current applications of F.D.G.-PET in patients with cervix cancer. (authors)

  20. Positron emission tomography: Physics, instrumentation, and image analysis

    International Nuclear Information System (INIS)

    Porenta, G.

    1994-01-01

    Positron emission tomography (PET) is a noninvasive diagnostic technique that permits reconstruction of cross-sectional images of the human body which depict the biodistribution of PET tracer substances. A large variety of physiological PET tracers, mostly based on isotopes of carbon, nitrogen, oxygen, and fluorine is available and allows the in vivo investigation of organ perfusion, metabolic pathways and biomolecular processes in normal and diseased states. PET cameras utilize the physical characteristics of positron decay to derive quantitative measurements of tracer concentrations, a capability that has so far been elusive for conventional SPECT (single photon emission computed tomography) imaging techniques. Due to the short half lives of most PET isotopes, an on-site cyclotron and a radiochemistry unit are necessary to provide an adequate supply of PET tracers. While operating a PET center in the past was a complex procedure restricted to few academic centers with ample resources. PET technology has rapidly advanced in recent years and has entered the commercial nuclear medicine market. To date, the availability of compact cyclotrons with remote computer control, automated synthesis units for PET radiochemistry, high-performance PET cameras, and userfriendly analysis workstations permits installation of a clinical PET center within most nuclear medicine facilities. This review provides simple descriptions of important aspects concerning physics, instrumentation, and image analysis in PET imaging which should be understood by medical personnel involved in the clinical operation of a PET imaging center. (author)

  1. Basic principles of 18F-fluoro-deoxyglucose positron emission tomography

    International Nuclear Information System (INIS)

    Standke, R.

    2002-01-01

    Positron emission tomography uses photons to receive regional information about dynamic, physiologic, and biochemical processes in the living body. A positron decay is measured indirectly by the simultaneous registration of both gamma rays created by the annihilation. The event is counted, if two directly opposite located detectors register gamma rays in coincidence. Unfortunately the detectors of a positron emission tomography system do not register only true coincident events. There are also scattered and random coincidences. Different types of positron tomographs are presented and scintillation crystals, which are in use for positron emission tomography are discussed. The 2D- and 3D-acquisition methods are described as well as preprocessing methods, such as correction for attenuation, scatter and dead time. For quantification the relative parameter standard uptake value (SUV) is explained. Finally hybrid systems, such as combined positron emission tomography/computed tomography scanners and the use of computed tomography data for attenuation correction are introduced. (author)

  2. Simulation of the annihilation emission of galactic positrons; Modelisation de l'emission d'annihilation des positrons Galactiques

    Energy Technology Data Exchange (ETDEWEB)

    Gillard, W

    2008-01-15

    Positrons annihilate in the central region of our Galaxy. This has been known since the detection of a strong emission line centered on an energy of 511 keV in the direction of the Galactic center. This gamma-ray line is emitted during the annihilation of positrons with electrons from the interstellar medium. The spectrometer SPI, onboard the INTEGRAL observatory, performed spatial and spectral analyses of the positron annihilation emission. This thesis presents a study of the Galactic positron annihilation emission based on models of the different interactions undergone by positrons in the interstellar medium. The models are relied on our present knowledge of the properties of the interstellar medium in the Galactic bulge, where most of the positrons annihilate, and of the physics of positrons (production, propagation and annihilation processes). In order to obtain constraints on the positrons sources and physical characteristics of the annihilation medium, we compared the results of the models to measurements provided by the SPI spectrometer. (author)

  3. 77 FR 71802 - Guidance on Investigational New Drug Applications for Positron Emission Tomography Drugs...

    Science.gov (United States)

    2012-12-04

    ... Positron Emission Tomography (PET) Drugs.'' The guidance is intended to assist manufacturers of PET drugs... one self-addressed adhesive label to assist that office in processing your requests. See the... ``Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs.'' The guidance summarizes the...

  4. Positron Emission Tomography (PET) and breast cancer in clinical practice

    International Nuclear Information System (INIS)

    Lavayssiere, Robert; Cabee, Anne-Elizabeth; Filmont, Jean-Emmanuel

    2009-01-01

    The landscape of oncologic practice has changed deeply during the past few years and there is now a need, through a multidisciplinary approach, for imaging to provide accurate evaluation of morphology and function and to guide treatment (Image Guided Therapy). Increasing emphasis has been put on Position Emission Tomography (PET) role in various cancers among clinicians and patients despite a general context of healthcare expenditure limitation. Positron Emission Tomography has currently a limited role in breast cancer, but also general radiologists and specialists should be aware of these indications, especially when staging aggressive cancers and looking for recurrence. Currently, the hybrid systems associating PET and Computed Tomography (CT) and in the same device [Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-32; Blodgett TM, Meltzer CM, Townsend DW. PET/CT: form and function. Radiology 2007;242:360-85; von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and futures directions. Radiology 2006;238(2):405-22], or PET-CT, are more commonly used and the two techniques are adding their potentialities. Other techniques, MRI in particular, may also compete with PET in some instance and as far as ionizing radiations dose limitation is considered, some breast cancers becoming some form of a chronic disease. Breast cancer is a very complex, non-uniform, disease and molecular imaging at large may contribute to a better knowledge and to new drugs development. Ongoing research, Positron Emission Mammography (PEM) and new tracers, are likely to bring improvements in patient care [Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET Imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;1(April (8)): 2005

  5. Positron Emission Tomography (PET) and breast cancer in clinical practice

    Energy Technology Data Exchange (ETDEWEB)

    Lavayssiere, Robert [Centre d' Imagerie Paris-Nord, 1, avenue Charles Peguy, 95200 Sarcelles (France); Institut du Sein Henri Hartmann (ISHH), 1, rue des Dames Augustines, 92200 Neuilly sur Seine (France)], E-mail: cab.lav@wanadoo.fr; Cabee, Anne-Elizabeth [Centre d' Imagerie Paris-Nord, 1, avenue Charles Peguy, 95200 Sarcelles (France); Institut du Sein Henri Hartmann (ISHH), 1, rue des Dames Augustines, 92200 Neuilly sur Seine (France); Centre RMX, 80, avenue Felix Faure, 75105 Paris (France); Filmont, Jean-Emmanuel [Institut du Sein Henri Hartmann (ISHH), 1, rue des Dames Augustines, 92200 Neuilly sur Seine (France); American Hospital of Paris, Nuclear Medicine, 63, boulevard Victor Hugo - BP 109, 92202 Neuilly sur Seine Cedex (France)

    2009-01-15

    The landscape of oncologic practice has changed deeply during the past few years and there is now a need, through a multidisciplinary approach, for imaging to provide accurate evaluation of morphology and function and to guide treatment (Image Guided Therapy). Increasing emphasis has been put on Position Emission Tomography (PET) role in various cancers among clinicians and patients despite a general context of healthcare expenditure limitation. Positron Emission Tomography has currently a limited role in breast cancer, but also general radiologists and specialists should be aware of these indications, especially when staging aggressive cancers and looking for recurrence. Currently, the hybrid systems associating PET and Computed Tomography (CT) and in the same device [Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-32; Blodgett TM, Meltzer CM, Townsend DW. PET/CT: form and function. Radiology 2007;242:360-85; von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and futures directions. Radiology 2006;238(2):405-22], or PET-CT, are more commonly used and the two techniques are adding their potentialities. Other techniques, MRI in particular, may also compete with PET in some instance and as far as ionizing radiations dose limitation is considered, some breast cancers becoming some form of a chronic disease. Breast cancer is a very complex, non-uniform, disease and molecular imaging at large may contribute to a better knowledge and to new drugs development. Ongoing research, Positron Emission Mammography (PEM) and new tracers, are likely to bring improvements in patient care [Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET Imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;1(April (8)): 2005].

  6. Positron emission tomography in pre-surgical evaluation of partial epilepsy in adults

    International Nuclear Information System (INIS)

    Semah, F.; Dupont, S.

    1999-01-01

    Positron emission tomography (PET) may be used to map regional cerebral glucose metabolism using 18 F-deoxyglucose in patients with partial epilepsy. An area of reduced glucose metabolism, that is commonly more extensive than the underlying anatomical abnormality, is found in most of the patients with medically refractory partial epilepsy. These functional lesions are very useful in the delineation of the epileptogenic focus prior to surgery. PET may also be used to demonstrate abnormalities in the binding of specific ligands, such as 11 C-flumazenil, to the central benzodiazepine-GABA A receptor complex. Focal decreases in benzodiazepine receptor binding is commonly seen at an epileptic focus, in a more restricted distribution than the area of hypo-metabolism. (author)

  7. Striatal [[sup 11]C]-N-methyl-spiperone binding in patients with focal dystonia (torticollis) using positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Leenders, K [Paul Scherrer Inst. (PSI), Villigen (Switzerland); Hartvig, P [Hospital Pharmacy, Univ. Hospital, Uppsala (Sweden); Forsgren, L; Holmgren, G; Almay, B [Dept. of Neurology, Umeaa Univ., Umeaa (Sweden); Eckernaes, S A [Dept. of Neurology, Univ. Hospital, Uppsala (Sweden); Lundqvist, H; Laangstroem, B [Uppsala Univ. PET-Center, Uppsala (Sweden)

    1993-01-01

    Specific binding of [[sup 11]C]-N-methyl-spiperone to striatal dopamine D2 receptors was assessed using positron emission tomography (PET) in 6 patients with adult-onset focal dystonia (predominantly spasmodic torticollis) and in 5 healthy subjects. No significant difference in average specific striatal tracer uptake between patients and healthy subjects was found. However, in the 5 patients showing lateralisation of clinical signs a trend to higher striatal tracer uptake in the contralateral hemisphere was observed. (authors).

  8. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism

    International Nuclear Information System (INIS)

    Booij, J.; Tissingh, G.; Winogrodzka, A.; Royen, E.A. van

    1999-01-01

    Parkinsonism is a feature of a number of neurodegenerative diseases, including Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. The results of post-mortem studies point to dysfunction of the dopaminergic neurotransmitter system in patients with parkinsonism. Nowadays, by using single-photon emission tomography (SPET) and positron emission tomography (PET) it is possible to visualise both the nigrostriatal dopaminergic neurons and the striatal dopamine D 2 receptors in vivo. Consequently, SPET and PET imaging of elements of the dopaminergic system can play an important role in the diagnosis of several parkinsonian syndromes. This review concentrates on findings of SPET and PET studies of the dopaminergic neurotransmitter system in various parkinsonian syndromes. (orig.)

  9. Clinical impact of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of neurological diseases

    International Nuclear Information System (INIS)

    Buck, A.; Kamel, E.

    2002-01-01

    In this review it will be discussed in which neurological disorders positron emission tomography can yield important diagnostic information. Because positron emission tomography is an expensive method indications have to be cleary defined. One important question concerns the differentiation of tumor recurrence and scar due to radiation therapy or an operation. The grading of brain tumors is another application. In HIV patients fluorodeoxyglucose positron emission tomography can separate lymphoma and toxoplasmosis. In the evaluation of dementia positron emission tomography can help to clarify the differential diagnosis. Another important area is the presurgical evaluation of epilepsy patients and patients with cerebrovascular disease in whom a surgical revascularization procedure is planned. In extrapyramidal disorders, positron emission tomography can often help to establish the final diagnosis. (author)

  10. 4.5 Tesla magnetic field reduces range of high-energy positrons -- Potential implications for positron emission tomography

    International Nuclear Information System (INIS)

    Wirrwar, A.; Vosberg, H.; Herzog, H.; Halling, H.; Weber, S.; Mueller-Gaertner, H.W.; Forschungszentrum Juelich GmbH

    1997-01-01

    The authors have theoretically and experimentally investigated the extent to which homogeneous magnetic fields up to 7 Tesla reduce the spatial distance positrons travel before annihilation (positron range). Computer simulations of a noncoincident detector design using a Monte Carlo algorithm calculated the positron range as a function of positron energy and magnetic field strength. The simulation predicted improvements in resolution, defined as full-width at half-maximum (FWHM) of the line-spread function (LSF) for a magnetic field strength up to 7 Tesla: negligible for F-18, from 3.35 mm to 2.73 mm for Ga-68 and from 3.66 mm to 2.68 mm for Rb-82. Also a substantial noise suppression was observed, described by the full-width at tenth-maximum (FWTM) for higher positron energies. The experimental approach confirmed an improvement in resolution for Ga-68 from 3.54 mm at 0 Tesla to 2.99 mm FWHM at 4.5 Tesla and practically no improvement for F-18 (2.97 mm at 0 Tesla and 2.95 mm at 4.5 Tesla). It is concluded that the simulation model is appropriate and that a homogeneous static magnetic field of 4.5 Tesla reduces the range of high-energy positrons to an extent that may improve spatial resolution in positron emission tomography

  11. Analysis of human cerebral functions using positron emission tomography (PET)

    International Nuclear Information System (INIS)

    Shibasaki, Takashi

    1984-01-01

    Positron emission tomography has two major advantages to analyse human cerebral functions in vivo. First, we can see the distribution of a variety of substance in the living (and doing something) human brain. Positron emitters, 11 C, 13 N, 15 O and 18 F, are made by medical cyclotron and are elements of natural substrates or easily tagged to substrate. Second, the distribution of the tracer is calculated to make a quantitative functional map in a reasonable spatial resolution over the entire brain in the same time. Not only cortical areas but also deeper structures show regional cerebral blood flow (rCBF) or local cerebral metabolic rates (LCMRs). Nowadays, PET is put to practical use for determination of mainly rCBF, LCMR for glucose (LCMRsub(glu)), LCMR for oxygen (LCMRsub(o2)) and regional cerebral blood volume (rCBV). There have been many other pilot studies, such as estimation of distribution of given neurotransmitters or modulators in the brain which also confirms the substances' role in the neuronal function, and observation of protein synthesis relating to memory function. (J.P.N.)

  12. Application of positron emission tomography in the lung

    International Nuclear Information System (INIS)

    Valind, S.O.; Wollmer, P.E.; Rhodes, C.G.

    1985-01-01

    The early application of positron emission tomography in the lung was mainly concerned with the investigation of the regional volume of the vascular and extravascular compartments, using measurements of fractional blood volume and lung density. However, in addition to its passive role in the exchange of oxygen and carbon dioxide, the lung exerts a number of active, metabolic functions such as the inactivation of circulating vasoactive compounds and the synthesis and release of biologically active substances. Furthermore, many of the pulmonary disorders originate at a cellular or metabolic level, or have metabolic consequences. Many of the substrates of biochemical reactions and the biologically active compounds, or their analogs, can be labeled with positron-emitting radioisotopes without disturbing their biological or biochemical characteristics. In combination with the development of the appropriate physiological and biochemical models, the quantitative measurements possible with PET provide a unique opportunity of regionally studying the metabolic processes of the lung of man in vivo. Hence, a range of different expressions of metabolism and of lung function can be evaluated and their interdependence can be studied regionally

  13. Evaluation of scintillators and semiconductor detectors to image three-photon positron annihilation for positron emission tomography

    International Nuclear Information System (INIS)

    Abuelhia, E.; Spyrou, N.M.; Kacperski, K.; College University, Middlesex Hospital, London

    2008-01-01

    Positron emission tomography (PET) is rapidly becoming the main nuclear imaging modality of the present century. The future of PET instrumentation relies on semiconductor detectors because of their excellent characteristics. Three-photon positron annihilation has been recently investigated as a novel imaging modality, which demands the crucial high energy resolution of semiconductor detector. In this work the evaluation of the NaI(Tl) scintillator and HPGe and CdZTe semiconductor detectors, to construct a simple three-photon positron annihilation scanner has been explored. The effect of detector and scanner size on spatial resolution (FWHM) is discussed. The characteristics: energy resolution versus count rate and point-spread function of the three-photon positron annihilation image profile from triple coincidence measurements were investigated. (author)

  14. Temporoparietal cortex in aphasia. Evidence from positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Metter, E.J.; Hanson, W.R.; Jackson, C.A.; Kempler, D.; van Lancker, D.; Mazziotta, J.C.; Phelps, M.E. (National Institute of Aging, Baltimore, MD (USA))

    1990-11-01

    Forty-four aphasic patients were examined with (F18)-fluorodeoxyglucose positron emission tomography in a resting state to determine whether consistent glucose metabolic abnormalities were present. Ninety-seven percent of subjects showed metabolic abnormalities in the angular gyrus, 89% in the supramarginal gyrus, and 87% in the lateral and transverse superior temporal gyrus. Pearson product moment correlations were calculated between regional metabolic measures and performance on the Western Aphasia Battery. No significant correlations were found between the Western Aphasia Battery scores and right hemisphere metabolic measures. Most left hemisphere regions correlated with more than one score from the Western Aphasia Battery. Temporal but not frontal regions had significant correlations to the comprehension score. The left temporoparietal region was consistently affected in these subjects, suggesting that common features in the aphasias were caused by left temporoparietal dysfunction, while behavioral differences resulted from (1) the extent of temporoparietal changes, and (2) dysfunction elsewhere in the brain, particularly the left frontal and subcortical areas.

  15. Evaluation of brain tumours by positron emission tomography

    International Nuclear Information System (INIS)

    Schober, O.; Meyer, G.J.

    1992-01-01

    The clinical application of positron emission tomography (PET) for the evaluation of brain tumours has proved clinically valuable. Amino acid and FDG-glucose PET provide information on the degree of malignancy and the prognosis during the initial evaluation. After therapy, the residual tumour can be visualized and recurrence can be differentiated from necrosis. Amino acids have advantages over FDG for these clinical applications. Blood flow, oxygen extraction and metabolism and blood-brain barrier permeability are of minor relevance in clinical situations. Comparison of PET with MRI and MRS will provide new data. The quantitative information of the unique information yielded by PET will lead to a more important clinical role, as will the extrapolation of this experience to the SPECT technique. (orig.) [de

  16. Temporoparietal cortex in aphasia. Evidence from positron emission tomography

    International Nuclear Information System (INIS)

    Metter, E.J.; Hanson, W.R.; Jackson, C.A.; Kempler, D.; van Lancker, D.; Mazziotta, J.C.; Phelps, M.E.

    1990-01-01

    Forty-four aphasic patients were examined with (F18)-fluorodeoxyglucose positron emission tomography in a resting state to determine whether consistent glucose metabolic abnormalities were present. Ninety-seven percent of subjects showed metabolic abnormalities in the angular gyrus, 89% in the supramarginal gyrus, and 87% in the lateral and transverse superior temporal gyrus. Pearson product moment correlations were calculated between regional metabolic measures and performance on the Western Aphasia Battery. No significant correlations were found between the Western Aphasia Battery scores and right hemisphere metabolic measures. Most left hemisphere regions correlated with more than one score from the Western Aphasia Battery. Temporal but not frontal regions had significant correlations to the comprehension score. The left temporoparietal region was consistently affected in these subjects, suggesting that common features in the aphasias were caused by left temporoparietal dysfunction, while behavioral differences resulted from (1) the extent of temporoparietal changes, and (2) dysfunction elsewhere in the brain, particularly the left frontal and subcortical areas

  17. Diagnosis and evaluation of gastric cancer by positron emission tomography

    Science.gov (United States)

    Wu, Chen-Xi; Zhu, Zhao-Hui

    2014-01-01

    Gastric cancer is the second leading cause of cancer mortality worldwide. The diagnosis of gastric cancer has been significantly improved with the broad availability of gastrointestinal endoscopy. Effective technologies for accurate staging and quantitative evaluation are still in demand to merit reasonable treatment and better prognosis for the patients presented with advanced disease. Preoperative staging using conventional imaging tools, such as computed tomography (CT) and endoscopic ultrasonography, is inadequate. Positron emission tomography (PET), using 18F-fluorodeoxyglucose (FDG) as a tracer and integrating CT for anatomic localization, holds a promise to detect unsuspected metastasis and has been extensively used in a variety of malignancies. However, the value of FDG PET/CT in diagnosis and evaluation of gastric cancer is still controversial. This article reviews the current literature in diagnosis, staging, response evaluation, and relapse monitoring of gastric cancer, and discusses the current understanding, improvement, and future prospects in this area. PMID:24782610

  18. Positron Emission Tomography: state of the art and future developments

    International Nuclear Information System (INIS)

    Pizzichemi, M.

    2016-01-01

    Positron emission tomography (PET) plays a fundamental role in medical imaging, with a wide range of applications covering, among the others, oncology, neurology and cardiology. PET has undergone a steady technological evolution since its introduction in mid 20th century, from the development of 3D PET in the late 1980s, to the invention of PET/CT in the 1990s and more recently with the introduction of PET/MR scanners. The current research topics aiming to develop the next generation of PET scanners are summarized in this paper, focusing on the efforts to increase the sensitivity of the detectors, as long as improving their timing, spatial and energy resolutions, with the final goal of reducing the amount of radioactive dose received by the patients and the duration of the exams while improving at the same time the detectability of lesions.

  19. Positron emission tomography with gamma camera in coincidence mode

    International Nuclear Information System (INIS)

    Hertel, A.; Hoer, G.

    1999-01-01

    Positron emission tomography using F-18 FDG has been estbalished in clinical diagnostics with first indications especially in oncology. To install a conventional PET tomography (dedicated PET) is financially costly and restricted to PET examinations only. Increasing demand for PET diagnostics on one hand and restricted financial resources in the health system on the other hand led industry to develop SPECT cameras to be operated in coincidence mode (camera PET) in order to offer nuclear medicine physicians cost-effective devices for PET diagnostic. At the same time camera PET is inferior to conventional PET regarding sensitivity and detection-efficiency for 511 keV photons. Does camera-PET offer a reliable alternative to conventional PET? The first larger comparative studies are now available, so a first apraisal about the technical clinical performance of camera-PET can be done. (orig.) [de

  20. Development of the LBNL positron emission mammography camera

    International Nuclear Information System (INIS)

    Huber, Jennifer S.; Choong, Woon-Seng; Wang, Jimmy; Maltz, Jonathon S.; Qi, Jinyi; Mandelli, Emanuele; Moses, William W.

    2002-01-01

    We present the construction status of the LBNL Positron Emission Mammography (PEM) camera, which utilizes a PET detector module with depth of interaction measurement consisting of 64 LSO crystals (3x3x30 mm3) coupled on one end to a single photomultiplier tube (PMT) and on the opposite end to a 64 pixel array of silicon photodiodes (PDs). The PMT provides an accurate timing pulse, the PDs identify the crystal of interaction, the sum provides a total energy signal, and the PD/(PD+PMT) ratio determines the depth of interaction. We have completed construction of all 42 PEM detector modules. All data acquisition electronics have been completed, fully tested and loaded onto the gantry. We have demonstrated that all functions of the custom IC work using the production rigid-flex boards and data acquisition system. Preliminary detector module characterization and coincidence data have been taken using the production system, including initial images

  1. Positron emission tomography (PET) for oncologic applications in oral region

    International Nuclear Information System (INIS)

    Shozushima, Masanori; Terasaki, Kazunori

    2004-01-01

    A rapidly emerging clinical application of positron emission tomography (PET) is the detection of cancer with radionuclide tracer, because it provides information unavailable by ultrasound, computed tomography or magnetic resonance imaging. The most commonly used radiotracer for PET oncologic imaging is fluorine-18-labeled fluorodeoxyglucose ( 18 F-FDG). Early studies show PET has potential value in viewing the region of the tumor, detecting, staging, grading, monitoring response to anticancer therapy, and differentiating recurrent or residual disease from post treatment changes. However, limitations of FDG-PET in the head and neck region, namely, physiological FDG uptake in the salivary glands and palatine tonsils, have been reported, increasing the false-positive rates in image interpretation. This review was designed to address these distinctions of oral cancer PET imaging: specialization of PET equipment, cancer cell metabolism, proliferation and tracers, clinical diagnosis of oral cancer with PET, pitfalls in oncologic diagnosis with FDG-PET imaging. (author)

  2. Axial positrons emission tomography: from mouse to human brain imaging

    International Nuclear Information System (INIS)

    Brard, Emmanuel

    2013-01-01

    Positrons emission tomography is a nuclear imaging technics using nuclear decays. It is used both in clinical and preclinical studies. The later requires the use of small animals such as the mouse. The objective is to obtain the best signal with the best spatial resolution. Yet, a weight ratio between humans and mice indicates the need of a sub-millimeter resolution. A conventional scanner is based on detection modules surrounding the object to image and arranged perpendicularly. This implies a strong relationship between efficiency and spatial resolution. This work focuses on the axial geometry in which detection modules are arranged parallel to the object. This limits the relationship between the figures of merit, leading to both high spatial resolution and efficiency. The simulations of prototypes showed great perspectives in term of sub-millimeter resolution with efficiencies of 15 or 40% according to the scanner's axial extension. These results indicate great perspectives for both clinical and preclinical imaging. (author)

  3. A Case of Corticobasal Degeneration Studied with Positron Emission Tomography

    Directory of Open Access Journals (Sweden)

    H. Nagasawa

    1993-01-01

    Full Text Available We measured cerebral blood flow, oxygen metabolism, glucose utilization, and dopamine metabolism in the brain of a patient with corticobasal degeneration using positron emission tomography (PET. The clinical picture is distinctive, comprising features referable to both cortical and basal ganglionic dysfunction. Brain imagings of glucose and dopamine metabolism can demonstrate greater abnormalities in the cerebral cortex and in the striatum contralateral to the more affected side than those of blood flow and oxygen metabolism. This unique combination study measuring both cerebral glucose utilization and dopamine metabolism in the nigrostriatal system can provide efficient information about the dysfunctions which are correlated with individual clinical symptoms, and this study is essential to diagnosis of corticobasal degeneration.

  4. Differential diagnosis of depression: relevance of positron emission tomography

    International Nuclear Information System (INIS)

    Schwartz, J.M.; Baxter, L.R. Jr.; Mazziotta, J.C.; Gerner, R.H.; Phelps, M.E.

    1987-01-01

    The proper differential diagnosis of depression is important. A large body of research supports the division of depressive illness into bipolar and unipolar subtypes with respect to demographics, genetics, treatment response, and neurochemical mechanisms. Optimal treatment is different for unipolar and bipolar depressions. Treating a patient with bipolar depression as one would a unipolar patient may precipitate a serious manic episode or possibly even permanent rapid cycling disorder. The clinical distinction between these disorders, while sometimes difficult, can often be achieved through an increased diagnostic suspicion concerning a personal or family history of mania. Positron emission tomography and the FDG method, which allow in vivo study of the glucose metabolic rates for discrete cerebral structures, provide new evidence that bipolar and unipolar depression are two different disorders

  5. Lesion detection and quantitation of positron emission mammography

    International Nuclear Information System (INIS)

    Qi, Jinyi; Huesman, Ronald H.

    2001-01-01

    A Positron Emission Mammography (PEM) scanner dedicated to breast imaging is being developed at our laboratory. We have developed a list mode likelihood reconstruction algorithm for this scanner. Here we theoretically study the lesion detection and quantitation. The lesion detectability is studied theoretically using computer observers. We found that for the zero-order quadratic prior, the region of interest observer can achieve the performance of the prewhitening observer with a properly selected smoothing parameter. We also study the lesion quantitation using the test statistic of the region of interest observer. The theoretical expressions for the bias, variance, and ensemble mean squared error of the quantitation are derived. Computer simulations show that the theoretical predictions are in good agreement with the Monte Carlo results for both lesion detection and quantitation

  6. Evaluating patients with ischemic cerebrovascular disease using positron emission tomography

    International Nuclear Information System (INIS)

    Raichle, M.E.

    1982-01-01

    Recent advances in nuclear medicine imaging techniques offer an important alternative for the evaluation of therapy for ischemic cerebrovascular disease. In particular, positron emission tomography (PET), with its capacity to provide quantitative measurements of brain blood flow, metabolism and biochemistry on a truly regional basis, now offers the opportunity to evaluate therapy in terms of specific changes in these parameters. By doing this PET permits one to study the problem on an individual patient basis with each subject serving as his own control. The author has been pursuing this approach in patients considered candidates for superficial temporal artery-middle cerebral artery anastomosis to bypass major stenotic or occlusive lesions of the internal carotid or middle cerebral artery. The results indicate that PET is of considerable value in establishing much more exactly the pathophysiology of certain forms of ischemic cerebrovascular disease and evaluating a form of therapy designed to correct the basic underlying defect. (Auth./C.F.)

  7. Knowledge-based automated radiopharmaceutical manufacturing for Positron Emission Tomography

    International Nuclear Information System (INIS)

    Alexoff, D.L.

    1991-01-01

    This article describes the application of basic knowledge engineering principles to the design of automated synthesis equipment for radiopharmaceuticals used in Positron Emission Tomography (PET). Before discussing knowledge programming, an overview of the development of automated radiopharmaceutical synthesis systems for PET will be presented. Since knowledge systems will rely on information obtained from machine transducers, a discussion of the uses of sensory feedback in today's automated systems follows. Next, the operation of these automated systems is contrasted to radiotracer production carried out by chemists, and the rationale for and basic concepts of knowledge-based programming are explained. Finally, a prototype knowledge-based system supporting automated radiopharmaceutical manufacturing of 18FDG at Brookhaven National Laboratory (BNL) is described using 1stClass, a commercially available PC-based expert system shell

  8. Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease

    International Nuclear Information System (INIS)

    Naagren, Kjell; Halldin, Christer; Rinne, Juha O.

    2010-01-01

    Alzheimer's disease (AD) is a common degenerative neurological disease that is an increasing medical, economical, and social problem. There is evidence that a long ''asymptomatic'' phase of the disease exists where functional changes in the brain are present, but structural imaging for instance with magnetic resonance imaging remains normal. Positron emission tomography (PET) is one of the tools by which it is possible to explore changes in cerebral blood flow and metabolism and the functioning of different neurotransmitter systems. More recently, investigation of protein aggregations such as amyloid deposits or neurofibrillary tangles containing tau-protein has become possible. The purpose of this paper is to review the current knowledge on various 18 F- and 11 C-labelled PET tracers that could be used to study the pathophysiology of AD, to be used in the early or differential diagnosis or to be used in development of treatment and in monitoring of treatment effects. (orig.)

  9. Data acquisition electronics for positron emission mammography (PEM) detectors

    International Nuclear Information System (INIS)

    Martinez, J.D.; Sebastia, A.; Cerda, J.; Esteve, R.; Mora, F.J.; Toledo, J.F.; Benlloch, J.M.; Gimenez, N.; Gimenez, M.; Lerche, Ch. W.; Pavon, N.; Sanchez, F.

    2005-01-01

    Positron emission mammography (PEM) is an innovative technique to increase sensitivity and overcome the main drawbacks of conventional X-ray screening. However, dedicated PET imaging systems demand specific hardware solutions for data acquisition and processing that can take advantage of the reduction in the number of channels. Data acquisition issues can affect PEM scanners performance and they should be exhaustively addressed in order to exploit the increment in the event count rate. This is crucial in order to reduce both the scanning time and the total injected dose. This paper presents the electronics for our PEM camera prototype that enables us to achieve very high-count rates and perform comprehensive online processing. Results about acquisition in our detector for a typical clinical setup are studied using Monte Carlo simulation of hot lesion phantoms

  10. Brain abnormalities in murderers indicated by positron emission tomography.

    Science.gov (United States)

    Raine, A; Buchsbaum, M; LaCasse, L

    1997-09-15

    Murderers pleading not guilty by reason of insanity (NGRI) are thought to have brain dysfunction, but there have been no previous studies reporting direct measures of both cortical and subcortical brain functioning in this specific group. Positron emission tomography brain imaging using a continuous performance challenge task was conducted on 41 murderers pleading not guilty by reason of insanity and 41 age- and sex-matched controls. Murderers were characterized by reduced glucose metabolism in the prefrontal cortex, superior parietal gyrus, left angular gyrus, and the corpus callosum, while abnormal asymmetries of activity (left hemisphere lower than right) were also found in the amygdala, thalamus, and medial temporal lobe. These preliminary findings provide initial indications of a network of abnormal cortical and subcortical brain processes that may predispose to violence in murderers pleading NGRI.

  11. Investigation of language lateralization mechanism by Positron Emission Tomography

    International Nuclear Information System (INIS)

    Belin, Pascal

    1997-01-01

    As language lateralization in the brain left hemisphere is one of the most well known but less understood characteristics of the human brain, this research thesis reports the use of brain functional imaging to address some specific aspects of this lateralization. In a first part, the author reports the study of mechanisms of recovery from aphasia after a left hemisphere lesion within a population of aphasic right-handers. Based on a contrast between patients with a persistent aphasia despite usual language therapies, and patients with a significant recovery after a melodic and rhythmic therapy (TMR), a PET-based (positron emission tomography) activation study has been developed, based on the opposition between usual language stimuli and stimuli accentuated by TMR. In the second part, the author explored more systematically on sane patients the influence of some physical characteristics of auditory stimulation on the induced functional asymmetry [fr

  12. F-18-fluorodeoxyglucose-positron-emission tomography in neurology

    International Nuclear Information System (INIS)

    Fazekas, F.; Payer, F.

    2002-01-01

    Positron emission tomography using F-18-fluorodeoxyglucose (F-18-FDG-PET) is an ideal tool for imaging regional cerebral metabolism as glucose is the most important source of energy for neurons. Under physiologic conditions the pattern of metabolism reflects the state of cerebral activation which can be modulated by various stimuli to investigate cerebral organization. Pathologic conditions usually cause a drop in metabolism because of neuronal inactivity or loss. They can, however, also be associated with an increased rate of glucose metabolism such as in case of active epileptic foci or malignant tumors. As a consequence F-18-FDG-PET has become a valuable functional imaging modality especially for the diagnostic clarification of non-contributory or negative morphologic imaging results. Dementia, pre-surgical evaluation of epilepsy and neurooncology are currently frequent indications for referral to F-18-FDG-PET in neurology. (author)

  13. Basal ganglia disorders studied by positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Shinotoh, Hitoshi [Chiba Univ. (Japan). School of Medicine

    1994-04-01

    Recent development of positron emitting radioligands has made it possible to investigate the alterations of neurotransmitter systems associated with basal ganglia disorders in vivo. The functional integrity of nigro-striatal dopaminergic terminals may be studied with [[sup 18]F]6-fluoro-L-dopa ([[sup 18]F]dopa), and striatal dopamine receptor density with suitable PET ligands. [[sup 18]F]dopa uptake in the striatum (putamen) is markedly reduced in patients with Parkinson's disease (PD). [[sup 18]F]dopa-PET is capable of detecting sub-clinical nigral dysfunction in asymptomatic patients with familial PD and those who become Parkinsonian on conventional doses of dopamine receptor antagonists. While putamen [[sup 18]F]dopa uptake is reduced to a similar level in patients with multiple system atrophy (MSA) and PD, caudate [[sup 18]F] dopa uptake is lower in MSA than PD. However, [[sup 18]F]dopa PET cannot consistently distinguish MSA from PD because individual ranges of caudate [[sup 18]F]dopa uptake overlap. D[sub 1] and D[sub 2] receptor binding is markedly reduced in the striatum (posterior putamen) of MSA patients. Therefore, dopamine receptor imaging is useful for the differential diagnosis of MSA and PD. Similar marked reductions in putamen and caudate [[sup 18]F]dopa uptake have been observed in patients with progressive supranuclear palsy (PSP). Moderate reductions in D[sub 2] receptor binding have been reported in the striatum of PSP patients. The reduction in D[sub 2] receptor binding is more prominent in the caudate than putamen. Striatal [[sup 18]F]dopa uptake is normal or only mildly reduced in patients with dopa responsive dystonia (DRD). D[sub 2] receptor binding is markedly reduced in patients with Huntington's disease, while striatal [[sup 18]F]dopa uptake is normal or mildly reduced. In summary, PET can demonstrate characteristic patterns of disruption of dopaminergic systems associated with basal ganglia disorders. (J.P.N.) 55 refs.

  14. A simulation study of a method to reduce positron annihilation spread distributions using a strong magnetic field in positron emission tomography

    International Nuclear Information System (INIS)

    Iida, H.; Kanno, I.; Miura, S.; Murakami, M.; Takahashi, V.; Kemura, K.

    1986-01-01

    The positron trajectories have been three-dimensionally simulated using a Monte-Carlo method under various strength of the magnetic field. More than 5 tesla of the field confined the positrons effectively, resulting in increase of the probability of the annihilation within a limited small region, hence the higher spatial resolution in positron emission tomography

  15. 76 FR 6143 - Draft Guidance on Positron Emission Tomography Drug Applications-Content and Format for New Drug...

    Science.gov (United States)

    2011-02-03

    ...; formerly Docket No. 00D-0892] Draft Guidance on Positron Emission Tomography Drug Applications--Content and... Applications for Certain Positron Emission Tomography Drug Products; Availability,'' issued on March 10, 2000... and ANDAs.'' The draft guidance is intended to assist manufacturers of certain positron emission...

  16. The review of myocardial positron emission computed tomography and positron imaging by gamma camera

    Energy Technology Data Exchange (ETDEWEB)

    Ohtake, Tohru [Tokyo Univ. (Japan). Faculty of Medicine

    1998-04-01

    To measure myocardial blood flow, Nitrogen-13 ammonia, Oxygen-15 water, Rubidium-82 and et al. are used. Each has merit and demerit. By measuring myocardial coronary flow reserve, the decrease of flow reserve during dipyridamole in patients with hypercholesterolemia or diabetes mellitus without significant coronary stenosis was observed. The possibility of early detection of atherosclerosis was showed. As to myocardial metabolism, glucose metabolism is measured by Fluorine-18 fluorodeoxyglucose (FDG), and it is considered as useful for the evaluation of myocardial viability. We are using FDG to evaluate insulin resistance during insulin clamp in patients with diabetes mellitus by measuring glucose utilization rate of myocardium and skeletal muscle. FFA metabolism has been measured by {sup 11}C-palmitate, but absolute quantification has not been performed. Recently the method for absolute quantification was reported, and new radiopharmaceutical {sup 18}F-FTHA was reported. Oxygen metabolism has been estimated by {sup 11}C-acetate. Myocardial viability, cardiac efficiency was evaluated by oxygen metabolism. As to receptor or sympathetic nerve end, cardiac insufficiency or cardiac transplantation was evaluated. Imaging of positron emitting radiopharmaceutical by gamma camera has been performed. Collimator method is clinically useful for cardiac imaging of viability study. (author). 54 refs.

  17. Scintillation crystals for positron emission tomography having a non reflecting band

    International Nuclear Information System (INIS)

    Thompson, C.J.

    1992-01-01

    This invention relates generally to positron emission tomography, a sub-field of the class of medical imaging techniques using ionizing radiation and image reconstruction techniques; and more particularly to devices which use an array of scintillation detectors to detect the annihilation radiation from positron disintegration and use this information to reconstruct an image of the distribution of positron emitting isotope within a body section. 6 figs

  18. Novel targets for positron emission tomography (PET) radiopharmaceutical tracers for visualization of neuroinflammation

    Science.gov (United States)

    Shchepetkin, I.; Shvedova, M.; Anfinogenova, Y.; Litvak, M.; Atochin, D.

    2017-08-01

    Non-invasive molecular imaging techniques can enhance diagnosis of neurological diseases to achieve their successful treatment. Positron emission tomography (PET) imaging can identify activated microglia and provide detailed functional information based on molecular biology. This imaging modality is based on detection of isotope labeled tracers, which emit positrons. The review summarizes the developments of various radiolabeled ligands for PET imaging of neuroinflammation.

  19. Effectiveness of lead aprons in positron emission tomography

    International Nuclear Information System (INIS)

    Bezerra Fonseca, R.; Amaral, A.

    2008-01-01

    Full text: In the last two decades, Positron Emission Tomography (PET) has emerged as clinical diagnostic technique, becoming one of the fastest growing imaging tools in modern nuclear medicine. Because 511 keV annihilation photon energy is much higher than the photon with mean energy of 140 keV emitted in Single Photon Computed Tomography (SPECT), medical staff working in PET studies receive a higher dose than those working only with SPECT tracers do. As a result, special attention must be paid to keep radiation exposure as low as reasonably achievable (ALARA principle). Lead equivalent apron is the principal personal protective equipment for technologists occupationally exposed to ionizing radiation in medical procedures and may be an important component in the ALARA program. However, in practices involving PET, 0.5 mm lead equivalent aprons have been used regardless of photon's energy. In this context, this work was designed for evaluating radioprotective effectiveness of such aprons in PET procedures. For this, the operational quantities personal dose equivalent H p (0.07) and H p (10) have been assessed by using MCNP4C code in a model of individual exposure to small source of 511 keV photons, representing the situation of injection of the radiopharmaceutical, in two situations: technologists wearing and not wearing 0.5 mm lead aprons. To represent the technologist a mathematical anthropomorphic phantom was employed, and the simulated source to subject distances varied between 40 to 100 cm, in steps of 10 cm. The results showed no significant differences between the values obtained for H p (10) in the two situations, pointing out that that there is no radioprotective influence of wearing such aprons on PET practices. Compared to simulations without such device, H p (0.07) increased up about 26% when technologist is wearing radioprotective aprons, depending on the source to subject distance. On the basis of this work, 0.5 mm lead equivalent aprons should not be

  20. Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

    Energy Technology Data Exchange (ETDEWEB)

    Aboagye, Eric O.; Kenny, Laura M.; Myers, Melvyn [Imperial College London, Department of Surgery and Cancer, Faculty of Medicine, London (United Kingdom); Gilbert, Fiona J. [University of Cambridge, Radiology Department, Cambridge (United Kingdom); Fleming, Ian N. [University of Aberdeen, NCRI PET Research Network, Aberdeen Bioimaging Centre, Aberdeen (United Kingdom); Beer, Ambros J. [Technische Universitaet Munchen, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich (Germany); Cunningham, Vincent J. [University of Aberdeen, Institute of Medical Sciences, Aberdeen (United Kingdom); Marsden, Paul K. [St. Thomas' Hospital, Division of Imaging Sciences, PET Imaging Centre, London (United Kingdom); Visvikis, Dimitris [INSERM National Institute of Health and Clinical Sciences LaTIM, CHU Morvan, Brest (France); Gee, Antony D. [St. Thomas' Hospital, Division of Imaging Sciences, The Rayne Institute, London (United Kingdom); Groves, Ashley M. [University College London, University College Hospital, Institute of Nuclear Medicine, London (United Kingdom); Cook, Gary J. [St. Thomas' Hospital, KCL Division of Imaging, Sciences and Biomedical Engineering, PET Imaging Centre, London (United Kingdom); Kinahan, Paul E. [University of Washington, 222 Old Fisheries Center (FIS), Box 357987, Seattle, WA (United States); Clarke, Larry [Cancer Imaging Program, Imaging Technology Development Branch, Rockville, MD (United States)

    2012-07-15

    The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and radiotracers range from direct physiological functional tracers like [{sup 15}O]-water to macromolecular probes targeting integrin receptors expressed on neovasculature. Finally we make recommendations on ways to incorporate such measurements of tumour vascularity into early clinical trials of novel therapeutics. (orig.)

  1. Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer

    DEFF Research Database (Denmark)

    Bouchelouche, Kirsten; Capala, Jacek; Oehr, Peter

    2009-01-01

    of a number of diagnostic and therapeutic strategies. J591, a monoclonal antibody, which targets the extracellular domain of prostate-specific membrane antigen, shows promising results. HER2 receptors may also have a potential as target for PET/CT imaging and RIT of advanced prostate cancer. SUMMARY: PET......PURPOSE OF REVIEW: Traditional morphologically based imaging modalities are now being complemented by positron emission tomography (PET)/computed tomography (CT) in prostate cancer. Metastatic prostate cancer is an attractive target for radioimmunotherapy (RIT) as no effective therapies...... are available. This review highlights the most important achievements within the last year in PET/CT and RIT of prostate cancer. RECENT FINDINGS: Conflicting results exist on the use of choline for detection of malignant disease in the prostate gland. The role of PET/CT in N-staging remains to be elucidated...

  2. Positron Emission Tomography in clinical research and clinical diagnosis: tracer modelling and radioreceptors

    International Nuclear Information System (INIS)

    Beckers, C.; Goffinet, A.; Bol, A.

    1989-01-01

    Positron emission tomography (PET) allows noninvasive studies of different metabolic pathways in man in a unique way. Human biochemistry can now be studied using physiological tracers like glucose or oxygen; promising investigations are now underway with various neurotransmitters. The aim of this workshop, sponsored by the European Community, has been to convene a group of experts to discuss more deeply the problems related to the study of receptors and energy metabolism, and this particularly in relationship with the compartmental analysis and the modelling of the data. Up to now, these have mostly been accumulated for the brain and heart. Oncology is now a growing field of interest and more applications are certain to arise in the near future. The papers included in this volume summarize the main points discussed during the workshop. (author). refs.; figs.; tabs

  3. single photon emission tomography and positron emission tomography - Part 1 (October 2012), Part 2 (October 2010)

    International Nuclear Information System (INIS)

    Buvat, Irene

    2010-10-01

    The objective of this lecture is to present the single photon emission computed tomography (SPECT) and the positron emission tomography (PET) imaging techniques. Part 1 Content: 1 - Introduction: anatomic, functional and molecular imaging; 2 - Radiotracers: chemical and physical constraints, gamma photon emitters, positon emitters, radioisotopes production, emitters type and imaging techniques; 3 - Gamma cameras; 4 - Quantification in emission tomography: attenuation, scattering, un-stationary spatial resolution; 5 - Synthesis and conclusion. Part 2 content: 1 - Positon emitters; 2 - Positons detection: Coincidence detection (electronic collimation, PET detectors with gamma cameras, dedicated PET detectors, spectrometry); PET detectors type; time-of-flight PET; 2D PET; 3D PET; 3 - Quantification in emission tomography: detected events, attenuation, scattering, fortuitous coincidences, standardisation; 4 - Common SPECT and PET problems: partial volume effect, movement, tomographic reconstruction, calibration, dead time; 5 - Synthesis and conclusion

  4. Relevance of positron emission tomography (PET) in oncology

    International Nuclear Information System (INIS)

    Weber, W.A.; Avril, N.; Schwaiger, M.

    1999-01-01

    Background: The clinical use of positron emission tomography (PET) for detection and staging of malignant tumors is rapidly increasing. Furthermore, encouraging results for monitoring the effects of radio- and chemotherapy have been reported. Methods: This review describes the technical principles of PET and the biological characteristics of tracers used in oncological research and patient studies. The results of clinical studies published in peer reviewed journals during the last 5 years are summarized and clinical indications for PET scans in various tumor types are discussed. Results and Conclusions: Numerous studies have documented the high diagnostic accuracy of PET studies using the glucose analogue F-18-fluordeoxyglucose (FDG-PET) for detection and staging of malignant tumors. In this field, FDG-PET has been particularly successful in lung cancer, colorectal cancer, malignant lymphoma and melanoma. Furthermore, FDG-PET has often proven to be superior to morphological imaging techniques for differentation of tumor recurrence from scar tissue. Due to the high glucose utilization of normal gray matter radiolabeled amino-acids like C-11-methionine are superior to FDG for detection and delineation of brain tumors by PET. In the future, more specific markers of tumor cell proliferation and gene expression may allow the application of PET not only for dianostic imaging also but for non-invasive biological characterization of malignant tumors and early monitoring of therapeutic interventions. (orig.) [de

  5. Measurement of regional cerebral blood flow by positron emission tomography

    International Nuclear Information System (INIS)

    Herscovitch, P.; Powers, W.J.

    1987-01-01

    The principal advantage of positron emission tomography over other methods for measuring cerebral blood flow stems from the accurate, quantitative three-dimensional measurements of regional brain radioactivity that are possible with this technique. As a result, accurate quantitative measurements of regional cerebral blood flow can be obtained for both superficial and deep cerebral structures. The value of PET for investigating central nervous system physiology and pathology extends far beyond this, however. Through the use of different radiotracers and appropriate mathematical models, PET can be applied to the measurement of a wide variety of physiologic variables. Measurements of rCBF tell only part of the story. Experience with PET and with a variety of other techniques has taught us that rCBF is at times a poor indicator of the metabolic, functional, and biochemical status of cerebral tissue. It is only by understanding the interaction of all of these factors that our understanding of neurologic disease can advance. It is in the investigation of these complex relationships that the real value of PET resides

  6. European health telematics networks for positron emission tomography

    Science.gov (United States)

    Kontaxakis, George; Pozo, Miguel Angel; Ohl, Roland; Visvikis, Dimitris; Sachpazidis, Ilias; Ortega, Fernando; Guerra, Pedro; Cheze-Le Rest, Catherine; Selby, Peter; Pan, Leyun; Diaz, Javier; Dimitrakopoulou-Strauss, Antonia; Santos, Andres; Strauss, Ludwig; Sakas, Georgios

    2006-12-01

    A pilot network of positron emission tomography centers across Europe has been setup employing telemedicine services. The primary aim is to bring all PET centers in Europe (and beyond) closer, by integrating advanced medical imaging technology and health telematics networks applications into a single, easy to operate health telematics platform, which allows secure transmission of medical data via a variety of telecommunications channels and fosters the cooperation between professionals in the field. The platform runs on PCs with Windows 2000/XP and incorporates advanced techniques for image visualization, analysis and fusion. The communication between two connected workstations is based on a TCP/IP connection secured by secure socket layers and virtual private network or jabber protocols. A teleconsultation can be online (with both physicians physically present) or offline (via transmission of messages which contain image data and other information). An interface sharing protocol enables online teleconsultations even over low bandwidth connections. This initiative promotes the cooperation and improved communication between nuclear medicine professionals, offering options for second opinion and training. It permits physicians to remotely consult patient data, even if they are away from the physical examination site.

  7. Characterization of time resolved photodetector systems for Positron Emission Tomography

    CERN Document Server

    Powolny, François

    The main topic of this work is the study of detector systems composed of a scintillator, a photodetector and readout electronics, for Positron Emission Tomography (PET). In particular, the timing properties of such detector systems are studied. The first idea is to take advantage of the good timing properties of the NINO chip, which is a fast preamplifier-discriminator developed for the ALICE Time of flight detector at CERN. This chip uses a time over threshold technique that is to be applied for the first time in medical imaging applications. A unique feature of this technique is that it delivers both timing and energy information with a single digital pulse, the time stamp with the rising edge and the energy from the pulse width. This entails substantial simplification of the entire readout architecture of a tomograph. The scintillator chosen in the detector system is LSO. Crystals of 2x2x10mm3 were used. For the photodetector, APDs were first used, and were then replaced by SiPMs to make use of their highe...

  8. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem

    International Nuclear Information System (INIS)

    Kato, Takashi; Fukatsu, Hiroshi; Ito, Kengo; Tadokoro, Masanori; Ota, Toyohiro; Ikeda, Mitsuru; Isomura, Takayuki; Ito, Shigeki; Nishino, Masanari; Ishigaki, Takeo

    1995-01-01

    The aim of this study was to examine the significance and problems of 2-[fluorine-18]-2-deoxy-d-glucose (FDG) positron emission tomography (PET) in diagnosing pancreatic cancer and mass-forming pancreatitis (MFP). PET, X-ray computed tomography (CT) and magnetic resonance (MR) imaging were performed in 15 patients with pancreatic cancer and nine patients with MFP. The areas of the PET scan were determined according to the markers drawn on the patients at CT or MR imaging. Regions of interests (ROIs) were placed by reference to the CT or MR images corresponding to the PET images. Tissue metabolism was evaluated by the differential absorption ratio (DAR) at 50 min after intravenous injection of FDG [DAR = tissue tracer concentration/(injected dose/body weight). The DAR value differed significantly in pancreatic cancer (mean±SD, 4.64±1.94) and MFP (mean±SD, 2.84±2.22) (P<0.05). In one false-negative case (mucinous adenocarcinoma), the tumour contained a small number of malignant cells. In one false-positive case, lymphocytes accumulated densely in the mass in the pancreatic head. Further studies are necessary to investigate the histopathological characteristics (especially the cellularity) and other factors affecting the FDG DAR on PET images. (orig.)

  9. Utilisation of spatial and temporal correlations in positron emission tomography

    International Nuclear Information System (INIS)

    Sureau, F.

    2008-06-01

    In this thesis we propose, implement, and evaluate algorithms improving spatial resolution in reconstructed images and reducing data noise in positron emission tomography imaging. These algorithms have been developed for a high resolution tomograph (HRRT) and applied to brain imaging, but can be used for other tomographs or studies. We first developed an iterative reconstruction algorithm including a stationary and isotropic model of resolution in image space, experimentally measured. We evaluated the impact of such a model of resolution in Monte-Carlo simulations, physical phantom experiments and in two clinical studies by comparing our algorithm with a reference reconstruction algorithm. This study suggests that biases due to partial volume effects are reduced, in particular in the clinical studies. Better spatial and temporal correlations are also found at the voxel level. However, other methods should be developed to further reduce data noise. We then proposed a maximum a posteriori de-noising algorithm that can be used for dynamic data to de-noise temporally raw data (sino-grams) or reconstructed images. The a priori modeled the coefficients in a wavelet basis of all the signals without noise (in an image or sinogram). We compared this technique with a reference de-noising method on replicated simulations. This illustrates the potential benefits of our approach of sinogram de-noising. (author)

  10. Positron emission tomography scans on kanji and kana

    International Nuclear Information System (INIS)

    Sakurai, Yasuhisa

    2002-01-01

    We reanalyzed our positron emission tomography (PET) study on reading of Japanese kanji (morphogram) words, kana (phonogram) words and kana nonwords, using Statistical Parametric Mapping (SPM). The basal occipital and occipito-temporal areas were activated in common, among which activity was most pronounced in the fusiform/inferior temporal gyri with kanji and in the inferior occipital gyrus with kana. The results were consistent with the clinical observations that damage to the posterior inferior temporal cortex including the fusiform/inferior temporal gyri causes alexia with agraphia for kanji, whereas damage to the posterior occipital area including the inferior occipital gyrus causes pure alexia for kana. Bases on the present results and the lesion studies, a dual-route hypothesis that modifies Iwata's model of reading about the Japanese language was proposed. That is, the middle occipital gyrus, deep perisylvian temporoparietal cortex and posterior temporal gyrus constitute a dorsal route for reading and process phonology for words, whereas the inferior occipital, fusiform and posterior inferior temporal gyri constitute a ventral route for reading and process orthography and lexico-semantics for words. The ventral route may gain dominance in reading, according as a word is repeatedly presented. (author)

  11. Automated identification of the lung contours in positron emission tomography

    International Nuclear Information System (INIS)

    Nery, F; Ferreira, N C; Faustino, R; Silva, J Silvestre; Caramelo, F J

    2013-01-01

    Positron Emission Tomography (PET) is a nuclear medicine imaging technique that permits to analyze, in three dimensions, the physiological processes in vivo. One of the areas where PET has demonstrated its advantages is in the staging of lung cancer, where it offers better sensitivity and specificity than other techniques such as CT. On the other hand, accurate segmentation, an important procedure for Computer Aided Diagnostics (CAD) and automated image analysis, is a challenging task given the low spatial resolution and the high noise that are intrinsic characteristics of PET images. This work presents an algorithm for the segmentation of lungs in PET images, to be used in CAD and group analysis in a large patient database. The lung boundaries are automatically extracted from a PET volume through the application of a marker-driven watershed segmentation procedure which is robust to the noise. In order to test the effectiveness of the proposed method, we compared the segmentation results in several slices using our approach with the results obtained from manual delineation. The manual delineation was performed by nuclear medicine physicians that used a software routine that we developed specifically for this task. To quantify the similarity between the contours obtained from the two methods, we used figures of merit based on region and also on contour definitions. Results show that the performance of the algorithm was similar to the performance of human physicians. Additionally, we found that the algorithm-physician agreement is similar (statistically significant) to the inter-physician agreement.

  12. Positron emission tomography/computed tomography imaging and rheumatoid arthritis.

    Science.gov (United States)

    Wang, Shi-Cun; Xie, Qiang; Lv, Wei-Fu

    2014-03-01

    Rheumatoid arthritis (RA) is a phenotypically heterogeneous, chronic, destructive inflammatory disease of the synovial joints. A number of imaging tools are currently available for evaluation of inflammatory conditions. By targeting the upgraded glucose uptake of infiltrating granulocytes and tissue macrophages, positron emission tomography/computed tomography with fluorine-18 fluorodeoxyglucose ((18) F-FDG PET/CT) is available to delineate inflammation with high sensitivity. Recently, several studies have indicated that FDG uptake in affected joints reflects the disease activity of RA. In addition, usage of FDG PET for the sensitive detection and monitoring of the response to treatment has been reported. Combined FDG PET/CT enables the detailed assessment of disease in large joints throughout the whole body. These unique capabilities of FDG PET/CT imaging are also able to detect RA-complicated diseases. Therefore, PET/CT has become an excellent ancillary tool to assess disease activity and prognosis in RA. © 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

  13. Simultaneous in vivo positron emission tomography and magnetic resonance imaging.

    Science.gov (United States)

    Catana, Ciprian; Procissi, Daniel; Wu, Yibao; Judenhofer, Martin S; Qi, Jinyi; Pichler, Bernd J; Jacobs, Russell E; Cherry, Simon R

    2008-03-11

    Positron emission tomography (PET) and magnetic resonance imaging (MRI) are widely used in vivo imaging technologies with both clinical and biomedical research applications. The strengths of MRI include high-resolution, high-contrast morphologic imaging of soft tissues; the ability to image physiologic parameters such as diffusion and changes in oxygenation level resulting from neuronal stimulation; and the measurement of metabolites using chemical shift imaging. PET images the distribution of biologically targeted radiotracers with high sensitivity, but images generally lack anatomic context and are of lower spatial resolution. Integration of these technologies permits the acquisition of temporally correlated data showing the distribution of PET radiotracers and MRI contrast agents or MR-detectable metabolites, with registration to the underlying anatomy. An MRI-compatible PET scanner has been built for biomedical research applications that allows data from both modalities to be acquired simultaneously. Experiments demonstrate no effect of the MRI system on the spatial resolution of the PET system and <10% reduction in the fraction of radioactive decay events detected by the PET scanner inside the MRI. The signal-to-noise ratio and uniformity of the MR images, with the exception of one particular pulse sequence, were little affected by the presence of the PET scanner. In vivo simultaneous PET and MRI studies were performed in mice. Proof-of-principle in vivo MR spectroscopy and functional MRI experiments were also demonstrated with the combined scanner.

  14. Quantifying the limitations of small animal positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Oxley, D.C. [Department of Physics, University of Liverpool, Liverpool L69 7ZE (United Kingdom)], E-mail: dco@ns.ph.liv.ac.uk; Boston, A.J.; Boston, H.C.; Cooper, R.J.; Cresswell, J.R.; Grint, A.N.; Nolan, P.J.; Scraggs, D.P. [Department of Physics, University of Liverpool, Liverpool L69 7ZE (United Kingdom); Lazarus, I.H. [STFC Daresbury Laboratory, Warrington, WA4 4AD Cheshire (United Kingdom); Beveridge, T.E. [School of Materials and Engineering, Monash University, Melbourne (Australia)

    2009-06-01

    The application of position sensitive semiconductor detectors in medical imaging is a field of global research interest. The Monte-Carlo simulation toolkit GEANT4 [ (http://geant4.web.cern.ch/geant4/)] was employed to improve the understanding of detailed {gamma}-ray interactions within the small animal Positron Emission Tomography (PET), high-purity germanium (HPGe) imaging system, SmartPET [A.J. Boston, et al., Oral contribution, ANL, Chicago, USA, 2006]. This system has shown promising results in the field of PET [R.J. Cooper, et al., Nucl. Instr. and Meth. A (2009), accepted for publication] and Compton camera imaging [J.E. Gillam, et al., Nucl. Instr. and Meth. A 579 (2007) 76]. Images for a selection of single and multiple point, line and phantom sources were successfully reconstructed using both a filtered-back-projection (FBP) [A.R. Mather, Ph.D. Thesis, University of Liverpool, 2007] and an iterative reconstruction algorithm [A.R. Mather, Ph.D. Thesis, University of Liverpool, 2007]. Simulated data were exploited as an alternative route to a reconstructed image allowing full quantification of the image distortions introduced in each phase of the data processing. Quantifying the contribution of uncertainty in all system components from detector to reconstruction algorithm allows the areas in need of most attention on the SmartPET project and semiconductor PET to be addressed.

  15. Positron emission tomography in degenerative disorders of the dopaminergic system

    Energy Technology Data Exchange (ETDEWEB)

    Karbe, H; Holthoff, V; Huber, M; Herholz, K; Wienhard, K; Wagner, R; Heiss, W D [Universitaetsklinik fuer Neurologie und Max-Planck-Institut fuer neurologische Forschung, Koeln (Germany)

    1992-01-01

    21 patients who had Parkinson's disease (PD), PD plus dementia of Alzheimer type (PDAT) or progressive supranuclear palsy (PSP), were studied with positron emission tomography (PET) using ({sup 18}F)-2-fluoro-2-deoxy-D-glucose (FDG). In one patient with strictly unilateral PD side differences in striatal dopa uptake were studied with 6-({sup 18}F)fluoro-L-dopa (F-dopa). In patients with PD PET with FDG did not show any significant change in regional cerebral metabolic rates for glucose (rCMR(Glu)). In PDAT glucose metabolism was generally reduced, the most severe decrease was found in parietal cortex. The metabolic pattern was similar to that typically found in patients with Alzheimer's disease (AD). In the patient with strictly unilateral PD rCMR(Glu) was normal, F-dopa PET, however, revealed a distinct reduction of dopa uptake in the contralateral putamen. In PSP glucose metabolism was significantly decreased in subcortical regions (caudatum, putamen and brainstem) and in frontal cortex. Thus PET demonstrated a clear difference of metabolic pattern between PDAT and PSP. (authors).

  16. Positron Emission Tomography with Three-Dimensional Reconstruction

    Energy Technology Data Exchange (ETDEWEB)

    Erlandsson, K.

    1996-10-01

    The development of two different low-cost scanners for positron emission tomography (PET) based on 3D acquisition are presented. The first scanner consists of two rotating scintillation cameras, and produces quantitative images, which have shown to be clinically useful. The second one is a system with two opposed sets of detectors, based on the limited angle tomography principle, dedicated for mammographic studies. The development of low-cost PET scanners can increase the clinical impact of PET, which is an expensive modality, only available at a few centres world-wide and mainly used as a research tool. A 3D reconstruction method was developed that utilizes all the available data. The size of the data-sets is considerably reduced, using the single-slice rebinning approximation. The 3D reconstruction is divided into 1D axial deconvolution and 2D transaxial reconstruction, which makes it relatively fast. This method was developed for the rotating scanner, but was also implemented for multi-ring scanners with and without inter plane septa. An iterative 3D reconstruction method was developed for the limited angle scanner, based on the new concept of `mobile pixels`, which reduces the finite pixel errors and leads to an improved signal to noise ratio. 100 refs.

  17. Positron Emission Tomography with Three-Dimensional Reconstruction

    International Nuclear Information System (INIS)

    Erlandsson, K.

    1996-10-01

    The development of two different low-cost scanners for positron emission tomography (PET) based on 3D acquisition are presented. The first scanner consists of two rotating scintillation cameras, and produces quantitative images, which have shown to be clinically useful. The second one is a system with two opposed sets of detectors, based on the limited angle tomography principle, dedicated for mammographic studies. The development of low-cost PET scanners can increase the clinical impact of PET, which is an expensive modality, only available at a few centres world-wide and mainly used as a research tool. A 3D reconstruction method was developed that utilizes all the available data. The size of the data-sets is considerably reduced, using the single-slice rebinning approximation. The 3D reconstruction is divided into 1D axial deconvolution and 2D transaxial reconstruction, which makes it relatively fast. This method was developed for the rotating scanner, but was also implemented for multi-ring scanners with and without inter plane septa. An iterative 3D reconstruction method was developed for the limited angle scanner, based on the new concept of 'mobile pixels', which reduces the finite pixel errors and leads to an improved signal to noise ratio. 100 refs

  18. Therapy response evaluation with positron emission tomography-computed tomography.

    Science.gov (United States)

    Segall, George M

    2010-12-01

    Positron emission tomography-computed tomography with F-18-fluorodeoxyglucose is widely used for evaluation of therapy response in patients with solid tumors but has not been as readily adopted in clinical trials because of the variability of acquisition and processing protocols and the absence of universal response criteria. Criteria proposed for clinical trials are difficult to apply in clinical practice, and gestalt impression is probably accurate in individual patients, especially with respect to the presence of progressive disease and complete response. Semiquantitative methods of determining tissue glucose metabolism, such as standard uptake value, can be a useful descriptor for levels of tissue glucose metabolism and changes in response to therapy if technical quality control measures are carefully maintained. The terms partial response, complete response, and progressive disease are best used in clinical trials in which the terms have specific meanings and precise definitions. In clinical practice, it may be better to use descriptive terminology agreed upon by imaging physicians and clinicians in their own practice. Copyright © 2010. Published by Elsevier Inc.

  19. Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography

    Directory of Open Access Journals (Sweden)

    Hossein Jadvar

    2015-07-01

    Full Text Available Prostate cancer remains a major public health problem worldwide. Imaging plays an important role in the assessment of disease at all its clinical phases, including staging, restaging after definitive therapy, evaluation of therapy response, and prognostication. Positron emission tomography with a number of biologically targeted radiotracers has been demonstrated to have potential diagnostic and prognostic utility in the various clinical phases of this prevalent disease. Given the remarkable biological heterogeneity of prostate cancer, one major unmet clinical need that remains is the non-invasive imaging-based characterization of prostate tumors. Accurate tumor characterization allows for image-targeted biopsy and focal therapy as well as facilitates objective assessment of therapy effect. PET in conjunction with radiotracers that track the thymidine salvage pathway of DNA synthesis may be helpful to fulfill this necessity. We review briefly the preclinical and pilot clinical experience with the two major cellular proliferation radiotracers, [18F]-3’-deoxy-3’-fluorothymidine and [18F]-2’-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil in prostate cancer.

  20. Carbon-11-methionine positron emission tomography imaging of chordoma

    Energy Technology Data Exchange (ETDEWEB)

    Zhang, Hong [Department of Medical Imaging, National Institute of Radiological Sciences, Chiba (Japan); Department of Medical Imaging, Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1, Anagawa, Inage-ku, 263-8555, Chiba (Japan); Yoshikawa, Kyosan; Tamura, Katsumi; Sagou, Kenji; Kandatsu, Susumu [Clinical Diagnosis Section, National Institute of Radiological Sciences, Chiba (Japan); Tian, Mei; Suhara, Tetsuya; Suzuki, Kazutoshi; Tanada, Shuji [Department of Medical Imaging, National Institute of Radiological Sciences, Chiba (Japan); Tsujii, Hirohiko [Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba (Japan)

    2004-09-01

    Chordoma is a rare malignant bone tumor that arises from notochord remnants. This is the first trial to investigate the utility of {sup 11}C-methionine (MET) positron emission tomography (PET) in the imaging of chordoma before and after carbon-ion radiotherapy (CIRT). Fifteen patients with chordoma were investigated with MET-PET before and after CIRT and the findings analyzed visually and quantitatively. Tumor MET uptake was evaluated by tumor-to-nontumor ratio (T/N ratio). In 12 (80%) patients chordoma was clearly visible in the baseline MET-PET study with a mean T/N ratio of 3.3{+-}1.7. The MET uptake decreased significantly to 2.3{+-}1.4 after CIRT (P<0.05). A significant reduction in tumor MET uptake of 24% was observed after CIRT. Fourteen (93%) patients showed no local recurrence after CIRT with a median follow-up time of 20 months. This study has demonstrated that MET-PET is feasible for imaging of chordoma. MET-PET could provide important tumor metabolic information for the therapeutic monitoring of chordoma after CIRT. (orig.)

  1. Carbon-11-methionine positron emission tomography imaging of chordoma

    International Nuclear Information System (INIS)

    Zhang, Hong; Yoshikawa, Kyosan; Tamura, Katsumi; Sagou, Kenji; Kandatsu, Susumu; Tian, Mei; Suhara, Tetsuya; Suzuki, Kazutoshi; Tanada, Shuji; Tsujii, Hirohiko

    2004-01-01

    Chordoma is a rare malignant bone tumor that arises from notochord remnants. This is the first trial to investigate the utility of 11 C-methionine (MET) positron emission tomography (PET) in the imaging of chordoma before and after carbon-ion radiotherapy (CIRT). Fifteen patients with chordoma were investigated with MET-PET before and after CIRT and the findings analyzed visually and quantitatively. Tumor MET uptake was evaluated by tumor-to-nontumor ratio (T/N ratio). In 12 (80%) patients chordoma was clearly visible in the baseline MET-PET study with a mean T/N ratio of 3.3±1.7. The MET uptake decreased significantly to 2.3±1.4 after CIRT (P<0.05). A significant reduction in tumor MET uptake of 24% was observed after CIRT. Fourteen (93%) patients showed no local recurrence after CIRT with a median follow-up time of 20 months. This study has demonstrated that MET-PET is feasible for imaging of chordoma. MET-PET could provide important tumor metabolic information for the therapeutic monitoring of chordoma after CIRT. (orig.)

  2. Hepatic Pseudolymphoma with Fluorodeoxyglucose Uptake on Positron Emission Tomography

    Directory of Open Access Journals (Sweden)

    Kazuhiro Suzumura

    2017-12-01

    Full Text Available A 69-year-old woman with chronic hepatitis B was admitted to our hospital with a hepatic tumor. The levels of 2 tumor markers, carcinoembryonic antigen and carbohydrate antigen 19-9, were slightly elevated; however, the α-fetoprotein and protein levels induced by vitamin K antagonist II were within the normal limits. Abdominal ultrasonography showed a well-defined peripheral hypoechoic mass that was isoechoic and homogeneous on the inside. Computed tomography showed a poorly enhanced tumor of 13 mm in diameter in the 5th segment of the liver. Fluorodeoxyglucose positron emission tomography showed a slight uptake (maximum standard uptake value 3.4 by the hepatic tumor. These findings suggested cholangiocellular carcinoma, and we performed anterior segmentectomy of the liver. A histopathological examination showed a hepatic pseudolymphoma. The patient’s postoperative course was uneventful, and she remains alive without recurrence 5 months after undergoing surgery. In most cases, hepatic pseudolymphoma is preoperatively diagnosed as a malignant tumor and a definite diagnosis is made after resection. It is therefore necessary to consider hepatic pseudolymphoma as a differential diagnosis in patients with hepatic tumors.

  3. European health telematics networks for positron emission tomography

    International Nuclear Information System (INIS)

    Kontaxakis, George; Pozo, Miguel Angel; Ohl, Roland; Visvikis, Dimitris; Sachpazidis, Ilias; Ortega, Fernando; Guerra, Pedro; Cheze-Le Rest, Catherine; Selby, Peter; Pan, Leyun; Diaz, Javier; Dimitrakopoulou-Strauss, Antonia; Santos, Andres; Strauss, Ludwig; Sakas, Georgios

    2006-01-01

    A pilot network of positron emission tomography centers across Europe has been setup employing telemedicine services. The primary aim is to bring all PET centers in Europe (and beyond) closer, by integrating advanced medical imaging technology and health telematics networks applications into a single, easy to operate health telematics platform, which allows secure transmission of medical data via a variety of telecommunications channels and fosters the cooperation between professionals in the field. The platform runs on PCs with Windows 2000/XP and incorporates advanced techniques for image visualization, analysis and fusion. The communication between two connected workstations is based on a TCP/IP connection secured by secure socket layers and virtual private network or jabber protocols. A teleconsultation can be online (with both physicians physically present) or offline (via transmission of messages which contain image data and other information). An interface sharing protocol enables online teleconsultations even over low bandwidth connections. This initiative promotes the cooperation and improved communication between nuclear medicine professionals, offering options for second opinion and training. It permits physicians to remotely consult patient data, even if they are away from the physical examination site

  4. Biological imaging in radiation therapy: role of positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Nestle, Ursula; Hentschel, Michael; Grosu, Anca-Ligia [Departments of Radiation Oncology, University of Freiburg, Robert Koch Str. 3, 79106 Freiburg (Germany); Weber, Wolfgang [Nuclear Medicine, University of Freiburg, Robert Koch Str. 3, 79106 Freiburg (Germany)], E-mail: ursula.nestle@uniklinik-freiburg.de

    2009-01-07

    In radiation therapy (RT), staging, treatment planning, monitoring and evaluation of response are traditionally based on computed tomography (CT) and magnetic resonance imaging (MRI). These radiological investigations have the significant advantage to show the anatomy with a high resolution, being also called anatomical imaging. In recent years, so called biological imaging methods which visualize metabolic pathways have been developed. These methods offer complementary imaging of various aspects of tumour biology. To date, the most prominent biological imaging system in use is positron emission tomography (PET), whose diagnostic properties have clinically been evaluated for years. The aim of this review is to discuss the valences and implications of PET in RT. We will focus our evaluation on the following topics: the role of biological imaging for tumour tissue detection/delineation of the gross tumour volume (GTV) and for the visualization of heterogeneous tumour biology. We will discuss the role of fluorodeoxyglucose-PET in lung and head and neck cancer and the impact of amino acids (AA)-PET in target volume delineation of brain gliomas. Furthermore, we summarize the data of the literature about tumour hypoxia and proliferation visualized by PET. We conclude that, regarding treatment planning in radiotherapy, PET offers advantages in terms of tumour delineation and the description of biological processes. However, to define the real impact of biological imaging on clinical outcome after radiotherapy, further experimental, clinical and cost/benefit analyses are required. (topical review)

  5. Biological imaging in radiation therapy: role of positron emission tomography.

    Science.gov (United States)

    Nestle, Ursula; Weber, Wolfgang; Hentschel, Michael; Grosu, Anca-Ligia

    2009-01-07

    In radiation therapy (RT), staging, treatment planning, monitoring and evaluation of response are traditionally based on computed tomography (CT) and magnetic resonance imaging (MRI). These radiological investigations have the significant advantage to show the anatomy with a high resolution, being also called anatomical imaging. In recent years, so called biological imaging methods which visualize metabolic pathways have been developed. These methods offer complementary imaging of various aspects of tumour biology. To date, the most prominent biological imaging system in use is positron emission tomography (PET), whose diagnostic properties have clinically been evaluated for years. The aim of this review is to discuss the valences and implications of PET in RT. We will focus our evaluation on the following topics: the role of biological imaging for tumour tissue detection/delineation of the gross tumour volume (GTV) and for the visualization of heterogeneous tumour biology. We will discuss the role of fluorodeoxyglucose-PET in lung and head and neck cancer and the impact of amino acids (AA)-PET in target volume delineation of brain gliomas. Furthermore, we summarize the data of the literature about tumour hypoxia and proliferation visualized by PET. We conclude that, regarding treatment planning in radiotherapy, PET offers advantages in terms of tumour delineation and the description of biological processes. However, to define the real impact of biological imaging on clinical outcome after radiotherapy, further experimental, clinical and cost/benefit analyses are required.

  6. Clinical application of positron emission tomography imaging in urologic tumors

    International Nuclear Information System (INIS)

    Tang Ganghua; Wu Guangyuan

    2007-01-01

    Positron emission tomography (PET) is an advanced noninvasive molecular imaging modality that is being investigated for use in the differentiation, diagnosis, and guiding therapy ora variety of cancer types. FDG PET has the unique clinical value in the differentiation, diagnosis, and monitoring therapy of prostate, such as bladder, renal, and testicle cancer. However, high false-positive and false-negative findings are observed in the detection of these tumors with FDG PET. 11 C-Choline (CH) and 11 C-acetate (AC) can overcome the pitfall of FDG, and appear to be more successful than FGD in imaging prostate cancer and bladder cancer. The short half-life of 11 C prevents the widespread use of CH and AC and 18 F-fluorocholine (FCH) and 18 F-fluoroacetate (FAC) seem to be potential tracers. Potential clinical value of the new PET tracers, such as 3'-deoxy-3'- 18 F-fluorothymidine (FLT), 18 F-fluorodihydrotestosterone (FDHT), and 9-(4- 18 F-3-hydroxymethylbutyl)-guanine( 18 F-FHBG) in the detection of urologic tumors, can deserve further study. (authors)

  7. European health telematics networks for positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Kontaxakis, George [Universidad Politecnica de Madrid, ETSI Telecomunicacion, Madrid 28040 (Spain)]. E-mail: g.kontaxakis@upm.es; Pozo, Miguel Angel [Centro PET Complutense, Madrid 28040 (Spain); Universidad Complutense de Madrid, Instituto Pluridisciplinar, Madrid 28040 (Spain); Ohl, Roland [MedCom Gesellschaft fuer medizinische Bildverarbeitung mbH, Darmstadt 64283 (Germany); Visvikis, Dimitris [U650 INSERM, Lab. du Traitement de L' Information Medicale, University of Brest Occidentale, CHU Morvan, Brest 29609 (France); Sachpazidis, Ilias [Fraunhofer Institute for Computer Graphics, Darmstadt 64283 (Germany); Ortega, Fernando [Fundacion Instituto Valenciano de Oncologia, Valencia 46009 (Spain); Guerra, Pedro [Universidad Politecnica de Madrid, ETSI Telecomunicacion, Madrid 28040 (Spain); Cheze-Le Rest, Catherine [Dept. Medicine Nucleaire, CHU Morvan, Brest 29609 (France); Selby, Peter [MedCom Gesellschaft fuer medizinische Bildverarbeitung mbH, Darmstadt 64283 (Germany); Pan, Leyun [German Cancer Research Centre, Clinical Cooperation Unit Nuclear Medicine, Heidelberg 69120 (Germany); Diaz, Javier [Fundacion Instituto Valenciano de Oncologia, Valencia 46009 (Spain); Dimitrakopoulou-Strauss, Antonia [German Cancer Research Centre, Clinical Cooperation Unit Nuclear Medicine, Heidelberg 69120 (Germany); Santos, Andres [Universidad Politecnica de Madrid, ETSI Telecomunicacion, Madrid 28040 (Spain); Strauss, Ludwig [German Cancer Research Centre, Clinical Cooperation Unit Nuclear Medicine, Heidelberg 69120 (Germany); Sakas, Georgios [MedCom Gesellschaft fuer medizinische Bildverarbeitung mbH, Darmstadt 64283 (Germany); Fraunhofer Institute for Computer Graphics, Darmstadt 64283 (Germany)

    2006-12-20

    A pilot network of positron emission tomography centers across Europe has been setup employing telemedicine services. The primary aim is to bring all PET centers in Europe (and beyond) closer, by integrating advanced medical imaging technology and health telematics networks applications into a single, easy to operate health telematics platform, which allows secure transmission of medical data via a variety of telecommunications channels and fosters the cooperation between professionals in the field. The platform runs on PCs with Windows 2000/XP and incorporates advanced techniques for image visualization, analysis and fusion. The communication between two connected workstations is based on a TCP/IP connection secured by secure socket layers and virtual private network or jabber protocols. A teleconsultation can be online (with both physicians physically present) or offline (via transmission of messages which contain image data and other information). An interface sharing protocol enables online teleconsultations even over low bandwidth connections. This initiative promotes the cooperation and improved communication between nuclear medicine professionals, offering options for second opinion and training. It permits physicians to remotely consult patient data, even if they are away from the physical examination site.

  8. The natural history of misery perfusion in positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Nagata, Shinji; Fujii, Kiyotaka; Matsushima, Toshio; Fukui, Masashi; Sadoshima, Shouzou; Kuwabara, Yasuo (Kyushu Univ., Fukuoka (Japan). Faculty of Medicine)

    1992-03-01

    This report reviews the natural courses of misery perfusion in 5 patients with atherosclerotic cerebrovascular occlusion diseases. Cases 1 showed partial improvement and Case 2 showed deterioration of misery perfusion on positron emission tomography (PET). These 2 patients did not show any clinical changes during the follow-up periods. Case 3 showed remarkable improvement of misery perfusion during the 2-year follow-ups, but his neurological condition worsened. The EC-IC bypass improved both in PET and clinical symptoms. Case 4 had a stroke at the region of misery perfusion in PET. Case 5 had a lacunar infarction 2 years after the EC-IC bypass on the opposite side. PET taken one month before the stroke did not show any signs of hypoperfusion in the area of the lacunar infarction. Misery perfusion seems not to be a static but a dynamic condition that can develop into cerebral infarction by some hemodynamic stresses. Cerebral cortical or lobar infarction may occur in the region of severe misery perfusion. EC-IC bypass may prevent impending infarction of the cerebral cortex by improving the regional cerebral blood flow. However, EC-CI bypass will not prevent the lacunar infarction of the basal ganglia or internal capsule. (author).

  9. Quality assurance and radiation safety in positron emission tomography

    International Nuclear Information System (INIS)

    Kmetyuk, Ya.V.; Radosh, H.V.; Bezshyyko, O.A.; Golinka-Bezshyyko, L.O.; Kadenko, I.M.; Kazinova, O.A.; Nagai, A.O.

    2012-01-01

    Scientific studies, clinical experience and economic analysis have shown that the positron emission tomography (PET) is clinically and cost effective cancer diagnostics method. Combined PET and computed tomography (PET/CT) has proven clinical utility, particularly in the diagnosis, staging or restaging malignant disease and metastases, surgical planning, radiation therapy planning and evaluation of treatment response. The use of PET/CT has grown substantially in the past few years, with an increasing number of hospitals and installations of PET/CT imaging centers each year. In the same time combination of 2 procedures, each of which impart a radiation dose and, as a result, increases the deleterious influence for health, creates additional radiation safety issues. In these conditions the role of quality assurance (QA) and quality control (QC) programs is getting more and more important. We considered main QA and radiation safety requirements for whole PET technology chain from radio-pharmacy facilities to PET/CT scanning and patient release criteria. All these issues were considered and assessed having the example of PET facilities and technology chain of All-Ukrainian Center for Radiosurgery of the Clinical Hospital 'Feofania'

  10. Variation in positron emission tomography use after colon cancer resection.

    Science.gov (United States)

    Bailey, Christina E; Hu, Chung-Yuan; You, Y Nancy; Kaur, Harmeet; Ernst, Randy D; Chang, George J

    2015-05-01

    Colon cancer surveillance guidelines do not routinely include positron emission tomography (PET) imaging; however, its use after surgical resection has been increasing. We evaluated the secular patterns of PET use after surgical resection of colon cancer among elderly patients and identified factors associated with its increasing use. We used the SEER-linked Medicare database (July 2001 through December 2009) to establish a retrospective cohort of patients age ≥ 66 years who had undergone surgical resection for colon cancer. Postoperative PET use was assessed with the test for trends. Patient, tumor, and treatment characteristics were analyzed using univariable and multivariable logistic regression analyses. Of the 39,221 patients with colon cancer, 6,326 (16.1%) had undergone a PET scan within 2 years after surgery. The use rate steadily increased over time. The majority of PET scans had been performed within 2 months after surgery. Among patients who had undergone a PET scan, 3,644 (57.6%) had also undergone preoperative imaging, and 1,977 (54.3%) of these patients had undergone reimaging with PET within 2 months after surgery. Marriage, year of diagnosis, tumor stage, preoperative imaging, postoperative visit to a medical oncologist, and adjuvant chemotherapy were significantly associated with increased PET use. PET use after colon cancer resection is steadily increasing, and further study is needed to understand the clinical value and effectiveness of PET scans and the reasons for this departure from guideline-concordant care. Copyright © 2015 by American Society of Clinical Oncology.

  11. Image-reconstruction algorithms for positron-emission tomography systems

    International Nuclear Information System (INIS)

    Cheng, S.N.C.

    1982-01-01

    The positional uncertainty in the time-of-flight measurement of a positron-emission tomography system is modelled as a Gaussian distributed random variable and the image is assumed to be piecewise constant on a rectilinear lattice. A reconstruction algorithm using maximum-likelihood estimation is derived for the situation in which time-of-flight data are sorted as the most-likely-position array. The algorithm is formulated as a linear system described by a nonseparable, block-banded, Toeplitz matrix, and a sine-transform technique is used to implement this algorithm efficiently. The reconstruction algorithms for both the most-likely-position array and the confidence-weighted array are described by similar equations, hence similar linear systems can be used to described the reconstruction algorithm for a discrete, confidence-weighted array, when the matrix and the entries in the data array are properly identified. It is found that the mean square-error depends on the ratio of the full width at half the maximum of time-of-flight measurement over the size of a pixel. When other parameters are fixed, the larger the pixel size, the smaller is the mean square-error. In the study of resolution, parameters that affect the impulse response of time-of-flight reconstruction algorithms are identified. It is found that the larger the pixel size, the larger is the standard deviation of the impulse response. This shows that small mean square-error and fine resolution are two contradictory requirements

  12. Estimation of intersubject variability of cerebral blood flow measurements using MRI and positron emission tomography

    DEFF Research Database (Denmark)

    Henriksen, Otto Mølby; Larsson, Henrik B W; Hansen, Adam E

    2012-01-01

    PURPOSE: To investigate the within and between subject variability of quantitative cerebral blood flow (CBF) measurements in normal subjects using various MRI techniques and positron emission tomography (PET). MATERIALS AND METHODS: Repeated CBF measurements were performed in 17 healthy, young...

  13. Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging

    DEFF Research Database (Denmark)

    Bouchelouche, Kirsten; Turkbey, Baris; Choyke, Peter

    2010-01-01

    , and molecular imaging information. Developments in imaging technologies, specifically magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT), have improved the detection rate of prostate cancer. MRI has improved lesion detection and local staging. Furthermore, MRI...

  14. Measurement of blood-brain barrier permeability with positron emission tomography in patients with multiple sclerosis

    International Nuclear Information System (INIS)

    Fieschi, C.; Pozzilli, C.; Bernardi, S.; Bozzao, L.; Lenzi, G.L.; Picozzi, P.; Iannotti, F.; Conforti, P.

    1988-01-01

    The purpose of the investigation was to elucidate the role of positron emission tomography using 68 Ga-EDTA in the study of blood-brain barrier abnormalities associated with multiple sclerosis. 14 refs.; 1 figure

  15. Readout of scintillator light with avalanche photodiodes for positron emission tomography

    International Nuclear Information System (INIS)

    Chen, Ruru; Fremout, A.; Tavernier, S.; Bruyndonckx, P.; Clement, D.; Loude, J.-F.; Morel, C.

    1999-01-01

    The noise properties and other relevant characteristics of avalanche photodiodes have been investigated with the perspective of replacing photomultiplier tubes in positron emission tomography. It is clearly demonstrated that they are a valid alternative to photomultiplier tubes in this application

  16. Imaging Atherosclerosis with Hybrid Positron Emission Tomography/Magnetic Resonance Imaging

    DEFF Research Database (Denmark)

    Ripa, Rasmus Sejersten; Kjær, Andreas

    2015-01-01

    Noninvasive imaging of atherosclerosis could potentially move patient management towards individualized triage, treatment, and followup. The newly introduced combined positron emission tomography (PET) and magnetic resonance imaging (MRI) system could emerge as a key player in this context. Both...

  17. Measurement of regional cerebral glucose utilization in man by positron emission tomography

    International Nuclear Information System (INIS)

    Baron, J.C.

    1986-05-01

    The various methods available for the study of regional cerebral glucose consumption in man by positron emission tomography are described and their applications, limitations and principal physiopathological results are presented [fr

  18. Software development for modeling positrons emission tomograph scanners

    International Nuclear Information System (INIS)

    Vieira, Igor Fagner

    2013-01-01

    The Geant4 Application for Tomographic Emission (GATE) is an international platform recognized and used to develop Computational Model Exposure (CME) in the context of Nuclear Medicine, although currently there are dedicated modules for applications in Radiotherapy and Computed Tomography (CT). GATE uses Monte Carlo (MC) methods, and has a scripting language of its own. The writing of scripts for simulation of a PET scanner in GATE involves a number of interrelated steps, and the accuracy of the simulation is dependent on the correct setup of the geometries involved, since the physical processes depend on them, as well as the modeling of electronic detectors in module Digitizer, for example. The manual implementation of this setup can be a source of errors, especially for users without experience in the field of simulations or without any previous knowledge of a programming language, and also due to the the fact that the modeling process in GATE still remains bounded to LINUX / UNIX based systems, an environment only familiar to a few. This becomes an obstacle for beginners and prevents the use of GATE by a larger number of users interested in optimizing their experiments and/or clinical protocols through a more accessible, fast and friendly application. The objective of this work is therefore to develop a user-friendly software for the modeling of Positron Emission Tomography called GUIGATE (Graphical User Interface for GATE), with specific modules dedicated to quality control in PET scanners. The results exhibit the features available in this first version of GUIGATE, present in a set of windows that allow users to create their input files, perform and display in real time the model and analyze its output file in a single environment, allowing so intuitively access the entire architecture of the GATE simulation and to CERN's data analyzer, the ROOT. (author)

  19. Synthesis of the radiopharmaceuticals for positron emission tomography

    International Nuclear Information System (INIS)

    Biricova, V.; Kuruc, J.

    2007-01-01

    In this paper is shown a short overview of the biogenic positron radiopharmaceuticals production and a brief summary of some PET preparation synthesis. At the end the overview of some forward-looking positron radionuclides, which can be used for a preparation of the PET radiopharmaceuticals is said. A short review of diagnostic use of PET radiopharmaceuticals is presented (authors)

  20. RELIABILITY OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IN EVALUATION OF TESTICULAR CARCINOMA PATIENTS.

    Science.gov (United States)

    Nikoletić, Katarina; Mihailović, Jasna; Matovina, Emil; Žeravica, Radmila; Srbovan, Dolores

    2015-01-01

    The study was aimed at assessing the reliability of 18F-fluorodeoxyglucose positron emission tomography-computed tomography scan in evaluation of testicular carcinoma patients. The study sample consisted of 26 scans performed in 23 patients with testicular carcinoma. According to the pathohistological finding, 14 patients had seminomas, 7 had nonseminomas and 2 patients had a mixed histological type. In 17 patients, the initial treatment was orchiectomy+chemotherapy, 2 patients had orchiectomy+chemotherapy+retroperitoneal lymph node dissection, 3 patients had orchiectomy only and one patient was treated with chemotherapy only. Abnormal computed tomography was the main cause for the oncologist to refer the patient to positron emission tomography-computed tomography scan (in 19 scans), magnetic resonance imaging abnormalities in 1 scan, high level oftumor markers in 3 and 3 scans were perforned for follow-up. Positron emission tomography-computed tomography imaging results were compared with histological results, other imaging modalities or the clinical follow-up of the patients. Positron emission tomography-computed tomography scans were positive in 6 and negative in 20 patients. In two patients, positron emission tomography-computed tomography was false positive. There were 20 negative positron emission omography-computed tomography scans perforned in 18 patients, one patient was lost for data analysis. Clinically stable disease was confirmed in 18 follow-up scans performed in 16 patients. The values of sensitivty, specificity, accuracy, and positive- and negative predictive value were 60%, 95%, 75%, 88% and 90.5%, respectively. A hgh negative predictive value obtained in our study (90.5%) suggests that there is a small possibility for a patient to have future relapse after normal positron emission tomography-computed tomography study. However, since the sensitivity and positive predictive value of the study ire rather low, there are limitations of positive

  1. Analysis of solute transport in plants using positron emission tomography

    International Nuclear Information System (INIS)

    Partelova, D.

    2016-01-01

    In the first part of the work, geometrically and radiochemically characterized standards (phantoms) imitating the plant tissues and allowing the exact quantification of visualised radioindicator in plant tissues were designed and prepared within the study of visual and analytical characteristics of used positron emission tomograph (microPET system) commercially developed for animal objects at visualization of thin objects. Individual experiments carried out by exposure of excised leaves of tobacco (Nicotiana tabacum L.) or radish (Raphanus sativus L.) in solutions of 2-deoxy-2-fluoro-D-glucose labelled with positron emitter 18 F (2-[ 18 F]FDG) containing 10-, 100-, or 1000-times higher concentrations of D-glucose (c glu ) in comparison with the original 2-[ 18 F]FDG solution showed that the significant changes in visualisation of 2-[ 18 F]FDG distribution as well as in chemical portion of 2-[ 18 F]FDG within the leaf blade were observed as result of increased c glu . In the experiments with the whole plants of tobacco or radish exposed in 2-[ 18 F]FDG solution through the root system, only minimal translocation of 18 F radioactivity into the above-ground parts of plants, also in the case of increased c glu , was observed, which suggest the role of root system as a selective barrier of 2-[ 18 F]FDG transport from roots to the above-ground parts. On the basis of mentioned knowledge and analytical approaches (application of prepared phantoms), the dynamic study of 2-[ 18 F]FDG uptake and transport within the excised leaf of tobacco or whole radish plant was carried out. The description of these processes was realized through the 3D PET images and through the quantification of 2-[ 18 F]FDG distribution within the chosen regions of interest from the point of view of accumulated 18 F radioactivity (in Bq) or amount of D-glucose (in μg) as well. Application of methods of multivariate analysis allows to found the similarities between studied objects mainly from the point

  2. Positron emission computerized tomography: a potential tool for in vivo quantitation of the distribution of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Huebner, K.F.; King, P.; Gibbs, W.D.; Washburn, L.C.; Hayes, R.L.

    1981-01-01

    The principles and some of the difficulties in quantitative positron emission computerized tomography have been discussed. We have shown that randoms and scattered events are a major cause of noise and counting errors in positron emission computerized tomography. The noise has been identified as a convoluting process and a mathematical solution has been presented. Examples of phantom studies and in vivo measurements have demonstrated that the distribution of positron emitting radiopharmaceuticals can be quantitated with much improved accuracy using the deconvolution equation to remove undesired noise

  3. Positron emission tomography, physical bases and comparaison with other techniques

    International Nuclear Information System (INIS)

    Guermazi, Fadhel; Hamza, F; Amouri, W.; Charfeddine, S.; Kallel, S.; Jardak, I.

    2013-01-01

    Positron emission tomography (PET) is a medical imaging technique that measures the three-dimensional distribution of molecules marked by a positron-emitting particle. PET has grown significantly in clinical fields, particularly in oncology for diagnosis and therapeutic follow purposes. The technical evolutions of this technique are fast. Among the technical improvements, is the coupling of the PET scan with computed tomography (CT). PET is obtained by intravenous injection of a radioactive tracer. The marker is usually fluorine ( 18 F) embedded in a glucose molecule forming the 18-fluorodeoxyglucose (FDG-18). This tracer, similar to glucose, binds to tissues that consume large quantities of the sugar such cancerous tissue, cardiac muscle or brain. Detection using scintillation crystals (BGO, LSO, LYSO) suitable for high energy (511keV) recognizes the lines of the gamma photons originating from the annihilation of a positron with an electron. The electronics of detection or coincidence circuit is based on two criteria: a time window, of about 6 to 15 ns, and an energy window. This system measures the true coincidences that correspond to the detection of two photons of 511 kV from the same annihilation. Most PET devices are constituted by a series of elementary detectors distributed annularly around the patient. Each detector comprises a scintillation crystal matrix coupled to a finite number (4 or 6) of photomultipliers. The electronic circuit, or the coincidence circuit, determines the projection point of annihilation by means of two elementary detectors. The processing of such information must be extremely fast, considering the count rates encountered in practice. The information measured by the coincidence circuit is then positioned in a matrix or sinogram, which contains a set of elements of a projection section of the object. Images are obtained by tomographic reconstruction by powerful computer stations equipped with a software tools allowing the analysis and

  4. Positron emission tomography (PET) studies of dopaminergic/cholinergic interactions in the baboon brain

    International Nuclear Information System (INIS)

    Dewey, S.L.; Brodie, J.D.; Fowler, J.S.; MacGregor, R.R.; Schlyer, D.J.; King, P.T.; Alexoff, D.L.; Volkow, N.D.; Shiue, C.Y.; Wolf, A.P.

    1990-01-01

    Interactions between the dopaminergic D2 receptor system and the muscarinic cholinergic system in the corpus striatum of adult female baboons (Papio anubis) were examined using positron emission tomography (PET) combined with [18F]N-methylspiroperidol [( 18F]NMSP) (to probe D2 receptor availability) and [N-11C-methyl]benztropine (to probe muscarinic cholinergic receptor availability). Pretreatment with benztropine, a long-lasting anticholinergic drug, bilaterally reduced the incorporation of radioactivity in the corpus striatum but did not alter that observed in the cerebellum or the rate of metabolism of [18F]NMSP in plasma. Pretreatment with unlabelled NMSP, a potent dopaminergic antagonist, reduced the incorporation of [N-11C-methyl]benztropine in all brain regions, with the greatest effect being in the corpus striatum greater than cortex greater than thalamus greater than cerebellum, but did not alter the rate of metabolism of the labelled benztropine in the plasma. These reductions in the incorporation of either [18F]NMSP or [N-11C-methyl]benztropine exceeded the normal variation in tracer incorporation in repeated studies in the same animal. This study demonstrates that PET can be used as a tool for investigating interactions between neurochemically different yet functionally linked neurotransmitters systems in vivo and provides insight into the consequences of multiple pharmacologic administration

  5. Effect of tissue heterogeneity on quantification in positron emission tomography

    International Nuclear Information System (INIS)

    Blomqvist, G.; Lammertsma, A.A.; Mazoyer, B.; Wienhard, K.

    1995-01-01

    As a result of the limited spatial resolution of positron emission tomographic scanners, the measurements of physiological parameters are compromised by tissue heterogeneity. The effect of tissue heterogeneity on a number of parameters was studied by simulation and an analytical method. Five common tracer models were assessed. The input and tissue response functions were assumed to be free from noise and systematic errors. The kinetic model was assumed to be perfect. Two components with different kinetics were mixed in different proportions and contrast with respect to the model parameters. Different experimental protocols were investigated. Of three methods investigated for the measurement of cerebral blood flow (CBF) (steady state, dynamic, integral), the second one was least sensitive to errors caused by tissue heterogeneity and the main effect was an underestimation of the distribution volume. With the steady state method, errors in oxygen extraction fraction caused by tissue heterogeneity were always found to be less than the corresponding errors in CBF. For myocardial blood flow the steady state method was found to perform better than the bolus method. The net accumulation of substrate (i.e. rCMR glc in the case of glucose analogs) was found to be comparatively insensitive to tissue heterogeneity. Individual rate constans such as k 2 and k 3 for efflux and metabolism of the substrate in the pool of unmetabolized substrate in the tissue, respectively, were found to be more sensitive. In studies of radioligand binding, using only tracer doses, the effect of tissue heterogeneity on the parameter k on .B max could be considerable. In studies of radioligand binding using a protocol with two experiments, one with high and one with low specific activity, B max was found to be insensitive while K d was very sensitive to tissue heterogeneity. (orig.)

  6. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma

    International Nuclear Information System (INIS)

    Ho, Kung-Chu; Yen, Tzu-Chen; Lai, Chyong-Huey; Wu, Tzu-I; Chang, Ting-Chang; Huang, Huei-Jean; Ng, Koon-Kwan; Lin, Gigin; Wang, Chun-Chieh; Hsueh, Swei

    2008-01-01

    Uterine carcinosarcomas clinically confined to the uterus usually harbor occult metastases. We conducted a pilot study to evaluate the value of 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in uterine carcinosarcoma. Patients with histologically confirmed uterine carcinosarcoma were enrolled. Abdominal and pelvic magnetic resonance imaging (MRI)/whole-body computed tomography (CT) scan, and whole-body 18 F-FDG PET or PET/CT were undertaken for primary staging, evaluating response, and restaging/post-therapy surveillance. The clinical impact of 18 F-FDG PET was determined on a scan basis. A total of 19 patients were recruited and 31 18 F-FDG PET scans (including 8 scans performed on a PET/CT scanner) were performed. Positive impacts of scans were found in 36.8% (7/19) for primary staging, 66.7% (2/3) for monitoring response, and 11.1% (1/9) for restaging/post-therapy surveillance. PET excluded falsely inoperable disease defined by MRI in two patients. Aggressive treatment applying to three patients with PET-defined resectable stage IVB disease seemed futile. Two patients died of disease shortly after salvage therapy restaged by PET. With PET monitoring, one stage IVB patient treated by targeted therapy only was alive with good performance. Using PET did not lead to improvement of overall survival of this series compared with the historical control (n = 35) (P 0.779). The preliminary results suggest that 18 F-FDG PET is beneficial in excluding falsely inoperable disease for curative therapy and in making a decision on palliation for better quality of life instead of aggressive treatment under the guidance of PET. PET seems to have limited value in post-therapy surveillance or restaging after failure. (orig.)

  7. Oxygen-15 labelled water production for positron emission tomography

    International Nuclear Information System (INIS)

    Janus, A.; Sachinidis, J.I.; Chan, J.G.; Tochon-Danguy, H.J.

    1998-01-01

    Full text: Functional imaging using positron emission tomography (PET) and 15 O-labelled compounds is both scientifically and clinically challenging. The short half-life of oxygen-15 (t 1/2 = 2 min) allows for multiple administration to a patient without exceeding acceptable levels of absorbed radiation dose and without excessive delay between administrations. The clinical usefulness of [ 15 O]-labelled water for cerebral blood flow measurements has been well established. Here we report the development and construction of a [ 15 O]water generator based on an earlier design from Hammersmith Hospital, London. The cyclotron produces a continuous flow of [ 15 O]O 2 gas by the irradiation of a natural nitrogen target (1% O 2 in N 2 ) with a 5 MeV deuteron beam, via the nuclear reaction ( 14 N(d,n) 15 O). The radioactive gas is then mixed with 5% hydrogen in nitrogen and piped to the water generator located in the scanner room. The O 2 /N 2 gas mixture is reacted over a palladium catalyst at 1500 deg C to produce [ 15 O]H 2 O vapour. The vapour passes through an exchanger where it diffuses across a semi-permeable membrane (cellulose acetate) into saline solution. At the optimum gas flow- rate of 500 mL/min, more than 95% of the radioactive oxygen is converted to radioactive water. Waste radioactive gas is piped back to the cyclotron vault to decay before release into the atmosphere. The saline solution (0.9% NaCl) is pumped continuously through the system at 6 mL/min with an infusion pump (3M AVI470). The present system has been in operation for more than a year and has been used for clinical evaluation of stroke patients and for brain activation research studies

  8. Study of brain metabolism using positron emission computed tomography

    Energy Technology Data Exchange (ETDEWEB)

    Heiss, W D

    1983-03-21

    Positron emission tomography permits the three-dimensional regional measurement of metabolism and blood flow in the brain. For the determination of cerebral metabolic rates of glucose by PET /sup 18/fluordeoxyglucose is usually applied: cerebral metabolic rate of glucose was found to be 36 to 47 ..mu..mol/100 g/min in the grey matter and 23 to 29 ..mu..mol/100 g/min in the white matter of normal volunteers. During physiologic activation metabolic rate of glucose is increased in the respective brain areas in relation to the strength and complexity of the stimulation. In patients suffering from ischaemic stroke glucose metabolism is markedly decreased within the infarction. Additonally, glucose metabolism is reduced by 20% in morphologically intact areas of the homolateral cortex, in the basal ganglia, in the cortical area contralateral to the infarction and in the contralateral cerebellum. This remote reduction of glucose utilization is probably caused by functional inactivation of these brain structures; it could be responsible for the diffuse organic syndrome in stroke victims not caused by the focal lesion. In patients suffering from dementia of the multi-infarct type and of the Alzheimer type glucose metabolism is reduced; the lesions in Alzheimer cases are most prominent in partietal and frontal cortical areas. In Chorea Huntington cases glucose metabolism is primarily disturbed in the striate, especially in the caudate nucleus; in these cases the metabolic disturbance can be detected earlier than the atrophy in computed tomograms. Disturbances of glucose and oxygen utilization are not necessary causes, but may also be sequelae od functional impairment. Additional information on pathogentic mechanisms may be obtained by the investigation of the protein synthesis.

  9. Diagnosis of temporal lobe epilepsy by positron emission tomography

    International Nuclear Information System (INIS)

    Shimizu, Hiroyuki; Ishijima, Buichi; Iio, Masaaki.

    1985-01-01

    Positron emission tomography(PET) was performed in 18 temporal lobe epileptics. About 20 mCi of 11 C-glucose was perorally administered to the patients and 30 minutes later scanning was started when the transport of 11 C-glucose from blood to the brain tissue reached equilibrium. At the level of 25mm above orbitomeatal line, the slice image of the temporal lobe shows a relatively high metabolic oval ring involving the amygdala, hippocapal formation and the hippocampal gyrus medially and the T 1 , T 2 and T 3 neocortices laterally in normal subjects. The epileptic focus, when detected on PET images, was observed as a defect in this oval ring. In 15(83.3%) out of 18 cases, the location of epileptic focus was confirmed as a low metabolic defect. This diagnosis rate was higher than that of other focal epilepsy by PET study. The locations of foci were devided into three types: mesial (5 cases), lateral (4 cases) and combined (6 cases). The seizure symptoms of the patients were analyzed in terms of the correspondence to the focus types. The results showed that automatism and pseudoabsence had a close relation to the mesial and combined types and psychical, vertiginous or visual seizures correlated to the combined and lateral types. Visceral or motor seizures were induced equally by any focus types. These facts suggested that automatism and pseudoabsence were correlated with the mesial organs such as the amygdala and hippocampus and psychical, vertiginous or visual seizures had origin in lateral neocortices. Visceral or motor seizures were supposed to be the results of the spread from the temporal focus to the adjacent structures. It was concluded that PET was very useful in localization diagnosis of temporal lobe epilepsy. In surgical treatment of epilepsy, in which the knowledge of the exact extent of epileptic foci is strongly demanded, PET study will offer invaluable data to the strategy of operation and foreseeing its prognosis. (author)

  10. Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumors

    International Nuclear Information System (INIS)

    Gasparri, R.; Rezende, G. C.; Brambilla, D.; Petrella, F.; Galetta, D.; Spaggiari, L.; Fazio, N.; Maisonneuve, P.; Travaini, L. L.; Paganelli, G.

    2015-01-01

    The role of fluorodeoxyglucose positron emission tomography (FDG-PET) as an additional investigation to computer tomography for pulmonary carcinoid tumors remains controversial. The aim of this study was to assess the role of FDG-PET for the diagnosis and staging of pulmonary carcinoid tumors. It has been performed a retrospective mono-institutional analysis of data from 97 patients with pathologically confirmed pulmonary carcinoid tumor who had been operated on between July 1998 and April 2009 and had had a preoperative FDG-PET scan performed. Sixty-five (67%) of the 97 tumors were typical (TC) and 32 (33%) atypical (AC) carcinoid tumors. Overall FDG-PET sensitivity was 67% being lower for TC (60%) than for AC (81%) (P=0.04). FDG-PET negative tumors were smaller than FDG-PET positive tumors, with a respective median size of 15 and 17 mm (P=0.02). Median SUVmax for FDG-PET-positive tumors was 4.0 (2.8-5.1) with no difference between TC and AC tumors. Median Ki-67 expression was respectively 4.7% and 3.1% for FDG-PET positive and FDG-PET negative tumors (P=0.05). During a median follow-up of 49 months (interquartile range 30-63 months), 9 patients (4TC, 5AC) developed recurrent disease. Neither SUVmax nor Ki-67 expression resulted associated with disease-free survival. With an overall sensitivity of 67%, FDG-PET has shown to be useful in the preoperative work-up of patients with suspect lung carcinoid tumors. In particular it could have a role in larger tumors. These results warrant a prospective evaluation of FDG-PET in the staging of lung carcinoid tumor.

  11. Effect of tissue heterogeneity on quantification in positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Blomqvist, G [Dept. of Clinical Neuroscience, Experimental Alcohol and Drug Addiction Research Section, Karolinska Hospital, Stockholm (Sweden); Lammertsma, A A [PET Methodology Group, Cyclotron Unit, MRC Clinical Sciences Centre, Royal Postgraduate Medical School, Hammersmith Hospital, London (United Kingdom); Mazoyer, B [Service Hospitalier Frederic Joliot CEA/Dept. de Biologie, Hopital d` Orsay and Antenne d` Informatique Medicale, Hopital Robert Debre, Paris (France); Wienhard, K [Max-Planck-Inst. fuer Neurologische Forschung, Koeln (Germany)

    1995-07-01

    As a result of the limited spatial resolution of positron emission tomographic scanners, the measurements of physiological parameters are compromised by tissue heterogeneity. The effect of tissue heterogeneity on a number of parameters was studied by simulation and an analytical method. Five common tracer models were assessed. The input and tissue response functions were assumed to be free from noise and systematic errors. The kinetic model was assumed to be perfect. Two components with different kinetics were mixed in different proportions and contrast with respect to the model parameters. Different experimental protocols were investigated. Of three methods investigated for the measurement of cerebral blood flow (CBF) (steady state, dynamic, integral), the second one was least sensitive to errors caused by tissue heterogeneity and the main effect was an underestimation of the distribution volume. With the steady state method, errors in oxygen extraction fraction caused by tissue heterogeneity were always found to be less than the corresponding errors in CBF. For myocardial blood flow the steady state method was found to perform better than the bolus method. The net accumulation of substrate (i.e. rCMR{sub glc} in the case of glucose analogs) was found to be comparatively insensitive to tissue heterogeneity. Individual rate constans such as k{sub 2} and k{sub 3} for efflux and metabolism of the substrate in the pool of unmetabolized substrate in the tissue, respectively, were found to be more sensitive. In studies of radioligand binding, using only tracer doses, the effect of tissue heterogeneity on the parameter k{sub on}.B{sub max} could be considerable. In studies of radioligand binding using a protocol with two experiments, one with high and one with low specific activity, B{sub max} was found to be insensitive while K{sub d} was very sensitive to tissue heterogeneity. (orig.)

  12. Positron emission tomography in urological cancer; Positronenemissionstomographie bei urologischen Tumoren

    Energy Technology Data Exchange (ETDEWEB)

    Wit, M. de [Universitaetskrankenhaus Eppendorf, Hamburg (Germany). Abt. Onkologie/Haematologie, Medizinische Klinik; Kotzerke, J. [Universitaetsklinikum Ulm (DE). Radiologie III (Nuklearmedizin)

    2000-09-01

    In staging cancer of the urinary bladder, the kidneys and the prostate and of testicular cancer there is a need for detecting tumor involvement of the lymph nodes to avoid surgical exploration. Positron emission tomography (PET) using fluorodeoxyglucose (FDG) can detect tumorous lymph nodes (sensitivity: 70%, specificity: 85%) which is helpful for several patients. In carcinoma of the prostate, other radiotracers than FDG (e.g. C-11-choline) might be more sensitive to detect tumorous lymph nodes. Up to now no diagnostical benefit of PET in germ cell tumors could be demonstrated in the published small series. In principle FDG-PET is useful in diagnosis of recurrence. In germ cell cancer FDG-PET seems to identify effectively persistent vital tumor tissue after chemotherapy. A multicenter study was initiated to demonstrate the potential of FDG-PET in a sufficient number of patients with germ cell tumor. (orig.) [German] Bei Harnblasen-, Nieren-, Prostata- und Hodenkarzinomen besteht aus klinischer Sicht ein Bedarf an verbessertem Lymphknoten-Staging, um die operative Evaluation zu vermeiden. Die Positronenemissionstomographie (PET) mit Fluordeoxyglukose (FDG) kann daher im Einzelfall bei Harnblasen- und Nierenkarzinomen hilfreich sein (bei Sensitivitaet um 70% und Spezifitaet um 85%). Beim Prostatakarzinom koennten sich andere Radiotracer (z.B. C-11-Cholin) bei der Detektion von tumoroesen Lymphknoten ueberlegen erweisen. Bei Keimzelltumoren konnte ein Nutzen der PET im primaeren Staging bei den bisher publizierten kleinen Studien nicht nachgewiesen werden. Fuer die Rezidivdiagnostik ist bei den genannten Tumoren aus grundsaetzlicher Ueberlegung der Einsatz von DFG-PET sinnvoll. Die Erkennung von vitalem malignen Tumorgewebe nach Chemotherapie erscheint bei Keimzelltumoren mit FDG-PET weitgehend sicher zu gelingen. Eine multizentrische Studie wurde begonnen, die hierueber Aufschluss geben wird. (orig.)

  13. Alcohol ADME in primates studied with positron emission tomography.

    Directory of Open Access Journals (Sweden)

    Zizhong Li

    Full Text Available The sensitivity to the intoxicating effects of alcohol as well as its adverse medical consequences differ markedly among individuals, which reflects in part differences in alcohol's absorption, distribution, metabolism, and elimination (ADME properties. The ADME of alcohol in the body and its relationship with alcohol's brain bioavailability, however, is not well understood.The ADME of C-11 labeled alcohol, CH(3 (11CH(2OH, 1 and C-11 and deuterium dual labeled alcohol, CH(3 (11CD(2OH, 2 in baboons was compared based on the principle that C-D bond is stronger than C-H bond, thus the reaction is slower if C-D bond breaking occurs in a rate-determining metabolic step. The following ADME parameters in peripheral organs and brain were derived from time activity curve (TAC of positron emission tomography (PET scans: peak uptake (C(max; peak uptake time (T(max, half-life of peak uptake (T(1/2, the area under the curve (AUC(60 min, and the residue uptake (C(60 min.For 1 the highest uptake occurred in the kidney whereas for 2 it occurred in the liver. A deuterium isotope effect was observed in the kidneys in both animals studied and in the liver of one animal but not the other. The highest uptake for 1 and 2 in the brain was in striatum and cerebellum but 2 had higher uptake than 1 in all brain regions most evidently in thalamus and cingulate. Alcohol's brain uptake was significantly higher when given intravenously than when given orally and also when the animal was pretreated with a pharmacological dose of alcohol.The study shows that alcohol metabolism in peripheral organs had a large effect on alcohol's brain bioavailability. This study sets the stage for clinical investigation on how genetics, gender and alcohol abuse affect alcohol's ADME and its relationship to intoxication and medical consequences.

  14. Anomalous positron emission in heavy ion-collisions

    International Nuclear Information System (INIS)

    Kienle, P.

    1986-09-01

    In section two we shortly present the experimental methods and first results on positron lines. Section three deals with the dependence of the positron line production on the charge of the collision system, bombarding energy and scattering angle. The results of the first e + -e - -coincidence studies are reviewed in section 4. In the last paragraph we make some remarks on future developments of the experimental methods. (orig./HSI)

  15. Neuroleptic binding sites: specific labeling in mice with [18F]haloperidol, a potential tracer for positron emission tomography

    International Nuclear Information System (INIS)

    Zanzonico, P.B.; Bigler, R.E.; Schmall, B.

    1983-01-01

    Haloperidol labeled with fluorine- 18 (T 1/2 . 110 min, positron emission 97%), prepared yielding .04 Ci/millimole by the Balz-Schiemann reaction, was evaluated in a murine model as a potential radiotracer for noninvasive determination, by positron-emission tomography, of regional concentrations of brain dopamine receptors in patients. As the haloperidol dose in mice was increased from 0.01 to 1000 micrograms/kg, the relative concentration of [ 18 F]haloperidol (microCi per g specimen/microCi per g of body mass), at one hour after injection decreased from 30 to 1.0 in the striatum and from 8.0 to 1.0 in the cerebellum. The striatal radioactivity, plotted as relative concentration against log of dose, decreased sigmoidally, presumably reflecting competition between labeled and unlabeled haloperidol for a single class of accessible binding sites. Because the cerebellum is relatively deficient in dopamine receptors, the observed decrease in cerebellar radioactivity may reflect a saturable component of haloperidol transport into brain. The high brain concentrations and the unexpectedly high striatum-to-cerebellum concentration ratios (greater than 4 at haloperidol doses less than or equal to 1 microgram/kg) suggest that [ 18 F]haloperidol warrants further investigation as a potential radiotracer for dopamine receptors

  16. Synthesis of novel ligands for neuro-inflammation imaging using Positron Emission Tomography

    International Nuclear Information System (INIS)

    Cacheux, Fanny

    2016-01-01

    Neuro-inflammation plays an important role in many neuro-degenerative diseases (Alzheimer, Parkinson, Multiple sclerosis..) and recent developments in molecular imaging provide today new insights into the diagnostic and the treatment management of these diseases. Among the existing imaging techniques, the highly sensitive and quantitative nuclear modalities SPECT (single photon emission computed tomography) but especially PET (positron emission tomography) play key roles. My PhD program is devoted to the design and synthesis of novel radioligands, all dedicated to the imaging of specific targets and processes linked to neuro-inflammation. For this, PET and the short-lived positron-emitter fluorine-18 (T 1/2 : 109.8 min) remain the main focuses. The project has been divided into two sections, the first one concentrates on the development of novel ligands targeting the Translocator Protein 18 kDa (TSPO). Indeed, this target is today recognized as an early bio-marker of neuro-inflammatory processes and PK11195, an isoquinoline carboxamide labelled with carbon-11, was, in the late 80's, the first reported PET-radioligand. More recently, new compounds, all belonging to different chemical classes, have emerged and notably the pyrazolopyrimidine acetamide [ 11 C]DPA-713 and the pyridazinoindole acetamide [ 11 C]SSR180575. Within the first section of my PhD, novel derivatives of both DPA-713 and SSR180575 have been synthesized and in vitro characterized. Dedicated precursors for labelling were also developed for the most promising candidates, and radiolabelling has been performed. Some results have been presented at the 21. International Symposium on Radiopharmaceutical Sciences (Columbia, MO, USA - May 26-31, 2015).The second part of my PhD, deals with the development of ligands for alternative targets to the TSPO, like the type-2 cannabinoid receptor (CB2R) and the purinergic P2Y14/P2Y12 receptors, the latter emerging today as a hot topic for imaging opportunities

  17. A new methodology of second messenger imaging for higher cortical functions by positron emission tomography

    International Nuclear Information System (INIS)

    Imahori, Yoshio; Ueda, Satoshi

    1992-01-01

    Neuronal manifestations are driven by second messenger systems in central nervous system through the neuronal transmission process. Receptor-mediated phosphatidylinositol (PI) response images may reflect neuronal activation in higher cortical function with a high sensitivity based on the common amplifying mechanism of the second messenger. Many bioactive compounds related to PI turnover have simple carbohydrate structures without amines and [ 11 C]ethylketene acylation has been found as the most effective labeling method of these compounds for positron emission tomography. [ 11 C]ethylketene was produced by the pyrolytic decomposition of [1- 11 C]butyric acid. This new method was made possible by the reaction under the no-carrier-added condition. To visualize the response in vivo, we synthesized sn-1,2-[ 11 C]diacylglycerols (DAGs) as a specific tracer for the PI response and [ 11 C]phorbol esters as a ligand for protein kinase C. In autoradiographic studies it was demonstrated that sn-1,2-[ 11 C]DAGs incorporation sites were discretely localized especially in the neocortex, which were concomitant with columnar structures. These results suggested that sn-1,2-[ 11 C]DAG can serve as an extrinsic substrate for the PI turnover by the phosphorylation mechanism and intensive neuronal processing, as a higher cortical function, occurs in these areas on the basis of receptor-mediated PI response. (author)

  18. Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography

    International Nuclear Information System (INIS)

    Dolle, F.; Luus, C.; Reynolds, A.; Kassiou, M.

    2009-01-01

    The translocator protein (18 kDa) (TSPO), formerly known as the peripheral benzodiazepine receptor (PBR), was originally identified as an alternate binding site for the central benzodiazepine receptor (CBR) ligand, diazepam, in the periphery, but has now been distinguished as a novel site. The TSPO is ubiquitously expressed in peripheral tissues but only minimally in the healthy brain and increased levels of TSPO expression have been noted in neuro inflammatory conditions such as Alzheimer's disease, Parkinson's disease and stroke. This increase in TSPO expression has been reported to coincide with the process of micro-glial activation, whereby the brain's intrinsic immune system becomes active. Therefore, by using recently developed high affinity, selective TSPO ligands in conjunction with functional imaging modalities such as positron emission tomography (PET), it becomes possible to study the process of micro-glial activation in the living brain. A number of high affinity ligands, the majority of which are C, N-substituted acetamide derivatives, have been successfully radiolabelled and used in in vivo studies of the TSPO and the process of micro-glial activation. This review highlights recent achievements (up to December 2008) in the field of functional imaging of the TSPO as well as the radio-syntheses involved in such studies. (authors)

  19. Positron emission tomography molecular imaging of dopaminergic system in drug addiction.

    Science.gov (United States)

    Hou, Haifeng; Tian, Mei; Zhang, Hong

    2012-05-01

    Dopamine (DA) is involved in drug reinforcement, but its role in drug addiction remains unclear. Positron emission tomography (PET) is the first technology used for the direct measurement of components of the dopaminergic system in the living human brain. In this article, we reviewed the major findings of PET imaging studies on the involvement of DA in drug addiction, especially in heroin addiction. Furthermore, we summarized PET radiotracers that have been used to study the role of DA in drug addiction. To investigate presynaptic function in drug addiction, PET tracers have been developed to measure DA synthesis and transport. For the investigation of postsynaptic function, several radioligands targeting dopamine one (D1) receptor and dopamine two (D2) receptor are extensively used in PET imaging studies. Moreover, we also summarized the PET imaging findings of heroin addiction studies, including heroin-induced DA increases and the reinforcement, role of DA in the long-term effects of heroin abuse, DA and vulnerability to heroin abuse and the treatment implications. PET imaging studies have corroborated the role of DA in drug addiction and increase our understanding the mechanism of drug addiction. Copyright © 2012 Wiley Periodicals, Inc.

  20. Low-energy positron and electron diffraction and positron-stimulated secondary electron emission from Cu(100)

    International Nuclear Information System (INIS)

    Weiss, A.H.

    1983-01-01

    The results of two series of experiments are reported. In the first, an electrostatically guided beam of low-energy (40-400 eV) positrons, delta/sub p/ was used to study low-energy positron diffraction (LEPD) from a Cu(100) surface under ultrahigh-vacuum conditions. Low-energy electron diffraction (LEED) data were obtained from the same sample in the same apparatus. Comparison of LEPD and LEED intensity versus energy data with model calculations made using computer programs developed by C.B. Duke and collaborators indicated that: LEPD data is adequately modeled using potentials with no exchange-correlation term. The inelastic mean free path, lambda/sub ee/, is shorter for positrons than for electrons at low (< approx.80 eV). LEED is better than LEPD at making a determination of the first-layer spacing of Cu(100) for the particular data set reported. In the second set of experiments, the same apparatus and sample were used to compare positron- and electron-stimulated secondary-electron emission (PSSEE and ESSEE). The results were found to be consistent with existing models of secondary-electron production for metals. The energy distributions of secondary-electrons had broad low-energy (<10 eV) peaks for both positron and electron stimulation. But the PSEE distribution showed no elastic peak. Measurements of secondary-electron angular distributions, found to be cosine-like in both the PSSEE and ESSEE case, were used to obtain total secondary yield ratios, delta, at four beam energies ranging from 40-400 eV. The secondary yield ratio for primary positrons and the yield for primary electrons, delta/sub e/, were similar at these energies. For 400-eV primary particles the secondary yields were found to be delta/sub p/ = 0.94 +/- 0.12 and delta/sub e/ = 0.94 +/- 0./12, giving a ratio of unity for positron-stimulated secondary yield to electron-stimulated secondary yield

  1. Evaluation of esophageal cancer by positron emission tomography

    International Nuclear Information System (INIS)

    Himeno, Shinji; Yasuda, Seiei; Shimada, Hideo; Tajima, Tomoo; Makuuchi, Hiroyasu

    2002-01-01

    A retrospective study was performed to determine the indications for positron emission tomography (PET) using [ 18 F]fluorodeoxyglucose (FDG) in patients with esophageal cancer, including those with early cancer, and to investigate whether the tumor-to-normal ratio (T/N ratio) could be used as a substitute for the standardized uptake value (SUV). Thirty-six patients were included in the study. Thirty-one patients who had 36 biopsy-proven lesions (35 squamous cell carcinomas and one small cell carcinoma) underwent PET study prior to treatment. PET images were evaluated visually and the relationship between the depth of invasion and the PET findings were examined in 22 lesions of 19 patients from whom specimens were obtained from the primary tumor by surgery or endoscopic mucosal resection. PET results were also compared with computed tomography (CT) and endoscopic ultrasonography (EUS) for detection of regional lymph node metastases in 18 patients who underwent extended lymph node dissection. Five patients underwent PET studies for the detection of recurrence and the PET findings were compared with their CT findings. The T/N ratio and the SUV were calculated for 20 primary tumors. Among the 15 tumors that were pT1b or greater, all 15 were positive on PET and all seven of the lesions confined to the mucosa (Tis or T1a) were negative. The sensitivity, specificity and accuracy of detecting nodal involvement were, respectively, 37.5, 96.1 and 88.3% by CT, 30.8, 88.5 and 81.0% by EUS and 41.7, 100 and 92.2% by PET. More sites of recurrence were detected by PET than by CT. There was no statistically significant correlation between the SUV and the T/N ratio. PET imaging can detect primary esophageal cancer with a depth of invasion of T1b or greater, but Tis and T1a tumors are undetectable. PET seems to be more accurate than CT or EUS for diagnosing lymph node metastasis. The T/N ratio cannot be used as a substitute for the SUV. (author)

  2. Fabrication of polycrystalline scintillators for the positron emission tomography (PET)

    International Nuclear Information System (INIS)

    Karim, Kamran Said

    2010-01-01

    Transparent ceramics are becoming more and more important for two new types of applications. On the one hand in cases where high mechanical and thermal demands in combination with optical properties are required, on the other hand where the optical properties of transparent materials like glass are not sufficient e.g. in positron-emission-tomography (PET) diagnostics. Most state of the art PET-scanners are using high-priced single crystals as scintillator material. The technological challenge is to replace single crystal by cost-efficient transparent ceramics. Producing transparent ceramics is ordered in synthesis of the powders and in manufacturing of these into transparent ceramics. The aim of this work was to synthesize single phase yttrium-alumina-and Luthetiumalumina-garnet (YAG, LuAG) powders partially doped with neodymium or praseodymium by four different synthesis routes (Pechini-synthesis, sol-gel-route, coprecipitation and solid state reactions). Additionally industrial LuAG and LuPO 4 powders were characterized and manufactured. The powders were processed as submicron- and nanopowders. The compaction of nanopowder greenbodies sintered at high temperatures leads to a ''cross-over'' between both manufacturing route. Newly produced single-phase powders were homogenized with additions of sintering additives like tetraethyl orthosilicate (TEOS) and binders like polyvinyl alcohol (PVA). Moulding the powders were carried out by uniaxial pressing, cold isostatic pressing and in individual cases also by slip casting. The achieved green densities were in a range of 25-42 %. Examination of calcination behaviour leads to a calcination temperature of 1000 C with 2 hours dwell time in air atmosphere. Only solid state reactions resulted into transparent YAG, YAG:Pr, LuAG, LuAG:Pr ceramics. Solid state reactions of nanopowders resulted in heterogeneously transparent samples. Ceramics made by powders of other synthetic routes gave nontransparent ceramics due to porosity

  3. Positron Emission Tomography Imaging Using Radiolabeled Inorganic Nanomaterials

    Science.gov (United States)

    Sun, Xiaolian; Cai, Weibo; Chen, Xiaoyuan

    2015-01-01

    CONSPECTUS Positron emission tomography (PET) is a radionuclide imaging technology that plays an important role in preclinical and clinical research. With administration of a small amount of radiotracer, PET imaging can provide a noninvasive, highly sensitive, and quantitative readout of its organ/tissue targeting efficiency and pharmacokinetics. Various radiotracers have been designed to target specific molecular events. Compared with antibodies, proteins, peptides, and other biologically relevant molecules, nanoparticles represent a new frontier in molecular imaging probe design, enabling the attachment of different imaging modalities, targeting ligands, and therapeutic payloads in a single vector. We introduce the radiolabeled nanoparticle platforms that we and others have developed. Due to the fundamental differences in the various nanoparticles and radioisotopes, most radiolabeling methods are designed case-by-case. We focus on some general rules about selecting appropriate isotopes for given types of nanoparticles, as well as adjusting the labeling strategies according to specific applications. We classified these radiolabeling methods into four categories: (1) complexation reaction of radiometal ions with chelators via coordination chemistry; (2) direct bombardment of nanoparticles via hadronic projectiles; (3) synthesis of nanoparticles using a mixture of radioactive and nonradioactive precursors; (4) chelator-free postsynthetic radiolabeling. Method 1 is generally applicable to different nanomaterials as long as the surface chemistry is well-designed. However, the addition of chelators brings concerns of possible changes to the physicochemical properties of nanomaterials and detachment of the radiometal. Methods 2 and 3 have improved radiochemical stability. The applications are, however, limited by the possible damage to the nanocomponent caused by the proton beams (method 2) and harsh synthetic conditions (method 3). Method 4 is still in its infancy

  4. Towards high-resolution positron emission tomography for small volumes

    International Nuclear Information System (INIS)

    McKee, B.T.A.

    1982-01-01

    Some arguments are made regarding the medical usefulness of high spatial resolution in positron imaging, even if limited to small imaged volumes. Then the intrinsic limitations to spatial resolution in positron imaging are discussed. The project to build a small-volume, high resolution animal research prototype (SHARP) positron imaging system is described. The components of the system, particularly the detectors, are presented and brief mention is made of data acquisition and image reconstruction methods. Finally, some preliminary imaging results are presented; a pair of isolated point sources and 18 F in the bones of a rabbit. Although the detector system is not fully completed, these first results indicate that the goals of high sensitivity and high resolution (4 mm) have been realized. (Auth.)

  5. Potentials of positron emission tomography for regional cerebral blood flow evaluation

    International Nuclear Information System (INIS)

    Depresseux, J.C.

    1982-01-01

    A general overview of the potentials of positron emission tomography and of positron-emitting radiopharmaceuticals for the evaluation of regional cerebral blood flow is proposed and discussed. Specific characteristics of this technique are described, with special stress on conceptual and methodological implications. Four different approaches to the problem of the determination of cerebral blood flow are distinguished: trapping equilibrium methods, steady state equilibrium methods, clearance methods and convoluted kinetic methods [fr

  6. Positron emission tomography of malignant tumours at head and neck. Evaluation of the diagnostic value of positron emission tomography by comparison with computed tomography

    International Nuclear Information System (INIS)

    Kettler, Nele

    2011-01-01

    Imaging methods for early, accurate diagnosis and aftercare of malignant growths is currently one of the most important research topics. The objective of this thesis is to evaluate the diagnostic value of FDG-positron emission tomography by comparison with computed tomography for patients with squamous cell carcinoma, malignant melanoma or sarcoma at head and neck. Measurement criteria are sensitivity and specificity. A retrospective evaluation of 100 examinations on 85 patients of University clinic Aachen was performed. The examination reports were supported by reports from histology, positron emission tomography and computed tomography. In each case, the histological results were assumed to provide a reliable benchmark. Sensitivity and specificity for the primary tumour site, metastatic lymphatic nodes and defined anatomic structures were compared across all patients. Comparisons were also performed on sub groups separated by gender, cancer type and the time and frequency at which tumours arose. The statistic analysis was done with MedCalc. Results: The results for sensitivity and specificity of the primary tumour site were 86.42% and 42.86%, and 64.71% and 66.07%, for positron emission tomography and computed tomography respectively. The results for the lymphatic nodes were 51.52% and 92.86% and 64.71% and 66.07%. When the constituent anatomic structures were evaluated separately, the specificity was significantly higher. The separation by gender showed no difference. Because the classification by tumor type resulted in samples that were of varying size, a comparison was difficult. For the diagnosis of primary tumours, the examination with positron emission tomography was superior, whereas computed tomography proved more effective for the diagnosis of recurrent tumours. For the diagnosis of the main tumour site, both methods were shown to be equally suitable. For the assessment of lymphatic nodes, positron emission tomography was superior to computed tomography

  7. Laparoscopic Scar: a mimicker of Sister Mary Joseph's nodule on positron emission tomography/CT

    International Nuclear Information System (INIS)

    Setty, B.; Blake, M.A.; Holalkere, N.S.; Blaszkowsky, L.S.; Fischman, A.

    2006-01-01

    Positron emission tomography/CT is an established imaging method in the diagnosis and staging of cancers. 18 F -fluoro-2-deoxy-D-glucose (FDG) is the most commonly used radiotracer in positron emission tomography/CT. It is a tumour viability agent and usually its uptake within a lesion reflects the presence of a viable tumour tissue. However, false-positive FDG uptake is known to occur in benign processes of either inflammatory or infectious aetiology. We describe FDG uptake at the site of laparoscopic scar that mimicked Sister Mary Joseph's nodule in a patient with gastric adenocarcinoma. Here, the knowledge of the patient's history and subtle imaging findings helped in accurate staging of the patient. In this case report, we emphasize the value of the knowledge of the patient history and awareness of different pitfalls of FDG to achieve a correct diagnosis on positron emission tomography/CT

  8. Homotopic non-local regularized reconstruction from sparse positron emission tomography measurements

    International Nuclear Information System (INIS)

    Wong, Alexander; Liu, Chenyi; Wang, Xiao Yu; Fieguth, Paul; Bie, Hongxia

    2015-01-01

    Positron emission tomography scanners collect measurements of a patient’s in vivo radiotracer distribution. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule, and the tomograms must be reconstructed from projections. The reconstruction of tomograms from the acquired PET data is an inverse problem that requires regularization. The use of tightly packed discrete detector rings, although improves signal-to-noise ratio, are often associated with high costs of positron emission tomography systems. Thus a sparse reconstruction, which would be capable of overcoming the noise effect while allowing for a reduced number of detectors, would have a great deal to offer. In this study, we introduce and investigate the potential of a homotopic non-local regularization reconstruction framework for effectively reconstructing positron emission tomograms from such sparse measurements. Results obtained using the proposed approach are compared with traditional filtered back-projection as well as expectation maximization reconstruction with total variation regularization. A new reconstruction method was developed for the purpose of improving the quality of positron emission tomography reconstruction from sparse measurements. We illustrate that promising reconstruction performance can be achieved for the proposed approach even at low sampling fractions, which allows for the use of significantly fewer detectors and have the potential to reduce scanner costs

  9. Use of positron emission tomography in colorectal cancer; Uso de la tomografia de emision de positrones en el cancer colorrectal

    Energy Technology Data Exchange (ETDEWEB)

    Gonzalez E, Patricio; Jofre E, Josefina; Massardo V, Teresa; Humeres, Pamela; Canessa G, Jose; Sierralta C, Paulina [Hospital Militar de Santiago, Medicina Nuclear, Centro PET de Imagenes Moleculares, Santiago (Chile)

    2002-07-01

    The value of PET (Positron Emission Tomography) in colorectal cancer is presented. PET is a novel technique that uses F-18-FDG (fluorodeoxiglucose) to assess glucose metabolism by whole body imaging. It has been demonstrated that malignant cells have both increase of glucose uptake and utilization. In colorectal cancer, PET is indicated for staging, assess recurrence, liver metastasis and treatment follow-up. PET is more sensitive and specific than CT (Computed Tomography) and is cost effective. In 30% of cases PET may change patient management, avoiding unnecessary procedures (au)

  10. Dynamic positron emission tomography for study of cerebral hemodynamics in a cross section of the head using positron-emitting 68Ga-EDTA and 77Kr

    International Nuclear Information System (INIS)

    Yamamoto, Y.L.; Thompson, C.J.; Meyer, E.; Robertson, J.S.; Feindel, W.

    1977-01-01

    Dynamic positron emission tomographic studies were performed on over 120 patients with occlusive cerebrovascular disease, arteriovenous malformations, and brain tumors, using the positron section scanner, consisting of a ring of 32 scintillation detectors. The radiopharmaceuticals were nondiffusible 68 Ga-EDTA for transit time and uptake studies and the diffusible tracer, 77 Kr, for quantitative regional cerebral blood flow studies in every square centimeter of the cross section of the head. The results of dynamic positron emission tomography in correlation with the results from the gamma scintillation camera dynamic studies and computed tomography (CT) scans are discussed

  11. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer

    International Nuclear Information System (INIS)

    Greven, K.M.; Williams, D.W. III; Keyes, J.W. Jr.; McGuirt, W.F.; Harkness, B.A.; Watson, N.E. Jr.; Raben, M.; Frazier, L.C.; Geisinger, K.R.; Capellari, J.O.

    1994-01-01

    Distinguishing persistent or recurrent tumor from postradiation edema, or soft tissue/cartilage necrosis in patients treated for carcinoma of the larynx can be difficult. Because recurrent tumor is often submucosal, multiple deep biopsies may be necessary before a diagnosis can be established. Positron emission tomography with 18F-2-fluro-2-deoxglucose (FDG) was studied for its ability to aid in this problem. Positron emission tomography (18FDG) scans were performed on 11 patients who were suspected of having persistent or recurrent tumor after radiation treatment for carcinoma of the larynx. Patients underwent thorough history and physical examinations, scans with computerized tomography, and pathologic evaluation when indicated. Standard uptake values were used to quantitate the FDG uptake in the larynx. The time between completion of radiation treatment and positron emission tomography examination ranged from 2 to 26 months with a median of 6 months. Ten patients underwent computed tomography (CT) of the larynx, which revealed edema of the larynx (six patients), glottic mass (four patients), and cervical nodes (one patient). Positron emission tomography scans revealed increased FDG uptake in the larynx in five patients and laryngectomy confirmed the presence of carcinoma in these patients. Five patients had positron emission tomography results consistent with normal tissue changes in the larynx, and one patient had increased FDG uptake in neck nodes. This patient underwent laryngectomy, and no cancer was found in the primary site, but nodes were pathologically positive. One patient had slightly elevated FDG uptake and negative biopsy results. The remaining patients have been followed for 11 to 14 months since their positron emission studies and their examinations have remained stable. In patients without tumor, average standard uptake values of the larynx ranged from 2.4 to 4.7, and in patients with tumor, the range was 4.9 to 10.7. 18 refs., 3 figs., 1 tab

  12. Defining a radiotherapy target with positron emission tomography

    International Nuclear Information System (INIS)

    Black, Quinten C.; Grills, Inga S.; Kestin, Larry L.; Wong, Ching-Yee O.; Wong, John W.; Martinez, Alvaro A.; Yan Di

    2004-01-01

    Purpose: F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging is now considered the most accurate clinical staging study for non-small-cell lung cancer (NSCLC) and is also important in the staging of multiple other malignancies. Gross tumor volume (GTV) definition for radiotherapy, however, is typically based entirely on computed tomographic data. We performed a series of phantom studies to determine an accurate and uniformly applicable method for defining a GTV with FDG-PET. Methods and materials: A model-based method was tested by a phantom study to determine a threshold, or unique cutoff of standardized uptake value based on body weight (standardized uptake value [SUV]) for FDG-PET based GTV definition. The degree to which mean target SUV, background FDG concentration, and target volume influenced that GTV definition were evaluated. A phantom was constructed consisting of a 9.0-L cylindrical tank. Glass spheres with volumes ranging from 12.2 to 291.0 cc were suspended within the tank, with a minimum separation of 4 cm between the edges of the spheres. The sphere volumes were selected based on the range of NSCLC patient tumor volumes seen in our clinic. The tank and spheres were filled with a variety of known concentrations of FDG in several experiments and then scanned using a General Electric Advance PET scanner. In the initial experiment, six spheres with identical volumes were filled with varying concentrations of FDG (mean SUV 1.85 ∼ 9.68) and suspended within a background bath of FDG at a similar concentration to that used in clinical practice (0.144 μCi/mL). The second experiment was identical to the first, but was performed at 0.144 and 0.036 μCi/mL background concentrations to determine the effect of background FDG concentration on sphere definition. In the third experiment, six spheres with volumes of 12.2 to 291.0 cc were filled with equal concentrations of FDG and suspended in a standard background FDG concentration of 0.144

  13. Cognitive Function and Monoamine Neurotransmission in Schizophrenia: Evidence From Positron Emission Tomography Studies

    Directory of Open Access Journals (Sweden)

    Harumasa Takano

    2018-05-01

    Full Text Available Positron emission tomography (PET is a non-invasive imaging technique used to assess various brain functions, including cerebral blood flow, glucose metabolism, and neurotransmission, in the living human brain. In particular, neurotransmission mediated by the monoamine neurotransmitters dopamine, serotonin, and norepinephrine, has been extensively examined using PET probes, which specifically bind to the monoamine receptors and transporters. This useful tool has revealed the pathophysiology of various psychiatric disorders, including schizophrenia, and the mechanisms of action of psychotropic drugs. Because monoamines are implicated in various cognitive processes such as memory and executive functions, some PET studies have directly investigated the associations between monoamine neurotransmission and cognitive functions in healthy individuals and patients with psychiatric disorders. In this mini review, I discuss the findings of PET studies that investigated monoamine neurotransmission under resting conditions, specifically focusing on cognitive functions in patients with schizophrenia. With regard to the dopaminergic system, some studies have examined the association of dopamine D1 and D2/D3 receptors, dopamine transporters, and dopamine synthesis capacity with various cognitive functions in schizophrenia. With regard to the serotonergic system, 5-HT1A and 5-HT2A receptors have been studied in the context of cognitive functions in schizophrenia. Although relatively few PET studies have examined cognitive functions in patients with psychiatric disorders, these approaches can provide useful information on enhancing cognitive functions by administering drugs that modulate monoamine transmission. Moreover, another paradigm of techniques such as those exploring the release of neurotransmitters and further development of radiotracers for novel targets are warranted.

  14. Role and impact of [18F]-fluorodeoxyglucose positron emission tomography in recurrent breast cancer

    International Nuclear Information System (INIS)

    Grahek, D.; Montravers, F.; Aide, N.; Kerrou, K.; Talbot, J.N.

    2004-01-01

    [18F]-fluorodeoxyglucose positron emission tomography is widely used in oncology to detect malignant tissue, assess the extent of the disease and follow up treatment. In breast cancer, recurrence detection seems to be the leading indication of [18F] fluorodeoxyglucose positron emission tomography. This review, including recent publications, aims to evaluate its role to detect the recurrent malignant. tissue when tumour marker levels are isolatedly rising and to evaluate the extent of-the disease. The first impact studies reveal its important role in the management of the patients suspected of breast cancer recurrence. (author)

  15. A BGO detector for Positron Emission Profiling in catalysts

    International Nuclear Information System (INIS)

    Mangnus, A.V.G.; Cunningham, R.H.; Santen, R.A. van; Voigt, M.J.A. de

    1995-01-01

    As part of a project to study the reaction kinetics in catalysts, a detector system has been designed and built. The detector will measure in one dimension the activity distribution of positron emitters in catalyst reactors under operational conditions as a function of time. The detector consists of two arrays of ten BGO crystals each and has the flexibility to measure with high sensitivity the activity profile in various reactor sizes; the position resolution that can be reached is 3 mm. (orig.)

  16. Fluorodeoxyglucose and C-Choline positron emission tomography for distinction of metastatic plexopathy and neuritis : a case report

    NARCIS (Netherlands)

    Bartels, Anna L.; Zeebregts, Clark J; Enting, Roeline; Slart, Riemer Hja

    2009-01-01

    INTRODUCTION: Fluorodeoxyglucose positron emission tomography scanning has an established role in the diagnostic work-up of many malignant diseases and also in the evaluation of cancer treatment response. Fluorodeoxyglucose positron emission tomography may, however be non-specific as infectious

  17. Intrinsic spatial resolution limitations due to differences between positron emission position and annihilation detection localization

    International Nuclear Information System (INIS)

    Perez, Pedro; Malano, Francisco; Valente, Mauro

    2012-01-01

    Since its successful implementation for clinical diagnostic, positron emission tomography (PET) represents the most promising medical imaging technique. The recent major growth of PET imaging is mainly due to its ability to trace the biologic pathways of different compounds in the patient's body, assuming the patient can be labeled with some PET isotope. Regardless of the type of isotope, the PET imaging method is based on the detection of two 511-keV gamma photons being emitted in opposite directions, with almost 180 deg between them, as a consequence of electron-positron annihilation. Therefore, this imaging method is intrinsically limited by random uncertainties in spatial resolutions, related with differences between the actual position of positron emission and the location of the detected annihilation. This study presents an approach with the Monte Carlo method to analyze the influence of this effect on different isotopes of potential implementation in PET. (author)

  18. Cerebral metabolic data obtained by positron emission tomography in physiological aging. A review of the literature

    Energy Technology Data Exchange (ETDEWEB)

    Pellat, J; Hommel, M

    1987-06-18

    Following a summary of the general principles and limitations of metabolic measurements by positron emission tomography and of the different indices used to interpret the data, the authors review the results of published studies on physiological aging. Globally, with strict inclusion criteria absolute metabolic values at rest and under partial sensorial deprivation are little or not modified by age. In contrast, functional interactions between regions, as deduced from metabolic intercorrelations, are perhaps different in elderly people. In any case, positron emission tomography seems to discriminate between normal aging and different patterns of pathological aging. Technical improvements, more refined neuropsychological correlations and the use of dynamic activation paradigms will no doubt provide, in the future, a better definition of normal and pathological aging as positron tomography.

  19. Cerebral metabolic data obtained by positron emission tomography in physiological aging. A review of the literature

    International Nuclear Information System (INIS)

    Pellat, J.; Hommel, M.

    1987-01-01

    Following a summary of the general principles and limitations of metabolic measurements by positron emission tomography and of the different indices used to interpret the data, the authors review the results of published studies on physiological aging. Globally, with strict inclusion criteria absolute metabolic values at rest and under partial sensorial deprivation are little or not modified by age. In contrast, functional interactions between regions, as deduced from metabolic intercorrelations, are perhaps different in elderly people. In any case, positron emission tomography seems to discriminate between normal aging and different patterns of pathological aging. Technical improvements, more refined neuropsychological correlations and the use of dynamic activation paradigms will no doubt provide, in the future, a better definition of normal and pathological aging as positron tomography [fr

  20. Time resolution in scintillator based detectors for positron emission tomography

    International Nuclear Information System (INIS)

    Gundacker, S.

    2014-01-01

    In the domain of medical photon detectors L(Y)SO scintillators are used for positron emission tomography (PET). The interest for time of flight (TOF) in PET is increasing since measurements have shown that new crystals like L(Y)SO coupled to state of the art photodetectors, e.g. silicon photomultipliers (SiPM), can reach coincidence time resolutions (CTRs) of far below 500ps FWHM. To achieve these goals it is important to study the processe in the whole detection chain, i.e. the high energy particle or gamma interaction in the crystal, the scintillation process itself, the light propagation in the crystal with the light transfer to the photodetector, and the electronic readout. In this thesis time resolution measurements for a PET like system are performed in a coincidence setup utilizing the ultra fast amplifier discriminator NINO. We found that the time-over-threshold energy information provided by NINO shows a degradation in energy resolution for higher SiPM bias voltages. This is a consequence of the increasing dark count rate (DCR) of the SiPM with higher bias voltages together with the exponential decay of the signal. To overcome this problem and to operate the SiPM at its optimum voltage in terms of timing we developed a new electronic board that employs NINO only as a low noise leading edge discriminator together with an analog amplifier which delivers the energy information. With this new electronic board we indeed improved the measured CTR by about 15%. To study the limits of time resolution in more depth we measured the CTR with 2x2x3mm3 LSO:Ce codoped 0.4%Ca crystals coupled to commercially available SiPMs (Hamamatsu S10931-50P MPPC) and achieved a CTR of 108±5ps FWHM at an energy of 511keV. We determined the influence of the data acquisition system and the electronics on the CTR to be 27±2ps FWHM and thus negligible. To quantitatively understand the measured values, we developed a Monte Carlo simulation tool in MATLAB that incorporates the timing

  1. MRI and {sup 18}F-fluorodeoxyglucose positron emission tomography in hemimegalencephaly

    Energy Technology Data Exchange (ETDEWEB)

    Hoffmann, K.T.; Liebig, T.; Hosten, N. [Departments of Radiology and Nuclear Medicine, Virchow-Klinikum, Charite, Berlin (Germany); Amthauer, H.; Farahati, J.; Felix, R. [Departments of Radiology and Nuclear Medicine, Virchow-Klinikum, Charite, Berlin (Germany); PET-Centre Berlin, Virchow-Klinikum, Charite, Humboldt-University, Berlin (Germany); Etou, A.; Lehmann, T.N. [Department of Neurosurgery, Virchow-Klinikum, Charite, Humboldt-University, Berlin (Germany)

    2000-10-01

    We report hemimegalencephaly in a 44-year-old woman with mental retardation, epilepsy and a mild hemiparesis. In addition to typical findings on MRI, 2-deoxy-2[{sup 18}F]fluorodeoxyglucose positron-emission tomography (PET) demonstrated glucose hypometabolism of the affected hemisphere. The results of PET have been coregistered with morphological information from the MRI studies by image fusion. (orig.)

  2. Synthesis and biodistribution of [C-11]procaterol, a beta(2)-adrenoceptor agonist for positron emission tomography

    NARCIS (Netherlands)

    Visser, TJ; van der Wouden, EA; van Waarde, A; Doze, P; Elsinga, PH; Vaalburg, W

    The potent, subtype-selective radioligand (+/-)-erythro-5-(1-hydroxy-2-[C-11]isopropyl-aminobutyl)-8-hydroxy-carbostyril ([C-11]procaterol) was synthesized and evaluated for visualization of pulmonary beta(2)-adrenoceptors with positron emission tomography (PET). Procaterol was labelled by reductive

  3. Positron emission CT and X-ray CT findings in chronic obstructive pulmonary diseases

    Energy Technology Data Exchange (ETDEWEB)

    Sato, Yoshikazu; Murata, Kiyoshi; Ito, Harumi; Senda, Michio; Yonekura, Yoshiharu; Konishi, Junji; Nishimura, Koichi; Izumi, Takahide; Oshima, Shunsaku

    1987-08-01

    Positron emission CT and X-ray CT were performed in fifteen patients with emphysema confirmed SAB and twelve patients with clinical DPB. In patients with emphysema, 20 of 36 areas showed a central pattern and their perfusion scintigrams showed stripe-signs. On the other hand, the patients with DPB showed outer layer progression of the disease.

  4. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling

    NARCIS (Netherlands)

    Bowen, S.R.; Kogel, A.J. van der; Nordsmark, M.; Bentzen, S.M.; Jeraj, R.

    2011-01-01

    PURPOSE: Unique uptake and retention mechanisms of positron emission tomography (PET) hypoxia tracers make in vivo comparison between them challenging. Differences in imaged uptake of two common hypoxia radiotracers, [(61)Cu]Cu-ATSM and [(18)F]FMISO, were characterized via computational modeling to

  5. 77 FR 8262 - Draft Guidance on Investigational New Drug Applications for Positron Emission Tomography Drugs...

    Science.gov (United States)

    2012-02-14

    ... DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2012-D-0081] Draft Guidance on Investigational New Drug Applications for Positron Emission Tomography Drugs; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug...

  6. Monitoring variables affecting positron emission tomography measurements of cerebral blood flow in anaesthetized pigs

    DEFF Research Database (Denmark)

    Alstrup, Aage Kristian Olsen; Zois, Nora Elisabeth; Simonsen, Mette

    Background: Positron emission tomography (PET) imaging of anaesthetised pig brains is a useful tool in neuroscience. Stable cerebral blood flow (CBF) is essential for PET, since variations can affect the kinetics of several radiotracers. However, the impact of physiological factors regulating CBF...

  7. Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma

    DEFF Research Database (Denmark)

    André, Marc P.E.; Girinsky, Théodore; Federico, Massimo

    2017-01-01

    Purpose Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron emission tomography (PET) scan may improve selection of patients who need reduced or more intensive treatments. Methods We performed...

  8. A positron emission tomography study of wind-up pain in chronic postherniotomy pain

    DEFF Research Database (Denmark)

    Kupers, Ron; Lonsdale, Markus Georg; Aasvang, Eske Kvanner

    2011-01-01

    -induced wind-up pain in neuropathic pain patients. We therefore used positron emission tomography (PET) to investigate the cerebral response pattern of mechanical wind-up pain in a homogenous group of 10 neuropathic pain patients with long-standing postherniotomy pain in the groin area. Patients were scanned...

  9. Positron emission tomography in the diagnosis and staging of lung cancer

    DEFF Research Database (Denmark)

    Fischer, B M; Mortensen, J; Højgaard, L

    2001-01-01

    positron emission tomography (PET) and gamma-camera PET in the diagnostic investigation of non-small-cell lung cancer (NSCLC). A systematic literature search was carried out in the MEDLINE and EMBASE databases and the Cochrane Controlled Trials Register. We identified 55 original works on the diagnostic...

  10. Hypoxia positron emission tomography imaging: combining information on perfusion and tracer retention to improve hypoxia specificity

    DEFF Research Database (Denmark)

    Busk, Morten; Munk, Ole L; Jakobsen, Steen S

    2017-01-01

    BACKGROUND: Static positron emission tomography (PET) allows mapping of tumor hypoxia, but low resolution and slow tracer retention/clearance results in poor image contrast and the risk of missing areas where hypoxic cells and necrosis are intermixed. Fully dynamic PET may improve accuracy but scan...

  11. Positron emission tomography in the follow-up of cutaneous malignant melanoma patients

    DEFF Research Database (Denmark)

    Danielsen, Maria; Højgaard, Liselotte; Kjær, Andreas

    2014-01-01

    node involvement and distant metastases, accentuating the importance of close surveillance to identify disease progression at an early stage, and thereby detect recurrences amenable to treatment. Positron emission tomography (PET) has already been proven useful in the staging of CMM, but the utility...

  12. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

    DEFF Research Database (Denmark)

    Binderup, Tina; Knigge, Ulrich; Loft, Annika

    2010-01-01

    PURPOSE: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is currently not used on a routine basis for imaging of neuroendocrine (NE) tumors. The aim of this study was to investigate the prognostic value of FDG-PET in patients with NE tumors. EXPERIMENTAL DESIGN: Ninety...

  13. Monitoring of herpes simplex virus thymidine kinase enzyme activity using positron emission tomography

    NARCIS (Netherlands)

    Hospers, GAP; Calogero, Anna; van Waarde, A; Doze, P; Vaalburg, W; Mulder, NH; de Vries, EFJ

    2000-01-01

    9-[(1-[F-18]Fluoro-3-hydroxy-2-propoxy)methyl]guanine ([F-18]FHPG) wasevaluated as a tracer for noninvasive positron emission tomography (PET) imaging of herpes simplex virus type 1 thymidine kinase (HSV-tk) gene expression. C6 rat glioma cells with and without the HSV-tk gene were incubated with

  14. Activity-based costing evaluation of a [F-18]-fludeoxyglucose positron emission tomography study

    NARCIS (Netherlands)

    Krug, Bruno; Van Zanten, Annie; Pirson, Anne-Sophie; Crott, Ralph; Vander Borght, Thierry

    2009-01-01

    Objective: The aim of the study is to use the activity-based costing approach to give a better insight in the actual cost structure of a positron emission tomography procedure (FDG-PET) by defining the constituting components and by simulating the impact of possible resource or practice changes.

  15. Recurrent ovarian endodermal sinus tumor: demonstration by computed tomography, magnetic resonance imaging, and positron emission tomography

    International Nuclear Information System (INIS)

    Romero, J.A.; Kim, E.E.; Tresukosol, D.; Kudelka, A.P.; Edwards, C.L.; Kavanagh, J.J.

    1995-01-01

    We report a case of recurrent endodermal sinus tumor of the ovary that was identified and/or clearly depicted by computed tomography, magnetic resonance imaging, and positron emission tomography. The potential roles of various imaging modalities in the detection of recurrent endodermal sinus tumor are discussed. (orig.)

  16. Tomography by positrons emission: integral unit to the service of Mexico

    International Nuclear Information System (INIS)

    Lopez D, F.A.

    2005-01-01

    The applications of the Positron emission tomography (PET) together with the one radiopharmaceutical 2 - [ 18 F]-fluoro-2-deoxy-D-glucose in the area of the medical imaging is expanding quickly and it possesses a bigger impact at the moment in favor of those patient to who suffers an oncological, cardiac or neurological illness in Mexico. (Author)

  17. Cobalt-55 positron emission tomography in traumatic brain injury : A pilot study

    NARCIS (Netherlands)

    Jansen, HML; vanderNaalt, J; vanZomeren, AH; Paans, AMJ; VeenmavanderDuin, L; Hew, JM; Pruim, J; Minderhoud, JM; Korf, J

    Traumatic brain injury is usually assessed with the Glasgow coma scale (GCS), CT, or MRI. After such injury, the injured brain tissue is characterised by calcium mediated neuronal damage and inflammation. Positron emission tomography with the isotope cobalt-55 (Go-PET) as a calcium tracer enables

  18. Statistical properties of compartmental model parameters extracted from dynamic positron emission tomography experiments

    International Nuclear Information System (INIS)

    Mazoyer, B.M.; Huesman, R.H.; Budinger, T.F.; Knittel, B.L.

    1986-01-01

    Over the past years a major focus of research in physiologic studies employing tracers has been the computer implementation of mathematical methods of kinetic modeling for extracting the desired physiological parameters from tomographically derived data. A study is reported of factors that affect the statistical properties of compartmental model parameters extracted from dynamic positron emission tomography (PET) experiments

  19. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in evaluation of residual intramuscular myxoma

    International Nuclear Information System (INIS)

    Zade, Anand; Ahire, Archana; Shetty, Shishir; Rai, Sujith; Bokka, Rajashekharrao; Velumani, Arokiaswamy; Kabnurkar, Rasika

    2015-01-01

    Intramuscular myxoma (IM) is a rare benign neoplasm. In a patient diagnosed with IM of left thigh, we report the utility of a postoperative fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography scan in assessing the efficacy of surgical excision

  20. Characterization of hepatic tumors using [11C]metomidate through positron emission tomography

    DEFF Research Database (Denmark)

    Roivainen, Anne; Naum, Alexandru; Nuutinen, Heikki

    2013-01-01

    ABSTRACT: BACKGROUND: Using positron emission tomography (PET), we compared two tracers, [11C]metomidate ([11C]MTO) and [11C]acetate ([11C]ACE), for the characterization of hepatic tumors. METHODS: Thirty-three patients underwent PET with [11C]MTO and [11C]ACE and magnetic resonance imaging (MRI...

  1. Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings

    NARCIS (Netherlands)

    Veltman, D.J.; Ruhe, H.G.; Booij, J.

    2010-01-01

    Mono-aminergic neurotransmitters, in particular serotonin (5-HT), are involved in regulating a large number of psychological and physiological functions, and abnormal 5-HT transmission has been implicated in a wide variety of neuropsychiatric disorders. Positron emission tomography (PET) is a

  2. A Monte Carlo simulation of the possible use of Positron Emission Tomography in proton radiotherapy

    International Nuclear Information System (INIS)

    Del Guerra, Alberto; Di Domenico, Giovanni; Gambaccini, Mauro; Marziani, Michele

    1994-01-01

    We have used the Monte Carlo technique to evaluate the applicability of Positron Emission Tomography to in vivo dosimetry for proton radiotherapy. A fair agreement has been found between Monte Carlo results and experimental data. The simulation shows that PET can be useful especially for in vivo Bragg's peak localization. ((orig.))

  3. Small animal positron emission tomography imaging and in vivo studies of atherosclerosis

    DEFF Research Database (Denmark)

    Hag, Anne Mette Fisker; Ripa, Rasmus Sejersten; Pedersen, Sune Folke

    2013-01-01

    Atherosclerosis is a growing health challenge globally, and despite our knowledge of the disease has increased over the last couple of decades, many unanswered questions remain. As molecular imaging can be used to visualize, characterize and measure biological processes at the molecular and cellu...... knowledge obtained from in vivo positron emission tomography studies of atherosclerosis performed in small animals....

  4. Positron emission tomography-computed tomography has a clinical impact for patients with cervical cancer

    DEFF Research Database (Denmark)

    Sandvik, Rikke Mulvad; Jensen, Pernille Tine; Hendel, Helle W

    2011-01-01

    Many studies have found that positron emission tomography-computed tomography (PET-CT) has a high sensitivity and specificity in the identification of metastasis in cervical cancer. Herlev Hospital, Denmark, has been performing PET-CTs in stage I-IV cervical cancer since 1 May 2006. The present...

  5. Diffuse nesidioblastosis diagnosed on a Ga-68 DOTATATE positron emission tomography/computerized tomography

    International Nuclear Information System (INIS)

    Arun, Sasikumar; Mittal, Bhagwant Rai; Shukla, Jaya; Bhattacharya, Anish; Kumar, Praveen

    2013-01-01

    The authors describe a 50 days old pre-term infant with persistent hyperinsulinemic hypoglycemia of infancy in whom 68 Ga DOTATATE positron emission tomography/computerized tomography scan showed diffusely increased tracer uptake in the entire pancreas with no abnormal tracer uptake anywhere else in the body, suggestive of a diffuse variant of nesidioblastosis. (author)

  6. Fluorodeoxyglucose-based positron emission tomography imaging to monitor drug responses in hematological tumors

    NARCIS (Netherlands)

    Newbold, Andrea; Martin, Ben P.; Cullinane, Carleen; Bots, Michael

    2014-01-01

    Positron emission tomography (PET) can be used to monitor the uptake of the labeled glucose analog fluorodeoxyglucose (¹⁸F-FDG), a process that is generally believed to reflect viable tumor cell mass. The use of ¹⁸F-FDG PET can be helpful in documenting over time the reduction in tumor mass volume

  7. Positron emission medical measurements with accelerated radioactive ion beams

    International Nuclear Information System (INIS)

    Llacer, J.

    1988-01-01

    This paper reviews in some detail the process by which a heavy ion accelerator can be used to inject positron emitting radioactive particles into a human body for a range of possible medical measurements. The process of radioactive beam generation and injection is described, followed by a study of the relationship between activity that can be injected versus dose to the patient as a function of which of the positron emitting ions is used. It is found that 6 C 10 and 10 Ne 19 are the two isotopes that appear more promising for injection into humans. The design considerations for a non-tomographic instrument to obtain images from beam injections are outlined and the results of 10 Ne 19 preliminary measurements with human phantoms and actual patients for the determination of end-of-range of cancer therapy ion beams is reported. Accuracies in the order of ±1 mm in the measurements of stopping point of a therapy beam with safe doses to the patient are reported. The paper concludes with a simple analysis of requirements to extend the technique to on-line verification of cancer treatment and to nuclear medicine research and diagnostics measurements. 17 refs.; 16 figs.; 3 tabs

  8. What have positron emission tomography and 'Zippy' told us about the neuropharmacology of drug addiction?

    Science.gov (United States)

    Cumming, Paul; Caprioli, Daniele; Dalley, Jeffrey W

    2011-08-01

    Translational molecular imaging with positron emission tomography (PET) and allied technologies offer unrivalled applications in the discovery of biomarkers and aetiological mechanisms relevant to human disease. Foremost among clinical PET findings during the past two decades of addiction research is the seminal discovery of reduced dopamine D(2/3) receptor expression in the striatum of drug addicts, which could indicate a predisposing factor and/or compensatory reaction to the chronic abuse of stimulant drugs. In parallel, recent years have witnessed significant improvements in the performance of small animal tomographs (microPET) and a refinement of animal models of addiction based on clinically relevant diagnostic criteria. This review surveys the utility of PET in the elucidation of neuropharmacological mechanisms underlying drug addiction. It considers the consequences of chronic drug exposure on regional brain metabolism and neurotransmitter function and identifies those areas where further research is needed, especially concerning the implementation of PET tracers targeting neurotransmitter systems other than dopamine, which increasingly have been implicated in the pathophysiology of drug addiction. In addition, this review considers the causal effects of behavioural traits such as impulsivity and novelty/sensation-seeking on the emergence of compulsive drug-taking. Previous research indicates that spontaneously high-impulsive rats--as exemplified by 'Zippy'--are pre-disposed to escalate intravenous cocaine self-administration, and subsequently to develop compulsive drug taking tendencies that endure despite concurrent adverse consequences of such behaviour, just as in human addiction. The discovery using microPET of pre-existing differences in dopamine D(2/3) receptor expression in the striatum of high-impulsive rats suggests a neural endophenotype that may likewise pre-dispose to stimulant addiction in humans. © 2011 The Authors. British Journal of

  9. Positron emission tomography of hepatic first-pass metabolism of ammonia in pig

    DEFF Research Database (Denmark)

    Keiding, S; Munk, O L; Roelsgaard, K

    2001-01-01

    Hepatic first-pass metabolism plays a key role in metabolic regulation and drug metabolism. Metabolic processes can be quantified in vivo by positron emission tomography scanning (PET). We wished to develop a PET technique to measure hepatic first-pass metabolism of ammonia. Seven anaesthetised...... pigs were given positron-labelled ammonia, (13)NH(3), into the portal vein and into the vena cava as successive 2-min infusions followed by 22-min dynamic liver scanning. Vena cava infusion data were used to account for recirculation of tracer and metabolites following the portal vein infusion...

  10. Positron emission tomography - a new technique for observing fluid behaviour in engineering systems

    International Nuclear Information System (INIS)

    Stewart, P.A.E.; Rogers, J.D.; Skelton, R.T.

    1988-01-01

    Positron emission tomography promises to become a powerful new technique for flow tracing and measurement within metal structures in general and operating engines in particular. The principles involved are outlined, and a mobile positron camera system being developed jointly by Rolls-Royce, Castrol, the University of Birmingham and the Rutherford-Appleton Laboratory of the SERC is described. Finally, illustrative examples of the camera's capability are presented drawn from its use to study lubricating fluid flow in the bearings of a Viper gas turbine engine on test up to 100% full power. (author)

  11. Three-dimensional imaging of hidden objects using positron emission backscatter

    International Nuclear Information System (INIS)

    Lee, Dongwon; Cowee, Misa; Fenimore, Ed; Galassi, Mark; Looker, Quinn; Mcneil, Wendy V.; Stonehill, Laura; Wallace, Mark

    2009-01-01

    Positron emission backscatter imaging is a technique for interrogation and three-dimensional (3-D) reconstruction of hidden objects when we only have access to the objects from one side. Using time-of-flight differences in detected direct and backscattered positron-emitted photons, we construct 3-D images of target objects. Recently at Los Alamos National Laboratory, a fully three-dimensional imaging system has been built and the experimental results are discussed in this paper. Quantitative analysis of images reconstructed in both two- and three-dimensions are also presented.

  12. Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [11C]raclopride and high-resolution positron emission tomography

    DEFF Research Database (Denmark)

    Alakurtti, Kati; Johansson, Jarkko J; Tuokkola, Terhi

    2013-01-01

    scanned with brain-dedicated high-resolution research tomography (HRRT, Siemens Medical Solutions, Knoxville, TN, USA) and [(11)C]raclopride. Coronally defined regions of interest (ROIs) of the caudate nucleus, putamen and ventral striatum (VST) were sampled plane-by-plane, 1.5mm apart, on spatially...... observed in the VST. The novelty of this study lies in the presentation, for the first time, of the D2/3 receptor binding gradients in each striatal subregion in the brains of living healthy humans. The high spatial resolution provided by HRRT enables frequent sampling of BPND along the longitudinal extent...

  13. Positron emission intensities in the decay of 64Cu, 76Br and 124I

    International Nuclear Information System (INIS)

    Qaim, S.M.; Bisinger, T.; Hilgers, K.; Nayak, D.; Coenen, H.H.

    2007-01-01

    The relatively long-lived positron emitters 64 Cu (t 1/2 = 12.7 h), 76 Br (t 1/2 = 16.2 h) and 124 I (t 1/2 = 4.18 d) are finding increasing applications in positron emission tomography (PET). For precise determination of their positron emission intensities, each radionuclide was prepared via a charged particle induced reaction in a ''no-carrier-added'' form and with high radionuclidic purity. It was then subjected to γ-ray and X-ray spectroscopy as well as to anticoincidence beta and γγ-coincidence counting. The positron emission intensities measured were: 64 Cu (17.8 ± 0.4)%, 76 Br (58.2 ± 1.9)% and 124 I (22.0 ± 0.5)%. The intensity of the weak 1346 keV γ-ray emitted in the decay of 64 Cu was determined as (0.54 ± 0.03)%. Some implications of the precisely determined nuclear data are discussed. (orig.)

  14. Vulnerability of positron emission tomography radiotracers to endogenous competition

    International Nuclear Information System (INIS)

    Laruelle, M.; Huang, Y.

    2001-01-01

    PET and SPECT neuro receptor imaging techniques combined with pharmacological challenges have been introduce to measure acute fluctuations of synaptic dopamine (DA) concentrations in the living human brain. Changes in the in vivo binding of radioligands following manipulation of transmitter levels are generally believed to be driven by binding competition between the radioligand and neurotransmitter. This imaging modality has been very successful in the study of DA transmission at D2 receptors. Yet, the extension of this technique to the study of other neurotransmitter systems has proven difficult. This paper reviews recent evidence suggesting that simple binding competition might not be the only phenomenon regulating transmitter-radioligand interactions in vivo, and examines emerging data indicating that receptor trafficking might also be involved. A better understanding of the mechanisms underlying these interactions should facilitate the development of PET and SPECT radiotracers suitable for the reporting of synaptic transmitter levels

  15. Vulnerability of positron emission tomography radiotracers to endogenous competition

    Energy Technology Data Exchange (ETDEWEB)

    Laruelle, M.; Huang, Y. [Columbia University College of Physicians and Surgeons and State Psychiatric Institute, Dept. of Psychiatry and Radiology, New York, NY (United States)

    2001-06-01

    PET and SPECT neuro receptor imaging techniques combined with pharmacological challenges have been introduce to measure acute fluctuations of synaptic dopamine (DA) concentrations in the living human brain. Changes in the in vivo binding of radioligands following manipulation of transmitter levels are generally believed to be driven by binding competition between the radioligand and neurotransmitter. This imaging modality has been very successful in the study of DA transmission at D2 receptors. Yet, the extension of this technique to the study of other neurotransmitter systems has proven difficult. This paper reviews recent evidence suggesting that simple binding competition might not be the only phenomenon regulating transmitter-radioligand interactions in vivo, and examines emerging data indicating that receptor trafficking might also be involved. A better understanding of the mechanisms underlying these interactions should facilitate the development of PET and SPECT radiotracers suitable for the reporting of synaptic transmitter levels.

  16. Positron Emission Tomography: Current Challenges and Opportunities for Technological Advances in Clinical and Preclinical Imaging Systems

    Science.gov (United States)

    Vaquero, Juan José; Kinahan, Paul

    2017-01-01

    Positron emission tomography (PET) imaging is based on detecting two time-coincident high-energy photons from the emission of a positron-emitting radioisotope. The physics of the emission, and the detection of the coincident photons, give PET imaging unique capabilities for both very high sensitivity and accurate estimation of the in vivo concentration of the radiotracer. PET imaging has been widely adopted as an important clinical modality for oncological, cardiovascular, and neurological applications. PET imaging has also become an important tool in preclinical studies, particularly for investigating murine models of disease and other small-animal models. However, there are several challenges to using PET imaging systems. These include the fundamental trade-offs between resolution and noise, the quantitative accuracy of the measurements, and integration with X-ray computed tomography and magnetic resonance imaging. In this article, we review how researchers and industry are addressing these challenges. PMID:26643024

  17. Positron Emission Tomography: Current Challenges and Opportunities for Technological Advances in Clinical and Preclinical Imaging Systems.

    Science.gov (United States)

    Vaquero, Juan José; Kinahan, Paul

    2015-01-01

    Positron emission tomography (PET) imaging is based on detecting two time-coincident high-energy photons from the emission of a positron-emitting radioisotope. The physics of the emission, and the detection of the coincident photons, give PET imaging unique capabilities for both very high sensitivity and accurate estimation of the in vivo concentration of the radiotracer. PET imaging has been widely adopted as an important clinical modality for oncological, cardiovascular, and neurological applications. PET imaging has also become an important tool in preclinical studies, particularly for investigating murine models of disease and other small-animal models. However, there are several challenges to using PET imaging systems. These include the fundamental trade-offs between resolution and noise, the quantitative accuracy of the measurements, and integration with X-ray computed tomography and magnetic resonance imaging. In this article, we review how researchers and industry are addressing these challenges.

  18. A new method of detection for a positron emission tomograph using a time of flight method

    International Nuclear Information System (INIS)

    Gresset, Christian.

    1981-05-01

    In the first chapter, it is shown the advantages of positron radioemitters (β + ) of low period, and the essential characteristics of positron tomographs realized at the present time. The second chapter presents the interest of an original technique of image reconstruction: the time of flight technique. The third chapter describes the characterization methods which were set for verifying the feasibility of cesium fluoride in tomography. Chapter four presents the results obtained by these methods. It appears that the cesium fluoride constitute presently the best positron emission associated to time of flight technique. The hypotheses made on eventual performances of such machines are validated by experiments with phantom. The results obtained with a detector (bismuth germanate) conserves all its interest in skull tomography [fr

  19. Emission tomography with positrons principle, physical performances of a ring detector and quantitative possibilities

    International Nuclear Information System (INIS)

    Soussaline, F.; Plummer, D.; Todd Pokropek, A.E.; Loc'h, C.; Comar, D.

    1979-01-01

    Satisfactory qualitative and quantitative data in positron emission tomography requires the use of a well adapted tomographic system. A number of parameters have been identified which can be considered as the critical characteristics for evaluation and intercomparison of such systems. Using these the choice of a single slice ring positron camera could be justified by its physical performance, which is presented and discussed. Series of physical and mathematical simulations allow an appropriate knowledge of such a system, which has been in use for more than a year in a clinical environment. These studies aid to the interpretation of very interesting physiopathologic studies. In principle, a positron tomographic system permits measurement of absolute quantitative concentration values, which are essential for precise metabolic studies. The main sources of error comprising the calibration of the system, the tail effects and the precision for attenuation correction are analysed. When taking in account these errors, a precision of the order of 10% should be obtainable [fr

  20. Fluorodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative

    International Nuclear Information System (INIS)

    McEwan, Louise M.; Wong, David; Yaxley, John

    2017-01-01

    Gallium-68 prostate specific membrane antigen ligand (Ga-68 PSMA) positron emission tomography/computed tomography (PET/CT) scanning is emerging as a useful imaging modality for the staging of suspected and known recurrent or metastatic prostate cancer and in staging of newly diagnosed higher grade prostate cancer. However, we have observed at our institution that in some cases of the more aggressive ductal variant, Ga-68 PSMA uptake has sometimes been poor compared with prominent 18-fluorodeoxyglucose (F-18 FDG) avidity seen in F-18 FDG PET/CT, which would suggest that FDG PET/CT scans are important in staging of ductal pattern prostate cancer.

  1. 18F-fluorodeoxyglucose positron emission tomography in colorectal cancer: value in primary staging and follow-up

    International Nuclear Information System (INIS)

    Joerg, L.; Heinisch, M.; Rechberger, E.; Kurz, F.; Klug, R.; Aufschnaiter, M; Hammer, J.; Langsteger, W.

    2002-01-01

    Positron emission tomography using 18 F-fluorodeoxyglucose (FDG-PET) is a encouraging imaging techniques allowing a highly sensitive whole-body search for malignant foci detected by their increased glucose metabolism compared with benign tissues. Several studies are now available that indicate its added value for diagnosis and staging of colorectal cancer. In all, patient management seems to be changed in 20-30 % of patients who undergo fluorodeoxyglucose positron emission tomography in addition to standard staging procedures. Fluorodeoxyglucose positron emission tomography is also useful in monitoring radiation therapy and chemotherapy. Regarding preoperative staging of primary colorectal cancer the literature is very limited. (author)

  2. Positron emission tomography studies in eating disorders: multireceptor brain imaging, correlates with behavior and implications for pharmacotherapy

    Energy Technology Data Exchange (ETDEWEB)

    Frank, Guido K. [Department of Child and Adolescent Psychiatry, Center for Eating Disorders Research, School of Medicine, University of California San Diego, San Diego, CA 92123 (United States); Kaye, Walter H. [Department of Psychiatry, Western Psychiatric Institute and Clinic, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 (United States)

    2005-10-01

    Modern imaging techniques that visualize disease-specific organ neurotransmitter or protein receptor sites are increasingly able to define pathological processes on a molecular level. One of those imaging modalities, positron emission tomography (PET), for the assessment of brain neuroreceptor binding has revolutionized the in vivo assessment of biologic markers that may be related to human behavior. Such studies may help identify chemical targets that may be directly related to psychiatric pathology and, thus, opportunities for pharmacological intervention. In this review, we describe results from PET studies in eating disorders (EDs). Eating disorders are frequently debilitating illnesses that are quite homogeneous in their presentation. Those studies that identified particular serotonin and dopamine receptor alterations can distinguish recovered ED subjects from controls as well as ED subgroups. Furthermore, correlations of receptor binding with behavioral constructs, such as harm avoidance or novelty seeking, could be found. These recognized receptors may now help us to move away from rather nonspecific treatment approaches in psychiatric research and clinic to the possibility of more syndrome- and symptom-specific treatment approaches.

  3. Positron emission tomography studies in eating disorders: multireceptor brain imaging, correlates with behavior and implications for pharmacotherapy

    International Nuclear Information System (INIS)

    Frank, Guido K.; Kaye, Walter H.

    2005-01-01

    Modern imaging techniques that visualize disease-specific organ neurotransmitter or protein receptor sites are increasingly able to define pathological processes on a molecular level. One of those imaging modalities, positron emission tomography (PET), for the assessment of brain neuroreceptor binding has revolutionized the in vivo assessment of biologic markers that may be related to human behavior. Such studies may help identify chemical targets that may be directly related to psychiatric pathology and, thus, opportunities for pharmacological intervention. In this review, we describe results from PET studies in eating disorders (EDs). Eating disorders are frequently debilitating illnesses that are quite homogeneous in their presentation. Those studies that identified particular serotonin and dopamine receptor alterations can distinguish recovered ED subjects from controls as well as ED subgroups. Furthermore, correlations of receptor binding with behavioral constructs, such as harm avoidance or novelty seeking, could be found. These recognized receptors may now help us to move away from rather nonspecific treatment approaches in psychiatric research and clinic to the possibility of more syndrome- and symptom-specific treatment approaches

  4. Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-dPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue

    International Nuclear Information System (INIS)

    Roesch, F.; Brockmann, J.; Koehle, M.

    1999-01-01

    [ 90 Y]DOTA-dPhe 1 -Tyr 3 -octreotide ([ 90 Y]-SMT487) has been suggested as a promising radiotherapeutic agent for somatostatin receptor-expressing tumours. In order to quantify the in vivo parameters of this compound and the radiation doses delivered to healthy organs, the analogue [ 86 Y]DOTA-dPhe 1 -Tyr 3 -octreotide was synthesised and its uptake measured in baboons using positron emission tomography (PET). [ 86 Y]DOTA-dPhe 1 -Tyr 3 -octreotide was administered at two different peptide concentrations, namely 2 and 100 μg peptide per m 2 body surface. The latter concentration corresponded to a radiotherapeutic dose. In a third protocol [ 86 Y]DOTA-dPhe 1 -Tyr 3 -octreotide was injected in conjunction with a simultaneous infusion of an amino acid solution that was high in l-lysine in order to lower the renal uptake of radioyttrium. Quantitative whole-body PET scans were recorded to measure the uptake kinetics for kidneys, liver, lung and bone. The individual absolute uptake kinetics were used to calculate the radiation doses for [ 90 Y]DOTA-dPhe 1 -Tyr 3 -octreotide according to the MIRD recommendations extrapolated to a 70-kg human. The highest radiation dose was received by the kidneys, with 2.1-3.3 mGy per MBq [ 90 Y]DOTA-dPhe 1 -Tyr 3 -octreotide injected. For the 100 μg/m 2 SMT487 protocol with amino acid co-infusion this dose was about 20%-40% lower than for the other two treatment protocols. The liver and the red bone marrow received doses ranging from 0.32 to 0.53 mGy and 0.03 to 0.07 mGy per MBq [ 90 Y]DOTA-dPhe 1 -Tyr 3 -octreotide, respectively. The average effective dose equivalent amounted to 0.23-0.32 mSv/MBq. The comparatively low estimated radiation doses to normal organs support the initiation of clinical phase I trials with [ 90 Y]DOTA-dPhe 1 -Tyr 3 -octreotide in patients with somatostatin receptor-expressing tumours. (orig.)

  5. Uptake kinetics of the somatostatin receptor ligand [{sup 86}Y]DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide ([{sup 86}Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the {sup 90}Y-labelled analogue

    Energy Technology Data Exchange (ETDEWEB)

    Roesch, F.; Brockmann, J. [Forschungszentrum Juelich GmbH (Germany). Inst. fuer Nuklearchemie; Herzog, H.; Muehlensiepen, H.; Mueller-Gaertner, H.W. [Forschungszentrum Juelich GmbH (Germany). Inst. fuer Medizin; Stolz, B.; Marbach, P. [Novartis Pharma AG, Basel (Switzerland); Koehle, M. [Klinikum der Freien Universitaet Berlin (Germany)

    1999-04-29

    [{sup 90}Y]DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide ([{sup 90}Y]-SMT487) has been suggested as a promising radiotherapeutic agent for somatostatin receptor-expressing tumours. In order to quantify the in vivo parameters of this compound and the radiation doses delivered to healthy organs, the analogue [{sup 86}Y]DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide was synthesised and its uptake measured in baboons using positron emission tomography (PET). [{sup 86}Y]DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide was administered at two different peptide concentrations, namely 2 and 100 {mu}g peptide per m{sup 2} body surface. The latter concentration corresponded to a radiotherapeutic dose. In a third protocol [{sup 86}Y]DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide was injected in conjunction with a simultaneous infusion of an amino acid solution that was high in l-lysine in order to lower the renal uptake of radioyttrium. Quantitative whole-body PET scans were recorded to measure the uptake kinetics for kidneys, liver, lung and bone. The individual absolute uptake kinetics were used to calculate the radiation doses for [{sup 90}Y]DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide according to the MIRD recommendations extrapolated to a 70-kg human. The highest radiation dose was received by the kidneys, with 2.1-3.3 mGy per MBq [{sup 90}Y]DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide injected. For the 100 {mu}g/m{sup 2} SMT487 protocol with amino acid co-infusion this dose was about 20%-40% lower than for the other two treatment protocols. The liver and the red bone marrow received doses ranging from 0.32 to 0.53 mGy and 0.03 to 0.07 mGy per MBq [{sup 90}Y]DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide, respectively. The average effective dose equivalent amounted to 0.23-0.32 mSv/MBq. The comparatively low estimated radiation doses to normal organs support the initiation of clinical phase I trials with [{sup 90}Y]DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide in patients with somatostatin receptor-expressing tumours. (orig

  6. Current knowledge on the sensitivity of the {sup 68}Ga-somatostatin receptor positron emission tomography and the SUV{sub max} reference range for management of pancreatic neuroendocrine tumours

    Energy Technology Data Exchange (ETDEWEB)

    Virgolini, Irene; Gabriel, Michael; Kroiss, Alexander; Guggenberg, Elisabeth von; Prommegger, Rupert; Warwitz, Boris; Nilica, Bernhard; Roig, Ilanos Geraldo; Rodrigues, Margarida; Uprimny, Christian [Medical University of Innsbruck, Department of Nuclear Medicine, Innsbruck (Austria)

    2016-10-15

    Physiologically increased pancreatic uptake at the head/uncinate process is observed in more than one-third of patients after injection of one of the three {sup 68}Ga-labelled octreotide-based peptides used for somatostatin (sst) receptor (r) imaging. There are minor differences between these {sup 68}Ga-sstr-binding peptides in the imaging setting. On {sup 68}Ga-sstr-imaging the physiological uptake can be diffuse or focal and usually remains stable over time. Differences in the maximal standardised uptake values (SUV{sub max}) reported for the normal pancreas as well as for pancreatic neuroendocrine tumour (PNET) lesions may be related to several factors, including (a) differences in the peptide binding affinities as well as differences in sstr subtype expression of pancreatic α- and β-cells, and heterogeneity / density of tumour cells, (b) differences in scanner resolution, image reconstruction techniques and acquisition protocols, (c) mostly retrospective study designs, (d) mixed patient populations, or (e) interference with medications such as treatment with long-acting sst analogues. The major limitation in most of the studies lies in the lack of histopathological confirmation of abnormal findings. There is a significant overlap between the calculated SUV{sub max}-values for physiological pancreas and PNET-lesions of the head/uncinate process that do not favour the use of quantitative parameters in the clinical setting. Anecdotal long-term follow-up studies have even indicated that increased uptake in the head/uncinate process still can turn out to be malignant over years of follow up. SUV{sub max}-data for the pancreatic body and tail are limited. Therefore, any visible focal tracer uptake in the pancreas must be considered as suspicious for malignancy irrespective of quantitative parameters. In general, sstr-PET/CT has significant implications for the management of NET patients leading to a change in treatment decision in about one-third of patients

  7. Study of brain uptake of etorphine, in vivo in the Baboon Papio-Papio, by positron emission tomography

    International Nuclear Information System (INIS)

    Artola, A.

    1983-01-01

    In order to study in vivo opiate receptors in brain, etorphine, a morphine-like drug was labelled with 11 C. Etorphine possesses an extremely high affinity for specific opiate binding sites. It passes easily through the blood-brain barrier. The brain pharmacokinetics of 11 C-etorphine was studied in vivo in the Baboon Papio-Papio, by positron emission tomography. 11 C-etorphine concentration reached its maximum two minutes after intravenous injection and then decreased rapidly. In some experiments, cyprenorphine, a morphine antagonist, was injected subsequently in order to study the displacement of the radioactive ligand from brain structures. Hepato-biliary and blood pharmacokinetics of 11 C-etorphine were also studied [fr

  8. A new graphic plot analysis for determination of neuroreceptor binding in positron emission tomography studies.

    Science.gov (United States)

    Ito, Hiroshi; Yokoi, Takashi; Ikoma, Yoko; Shidahara, Miho; Seki, Chie; Naganawa, Mika; Takahashi, Hidehiko; Takano, Harumasa; Kimura, Yuichi; Ichise, Masanori; Suhara, Tetsuya

    2010-01-01

    In positron emission tomography (PET) studies with radioligands for neuroreceptors, tracer kinetics have been described by the standard two-tissue compartment model that includes the compartments of nondisplaceable binding and specific binding to receptors. In the present study, we have developed a new graphic plot analysis to determine the total distribution volume (V(T)) and nondisplaceable distribution volume (V(ND)) independently, and therefore the binding potential (BP(ND)). In this plot, Y(t) is the ratio of brain tissue activity to time-integrated arterial input function, and X(t) is the ratio of time-integrated brain tissue activity to time-integrated arterial input function. The x-intercept of linear regression of the plots for early phase represents V(ND), and the x-intercept of linear regression of the plots for delayed phase after the equilibrium time represents V(T). BP(ND) can be calculated by BP(ND)=V(T)/V(ND)-1. Dynamic PET scanning with measurement of arterial input function was performed on six healthy men after intravenous rapid bolus injection of [(11)C]FLB457. The plot yielded a curve in regions with specific binding while it yielded a straight line through all plot data in regions with no specific binding. V(ND), V(T), and BP(ND) values calculated by the present method were in good agreement with those by conventional non-linear least-squares fitting procedure. This method can be used to distinguish graphically whether the radioligand binding includes specific binding or not.

  9. Regional myocardial blood flow, metabolism and function assessed noninvasively by positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Schelbert, H.R.; Phelps, M.E.; Hoffman, E.; Huang, S.; Kuhl, D.E.

    1979-01-01

    Positron emission computed tomography is a new technique for the noninvasive measure of myocardial blood flow, mechanical function and, in particular, metabolism. The capability of this new study means is due to the technological innovations of the imaging device and the availability of radioactive tracers that are specific for blood flow and metabolism. The device permits recording of cross-sectional images of the left ventricular myocardium that reflect quantitatively regional tracer tissue concentrations. By employing tracer kinetic models this new technique permits the measurement of regional glucose and fatty acid metabolism of the heart. While already an important new tool for investigative studies into cardiac physiology and pathophysiology, the clinical utility of positron emission tomography remains to be defined.

  10. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography

    International Nuclear Information System (INIS)

    Wolkin, A.; Jaeger, J.; Brodie, J.D.; Wolf, A.P.; Fowler, J.; Rotrosen, J.; Gomez-Mont, F.; Cancro, R.

    1985-01-01

    Local cerebral metabolic rates were determined by positron emission tomography and the deoxyglucose method in a group of 10 chronic schizophrenic subjects before and after somatic treatment and in eight normal subjects. Before treatment, schizophrenic subjects had markedly lower absolute metabolic activity than did normal controls in both frontal and temporal regions and a trend toward relative hyperactivity in the basal ganglia area. After treatment, their metabolic rates approached those seen in normal subjects in nearly all regions except frontal. Persistence of diminished frontal metabolism was manifested as significant relative hypofrontality. These findings suggest specific loci of aberrant cerebral functioning in chronic schizophrenia and the utility of positron emission tomography in characterizing these abnormalities

  11. Brain metabolism in autism. Resting cerebral glucose utilization rates as measured with positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Rumsey, J.M.; Duara, R.; Grady, C.; Rapoport, J.L.; Margolin, R.A.; Rapoport, S.I.; Cutler, N.R.

    1985-05-01

    The cerebral metabolic rate for glucose was studied in ten men (mean age = 26 years) with well-documented histories of infantile autism and in 15 age-matched normal male controls using positron emission tomography and (F-18) 2-fluoro-2-deoxy-D-glucose. Positron emission tomography was completed during rest, with reduced visual and auditory stimulation. While the autistic group as a whole showed significantly elevated glucose utilization in widespread regions of the brain, there was considerable overlap between the two groups. No brain region showed a reduced metabolic rate in the autistic group. Significantly more autistic, as compared with control, subjects showed extreme relative metabolic rates (ratios of regional metabolic rates to whole brain rates and asymmetries) in one or more brain regions.

  12. Brain metabolism in autism. Resting cerebral glucose utilization rates as measured with positron emission tomography

    International Nuclear Information System (INIS)

    Rumsey, J.M.; Duara, R.; Grady, C.; Rapoport, J.L.; Margolin, R.A.; Rapoport, S.I.; Cutler, N.R.

    1985-01-01

    The cerebral metabolic rate for glucose was studied in ten men (mean age = 26 years) with well-documented histories of infantile autism and in 15 age-matched normal male controls using positron emission tomography and (F-18) 2-fluoro-2-deoxy-D-glucose. Positron emission tomography was completed during rest, with reduced visual and auditory stimulation. While the autistic group as a whole showed significantly elevated glucose utilization in widespread regions of the brain, there was considerable overlap between the two groups. No brain region showed a reduced metabolic rate in the autistic group. Significantly more autistic, as compared with control, subjects showed extreme relative metabolic rates (ratios of regional metabolic rates to whole brain rates and asymmetries) in one or more brain regions

  13. A positron emission tomography study of cardiac sequelae in children with Kawasaki disease, 1

    International Nuclear Information System (INIS)

    Ohmochi, Yutaka

    1994-01-01

    This study quantitatively measured regional myocardial blood flow (MBF) and perfusable tissue fraction (pTF) in 25 children (mean age: 17.2±2.7) with Kawasaki disease using positron emission tomography and H 2 15 O. Patients were divided into three groups based on coronary angiographic findings. Group 1 consisted of 11 patients with normal coronary angiograms; Group 2, 7 patients with stenotic coronary lesions. There were no significant differences in MBF and pTF among 5 divided regions on the left ventricular wall. Average MBF at rest in Group 1 was 0.91±0.19 ml/min/g. There was a poor correlation between MBF estimated positron emission tomography and patient's age in Group 1. (r=-0.374, Y=-0.0234X + 1.254: p 2 15 O, to determine the functional capacity of coronary artery lesions and myocardial damage in children with Kawasaki disease. (author)

  14. Performance evaluation of BGO block detectors used in positron emission tomography and a coincidence system

    International Nuclear Information System (INIS)

    Kim, J. H.; Choi, Y.; Lim, K. C.; Lee, M. Y.; Woo, S. K.; Lee, K. H.; Kim, S. E.; Choi, Y. S.; Kim, B. T.

    1999-01-01

    We investigated the basic performances of the BGO block detectors, which is used in the GE Advance positron emission tomography. The block detector is composed of 36 small BGO crystals coupled to two 2-channel photomultiplier tubes. In this study, we measured the crystal map and the intrinsic energy resolution of the detector. The coincidence signals between the detectors were also obtained using F-18. The intrinsic energy resolution of the block detector was 69% FWHM at 140 keV and 33% FWHM at 511 keV. High quality crystal map and the coincidence signals between the detectors were successfully obtained. The timing resolution of the detectors are being measured. The results of this study demonstrate the feasibility of developing high performance positron emission tomography

  15. Derisking the Cu-Mediated 18F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands.

    Science.gov (United States)

    Taylor, Nicholas J; Emer, Enrico; Preshlock, Sean; Schedler, Michael; Tredwell, Matthew; Verhoog, Stefan; Mercier, Joel; Genicot, Christophe; Gouverneur, Véronique

    2017-06-21

    Molecules labeled with fluorine-18 ( 18 F) are used in positron emission tomography to visualize, characterize and measure biological processes in the body. Despite recent advances in the incorporation of 18 F onto arenes, the development of general and efficient approaches to label radioligands necessary for drug discovery programs remains a significant task. This full account describes a derisking approach toward the radiosynthesis of heterocyclic positron emission tomography (PET) radioligands using the copper-mediated 18 F-fluorination of aryl boron reagents with 18 F-fluoride as a model reaction. This approach is based on a study examining how the presence of heterocycles commonly used in drug development affects the efficiency of 18 F-fluorination for a representative aryl boron reagent, and on the labeling of more than 50 (hetero)aryl boronic esters. This set of data allows for the application of this derisking strategy to the successful radiosynthesis of seven structurally complex pharmaceutically relevant heterocycle-containing molecules.

  16. The electronics system for the LBNL positron emission mammography (PEM) camera

    CERN Document Server

    Moses, W W; Baker, K; Jones, W; Lenox, M; Ho, M H; Weng, M

    2001-01-01

    Describes the electronics for a high-performance positron emission mammography (PEM) camera. It is based on the electronics for a human brain positron emission tomography (PET) camera (the Siemens/CTI HRRT), modified to use a detector module that incorporates a photodiode (PD) array. An application-specified integrated circuit (ASIC) services the photodetector (PD) array, amplifying its signal and identifying the crystal of interaction. Another ASIC services the photomultiplier tube (PMT), measuring its output and providing a timing signal. Field-programmable gate arrays (FPGAs) and lookup RAMs are used to apply crystal-by-crystal correction factors and measure the energy deposit and the interaction depth (based on the PD/PMT ratio). Additional FPGAs provide event multiplexing, derandomization, coincidence detection, and real-time rebinning. Embedded PC/104 microprocessors provide communication, real-time control, and configure the system. Extensive use of FPGAs make the overall design extremely flexible, all...

  17. A feature point identification method for positron emission particle tracking with multiple tracers

    Energy Technology Data Exchange (ETDEWEB)

    Wiggins, Cody, E-mail: cwiggin2@vols.utk.edu [University of Tennessee-Knoxville, Department of Physics and Astronomy, 1408 Circle Drive, Knoxville, TN 37996 (United States); Santos, Roque [University of Tennessee-Knoxville, Department of Nuclear Engineering (United States); Escuela Politécnica Nacional, Departamento de Ciencias Nucleares (Ecuador); Ruggles, Arthur [University of Tennessee-Knoxville, Department of Nuclear Engineering (United States)

    2017-01-21

    A novel detection algorithm for Positron Emission Particle Tracking (PEPT) with multiple tracers based on optical feature point identification (FPI) methods is presented. This new method, the FPI method, is compared to a previous multiple PEPT method via analyses of experimental and simulated data. The FPI method outperforms the older method in cases of large particle numbers and fine time resolution. Simulated data show the FPI method to be capable of identifying 100 particles at 0.5 mm average spatial error. Detection error is seen to vary with the inverse square root of the number of lines of response (LORs) used for detection and increases as particle separation decreases. - Highlights: • A new approach to positron emission particle tracking is presented. • Using optical feature point identification analogs, multiple particle tracking is achieved. • Method is compared to previous multiple particle method. • Accuracy and applicability of method is explored.

  18. Regional myocardial blood flow, metabolism and function assessed noninvasively by positron emission tomography

    International Nuclear Information System (INIS)

    Schelbert, H.R.; Phelps, M.E.; Hoffman, E.; Huang, S.; Kuhl, D.E.

    1979-01-01

    Positron emission computed tomography is a new technique for the noninvasive measure of myocardial blood flow, mechanical function and, in particular, metabolism. The capability of this new study means is due to the technological innovations of the imaging device and the availability of radioactive tracers that are specific for blood flow and metabolism. The device permits recording of cross-sectional images of the left ventricular myocardium that reflect quantitatively regional tracer tissue concentrations. By employing tracer kinetic models this new technique permits the measurement of regional glucose and fatty acid metabolism of the heart. While already an important new tool for investigative studies into cardiac physiology and pathophysiology, the clinical utility of positron emission tomography remains to be defined

  19. Regional cerebral glucose metabolism during sevoflurane anaesthesia in healthy subjects studied with positron emission tomography

    DEFF Research Database (Denmark)

    Schlünzen, L; Juul, N; Hansen, K V

    2010-01-01

    BACKGROUND: The precise mechanism by which sevoflurane exerts its effects in the human brain remains unknown. In the present study, we quantified the effects of sevoflurane on regional cerebral glucose metabolism (rGMR) in the human brain measured with positron emission tomography. METHODS: Eight...... areas by 48-71% of the baseline (Pbrain metabolic reduction of GMR in all regions...... of the human brain, with the most marked metabolic suppression in the lingual gyrus, thalamus and occipital lobe....

  20. Dynamic positron emission tomography in man using small bismuth germanate crystals

    International Nuclear Information System (INIS)

    Derenzo, S.E.; Budinger, T.F.; Huesman, R.H.; Cahoon, J.L.

    1982-04-01

    Primary considerations for the design of positron emission tomographs for medical studies in humans are the need for high imaging sensitivity, whole organ coverage, good spatial resolution, high maximum data rates, adequate spatial sampling with minimum mechanical motion, shielding against out of plane activity, pulse height discrimination against scattered photons, and timing discrimination against accidental coincidences. We discuss the choice of detectors, sampling motion, shielding, and electronics to meet these objectives

  1. 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Tuberculosis: Spectrum of Manifestations.

    Science.gov (United States)

    Agarwal, Krishan Kant; Behera, Abhishek; Kumar, Rakesh; Bal, Chandrasekhar

    2017-01-01

    The objective of this article is to provide an illustrative tutorial highlighting the utility of 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography ( 18 F-FDG-PET/CT) imaging to detect spectrum of manifestations in patients with tuberculosis (TB). FDG-PET/CT is a powerful tool for early diagnosis, measuring the extent of disease (staging), and consequently for evaluation of response to therapy in patients with TB.

  2. Positron-emission tomography as a new direction in radiation medicine development (scientometric analysis)

    International Nuclear Information System (INIS)

    Artamonova, N.O.; Masyich, O.V.; Pavlyichenko, Yu.V.; Shepeljev, A.G.; Kuryilo, Yu.P.; Ponomarenko, T.O.

    2009-01-01

    The contemporary state and prospects of positron-emission tomography (PET) application in diagnosis of cancer diseases are investigated. The comparative analysis of the image of the topical field in Medline and INIS allowed to allocate the zones of intensive investigation of PET efficacy at cancer diseases, investigations of the brain, lungs, heart as well as to establish the peculiarities of the search depending on the features of their search interfaces

  3. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET)

    DEFF Research Database (Denmark)

    Graebe, M; Pedersen, Sune Folke; Borgwardt, L

    2008-01-01

    OBJECTIVES: Atherosclerosis is recognised as an inflammatory disease, and new diagnostic tools are warranted to evaluate plaque inflammatory activity and risk of cardiovascular events. We investigated [18]-fluorodeoxyglucose (FDG) uptake in vulnerable carotid plaques visualised by positron emission...... tomography (PET). Uptake was correlated to quantitative gene expression of known markers of inflammation and plaque vulnerability. METHODS: Ten patients with recent transient ischaemic attack and carotid artery stenosis (>50%) underwent combined FDG-PET and computed tomography angiography (CTA) the day...

  4. A tumor-targeted polymer theranostics platform for positron emission tomography and fluorescence imaging

    Czech Academy of Sciences Publication Activity Database

    Koziolová, Eva; Goel, S.; Chytil, Petr; Janoušková, Olga; Barnhart, T. E.; Cai, W.; Etrych, Tomáš

    2017-01-01

    Roč. 9, č. 30 (2017), s. 10906-10918 ISSN 2040-3364 R&D Projects: GA ČR(CZ) GA15-02986S; GA MZd(CZ) NV16-28594A; GA MŠk(CZ) LO1507 Institutional support: RVO:61389013 Keywords : N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers * positron emission tomography ( PET ) * fluorescence imaging Subject RIV: CD - Macromolecular Chemistry OBOR OECD: Polymer science Impact factor: 7.367, year: 2016

  5. Transcutaneous measurement of the arterial input function in positron emission tomography

    International Nuclear Information System (INIS)

    Litton, J.E.; Eriksson, L.

    1990-01-01

    Positron emission tomography (PET) provides a powerful tool in medical research. Biochemical function can be both precisely localized and quantitatively measured. To achieve reliable quantitation it is necessary to know the time course of activity concentration in the arterial blood during the measurement. In this study the arterial blood curve from the brachial artery is compared to the activity measured in the internal carotid artery with a new transcutaneous detector

  6. Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis

    OpenAIRE

    Jadvar, Hossein

    2015-01-01

    Prostate cancer is a prevalent public health problem worldwide. Over the past decade, there has been tremendous research activity in the potential use of positron emission tomography with a number of radiotracers targeted to various biological aspects of this complex tumor. Systematic reviews and meta-analysis are important contributions to the relevant literature that summarize the evidence while reducing the effect of various sources of bias in the published data. The accumulation of releva...

  7. A promising new mechanism of ionizing radiation detection for positron emission tomography: Modulation of optical properties

    OpenAIRE

    Tao, Li; Daghighian, Henry M.; Levin, Craig S.

    2016-01-01

    Using conventional scintillation detection, the fundamental limit in positron emission tomography (PET) time resolution is strongly dependent on the inherent temporal variances generated during the scintillation process, yielding an intrinsic physical limit for the coincidence time resolution of around 100 ps. On the other hand, modulation mechanisms of the optical properties of a material exploited in the optical telecommunications industry can be orders of magnitude faster. In this paper we...

  8. A statistical analysis of count normalization methods used in positron-emission tomography

    International Nuclear Information System (INIS)

    Holmes, T.J.; Ficke, D.C.; Snyder, D.L.

    1984-01-01

    As part of the Positron-Emission Tomography (PET) reconstruction process, annihilation counts are normalized for photon absorption, detector efficiency and detector-pair duty-cycle. Several normalization methods of time-of-flight and conventional systems are analyzed mathematically for count bias and variance. The results of the study have some implications on hardware and software complexity and on image noise and distortion

  9. Positron-emission tomography imaging of long-term shape recognition challenges

    OpenAIRE

    Rosier, A.; Cornette, L.; Dupont, P.; Bormans, G.; Michiels, J.; Mortelmans, L.; Orban, G. A.

    1997-01-01

    Long-term visual memory performance was impaired by two types of challenges: a diazepam challenge on acquisition and a sensory challenge on recognition. Using positron-emission tomography regional cerebral blood flow imaging, we studied the effect of these challenges on regional brain activation during the delayed recognition of abstract visual shapes as compared with a baseline fixation task. Both challenges induced a significant decrease in differential activation in the left fusiform gyrus...

  10. Noninvasive measurement of regional myocardial glucose metabolism by positron emission computed tomography

    International Nuclear Information System (INIS)

    Schelbert, H.R.; Phelps, M.E.

    While the results of regional myocardial glucose metabolism measurements using positron emission computed tomography ( 13 N-ammonia) are promising, their utility and value remains to be determined in man. If this technique can be applied to patients with acute myocardial ischemia or infarction it may permit delineation of regional myocardial segments with altered, yet still active metabolism. Further, it may become possible to evaluate the effects of interventions designed to salvage reversibly injured myocardium by this technique

  11. Dynamic Positron Emission Tomography [PET] in Man Using Small Bismuth Germanate Crystals

    Science.gov (United States)

    Derenzo, S. E.; Budinger, T. F.; Huesman, R. H.; Cahoon, J. L.

    1982-04-01

    Primary considerations for the design of positron emission tomographs for medical studies in humans are the need for high imaging sensitivity, whole organ coverage, good spatial resolution, high maximum data rates, adequate spatial sampling with minimum mechanical motion, shielding against out of plane activity, pulse height discrimination against scattered photons, and timing discrimination against accidental coincidences. We discuss the choice of detectors, sampling motion, shielding, and electronics to meet these objectives.

  12. A multicrystal two dimensional BGO detector system for positron emission tomography

    International Nuclear Information System (INIS)

    Casey, M.E.; Nutt, R.

    1986-01-01

    This paper presents a discussion of a new multicrystal detector system as it is implemented in Positron Emission Tomography. The system consists of a 32 x 8 matrix of BGO crystals, a tuned light pipe, and four photomultipliers. The electronics that decodes the position consists of fast preamps, gated integrators, and level comparators. This detector represents a major development toward reducing the cost of PET

  13. Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications

    International Nuclear Information System (INIS)

    Pagani, M.; Stone-Elander, S.; Larsson, S.A.

    1997-01-01

    The increasing amount of clinically relevant information obtained by positron emission tomography (PET), primarily with fluorine-18 labelled 2-deoxy-2-fluoro-d-glucose, has generated a demand for new routes for the widespread and cost-efficient use of positron-emitting radiopharmaceuticals. New dual-head single-photon emission tomography (SPET) cameras are being developed which offer coincidence detection with camera heads lacking a collimator or SPET imaging with specially designed collimators and additional photon shielding. Thus, not only satellite PET imaging units but also nuclear medicine units investing in these new SPET/PET systems need to examine all available alternatives for rational radionuclide supplies from host cyclotrons. This article examines 25 ''alternative'' positron-emitting radionuclides, discusses the impact of their decay properties on image quality and reviews methods for their production as well as for their application in imaging techniques. (orig.)

  14. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions

    DEFF Research Database (Denmark)

    Bachner, M; Loriot, Y; Gross-Goupil, M

    2012-01-01

    2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) has been recommended in international guidelines in the evaluation of postchemotherapy seminoma residuals. Our trial was designed to validate these recommendations in a larger group of patients.......2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) has been recommended in international guidelines in the evaluation of postchemotherapy seminoma residuals. Our trial was designed to validate these recommendations in a larger group of patients....

  15. The role of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer.

    Science.gov (United States)

    Crippa, Stefano; Salgarello, Matteo; Laiti, Silvia; Partelli, Stefano; Castelli, Paola; Spinelli, Antonello E; Tamburrino, Domenico; Zamboni, Giuseppe; Falconi, Massimo

    2014-08-01

    The role of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in pancreatic ductal adenocarcinoma is debated. We retrospectively assessed the value of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in addition to conventional imaging as a staging modality in pancreatic cancer. (18)Fluoro-deoxyglucose positron emission tomography/computed tomography was performed in 72 patients with resectable pancreatic carcinoma after multi-detector computed tomography positron emission tomography was considered positive for a maximum standardized uptake value >3. Overall, 21% of patients had a maximum standardized uptake value ≤ 3, and 60% of those had undergone neoadjuvant treatment (P=0.0001). Furthermore, 11% of patients were spared unwarranted surgery since positron emission tomography/computed tomography detected metastatic disease. All liver metastases were subsequently identified with contrast-enhanced ultrasound. Sensitivity and specificity of positron emission tomography/computed tomography for distant metastases were 78% and 100%. The median CA19.9 concentration was 48.8 U/mL for the entire cohort and 292 U/mL for metastatic patients (P=0.112). The widespread application of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic carcinoma seems not justified. It should be considered in selected patients at higher risk of metastatic disease (i.e. CA19.9>200 U/mL) after undergoing other imaging tests. Neoadjuvant treatment is significantly associated with low metabolic activity, limiting the value of positron emission tomography in this setting. Copyright © 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

  16. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning

    DEFF Research Database (Denmark)

    Ashraf, H; Dirksen, A; Jakobsen, Annika Loft

    2011-01-01

    In lung cancer screening the ability to distinguish malignant from benign nodules is a key issue. This study evaluates the ability of positron emission tomography (PET) and volume doubling time (VDT) to discriminate between benign and malignant nodules.......In lung cancer screening the ability to distinguish malignant from benign nodules is a key issue. This study evaluates the ability of positron emission tomography (PET) and volume doubling time (VDT) to discriminate between benign and malignant nodules....

  17. Tomography by positrons emission: integral unit to the service of Mexico; Tomografia por emision de positrones: unidad integral al servicio de Mexico

    Energy Technology Data Exchange (ETDEWEB)

    Lopez D, F A [Unidad PET-Ciclotron, Facultad de Medicina, UNAM (Mexico)

    2005-07-01

    The applications of the Positron emission tomography (PET) together with the one radiopharmaceutical 2 - [{sup 18} F]-fluoro-2-deoxy-D-glucose in the area of the medical imaging is expanding quickly and it possesses a bigger impact at the moment in favor of those patient to who suffers an oncological, cardiac or neurological illness in Mexico. (Author)

  18. High-resolution PET [Positron Emission Tomography] for Medical Science Studies

    Science.gov (United States)

    Budinger, T. F.; Derenzo, S. E.; Huesman, R. H.; Jagust, W. J.; Valk, P. E.

    1989-09-01

    One of the unexpected fruits of basic physics research and the computer revolution is the noninvasive imaging power available to today's physician. Technologies that were strictly the province of research scientists only a decade or two ago now serve as the foundations for such standard diagnostic tools as x-ray computer tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), ultrasound, single photon emission computed tomography (SPECT), and positron emission tomography (PET). Furthermore, prompted by the needs of both the practicing physician and the clinical researcher, efforts to improve these technologies continue. This booklet endeavors to describe the advantages of achieving high resolution in PET imaging.

  19. Time-of-flight positron emission tomography using optical fiber circuit

    International Nuclear Information System (INIS)

    Yamawaki, Masato; Katsumura, Yousuke; Suzuki, Takenori

    2008-01-01

    The measurement method and system architecture of a new time-of-flight positron emission tomography (TOF-PET) system are proposed. This system collects scintillation light using optical fibers connected directly to scintillators and measures the position of positron annihilation. Many scintillators are placed cylindrically whereby a pair of scintillators detects a pair of γ-rays generated at the positron annihilation point. Optical fiber circuits, most of which are bundles of optical fibers bound clockwise or counterclockwise around the cylinder of scintillators, collect light signals generated by γ-rays. These light signals are amplified by several photomultiplier tubes and processed using a single digital oscilloscope to determine the TOF of the positron annihilation γ-rays. One of the most important factors in the performance of the TOF-PET system is the TOF resolution. When fiber circuits are used for transmitting light signals, the dispersion of light signals and the decrease in light intensity are the major factors in the deterioration of the TOF resolution. The result of the preliminary experiment leads to the conclusion that the use of optical fibers degrades the intensity of light but does not severely degrade the TOF resolution. (author)

  20. Positron emission tomography in presurgical evaluation of epilepsy

    International Nuclear Information System (INIS)

    Willoch, F.; Arnold, S.; Noachtar, S.; Bartenstein, P.

    1997-01-01

    In a considerable proportion of patients with medically intractable partial epilepsies who are considered for surgery, the detection of a lesion with MRI or CT is not possible. Functional imaging methods can provide clinically useful information in these cases, being methods which enable localisation of functional abnormalities independent from EEG. There is an extensive knowledge about interictal PET-investigations with F-18 FDG. Many centers dealing with preoperative evaluation of epilepsy use this method as part of their diagnostic routine. Most studies report a decrease of glucose metabolism in topographic correlation to the EEG defined seizure origin in temporal lobe epilepsy in 70%-85% of the patients. The sensitivity reported for the detection of extratemporal foci is markedly lower. The mapping of neuronal structures with specific ligands, i.e. benzodiazepine receptor ligands has advantages compared to the detection of changes in flow and metabolism. It enables the differentiation of abnormalities in the neuronal texture of the brain from deactivated cortical areas. This is especially important when surgical procedures other than standard resection techniques are considered. The clinical importance of the functional imaging methods is that they help to decrease the amount of invasive EEG recordings in temporal lobe epilepsy. Furthermore, in extratemporal epilepsies functional imaging techniques facilitate the placement of the electrodes for invasive EEG recording. (orig.) [de

  1. Comparison of three /sup 18/F-labeled butyrophenone neuroleptic drugs in the baboon using positron emission tomography

    Energy Technology Data Exchange (ETDEWEB)

    Arnett, C D; Shiue, C Y; Wolf, A P; Fowler, J S; Logan, J; Watanabe, M

    1985-03-01

    The butyrophenone neuroleptics spiroperidol, benperidol, and haloperidol were radiolabeled with fluorine-/sup 18/ and studied in baboon brain using positron emission transaxial tomography (PETT). Pretreatment of the baboon with a high pharmacological dose of (+)-butaclamol reduced the specifically bound component of radioactivity distribution in the striatum to approximately the radioactivity distribution found in the cerebellum. Comparative studies of brain distribution kinetics over a 4-h period indicated that either (/sup 18/F)spiroperidol or (/sup 18/F)benperidol may be suitable for specific labeling of neuroleptic receptors. In an 8-h study with (/sup 18/F)spiroperidol, striatal radioactivity did not decline, suggesting that spiroperidol either has a very slow dissociation rate or that it binds irreversibly to these receptors in vivo. (/sup 18/F)Haloperidol may not be suitable for in vivo PETT studies, because of a relatively high component of nonspecific distribution and a faster dissociation from the receptor. Analysis of /sup 18/F in plasma after injection of (/sup 18/F)spiroperidol indicated rapid metabolism to polar and acidic metabolites, with only 40% of the total radioactivity being present as unchanged drug after 30 min. Analysis of the metabolic stability of the radioactively labeled compound in rat striatum indicated that greater than 95% of (/sup 18/F)spiroperidol remains unchanged after 4 h.

  2. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners.

    Science.gov (United States)

    Kinahan, Paul E; Hasegawa, Bruce H; Beyer, Thomas

    2003-07-01

    A synergy of positron emission tomography (PET)/computed tomography (CT) scanners is the use of the CT data for x-ray-based attenuation correction of the PET emission data. Current methods of measuring transmission use positron sources, gamma-ray sources, or x-ray sources. Each of the types of transmission scans involves different trade-offs of noise versus bias, with positron transmission scans having the highest noise but lowest bias, whereas x-ray scans have negligible noise but the potential for increased quantitative errors. The use of x-ray-based attenuation correction, however, has other advantages, including a lack of bias introduced from post-injection transmission scanning, which is an important practical consideration for clinical scanners, as well as reduced scan times. The sensitivity of x-ray-based attenuation correction to artifacts and quantitative errors depends on the method of translating the CT image from the effective x-ray energy of approximately 70 keV to attenuation coefficients at the PET energy of 511 keV. These translation methods are usually based on segmentation and/or scaling techniques. Errors in the PET emission image arise from positional mismatches caused by patient motion or respiration differences between the PET and CT scans; incorrect calculation of attenuation coefficients for CT contrast agents or metallic implants; or keeping the patient's arms in the field of view, which leads to truncation and/or beam-hardening (or x-ray scatter) artifacts. Proper interpretation of PET emission images corrected for attenuation by using the CT image relies on an understanding of the potential artifacts. In cases where an artifact or bias is suspected, careful inspection of all three available images (CT and PET emission with and without attenuation correction) is recommended. Copyright 2003 Elsevier Inc. All rights reserved.

  3. Software development for modeling positrons emission tomograph scanners; Desenvolvimento de um software para modelagem de tomografos por emissao de positrons

    Energy Technology Data Exchange (ETDEWEB)

    Vieira, Igor Fagner

    2013-08-01

    The Geant4 Application for Tomographic Emission (GATE) is an international platform recognized and used to develop Computational Model Exposure (CME) in the context of Nuclear Medicine, although currently there are dedicated modules for applications in Radiotherapy and Computed Tomography (CT). GATE uses Monte Carlo (MC) methods, and has a scripting language of its own. The writing of scripts for simulation of a PET scanner in GATE involves a number of interrelated steps, and the accuracy of the simulation is dependent on the correct setup of the geometries involved, since the physical processes depend on them, as well as the modeling of electronic detectors in module Digitizer, for example. The manual implementation of this setup can be a source of errors, especially for users without experience in the field of simulations or without any previous knowledge of a programming language, and also due to the the fact that the modeling process in GATE still remains bounded to LINUX / UNIX based systems, an environment only familiar to a few. This becomes an obstacle for beginners and prevents the use of GATE by a larger number of users interested in optimizing their experiments and/or clinical protocols through a more accessible, fast and friendly application. The objective of this work is therefore to develop a user-friendly software for the modeling of Positron Emission Tomography called GUIGATE (Graphical User Interface for GATE), with specific modules dedicated to quality control in PET scanners. The results exhibit the features available in this first version of GUIGATE, present in a set of windows that allow users to create their input files, perform and display in real time the model and analyze its output file in a single environment, allowing so intuitively access the entire architecture of the GATE simulation and to CERN's data analyzer, the ROOT. (author)

  4. Geneva University - The AX-PET experiment : A demonstrator for an axial Positron Emission Tomography

    CERN Multimedia

    Université de Genève

    2012-01-01

    Geneva University École de physique Département de physique nucléaire et corspusculaire 24, quai Ernest-Ansermet 1211 Genève 4 Tél.: (022) 379 62 73 Fax: (022) 379 69 92   Wednesday 14 March 2012 SEMINAIRE DE PHYSIQUE CORPUSCULAIRE 11.15 a.m. - Science II, Auditoire 1S081, 30, quai Ernest-Ansermet, 1211 Genève 4 The AX-PET experiment : A demonstrator for an axial Positron Emission Tomography Dr Chiara CASELLA   ETH Zurich   PET (Positron Emission Tomography) is a tool for in-vivo functional imaging, successfully used since the earliest days of nuclear medicine. It is based on the detection of the two coincident 511 keV photons from the annihilation of a positron, emitted from a radiotracer injected into the body. Tomographic analysis of the coincidence data allows for a 3D reconstructed image of the source distribution. The AX-PET experiment proposes a novel geometrical approach for a PET scanner, in which l...

  5. Carbon-11 and Fluorine-18 Labeled Amino Acid Tracers for Positron Emission Tomography Imaging of Tumors

    Science.gov (United States)

    Sun, Aixia; Liu, Xiang; Tang, Ganghua

    2017-12-01

    Tumor cells have an increased nutritional demand for amino acids(AAs) to satisfy their rapid proliferation. Positron-emitting nuclide labeled AAs are interesting probes and are of great importance for imaging tumors using positron emission tomography (PET). Carbon-11 and fluorine-18 labeled AAs include the [1-11C] amino acids, labeling alpha-C- amino acids, the branched-chain of amino acids and N-substituted carbon-11 labeled amino acids. These tracers target protein synthesis or amino acid(AA) transport, and their uptake mechanism mainly involves AA transport. AA PET tracers have been widely used in clinical settings to image brain tumors, neuroendocrine tumors, prostate cancer, breast cancer, non–small cell lung cancer (NSCLC) and hepatocellular carcinoma. This review focuses on the fundamental concepts and the uptake mechanism of AAs, AA PET tracers and their clinical applications.

  6. Enhancement of molecular sensitivity in positron emission tomography with quantum correlation of γ-ray photons

    Science.gov (United States)

    Sato, K.; Kobayashi, Y.

    2015-05-01

    Enhancement of molecular sensitivity in positron emission tomography (PET) has long been discussed with respect to imaging instrumentation and algorithms for data treatment. Here, the molecular sensitivity in PET is discussed on the basis of 2-dimensional coincident measurements of 511 keV γ ray photons resultant from two-photon annihilation. Introduction of an additional selection window based on the energy sum and difference of the coincidently measured γ ray photons, without any significant instrumental and algorithmic changes, showed an improvement in the signal-to-noise ratio (SNR) by an order of magnitude. Improvement of performance characteristics in the PET imaging system was demonstrated by an increase in the noise equivalent count rate (NECR) which takes both the SNR and the detection efficiency into consideration. A further improvement of both the SNR and the NECR is expected for the present system in real clinical and in-vivo environments, where much stronger positron sources are employed.

  7. Enhancement of molecular sensitivity in positron emission tomography with quantum correlation of γ-ray photons

    International Nuclear Information System (INIS)

    Sato, K.; Kobayashi, Y.

    2015-01-01

    Enhancement of molecular sensitivity in positron emission tomography (PET) has long been discussed with respect to imaging instrumentation and algorithms for data treatment. Here, the molecular sensitivity in PET is discussed on the basis of 2-dimensional coincident measurements of 511 keV γ ray photons resultant from two-photon annihilation. Introduction of an additional selection window based on the energy sum and difference of the coincidently measured γ ray photons, without any significant instrumental and algorithmic changes, showed an improvement in the signal-to-noise ratio (SNR) by an order of magnitude. Improvement of performance characteristics in the PET imaging system was demonstrated by an increase in the noise equivalent count rate (NECR) which takes both the SNR and the detection efficiency into consideration. A further improvement of both the SNR and the NECR is expected for the present system in real clinical and in-vivo environments, where much stronger positron sources are employed

  8. Visualization of muscles involved in unilateral tremor using 13N-ammonia and positron emission tomography

    International Nuclear Information System (INIS)

    Schelstraete, K.; Simons, M.; Deman, J.; Vermeulen, F.L.; Ghent Rijksuniversiteit; Goethals, P.; Bratzlavsky, M.

    1982-01-01

    Using positron emission computerized tomography (PCT), a high uptake of IV injected 13 N-ammonia was observed in the muscles of the right forearm and leg of a patient with a rightsided static tremor. In some mucles the concentration of 13 NH 3 was 8.5 times higher than in the symmetrical normal limb. Confrontation of the clinical, neurological, and electroyographic findings with the results of the PCT proved that the muscles with the high uptake corresponded to the muscles responsible for the tremulous movements. There is strong evidence that the high uptake of 13 NH 3 was related to the increased blood flow produced by the continuous rhythmic exercise of the muscles involved in the tremor. To our knowledge a similar observation has not been described before. It is suggested that the combined use of suitable positron emitters and PCT might provide a valuable tool for the noninvasive study of perfusion of individual skeletal muscles. (orig.)

  9. Primary neuroendocrine carcinoma of breast with liver and bone metastasis detected with fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography

    International Nuclear Information System (INIS)

    Kamaleshwaran, Koramadai Karuppusamy; Mohanan, Vyshak; Shibu, Deepu; Radhakrishnan, Edathuruthy Kalarikal; Shinto, Ajit Sugunan

    2014-01-01

    Cases of primary neuroendocrine carcinoma (NEC) of the breast have been reported, though rare. We report the case of a 45-year-old woman presented with jaundice and evaluated to have liver metastasis from neuroendocrine origin. She underwent whole body positron emission tomography/computed tomography, which showed left breast lesion and bone metastasis. Fine-needle aspiration (FNA) of breast revealed a NEC. A diagnosis of a primary NEC of the breast was rendered with hepatic and bone metastasis. She was treated with peptide receptor radionuclide therapy and is on follow-up

  10. (-)-N-[(11)C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2) receptors.

    Science.gov (United States)

    Hwang, D R; Kegeles, L S; Laruelle, M

    2000-08-01

    Imaging neuroreceptors with radiolabeled agonists might provide valuable information on the in vivo agonist affinity states of receptors of interest. We report here the radiosynthesis, biodistribution in rodents, and imaging studies in baboons of [(11)C]-labeled (-)-N-propyl-norapomorphine [(-)-NPA]. (-)-[(11)C]NPA was prepared by reacting norapomorphine with [(11)C]propionyl chloride and a lithium aluminum hydride reduction. [(11)C]Propionyl chloride was prepared by reacting [(11)C]CO(2) with ethylmagnesium bromide, followed by reacting with phthaloyl chloride. The radiochemical yield of (-)-[(11)C]NPA was 2.5% at end of synthesis (EOS), and the synthesis time was 60 min. The specific activity was 1700+/-1900 mCi/micromol ( N=7; ranged 110-5200 mCi/micromol at EOS). Rodent biodistribution studies showed high uptake of [(11)C](-)-NPA in D(2) receptor-rich areas, and the striatum/cerebellum ratios were 1.7, 3.4, and 4.4 at 5 min, 30 min, and 60 min postinjection, respectively. Pretreating the animals with haloperidol (1 mg/kg) decreased the striatum/cerebellum ratio at 30 min postinjection to 1.3. (-)-[(11)C]NPA was also evaluated via baboon positron emission tomography (PET) studies. Under control conditions ( N=4), rapid uptake of the tracer was observed and the striatum/cerebellum ratio reached 2.86+/-0.15 at 45 min postinjection. Following haloperidol pretreatment (0.2 mg/kg IV), the striatum/cerebellum ratio was 1.29 at 45 min postinjection. The result demonstrated the existence of specific binding of this new tracer to the D(2) receptor. To our knowledge, the current finding of a striatum/cerebellum ratio of 2.8 in baboon was the highest reported with a radiolabeled D(2) agonist. (-)-[(11)C]NPA is a promising new D(2) agonist PET tracer for probing D(2) receptors in vivo using PET.

  11. The effects of age on dopamine receptors measured by positron tomography in the living human brain

    International Nuclear Information System (INIS)

    Wong, D.F.; Wagner, E.N. Jr.; Dannals, R.F.

    1984-01-01

    C-11 n-methylspiperone has been used to measure dopamine (D2) receptors in the caudate and putamen of 30 normal persons. In vitro studies in rodent brain revealed a high affinity for dopamine (D2) receptors and five fold less for serotonin (S2) receptors. In vivo drug competition studies in rodents demonstrated that 90% of striatal binding is to dopamine receptors. In the frontal cortex, the majority of receptor binding is to serotonin receptors. Thirty normal volunteers aged 19 to 73 years were screened for normality by medical, neurological and neuropsychological examinations. Positron tomography was performed serially for 2 hours after injection. In 10 subjects there was good agreement between activity in arterial samples and that in venous samples from a heated hand. Binding in the dopamine rich caudate and putamen progressively increased while binding in the dopamine poor cerebellum decreased. The dopamine receptor density was estimated by the ratio of the caudate-to-cerebellar mean counts/pixel (Ca/Cb) and putamen-to-cerebellar mean counts/pixel (Pu/Cb). The ratios (Ca/Cb, Pu/Cb) increased linearly with time (r>0.95) for each subject. There was a decrease (Ca/Cb) with age (0.8%/yr) that could be approximated with a linear fit: (Ca/Cb = -.02 age + 3.92, r=.6). For the 21 males alone, the decrease was (1.1%/yr, r=.7 , p <.01), while for the 9 females there was no significant decrease with age. Similar findings were noted in the putamen. This decline in dopamine receptor density with age has been reported in rodent and human autopsy studies, but never before in the living human brain

  12. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study.

    Science.gov (United States)

    Gastaldelli, Amalia; Gaggini, Melania; Daniele, Giuseppe; Ciociaro, Demetrio; Cersosimo, Eugenio; Tripathy, Devjit; Triplitt, Curtis; Fox, Peter; Musi, Nicolas; DeFronzo, Ralph; Iozzo, Patricia

    2016-12-01

    Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1-RAs) act on multiple tissues, in addition to the pancreas. Recent studies suggest that GLP-1-RAs act on liver and adipose tissue to reduce insulin resistance (IR). Thus, we evaluated the acute effects of exenatide (EX) on hepatic (Hep-IR) and adipose (Adipo-IR) insulin resistance and glucose uptake. Fifteen male subjects (age = 56 ± 8 years; body mass index = 29 ± 1 kg/m 2 ; A1c = 5.7 ± 0.1%) were studied on two occasions, with a double-blind subcutaneous injection of EX (5 μg) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT). During OGTT, we measured hepatic (HGU) and adipose tissue (ATGU) glucose uptake with [ 18 F]2-fluoro-2-deoxy-D-glucose/positron emission tomography, lipolysis (RaGly) with [U- 2 H 5 ]-glycerol, oral glucose absorption (RaO) with [U- 13 C 6 ]-glucose, and hepatic glucose production (EGP) with [6,6- 2 H 2 ]-glucose. Adipo-IR and Hep-IR were calculated as (FFA 0-120min ) × (Ins 0-120min ) and (EGP 0-120min ) × (Ins 0-120min ), respectively. EX reduced RaO, resulting in reduced plasma glucose and insulin concentration from 0 to 120 minutes postglucose ingestion. EX decreased Hep-IR (197 ± 28 to 130 ± 37; P = 0.02) and increased HGU of orally administered glucose (23 ± 4 to 232 ± 89 [μmol/min/L]/[μmol/min/kg]; P = 0.003) despite lower insulin (23 ± 5 vs. 41 ± 5 mU/L; P < 0.02). EX enhanced insulin suppression of RaGly by decreasing Adipo-IR (23 ± 4 to 13 ± 3; P = 0.009). No significant effect of insulin was observed on ATGU (EX = 1.16 ± 0.15 vs. PLC = 1.36 ± 0.13 [μmol/min/L]/[μmol/min/kg]). Acute EX administration (1) improves Hep-IR, decreases EGP, and enhances HGU and (2) reduces Adipo-IR, improves the antilipolytic effect of insulin, and reduces plasma free fatty acid levels during OGTT. (Hepatology 2016;64:2028-2037). © 2016 by the American Association for the Study of Liver Diseases.

  13. Applications of nucleoside-based molecular probes for the in vivo assessment of tumour biochemistry using positron emission tomography (PET

    Directory of Open Access Journals (Sweden)

    Leonard I. Wiebe

    2007-05-01

    Full Text Available Positron emission tomography (PET is a non-invasive nuclear imaging technique. In PET, radiolabelled molecules decay by positron emission. The gamma rays resulting from positron annihilation are detected in coincidence and mapped to produce three dimensional images of radiotracer distribution in the body. Molecular imaging with PET refers to the use of positron-emitting biomolecules that are highly specific substrates for target enzymes, transport proteins or receptor proteins. Molecular imaging with PET produces spatial and temporal maps of the target-related processes. Molecular imaging is an important analytical tool in diagnostic medical imaging, therapy monitoring and the development of new drugs. Molecular imaging has its roots in molecular biology. Originally, molecular biology meant the biology of gene expression, but now molecular biology broadly encompasses the macromolecular biology and biochemistry of proteins, complex carbohydrates and nucleic acids. To date, molecular imaging has focused primarily on proteins, with emphasis on monoclonal antibodies and their derivative forms, small-molecule enzyme substrates and components of cell membranes, including transporters and transmembrane signalling elements. This overview provides an introduction to nucleosides, nucleotides and nucleic acids in the context of molecular imaging.A tomografia por emissão de pósitrons (TEP é uma técnica de imagem não invasiva da medicina nuclear. A TEP utiliza moléculas marcadas com emissores de radiação beta positiva (pósitrons. As radiações gama medidas que resultam do aniquilamento dos pósitrons são detectadas por um sistema de coincidência e mapeadas para produzir uma imagem tridimensional da distribuição do radiotraçador no corpo. A imagem molecular com TEP refere-se ao uso de biomoléculas marcadas com emissor de pósitron que são substratos altamente específicos para alvos como enzimas, proteínas transportadoras ou receptores prot

  14. Noninvasive assessment of canine myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography

    International Nuclear Information System (INIS)

    Brown, M.A.; Myears, D.W.; Bergmann, S.R.

    1988-01-01

    Noninvasive quantification of regional myocardial metabolism would be highly desirable to evaluate pathogenetic mechanisms of heart disease and their response to therapy. It was previously demonstrated that the metabolism of radiolabeled acetate, a readily utilized myocardial substrate predominantly metabolized to carbon dioxide (CO2) by way of the tricarboxylic acid cycle, provides a good index of oxidative metabolism in isolated perfused rabbit hearts because of tight coupling between the tricarboxylic acid cycle and oxidative phosphorylation. In the present study, in a prelude to human studies, the relation between myocardial clearance of carbon-11 (11C)-labeled acetate and myocardial oxygen consumption was characterized in eight intact dogs using positron emission tomography. Anesthetized dogs were studied during baseline conditions and again during either high or low work states induced pharmacologically. High myocardial extraction and rapid blood clearance of tracer yielded myocardial images of excellent quality. The turnover (clearance) of 11C radioactivity from the myocardium was biexponential with the mean half-time of the dominant rapid phase averaging 5.4 +/- 2.2, 2.8 +/- 1.3 and 11.1 +/- 1.3 min in control, high and low work load studies, respectively. No significant difference was found between the rate of clearance of 11C radioactivity from the myocardium measured noninvasively with positron emission tomography and the myocardial efflux of 11CO2 measured directly from the coronary sinus. The rate of clearance of the 11C radioactivity from the heart correlated closely with myocardial oxygen consumption (r = 0.90, p less than 0.001) as well as with the rate-pressure product (r = 0.95, p less than 0.001). Hence, the rate of oxidation of 11C-acetate can be determined noninvasively with positron emission tomography, providing a quantitative index of oxidative metabolism under diverse conditions

  15. FEASIBILITY OF POSITRON EMISSION TOMOGRAPHY OF DOSE DISTRIBUTION IN PROTON BEAM CANCER THERAPY

    International Nuclear Information System (INIS)

    BEEBE-WANG, J.J.; DILMANIAN, F.A.; PEGGS, S.G.; SCHLYEER, D.J.; VASKA, P.

    2002-01-01

    Proton therapy is a treatment modality of increasing utility in clinical radiation oncology mostly because its dose distribution conforms more tightly to the target volume than x-ray radiation therapy. One important feature of proton therapy is that it produces a small amount of positron-emitting isotopes along the beam-path through the non-elastic nuclear interaction of protons with target nuclei such as 12 C, 14 N, and 16 O. These radioisotopes, mainly 11 C, 13 N and 15 O, allow imaging the therapy dose distribution using positron emission tomography (PET). The resulting PET images provide a powerful tool for quality assurance of the treatment, especially when treating inhomogeneous organs such as the lungs or the head-and-neck, where the calculation of the dose distribution for treatment planning is more difficult. This paper uses Monte Carlo simulations to predict the yield of positron emitters produced by a 250 MeV proton beam, and to simulate the productions of the image in a clinical PET scanner

  16. Basic concepts on positron emission tomography in oncology and pediatric peculiarities

    International Nuclear Information System (INIS)

    Giammarile, F.; Pellet, O.

    2002-01-01

    (Positron Emission Tomography (PET) is an old functional imaging method, pertaining to the nuclear medicine field, based on the utilisation of positrons emitting nuclei, fixed on targeted molecules. Available since the Seventies, the clinical impact of PET grows daily, particularly in oncology. This method rests on the coincidence detection of the photons issued by the annihilation of the positron. It can be carried out on dedicated scans, equipped with a crown of detectors (PET camera) or on classical cameras whose crystal and electronic system has been adapted CDET camera). The 2-deoxy-2 fluoro-D-glucose marked with fluorine 18 [18FDG or FDG is a glucose analogue. Its cellular uptake uses the facilitated transport of glucose but its metabolism is partial because, contrary to this one, it remains within the cell. This allows functional studies (evaluation of glucose metabolism) on the cell. FDG uptake is thus increased under the pathological conditions comprising an increase in the consumption of glucose either by increase in glycolysis (malignant tumoral tissue) or by increase in the only anaerobic cycle (ischaemia). Consequently, this diagnostic method identifies in vivo the hyper-metabolism of malignant cells and provides a quantification of the tumoral glycolysis, during and after treatment. In Paediatrics, its diffusion and its use in clinical routine, are currently limited, because of the limited availability of the equipment. It is probable that with the awaited rise of PET in France, the paediatric applications will also see their place increasing in the diagnostic strategy of cancer. (authors)

  17. Hard photon emission from high energy electrons and positrons in single crystals

    International Nuclear Information System (INIS)

    Bajer, V.N.; Katkov, V.M.; Strakhovenko, V.M.

    1991-01-01

    A radiation of electrons and positrons in single crystals in coherent bremsstrahlung (CBS) region has been considered for the case when CBS has the most hard spectrum. Under this condition a particle moves near a crystalline plane (in fcc(d) crystal for axis (001) this is the plane (110)) and influence of the continuous plane potential should be taken into account. This potential gives additional contribution in soft part of the spectrum and affects on hard photon emission. Observation of this phenomena at high energy is discussed. 14 refs.; 5 figs.; 1 tab

  18. Caffeine and human cerebral blood flow: A positron emission tomography study

    International Nuclear Information System (INIS)

    Cameron, O.G.; Modell, J.G.; Hariharan, M.

    1990-01-01

    Positron emission tomography (PET) was used to quantify the effect of caffeine on whole brain and regional cerebral blood flow (CBF) in humans. A mean dose of 250 mg of caffeine produced approximately a 30% decrease in whole brain CBF; regional differences in caffeine effect were not observed. Pre-caffeine CBF strongly influenced the magnitude of the caffeine-induced decrease. Caffeine decreased p a CO 2 and increased systolic blood pressure significantly; the change in p a CO 2 did not account for the change in CBF. Smaller increases in diastolic blood pressure, heart rate, plasma epinephrine and norepinephrine, and subjectively reported anxiety were also observed

  19. Human hemispheric infarction studied by positron emission tomography and the 150 continuous inhalation technique

    International Nuclear Information System (INIS)

    Baron, J.-C.; Bousser, M.G.; Comar, D.; Kellershohn, C.

    1979-01-01

    Positron emission tomography (PET) offers an entirely new approach to the study of the pathophysiology of cerebral ischemic disorders. This is so because for the first time it is possible to obtain functional tomographic images that represent cerebral perfusion and metabolism in a regional basis. We report here a study of cerebral blood flow and oxygen extraction by means of the 15 O inhalation technique in a large number of human hemispheric infarctions. PET imaging with this non-invasive technique has permitted the description of hitherto unreported focal patterns of changes in the CBF/EO2 couple that may have important pathophysiologic and prognostic implications

  20. The potential application of silver and positron emission tomography for in vivo dosimetry during radiotherapy

    DEFF Research Database (Denmark)

    Hansen, Anders T; Hansen, Søren B; Petersen, Jørgen B

    2007-01-01

    of absorbed dose per gram of silver. This demonstrates that it is possible to derive absorbed doses from the radioactivity induced in silver by radiation when measured with the PET scanner. Even though the physical basis for this method is found to be sound, its application, for instance to perform quality......The possible use of silver as a material for in vivo dosimetry in radiotherapy was investigated. The investigation was carried out using a positron emission tomography (PET) scanner, two clinical accelerators and a phantom with silver implants. The phantom was irradiated several times to doses...